Blood O +
collection O +
for O +
RNA O +
studies O +
is O +
a O +
new O +
direction O -
. O +

Genetic O +
studies O +
of O +
longitudinal O +
phenotypes O +
hold O +
promise O +
for O +
elucidating O +
disease O +
mechanisms O +
and O +
risk O -
, O +
development O +
of O +
therapeutic O +
strategies O -
, O +
and O +
refining O +
selection O +
criteria O +
for O +
clinical O +
trials O -
. O +

Genome O -
- O -
wide O +
array O +
data O +
have O +
been O +
publicly O +
released O +
and O +
updated O -
, O +
and O +
several O +
neuroimaging O +
GWAS O +
have O +
recently O +
been O +
reported O +
examining O +
baseline O +
magnetic O +
resonance O +
imaging O +
measures O +
as O +
quantitative O +
phenotypes O -
. O +

Other O +
preliminary O +
investigations O +
include O +
copy O +
number O +
variation O +
in O +
mild O +
cognitive O +
impairment O +
and O +
Alzheimer O -
's O +
disease O +
and O +
GWAS O +
of O +
baseline O +
cerebrospinal O +
fluid O +
biomarkers O +
and O +
longitudinal O +
changes O +
on O +
magnetic O +
resonance O +
imaging O -
. O +

The O +
role O +
of O +
the O +
Alzheimer O -
's O +
Disease O +
Neuroimaging O +
Initiative O +
Genetics O +
Core O +
is O +
to O +
facilitate O +
the O +
investigation O +
of O +
genetic O +
influences O +
on O +
disease O +
onset O +
and O +
trajectory O +
as O +
reflected O +
in O +
structural O -
, O +
functional O -
, O +
and O +
molecular O +
imaging O +
changes O -
; O +
fluid O +
biomarkers O -
; O +
and O +
cognitive O +
status O -
. O +

Major O +
goals O +
include O +
( O -
1 O -
) O +
blood O +
sample O +
processing O -
, O +
genotyping O -
, O +
and O +
dissemination O -
, O +
( O -
2 O -
) O +
genome O -
- O -
wide O +
association O +
studies O +
( O -
GWAS O -
) O +
of O +
longitudinal O +
phenotypic O +
data O -
, O +
and O +
( O -
3 O -
) O +
providing O +
a O +
central O +
resource O -
, O +
point O +
of O +
contact O +
and O +
planning O +
group O +
for O +
genetics O +
within O +
the O +
Alzheimer O -
's O +
Disease O +
Neuroimaging O +
Initiative O -
. O +

Alzheimer O -
's O +
Disease O +
Neuroimaging O +
Initiative O +
biomarkers O +
as O +
quantitative O +
phenotypes O -
: O +
Genetics O +
core O +
aims O -
, O +
progress O -
, O +
and O +
plans O -
. O +

While O +
confirmation O +
is O +
required O -
, O +
this O +
study O +
suggests O +
that O +
microRNA O +
mutations O +
can O +
contribute O +
to O +
schizophrenia O -
. O +

One O +
ultra O -
- O -
rare O +
variant O +
was O +
identified O +
in O +
a O +
control O +
sample O +
( O -
with O +
a O +
history O +
of O +
depression O -
) O +
( O -
8 O -
/ O -
193 O +
versus O +
1 O -
/ O -
191 O -
, O +
p O +
= O +
0.02 O +
by O +
one O -
- O -
sided O +
Fisher O -
's O +
exact O +
test O -
, O +
odds O +
ratio O +
= O +
8.2 O -
) O -
. O +

These O +
variants O +
were O +
not O +
found O +
in O +
an O +
additional O +
7,197 O +
control O +
X O -
- O -
chromosomes O -
. O +

CONCLUSIONS O -
: O +
Functional O +
analyses O +
of O +
ectopically O +
expressed O +
copies O +
of O +
the O +
variant O +
miRNA O +
precursors O +
demonstrate O +
loss O +
of O +
function O -
, O +
gain O +
of O +
function O +
or O +
altered O +
expression O +
levels O -
. O +

In O +
addition O -
, O +
components O +
required O +
for O +
miRNA O +
processing O +
and/or O +
function O +
have O +
also O +
been O +
implicated O +
in O +
X O -
- O -
linked O +
mental O +
retardation O -
, O +
neurological O +
and O +
neoplastic O +
diseases O -
, O +
pointing O +
to O +
the O +
wide O +
ranging O +
involvement O +
of O +
miRNAs O +
in O +
disease O -
. O +

METHODS O +
AND O +
FINDINGS O -
: O +
To O +
explore O +
the O +
role O +
of O +
miRNAs O +
in O +
schizophrenia O -
, O +
59 O +
microRNA O +
genes O +
on O +
the O +
X O -
- O -
chromosome O +
were O +
amplified O +
and O +
sequenced O +
in O +
males O +
with O +
( O -
193 O -
) O +
and O +
without O +
( O -
191 O -
) O +
schizophrenia O +
spectrum O +
disorders O +
to O +
test O +
the O +
hypothesis O +
that O +
ultra O -
- O -
rare O +
mutations O +
in O +
microRNA O +
collectively O +
contribute O +
to O +
the O +
risk O +
of O +
schizophrenia O -
. O +

Here O +
we O +
provide O +
the O +
first O +
association O +
of O +
microRNA O +
gene O +
dysfunction O +
with O +
schizophrenia O -
. O +

Eight O +
ultra O -
- O -
rare O +
variants O +
in O +
the O +
precursor O +
or O +
mature O +
miRNA O +
were O +
identified O +
in O +
eight O +
distinct O +
miRNA O +
genes O +
in O +
4 O -
% O +
of O +
analyzed O +
males O +
with O +
schizophrenia O -
. O +

Evidence O +
for O +
X O -
- O -
chromosomal O +
schizophrenia O +
associated O +
with O +
microRNA O +
alterations O -
. O +

BACKGROUND O -
: O +
Schizophrenia O +
is O +
a O +
severe O +
disabling O +
brain O +
disease O +
affecting O +
about O +
1 O -
% O +
of O +
the O +
population O -
. O +

Individual O +
microRNAs O +
( O -
miRNAs O -
) O +
affect O +
moderate O +
downregulation O +
of O +
gene O +
expression O -
. O +

Specifically O -
, O +
we O +
highlight O +
the O +
importance O +
of O +
unbiased O +
association O +
studies O +
and O +
follow O -
- O -
up O +
functional O +
experiments O +
for O +
providing O +
a O +
clearer O +
picture O +
of O +
the O +
extent O +
to O +
which O +
microRNA O +
target O +
site O +
variations O +
are O +
relevant O +
in O +
various O +
human B-Species +
diseases O -
. O +

We O +
therefore O +
suggest O +
a O +
set O +
of O +
concrete O +
recommendations O +
to O +
guide O +
future O +
investigations O -
. O +

However O -
, O +
careful O +
assessment O +
of O +
these O +
studies O +
indicates O +
that O +
very O +
few O +
provide O +
a O +
combination O +
of O +
rigorous O +
genetic O +
and O +
functional O +
evidence O -
. O +

Several O +
studies O +
have O +
identified O +
genetic O +
variants O +
in O +
miRNA O +
target O +
sites O +
that O +
are O +
claimed O +
to O +
be O +
associated O +
with O +
disorders O +
ranging O +
from O +
Parkinson O -
's O +
disease O +
to O +
cancer O -
. O +

They O +
have O +
been O +
implicated O +
in O +
a O +
broad O +
range O +
of O +
biological O +
processes O -
, O +
and O +
miRNA O -
- O -
related O +
genetic O +
alterations O +
probably O +
underlie O +
more O +
human B-Species +
diseases O +
than O +
currently O +
appreciated O -
. O +

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
important O +
regulators O +
of O +
eukaryotic O +
gene O +
expression O -
. O +

MicroRNA O +
target O +
site O +
polymorphisms O +
and O +
human B-Species +
disease O -
. O +

Human B-Species +
traumatic O +
brain O +
injury O +
alters O +
plasma O +
microRNA O +
levels O -
. O +

Circulating O +
microRNAs O +
( O -
miRNAs O -
) O +
present O +
in O +
the O +
serum O -
/ O -
plasma O +
are O +
characteristically O +
altered O +
in O +
many O +
pathological O +
conditions O -
, O +
and O +
have O +
been O +
employed O +
as O +
diagnostic O +
markers O +
for O +
specific O +
diseases O -
. O +

We O +
examined O +
if O +
plasma O +
miRNA O +
levels O +
are O +
altered O +
in O +
patients B-Species +
with O +
traumatic O +
brain O +
injury O +
( O -
TBI O -
) O +
relative O +
to O +
matched O +
healthy O +
volunteers O -
, O +
and O +
explored O +
their O +
potential O +
for O +
use O +
as O +
diagnostic O +
TBI O +
biomarkers O -
. O +

The O +
plasma O +
miRNA O +
profiles O +
from O +
severe O +
TBI O +
patients B-Species +
( O -
Glasgow O +
Coma O +
Scale O +
[ O -
GCS O -
] O +
score O +
≤8 O -
) O +
and O +
age- O -
, O +
gender- O -
, O +
and O +
race O -
- O -
matched O +
healthy O +
volunteers O +
were O +
compared O +
by O +
microarray O +
analysis O -
. O +

Of O +
the O +
108 O +
miRNAs O +
identified O +
in O +
healthy O +
volunteer O +
plasma O -
, O +
52 O +
were O +
altered O +
after O +
severe O +
TBI O -
, O +
including O +
33 O +
with O +
decreased O +
and O +
19 O +
with O +
increased O +
relative O +
abundance O -
. O +

An O +
additional O +
8 O +
miRNAs O +
were O +
detected O +
only O +
in O +
the O +
TBI O +
plasma O -
. O +

We O +
used O +
quantitative O +
RT O -
- O -
PCR O +
to O +
determine O +
if O +
plasma O +
miRNAs O +
could O +
identify O +
TBI O +
patients B-Species +
within O +
the O +
first O +
24 O +
h O +
post O -
- O -
injury O -
. O +

Receiver O +
operating O +
characteristic O +
curve O +
analysis O +
indicated O +
that O +
miR-16 O -
, O +
miR-92a O -
, O +
and O +
miR-765 O +
were O +
good O +
markers O +
of O +
severe O +
TBI O +
( O -
0.89 O -
, O +
0.82 O -
, O +
and O +
0.86 O +
AUC O +
values O -
, O +
respectively O -
) O -
. O +

Multiple O +
logistic O +
regression O +
analysis O +
revealed O +
that O +
combining O +
these O +
miRNAs O +
markedly O +
increased O +
diagnostic O +
accuracy O +
( O -
100 O -
% O +
specificity O +
and O +
100 O -
% O +
sensitivity O -
) O -
, O +
compared O +
to O +
either O +
healthy O +
volunteers O +
or O +
orthopedic O +
injury O +
patients B-Species -
. O +

In O +
mild O +
TBI O +
patients B-Species +
( O -
GCS O +
score O +
> O +
12 O -
) O -
, O +
miR-765 O +
levels O +
were O +
unchanged O -
, O +
while O +
the O +
plasma O +
levels O +
of O +
miR-92a O +
and O +
miR-16 O +
were O +
significantly O +
increased O +
within O +
the O +
first O +
24 O +
h O +
of O +
injury O +
compared O +
to O +
healthy O +
volunteers O -
, O +
and O +
had O +
AUC O +
values O +
of O +
0.78 O +
and O +
0.82 O -
, O +
respectively O -
. O +

Plasma O -
- O -
derived O +
miRNA O +
biomarkers O -
, O +
used O +
in O +
combination O +
with O +
established O +
clinical O +
practices O +
such O +
as O +
imaging O -
, O +
neurocognitive O -
, O +
and O +
motor O +
examinations O -
, O +
have O +
the O +
potential O +
to O +
improve O +
TBI O +
patient B-Species +
classification O +
and O +
possibly O +
management O -
. O +

Our O +
results O +
demonstrate O +
that O +
circulating O +
miRNA O +
levels O +
are O +
altered O +
after O +
TBI O -
, O +
providing O +
a O +
rich O +
new O +
source O +
of O +
potential O +
molecular O +
biomarkers O -
. O +

MicroRNA-205 O +
inhibits O +
tumor O +
cell O +
migration O +
through O +
down O -
- O -
regulating O +
the O +
expression O +
of O +
the O +
LDL O +
receptor O -
- O -
related O +
protein O +
1 O -
. O +
Low O -
- O -
density O +
lipoprotein O +
receptor O -
- O -
related O +
protein O +
1 O +
( O -
LRP1 O -
) O +
is O +
a O +
multifunctional O +
endocytic O +
receptor O +
that O +
plays O +
critical O +
roles O +
in O +
the O +
pathogenesis O +
of O +
several O +
human B-Species +
diseases O +
including O +
tumor O +
metastasis O +
and O +
Alzheimer O -
's O +
disease O -
. O +

In O +
human B-Species +
cell O +
lines O -
, O +
we O +
found O +
that O +
miR-205 O +
down O -
- O -
regulates O +
the O +
expression O +
of O +
LRP1 O +
by O +
targeting O +
sequences O +
in O +
the O +
3'UTR O +
of O +
LRP1 O +
mRNA O -
. O +

However O -
, O +
mechanisms O +
that O +
regulate O +
LRP1 O +
expression O +
under O +
physiological O +
and O +
pathophysiological O +
conditions O +
are O +
not O +
unclear O -
. O +

The O +
ectopic O +
expression O +
of O +
miR-205 O +
also O +
significantly O +
mitigated O +
migration O +
of O +
both O +
U87 O +
and O +
SK O -
- O -
LU-1 O +
cells O -
. O +

This O +
effect O +
was O +
abolished O +
by O +
deleting O +
the O +
miR-205 O +
seed O +
site O +
in O +
the O +
3'UTR O +
of O +
LRP1 O -
. O +

These O +
results O -
, O +
for O +
the O +
first O +
time O -
, O +
demonstrate O +
that O +
expression O +
of O +
human B-Species +
LRP1 O +
is O +
regulated O +
in O +
part O +
by O +
a O +
specific O +
miRNA O -
, O +
leading O +
to O +
decreased O +
tumor O +
cell O +
migration O -
. O +

The O +
present O +
review O +
examines O +
the O +
various O +
miRNAs O +
that O +
have O +
been O +
identified O +
as O +
being O +
potentially O +
involved O +
in O +
T2D O -
, O +
focusing O +
on O +
the O +
insulin O -
- O -
sensitive O +
organs O -
: O +
white O +
adipose O +
tissue O -
, O +
liver O -
, O +
skeletal O +
muscle O +
and O +
the O +
insulin O -
- O -
producing O +
pancreatic O +
β O -
- O -
cells O -
. O +

miRNAs O +
are O +
involved O +
in O +
a O +
large O +
number O +
of O +
biological O +
functions O +
such O +
as O +
development O -
, O +
metabolism O -
, O +
immunity O +
and O +
diseases O +
such O +
as O +
cancer O -
, O +
cardiovascular O +
diseases O +
and O +
diabetes O -
. O +

miRNAs O +
are O +
small O +
22 O -
- O -
25-nt O -
- O -
long O +
untranslated O +
RNAs O +
that O +
negatively O +
regulate O +
the O +
translation O +
of O +
mRNAs O -
. O +

Although O +
T2D O +
seems O +
to O +
be O +
strongly O +
linked O +
to O +
environmental O +
factors O +
such O +
as O +
nutrition O +
and O +
lifestyle O -
, O +
studies O +
have O +
shown O +
that O +
genetic O +
factors O -
, O +
such O +
as O +
polymorphisms O +
associated O +
with O +
metabolic O +
genes O -
, O +
imprinting O -
, O +
fetal O +
programming O +
and O +
miRNA O +
( O -
microRNA O -
) O +
expression O -
, O +
could O +
also O +
contribute O +
to O +
the O +
development O +
of O +
this O +
disease O -
. O +

The O +
aetiology O +
and O +
molecular O +
mechanisms O +
of O +
T2D O +
are O +
not O +
fully O +
understood O -
, O +
but O +
compelling O +
evidence O +
points O +
to O +
a O +
link O +
between O +
T2D O -
, O +
obesity O -
, O +
dyslipidaemia O +
and O +
insulin O +
resistance O -
. O +

Improper O +
treatment O +
of O +
TD2 O +
can O +
lead O +
to O +
severe O +
complications O +
such O +
as O +
heart O +
disease O -
, O +
stroke O -
, O +
kidney O +
failure O -
, O +
blindness O +
and O +
nerve O +
damage O -
. O +

T2D O +
is O +
a O +
progressive O +
metabolic O +
disorder O +
characterized O +
by O +
reduced O +
insulin O +
sensitivity O -
, O +
insulin O +
resistance O +
and O +
pancreatic O +
β O -
- O -
cell O +
dysfunction O -
. O +

The O +
involvement O +
of O +
microRNAs O +
in O +
Type O +
2 O +
diabetes O -
. O +

T2D O +
( O -
Type O +
2 O +
diabetes O +
mellitus O -
) O +
is O +
a O +
major O +
health O +
issue O +
that O +
has O +
reached O +
epidemic O +
status O +
worldwide O -
. O +

Loss O +
of O +
microRNA O +
cluster O +
miR-29a O -
/ O -
b-1 O +
in O +
sporadic O +
Alzheimer O -
's O +
disease O +
correlates O +
with O +
increased O +
BACE1 O -
/ O -
beta O -
- O -
secretase O +
expression O -
. O +

Although O +
the O +
role O +
of O +
APP O +
and O +
PSEN O +
genes O +
in O +
genetic O +
Alzheimer O -
's O +
disease O +
( O -
AD O -
) O +
cases O +
is O +
well O +
established O -
, O +
fairly O +
little O +
is O +
known O +
about O +
the O +
molecular O +
mechanisms O +
affecting O +
Abeta O +
generation O +
in O +
sporadic O +
AD O -
. O +
Deficiency O +
in O +
Abeta O +
clearance O +
is O +
certainly O +
a O +
possibility O -
, O +
but O +
increased O +
expression O +
of O +
proteins O +
like O +
APP O +
or O +
BACE1 O -
/ O -
beta O -
- O -
secretase O +
may O +
also O +
be O +
associated O +
with O +
the O +
disease O -
. O +

We O +
therefore O +
investigated O +
changes O +
in O +
microRNA O +
( O -
miRNA O -
) O +
expression O +
profiles O +
of O +
sporadic O +
AD O +
patients B-Species +
and O +
found O +
that O +
several O +
miRNAs O +
potentially O +
involved O +
in O +
the O +
regulation O +
of O +
APP O +
and O +
BACE1 O +
expression O +
appeared O +
to O +
be O +
decreased O +
in O +
diseased O +
brain O -
. O +

We O +
show O +
here O +
that O +
miR-29a O -
, O +
-29b-1 O -
, O +
and O +
-9 O +
can O +
regulate O +
BACE1 O +
expression O +
in O +
vitro O -
. O +

The O +
miR-29a O -
/ O -
b-1 O +
cluster O +
was O +
significantly O +
( O -
and O +
AD O -
- O -
dementia O -
- O -
specific O -
) O +
decreased O +
in O +
AD O +
patients B-Species +
displaying O +
abnormally O +
high O +
BACE1 O +
protein O -
. O +

Similar O +
correlations O +
between O +
expression O +
of O +
this O +
cluster O +
and O +
BACE1 O +
were O +
found O +
during O +
brain O +
development O +
and O +
in O +
primary O +
neuronal O +
cultures O -
. O +

Finally O -
, O +
we O +
provide O +
evidence O +
for O +
a O +
potential O +
causal O +
relationship O +
between O +
miR-29a O -
/ O -
b-1 O +
expression O +
and O +
Abeta O +
generation O +
in O +
a O +
cell O +
culture O +
model O -
. O +

We O +
propose O +
that O +
loss O +
of O +
specific O +
miRNAs O +
can O +
contribute O +
to O +
increased O +
BACE1 O +
and O +
Abeta O +
levels O +
in O +
sporadic O +
AD O -
. O +

Taken O +
together O -
, O +
our O +
findings O +
indicate O +
that O +
miR-15b O +
regulates O +
cell O +
cycle O +
progression O +
in O +
glioma O +
cells O +
by O +
targeting O +
cell O +
cycle O -
- O -
related O +
molecules O -
. O +

Over O -
- O -
expression O +
of O +
miR-15b O +
resulted O +
in O +
cell O +
cycle O +
arrest O +
at O +
G0 O -
/ O -
G1 O +
phase O +
while O +
suppression O +
of O +
miR-15b O +
expression O +
resulted O +
in O +
a O +
decrease O +
of O +
cell O +
populations O +
in O +
G0 O -
/ O -
G1 O +
and O +
a O +
corresponding O +
increase O +
of O +
cell O +
populations O +
in O +
S O +
phase O -
. O +

We O +
further O +
showed O +
that O +
CCNE1 O +
( O -
encoding O +
cyclin O +
E1 O -
) O +
is O +
one O +
of O +
the O +
downstream O +
targets O +
of O +
miR-15b O -
. O +

We O +
have O +
recently O +
compared O +
the O +
miRNA O +
expression O +
profiles O +
between O +
normal O +
brain O +
and O +
glioma O +
tissues O +
from O +
Chinese O +
patients B-Species +
by O +
miRNA O +
microarray O +
and O +
identified O +
a O +
panel O +
of O +
differentially O +
expressed O +
miRNAs O -
. O +

Here O -
, O +
we O +
studied O +
the O +
function O +
of O +
one O +
miRNA O -
, O +
miR-15b O -
, O +
in O +
glioma O +
carcinogenesis O +
and O +
elucidated O +
its O +
downstream O +
targets O -
. O +

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
non O -
- O -
protein O -
- O -
coding O +
RNAs O +
that O +
function O +
as O +
post O -
- O -
transcriptional O +
gene O +
regulators O -
. O +

Recent O +
evidence O +
has O +
shown O +
that O +
miRNA O +
plays O +
a O +
pivotal O +
role O +
in O +
the O +
development O +
of O +
many O +
cancers O +
including O +
glioma O -
, O +
a O +
lethal O +
brain O +
cancer O -
. O +

MicroRNA-15b O +
regulates O +
cell O +
cycle O +
progression O +
by O +
targeting O +
cyclins O +
in O +
glioma O +
cells O -
. O +

Our O +
work O +
places O +
apl-1 O +
in O +
a O +
developmental O +
timing O +
pathway O +
and O +
may O +
provide O +
new O +
insights O +
into O +
the O +
time O -
- O -
dependent O +
progression O +
of O +
AD O -
. O +

Moreover O -
, O +
the O +
levels O +
of O +
the O +
apl-1 O +
transcription O +
are O +
modulated O +
by O +
the O +
activity O +
of O +
let-7 O +
family O +
microRNAs O -
. O +

apl-1 O +
expression O +
is O +
upregulated O +
during O +
the O +
last O +
larval O +
stage O +
in O +
hypodermal O +
seam O +
cells O +
which O +
is O +
transcriptionally O +
regulated O +
by O +
hbl-1 O -
, O +
lin-41 O +
and O +
lin-42 O -
. O +

On O +
the O +
other O +
hand O -
, O +
the O +
pathogenesis O +
of O +
amyloid O +
plaque O +
deposition O +
in O +
AD O +
is O +
thought O +
to O +
be O +
the O +
result O +
of O +
age O -
- O -
related O +
changes O +
with O +
unknown O +
mechanisms O -
. O +

Here O +
we O +
show O +
that O +
the O +
Caenorhabditis B-Species +
elegans I-Species +
homolog O +
of O +
APP O -
, O +
APP O -
- O -
like-1 O +
( O -
apl-1 O -
) O -
, O +
functions O +
with O +
and O +
is O +
under O +
the O +
control O +
of O +
molecules O +
regulating O +
developmental O +
progression O -
. O +

In O +
C. B-Species +
elegans I-Species -
, O +
the O +
timing O +
of O +
cell O +
fate O +
determination O +
is O +
controlled O +
by O +
the O +
heterochronic O +
genes O -
, O +
including O +
let-7 O +
microRNAs O -
. O +

C. B-Species +
elegans I-Species +
apl-1 O +
shows O +
significant O +
genetic O +
interactions O +
with O +
let-7 O +
family O +
microRNAs O +
and O +
let-7-targeted O +
heterochronic O +
genes O -
, O +
hbl-1 O -
, O +
lin-41 O +
and O +
lin-42 O -
. O +

The O +
expression O +
of O +
the O +
Alzheimer O -
's O +
amyloid O +
precursor O +
protein O -
- O -
like O +
gene O +
is O +
regulated O +
by O +
developmental O +
timing O +
microRNAs O +
and O +
their O +
targets O +
in O +
Caenorhabditis B-Species +
elegans I-Species -
. O +

Alzheimer O -
's O +
disease O +
( O -
AD O -
) O +
is O +
a O +
neurodegenerative O +
disorder O +
characterized O +
by O +
the O +
accumulation O +
of O +
dense O +
plaques O +
in O +
the O +
brain O -
, O +
resulting O +
in O +
progressive O +
dementia O -
. O +

A O +
major O +
plaque O +
component O +
is O +
the O +
beta O -
- O -
amyloid O +
peptide O -
, O +
which O +
is O +
a O +
cleavage O +
product O +
of O +
the O +
amyloid O +
precursor O +
protein O +
( O -
APP O -
) O -
. O +

Studies O +
of O +
dominant O +
inheritable O +
familial O +
AD O +
support O +
the O +
hypothesis O +
that O +
APP O +
is O +
critical O +
for O +
AD O +
development O -
. O +

We O +
will O +
describe O +
the O +
evidence O +
that O +
disruption O +
to O +
the O +
REST O +
regulon O +
brought O +
about O +
by O +
a O +
loss O +
of O +
interaction O +
between O +
REST O +
and O +
mutHtt O +
may O +
be O +
a O +
key O +
contributory O +
factor O +
in O +
the O +
widespread O +
dysregulation O +
of O +
gene O +
expression O +
in O +
HD O -
. O +

Transcriptional O +
dysregulation O +
of O +
coding O +
and O +
non O -
- O -
coding O +
genes O +
in O +
cellular O +
models O +
of O +
Huntington O -
's O +
disease O -
. O +

HD O +
( O -
Huntington O -
's O +
disease O -
) O +
is O +
a O +
late O +
onset O +
heritable O +
neurodegenerative O +
disorder O +
that O +
is O +
characterized O +
by O +
neuronal O +
dysfunction O +
and O +
death O -
, O +
particularly O +
in O +
the O +
cerebral O +
cortex O +
and O +
medium O +
spiny O +
neurons O +
of O +
the O +
striatum O -
. O +

This O +
is O +
followed O +
by O +
progressive O +
chorea O -
, O +
dementia O +
and O +
emotional O +
dysfunction O -
, O +
eventually O +
resulting O +
in O +
death O -
. O +

HD O +
is O +
caused O +
by O +
an O +
expanded O +
CAG O +
repeat O +
in O +
the O +
first O +
exon O +
of O +
the O +
HD O +
gene O +
that O +
results O +
in O +
an O +
abnormally O +
elongated O +
polyQ O +
( O -
polyglutamine O -
) O +
tract O +
in O +
its O +
protein O +
product O -
, O +
Htt O +
( O -
Huntingtin O -
) O -
. O +

Wild O -
- O -
type O +
Htt O +
is O +
largely O +
cytoplasmic O -
; O +
however O -
, O +
in O +
HD O -
, O +
proteolytic O +
N O -
- O -
terminal O +
fragments O +
of O +
Htt O +
form O +
insoluble O +
deposits O +
in O +
both O +
the O +
cytoplasm O +
and O +
nucleus O -
, O +
provoking O +
the O +
idea O +
that O +
mutHtt O +
( O -
mutant O +
Htt O -
) O +
causes O +
transcriptional O +
dysfunction O -
. O +

While O +
a O +
number O +
of O +
specific O +
transcription O +
factors O +
and O +
co O -
- O -
factors O +
have O +
been O +
proposed O +
as O +
mediators O +
of O +
mutHtt O +
toxicity O -
, O +
the O +
causal O +
relationship O +
between O +
these O +
Htt O -
/ O -
transcription O +
factor O +
interactions O +
and O +
HD O +
pathology O +
remains O +
unknown O -
. O +

Previous O +
work O +
has O +
highlighted O +
REST O +
[ O -
RE1 O +
( O -
repressor O +
element O +
1 O -
) O -
-silencing O +
transcription O +
factor O -
] O +
as O +
one O +
such O +
transcription O +
factor O -
. O +

Recent O +
evidence O +
has O +
also O +
shown O +
that O +
REST O +
regulates O +
transcription O +
of O +
regulatory O +
miRNAs O +
( O -
microRNAs O -
) O -
, O +
many O +
of O +
which O +
are O +
known O +
to O +
regulate O +
neuronal O +
gene O +
expression O +
and O +
are O +
dysregulated O +
in O +
HD O -
. O +
Thus O +
repression O +
of O +
miRNAs O +
constitutes O +
a O +
second O -
, O +
indirect O +
mechanism O +
by O +
which O +
REST O +
can O +
alter O +
the O +
neuronal O +
transcriptome O +
in O +
HD O -
. O +

Many O +
of O +
its O +
direct O +
target O +
genes O +
are O +
known O +
or O +
suspected O +
to O +
have O +
a O +
role O +
in O +
HD O +
pathogenesis O -
, O +
including O +
BDNF O +
( O -
brain O -
- O -
derived O +
neurotrophic O +
factor O -
) O -
. O +

REST O +
is O +
a O +
master O +
regulator O +
of O +
neuronal O +
genes O -
, O +
repressing O +
their O +
expression O -
. O +

An O +
understanding O +
of O +
how O +
microRNAs O +
influence O +
the O +
body O -
's O +
response O +
to O +
certain O +
drugs O +
and O +
how O +
these O +
affect O +
the O +
expression O +
of O +
microRNAs O -
, O +
will O +
be O +
of O +
key O +
importance O +
in O +
developing O +
drugs O +
with O +
greater O +
safety O +
and O +
efficacy O -
. O +

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
short O +
non O -
- O -
coding O +
RNAs O +
involved O +
in O +
post O -
- O -
transcriptional O +
regulation O +
of O +
gene O +
expression O -
. O +

Since O +
the O +
discovery O +
of O +
the O +
first O +
miRNA O +
gene O +
lin-4 O +
in O +
C. B-Species +
elegans I-Species -
, O +
over O +
500 O +
miRNAs O +
have O +
been O +
identified O +
in O +
humans B-Species +
and O +
the O +
list O +
is O +
growing O -
. O +

Their O +
biological O +
importance O -
, O +
initially O +
demonstrated O +
in O +
cancer O -
, O +
was O +
also O +
more O +
recently O +
discovered O +
in O +
many O +
other O +
pathologies O +
like O +
Alzheimer O -
's O +
disease O -
, O +
Parkinson O -
's O +
disease O -
, O +
viral O +
infections O -
, O +
diabetes O -
, O +
and O +
myopathies O -
. O +

In O +
the O +
present O +
review O +
we O +
will O +
summarize O +
miRNA O +
profiling O +
studies O +
in O +
human B-Species +
diseases O +
and O +
discuss O +
the O +
newly O +
discovered O +
link O +
between O +
microRNAs O +
and O +
drug O +
response O -
. O +

MicroRNAs O +
in O +
diseases O +
and O +
drug O +
response O -
. O +

Role O +
of O +
epigenetic O +
effectors O +
in O +
maintenance O +
of O +
the O +
long O -
- O -
term O +
persistent O +
bystander O +
effect O +
in O +
spleen O +
in O +
vivo O -
. O +

These O +
cancers O +
are O +
thought O +
to O +
be O +
linked O +
to O +
indirect O +
radiation O -
- O -
induced O +
bystander O +
effect O -
. O +

Radiation O +
therapy O +
is O +
a O +
primary O +
treatment O +
modality O +
for O +
brain O +
tumors O -
, O +
yet O +
it O +
has O +
been O +
linked O +
to O +
the O +
increased O +
incidence O +
of O +
secondary O -
, O +
post O -
- O -
radiation O +
therapy O +
cancers O -
. O +

Recent O +
evidence O +
suggests O +
that O +
bystander O +
effect O +
may O +
be O +
epigenetic O +
in O +
nature O -
; O +
however O -
, O +
characterization O +
of O +
epigenetic O +
mechanisms O +
involved O +
in O +
bystander O +
effect O +
generation O +
and O +
its O +
long O -
- O -
term O +
persistence O +
has O +
yet O +
to O +
be O +
defined O -
. O +

Bystander O +
effect O +
occurs O +
when O +
irradiated O +
cells O +
communicate O +
damage O +
to O +
nearby O -
, O +
non O -
- O -
irradiated O +
' O -
bystander O -
' O +
cells O -
, O +
ultimately O +
contributing O +
to O +
genome O +
destabilization O +
in O +
the O +
non O -
- O -
exposed O +
cells O -
. O +

We O +
found O +
that O +
localized O +
cranial O +
radiation O +
exposure O +
led O +
to O +
the O +
induction O +
of O +
bystander O +
effect O +
in O +
lead O -
- O -
shielded O -
, O +
distant O +
spleen O +
tissue O -
. O +

To O +
investigate O +
the O +
possibility O +
that O +
localized O +
X O -
- O -
ray O +
irradiation O +
induces O +
persistent O +
bystander O +
effects O +
in O +
distant O +
tissue O -
, O +
we O +
monitored O +
the O +
induction O +
of O +
epigenetic O +
changes O +
( O -
i.e. O +
alterations O +
in O +
DNA O +
methylation O -
, O +
histone O +
methylation O +
and O +
microRNA O +
( O -
miRNA O -
) O +
expression O -
) O +
in O +
the O +
rat B-Species +
spleen O +
tissue O +
24 O +
h O +
and O +
7 O +
months O +
after O +
localized O +
cranial O +
exposure O +
to O +
20 O +
Gy O +
of O +
X O -
- O -
rays O -
. O +

Further O -
, O +
irradiation O +
significantly O +
altered O +
expression O +
of O +
miR-194 O -
, O +
a O +
miRNA O +
putatively O +
targeting O +
both O +
DNA O +
methyltransferase-3a O +
and O +
MeCP2 O -
. O +

Specifically O -
, O +
this O +
exposure O +
caused O +
the O +
profound O +
epigenetic O +
dysregulation O +
in O +
the O +
bystander O +
spleen O +
tissue O +
that O +
manifested O +
as O +
a O +
significant O +
loss O +
of O +
global O +
DNA O +
methylation O -
, O +
alterations O +
in O +
methylation O +
of O +
long O +
interspersed O +
nucleotide O +
element-1 O +
( O -
LINE-1 O -
) O +
retrotransposable O +
elements O +
and O +
down O -
- O -
regulation O +
of O +
DNA O +
methyltransferases O +
and O +
methyl O -
- O -
binding O +
protein O +
methyl O +
CpG O +
binding O +
protein O +
2 O +
( O -
MeCP2 O -
) O -
. O +

This O +
study O +
is O +
the O +
first O +
to O +
report O +
conclusive O +
evidence O +
of O +
the O +
long O -
- O -
term O +
persistence O +
of O +
bystander O +
effects O +
in O +
radiation O +
carcinogenesis O +
target O +
organ O +
( O -
spleen O -
) O +
upon O +
localized O +
distant O +
exposure O +
using O +
the O +
doses O +
comparable O +
with O +
those O +
used O +
for O +
clinical O +
brain O +
tumor O +
treatments O -
. O +

Extensive O +
modulation O +
of O +
a O +
set O +
of O +
microRNAs O +
in O +
primary O +
glioblastoma O -
. O +

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
short O +
non O -
- O -
coding O +
RNA O +
molecules O +
playing O +
regulatory O +
roles O +
in O +
animals O +
and O +
plants O +
by O +
repressing O +
translation O +
or O +
cleaving O +
RNA O +
transcripts O -
. O +

The O +
specific O +
modulation O +
of O +
several O +
microRNAs O +
has O +
been O +
recently O +
associated O +
to O +
some O +
forms O +
of O +
human B-Species +
cancer O -
, O +
suggesting O +
that O +
these O +
short O +
molecules O +
may O +
represent O +
a O +
new O +
class O +
of O +
genes O +
involved O +
in O +
oncogenesis O -
. O +

In O +
our O +
study O -
, O +
we O +
examined O +
by O +
microarray O +
the O +
global O +
expression O +
levels O +
of O +
245 O +
microRNAs O +
in O +
glioblastoma O +
multiforme O -
, O +
the O +
most O +
frequent O +
and O +
malignant O +
of O +
primary O +
brain O +
tumors O -
. O +

The O +
analysis O +
of O +
both O +
glioblastoma O +
tissues O +
and O +
glioblastoma O +
cell O +
lines O +
allowed O +
us O +
to O +
identify O +
a O +
group O +
of O +
microRNAs O +
whose O +
expression O +
is O +
significantly O +
altered O +
in O +
this O +
tumor O -
. O +

The O +
most O +
interesting O +
results O +
came O +
from O +
miR-221 O -
, O +
strongly O +
up O -
- O -
regulated O +
in O +
glioblastoma O +
and O +
from O +
a O +
set O +
of O +
brain O -
- O -
enriched O +
miRNAs O -
, O +
miR-128 O -
, O +
miR-181a O -
, O +
miR-181b O -
, O +
and O +
miR-181c O -
, O +
which O +
are O +
down O -
- O -
regulated O +
in O +
glioblastoma O -
. O +

Pharmacologic O +
and O +
genetic O +
inhibition O +
of O +
p53 O +
corroborated O +
the O +
hypothesis O +
that O +
pre O -
- O -
miR-630 O +
( O -
but O +
not O +
pre O -
- O -
miR-181a O -
) O +
blocks O +
the O +
upstream O +
signaling O +
pathways O +
that O +
are O +
ignited O +
by O +
DNA O +
damage O +
and O +
converge O +
on O +
p53 O +
activation O -
. O +

Pre O -
- O -
miR-630 O +
arrested O +
A549 O +
cells O +
in O +
the O +
G0-G1 O +
phase O +
of O +
the O +
cell O +
cycle O -
, O +
correlating O +
with O +
increased O +
levels O +
of O +
the O +
cell O +
cycle O +
inhibitor O +
p27 O -
( O -
Kip1 O -
) O +
as O +
well O +
as O +
with O +
reduced O +
proliferation O +
rates O +
and O +
resulting O +
in O +
greatly O +
diminished O +
sensitivity O +
of O +
A549 O +
cells O +
to O +
the O +
late O +
S O -
- O -
G2-M O +
cell O +
cycle O +
arrest O +
mediated O +
by O +
CDDP O -
. O +

Altogether O -
, O +
these O +
results O +
identify O +
miR-181a O +
and O +
miR-630 O +
as O +
novel O +
modulators O +
of O +
the O +
CDDP O +
response O +
in O +
NSCLC O -
. O +

The O +
corresponding O +
synthetic O +
miRNA O +
precursors O +
( O -
pre O -
- O -
miRNAs O -
) O +
per O +
se O +
were O +
not O +
lethal O +
when O +
transfected O +
into O +
A549 O +
cells O +
yet O +
affected O +
cell O +
death O +
induction O +
by O +
CDDP O -
, O +
C2-ceramide O -
, O +
cadmium O -
, O +
etoposide O -
, O +
and O +
mitoxantrone O +
in O +
an O +
inducer O -
- O -
specific O +
fashion O -
. O +

Whereas O +
synthetic O +
miRNA O +
inhibitors O +
( O -
anti O -
- O -
miRNAs O -
) O +
targeting O +
miR-181a O +
and O +
miR-630 O +
failed O +
to O +
modulate O +
the O +
response O +
of O +
A549 O +
to O +
CDDP O -
, O +
pre O -
- O -
miR-181a O +
and O +
pre O -
- O -
miR-630 O +
enhanced O +
and O +
reduced O +
CDDP O -
- O -
triggered O +
cell O +
death O -
, O +
respectively O -
. O +

Pre O -
- O -
miR-181a O +
and O +
pre O -
- O -
miR-630 O +
consistently O +
modulated O +
mitochondrial O -
/ O -
postmitochondrial O +
steps O +
of O +
the O +
intrinsic O +
pathway O +
of O +
apoptosis O -
, O +
including O +
Bax O +
oligomerization O -
, O +
mitochondrial O +
transmembrane O +
potential O +
dissipation O -
, O +
and O +
the O +
proteolytic O +
maturation O +
of O +
caspase-9 O +
and O +
caspase-3 O -
. O +

In O +
addition O -
, O +
pre O -
- O -
miR-630 O +
blocked O +
early O +
manifestations O +
of O +
the O +
DNA O +
damage O +
response O -
, O +
including O +
the O +
phosphorylation O +
of O +
the O +
ataxia O -
- O -
telangiectasia O +
mutated O +
( O -
ATM O -
) O +
kinase O +
and O +
of O +
two O +
ATM O +
substrates O -
, O +
histone O +
H2AX O +
and O +
p53 O -
. O +

miR-181a O +
and O +
miR-630 O +
regulate O +
cisplatin O -
- O -
induced O +
cancer O +
cell O +
death O -
. O +

MicroRNAs O +
( O -
miRNA O -
) O +
are O +
noncoding O +
RNAs O +
that O +
regulate O +
multiple O +
cellular O +
processes O -
, O +
including O +
proliferation O +
and O +
apoptosis O -
. O +

We O +
used O +
microarray O +
technology O +
to O +
identify O +
miRNAs O +
that O +
were O +
upregulated O +
by O +
non O -
- O -
small O +
cell O +
lung O +
cancer O +
( O -
NSCLC O -
) O +
A549 O +
cells O +
in O +
response O +
to O +
cisplatin O +
( O -
CDDP O -
) O -
. O +

Although O +
microRNAs O +
are O +
being O +
extensively O +
studied O +
for O +
their O +
involvement O +
in O +
cancer O +
and O +
development O -
, O +
little O +
is O +
known O +
about O +
their O +
roles O +
in O +
Alzheimer O -
's O +
disease O +
( O -
AD O -
) O -
. O +

Joint O +
genome O -
- O -
wide O +
profiling O +
of O +
miRNA O +
and O +
mRNA O +
expression O +
in O +
Alzheimer O -
's O +
disease O +
cortex O +
reveals O +
altered O +
miRNA O +
regulation O -
. O +

These O +
data O +
provided O +
the O +
unique O +
opportunity O +
to O +
study O +
the O +
relationship O +
between O +
miRNA O +
and O +
mRNA O +
expression O +
in O +
normal O +
and O +
AD O +
brains O -
. O +

In O +
this O +
study O -
, O +
we O +
used O +
microarrays O +
for O +
the O +
first O +
joint O +
profiling O +
and O +
analysis O +
of O +
miRNAs O +
and O +
mRNAs O +
expression O +
in O +
brain O +
cortex O +
from O +
AD O +
and O +
age O -
- O -
matched O +
control O +
subjects O -
. O +

Comparative O +
analysis O +
with O +
independent O +
cancer O +
datasets O +
showed O +
that O +
such O +
miRNA O -
- O -
mRNA O +
expression O +
correlations O +
are O +
not O +
static O -
, O +
but O +
rather O +
context O -
- O -
dependent O -
. O +

Using O +
a O +
non O -
- O -
parametric O +
analysis O -
, O +
we O +
showed O +
that O +
the O +
levels O +
of O +
many O +
miRNAs O +
can O +
be O +
either O +
positively O +
or O +
negatively O +
correlated O +
with O +
those O +
of O +
their O +
target O +
mRNAs O -
. O +

Our O +
results O +
demonstrate O +
a O +
robust O +
relationship O +
between O +
the O +
levels O +
of O +
miRNAs O +
and O +
those O +
of O +
their O +
targets O +
in O +
the O +
brain O -
. O +

Subsequently O -
, O +
we O +
identified O +
a O +
large O +
set O +
of O +
miRNA O -
- O -
mRNA O +
associations O +
that O +
are O +
changed O +
in O +
AD O +
versus O +
control O -
, O +
highlighting O +
AD O -
- O -
specific O +
changes O +
in O +
the O +
miRNA O +
regulatory O +
system O -
. O +

This O +
has O +
implications O +
in O +
the O +
study O +
of O +
the O +
molecular O +
pathology O +
of O +
AD O -
, O +
as O +
well O +
as O +
miRNA O +
biology O +
in O +
general O -
. O +

In O +
this O +
review O -
, O +
we O +
focus O +
on O +
studies O +
addressing O +
the O +
role O +
of O +
various O +
microRNAs O +
in O +
heart O -
, O +
muscle O -
, O +
liver O -
, O +
pancreas O -
, O +
central O +
nervous O +
system O -
, O +
and O +
hematopoiesis O -
. O +

Large O +
numbers O +
and O +
quantities O +
of O +
different O -
, O +
small O +
RNA O +
molecules O +
are O +
present O +
in O +
the O +
cytoplasm O +
of O +
animal O +
and O +
plant O +
cells O -
. O +

MicroRNAs O +
in O +
organogenesis O +
and O +
disease O -
. O +

Since O +
their O +
discovery O +
in O +
the O +
1990s O +
a O +
multitude O +
of O +
basic O +
information O +
has O +
accumulated O -
, O +
which O +
has O +
identified O +
their O +
function O +
in O +
post O -
- O -
transcriptional O +
control O -
, O +
either O +
via O +
degradation O +
or O +
translational O +
inhibition O +
of O +
target O +
mRNAs O -
. O +

One O +
subclass O +
of O +
these O +
molecules O +
is O +
represented O +
by O +
the O +
noncoding O +
microRNAs O -
. O +

MicroRNA O +
expression O +
profiles O +
are O +
highly O +
dynamic O +
during O +
embryonic O +
development O +
and O +
in O +
adulthood O -
. O +

This O +
function O +
is O +
in O +
most O +
of O +
the O +
cases O +
a O +
finetuning O +
of O +
gene O +
expression O -
, O +
working O +
in O +
parallel O +
with O +
transcriptional O +
regulatory O +
processes O -
. O +

Evidence O +
from O +
gain- O +
and O +
loss O -
- O -
of O +
function O +
studies O +
indicates O +
roles O +
for O +
microRNAs O +
in O +
pathophysiologic O +
states O +
including O +
cardiac O +
hypertrophy O -
, O +
muscle O +
dystrophy O -
, O +
hepatitis O +
infection O -
, O +
diabetes O -
, O +
Parkinson O +
syndrome O -
, O +
hematological O +
malignancies O +
and O +
other O +
types O +
of O +
cancer O -
. O +

Misexpression O +
of O +
microRNAs O +
can O +
perturb O +
embryogenesis O -
, O +
organogenesis O -
, O +
tissue O +
homeostasis O +
and O +
the O +
cell O +
cycle O -
. O +

BACKGROUND O -
: O +
The O +
aberrant O +
expression O +
of O +
microRNAs O +
( O -
miRNAs O -
) O +
is O +
associated O +
with O +
a O +
variety O +
of O +
diseases O +
including O +
cancers O -
. O +

In O +
the O +
present O +
study O -
, O +
the O +
miRNA O +
expression O +
profile O +
was O +
examined O +
in O +
astrocytoma O -
, O +
a O +
malignant O +
and O +
prevalent O +
intracranial O +
tumour O +
in O +
adults O -
. O +

METHODS O -
: O +
We O +
screened O +
the O +
expression O +
profile O +
of O +
200 O +
miRNAs O +
in O +
a O +
training O +
sample O +
set O +
consisting O +
of O +
84 O +
astrocytoma O +
samples O +
and O +
20 O +
normal O +
adjacent O +
tissue O +
( O -
NAT O -
) O +
samples O +
using O +
the O +
method O +
of O +
stem O -
- O -
loop O +
quantitative O +
RT O -
- O -
PCR O -
. O +

The O +
significantly O +
altered O +
miRNAs O +
were O +
validated O +
in O +
another O +
independent O +
sample O +
set O +
consisting O +
of O +
40 O +
astrocytoma O +
samples O +
and O +
40 O +
NAT O +
samples O -
. O +

The O +
correlation O +
of O +
the O +
miRNA O +
levels O +
with O +
survival O +
in O +
astrocytoma O +
samples O +
was O +
estimated O +
by O +
performing O +
Kaplan O -
- O -
Meier O +
survival O +
analysis O +
and O +
univariate O -
/ O -
multivariate O +
Cox O +
proportional O +
hazard O +
regression O +
analysis O -
. O +

RESULTS O -
: O +
After O +
a O +
two O -
- O -
phase O +
selection O +
and O +
validation O +
process O -
, O +
seven O +
miRNAs O +
were O +
found O +
to O +
have O +
a O +
significantly O +
different O +
expression O +
profile O +
in O +
astrocytoma O +
samples O +
upon O +
comparison O +
to O +
the O +
NAT O +
samples O -
. O +

Unsupervised O +
clustering O +
analysis O +
further O +
revealed O +
the O +
great O +
potential O +
of O +
the O +
7-miRNA O +
profile O +
to O +
differentiate O +
between O +
tumours O +
and O +
normal O +
brain O +
tissues O -
. O +

The O +
down O -
- O -
regulation O +
of O +
hsa O -
- O -
miR-137 O +
in O +
astrocytomas O +
was O +
shown O +
to O +
be O +
associated O +
with O +
advanced O +
clinical O +
stages O +
of O +
this O +
disease O -
. O +

The O +
use O +
of O +
hsa O -
- O -
miR-21 O -
, O +
hsa O -
- O -
miR-181b O +
and O +
hsa O -
- O -
miR-106a O +
as O +
prognostic O +
indicators O +
of O +
astrocytoma O -
. O +

Using O +
Kaplan O -
- O -
Meier O +
survival O +
analysis O +
we O +
showed O +
that O +
low O +
expression O +
of O +
hsa O -
- O -
miR-181b O +
or O +
hsa O -
- O -
miR-106a O -
, O +
or O +
high O +
expression O +
of O +
hsa O -
- O -
miR-21 O +
was O +
significantly O +
associated O +
with O +
poor O +
patient B-Species +
survival O -
. O +

CONCLUSIONS O -
: O +
Our O +
results O +
suggest O +
a O +
great O +
potential O +
for O +
the O +
use O +
of O +
miRNA O +
profiling O +
as O +
a O +
powerful O +
diagnostic O +
and O +
prognostic O +
marker O +
in O +
defining O +
the O +
signature O +
of O +
astrocytomas O +
and O +
in O +
predicting O +
the O +
post O -
- O -
surgical O +
outcome O -
. O +

Moreover O -
, O +
Cox O +
proportional O +
hazard O +
regression O +
analysis O +
revealed O +
that O +
this O +
prognostic O +
impact O +
was O +
independent O +
of O +
other O +
clinicopathological O +
factors O -
. O +

Phosphodiesterase-4D O +
knock O -
- O -
out O +
and O +
RNA O +
interference O -
- O -
mediated O +
knock O -
- O -
down O +
enhance O +
memory O +
and O +
increase O +
hippocampal O +
neurogenesis O +
via O +
increased O +
cAMP O +
signaling O -
. O +

Phosphodiesterase-4 O +
( O -
PDE4 O -
) O +
plays O +
an O +
important O +
role O +
in O +
mediating O +
memory O +
via O +
the O +
control O +
of O +
intracellular O +
cAMP O +
signaling O -
; O +
inhibition O +
of O +
PDE4 O +
enhances O +
memory O -
. O +

However O -
, O +
development O +
of O +
PDE4 O +
inhibitors O +
as O +
memory O +
enhancers O +
has O +
been O +
hampered O +
by O +
their O +
major O +
side O +
effect O +
of O +
emesis O -
. O +

PDE4 O +
has O +
four O +
subtypes O +
( O -
PDE4A O -
- O -
D O -
) O +
consisting O +
of O +
25 O +
splice O +
variants O -
. O +

Mice B-Species +
deficient O +
in O +
PDE4D O +
displayed O +
memory O +
enhancement O +
in O +
radial O +
arm O +
maze O -
, O +
water O +
maze O -
, O +
and O +
object O +
recognition O +
tests O -
. O +

These O +
effects O +
were O +
mimicked O +
by O +
repeated O +
treatment O +
with O +
rolipram O +
in O +
wild O -
- O -
type O +
mice B-Species -
. O +

In O +
addition O -
, O +
similarly O +
as O +
rolipram O -
- O -
treated O +
wild O -
- O -
type O +
mice B-Species -
, O +
PDE4D O -
- O -
deficient O +
mice B-Species +
also O +
displayed O +
increased O +
hippocampal O +
neurogenesis O +
and O +
phosphorylated O +
cAMP O +
response O +
element O -
- O -
binding O +
protein O +
( O -
pCREB O -
) O -
. O +

Furthermore O -
, O +
microinfusion O +
of O +
lentiviral O +
vectors O +
that O +
contained O +
microRNAs O +
( O -
miRNAs O -
) O +
targeting O +
long O -
- O -
form O +
PDE4D O +
isoforms O +
into O +
bilateral O +
dentate O +
gyri O +
of O +
the O +
mouse B-Species +
hippocampus O +
downregulated O +
PDE4D4 O +
and O +
PDE4D5 O -
, O +
enhanced O +
memory O -
, O +
and O +
increased O +
hippocampal O +
neurogenesis O +
and O +
pCREB O -
. O +

Finally O -
, O +
while O +
rolipram O +
and O +
PDE4D O +
deficiency O +
shortened O +
α2 O +
adrenergic O +
receptor O -
- O -
mediated O +
anesthesia O -
, O +
a O +
surrogate O +
measure O +
of O +
emesis O -
, O +
miRNA O -
- O -
mediated O +
PDE4D O +
knock O -
- O -
down O +
in O +
the O +
hippocampus O +
did O +
not O -
. O +

The O +
present O +
results O +
suggest O +
that O +
PDE4D O -
, O +
in O +
particular O +
long O -
- O -
form O +
PDE4D O -
, O +
plays O +
a O +
critical O +
role O +
in O +
the O +
mediation O +
of O +
memory O +
and O +
hippocampal O +
neurogenesis O -
, O +
which O +
are O +
mediated O +
by O +
cAMP O -
/ O -
CREB O +
signaling O -
; O +
reduced O +
expression O +
of O +
PDE4D O -
, O +
or O +
at O +
least O +
PDE4D4 O +
and O +
PDE4D5 O -
, O +
in O +
the O +
hippocampus O +
enhances O +
memory O +
but O +
appears O +
not O +
to O +
cause O +
emesis O -
. O +

These O +
novel O +
findings O +
will O +
aid O +
in O +
the O +
development O +
of O +
PDE4 O +
subtype- O +
or O +
variant O -
- O -
selective O +
inhibitors O +
for O +
treatment O +
of O +
disorders O +
involving O +
impaired O +
cognition O -
, O +
including O +
Alzheimer O -
's O +
disease O -
. O +

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
known O +
to O +
influence O +
many O +
important O +
cellular O +
processes O -
, O +
including O +
proliferation O -
, O +
apoptosis O -
, O +
neurogenesis O -
, O +
angiogenesis O -
, O +
and O +
morphogenesis O -
, O +
all O +
processes O +
that O +
are O +
involved O +
in O +
TBI O +
pathophysiology O -
. O +

Multiple O +
cellular O -
, O +
molecular O -
, O +
and O +
biochemical O +
changes O +
contribute O +
to O +
outcome O +
after O +
traumatic O +
brain O +
injury O +
( O -
TBI O -
) O -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
used O +
a O +
microarray O +
platform O +
to O +
examine O +
changes O +
in O +
the O +
hippocampal O +
expression O +
levels O +
of O +
444 O +
verified O +
rodent O +
miRNAs O +
at O +
3 O +
and O +
24 O +
hr O +
after O +
controlled O +
cortical O +
impact O +
injury O -
. O +

However O -
, O +
it O +
has O +
not O +
yet O +
been O +
determined O +
whether O +
miRNA O +
expression O +
is O +
altered O +
after O +
TBI O -
. O +

We O +
extended O +
the O +
microarray O +
findings O +
using O +
quantitative O +
polymerase O +
chain O +
reaction O +
analysis O +
for O +
a O +
subset O +
of O +
the O +
miRNAs O +
with O +
altered O +
expression O +
levels O +
( O -
miR-107 O -
, O +
-130a O -
, O +
-223 O -
, O +
-292 O -
- O -
5p O -
, O +
-433 O -
- O -
3p O -
, O +
-451 O -
, O +
-541 O -
, O +
and O +
-711 O -
) O -
. O +

Our O +
analysis O +
found O +
50 O +
miRNAs O +
exhibited O +
decreased O +
expression O +
levels O +
and O +
35 O +
miRNAs O +
exhibited O +
increased O +
expression O +
levels O +
in O +
the O +
hippocampus O +
after O +
injury O -
. O +

Our O +
results O +
indicate O +
that O +
multiple O +
protein O +
targets O +
and O +
biological O +
processes O +
involved O +
in O +
TBI O +
pathophysiology O +
may O +
be O +
regulated O +
by O +
miRNAs O -
. O +

Bioinformatic O +
analysis O +
of O +
the O +
predicted O +
targets O +
for O +
this O +
panel O +
of O +
miRNAs O +
revealed O +
an O +
overrepresentation O +
of O +
proteins O +
involved O +
in O +
several O +
biological O +
processes O +
and O +
functions O +
known O +
to O +
be O +
initiated O +
after O +
injury O -
, O +
including O +
signal O +
transduction O -
, O +
transcriptional O +
regulation O -
, O +
proliferation O -
, O +
and O +
differentiation O -
. O +

Traumatic O +
brain O +
injury O +
alters O +
expression O +
of O +
hippocampal O +
microRNAs O -
: O +
potential O +
regulators O +
of O +
multiple O +
pathophysiological O +
processes O -
. O +

Potent O -
, O +
allele O +
selective O +
inhibition O +
of O +
HTT O +
by O +
mismatched O +
RNAs O +
provides O +
a O +
new O +
option O +
for O +
developing O +
HD O +
therapeutics O -
. O +

Switching O +
the O +
RNAi O +
mechanism O +
toward O +
that O +
used O +
by O +
miRNAs O +
by O +
introducing O +
one O +
or O +
more O +
mismatched O +
bases O +
into O +
these O +
duplex O +
RNAs O +
leads O +
to O +
potent O +
( O -
< O -
10 O +
nM O -
) O +
and O +
highly O +
selective O +
( O -
> O -
30-fold O +
relative O +
to O +
wild O -
- O -
type O +
HTT O -
) O +
inhibition O +
of O +
mutant O +
HTT O +
expression O +
in O +
patient B-Species -
- O -
derived O +
cells O -
. O +

We O +
observe O +
that O +
fully O +
complementary O +
duplex O +
RNAs O +
targeting O +
the O +
expanded O +
CAG O +
repeat O +
within O +
HTT O +
mRNA O +
block O +
expression O +
of O +
both O +
alleles O -
. O +

An O +
ideal O +
silencing O +
agent O +
would O +
block O +
expression O +
of O +
mutant O +
HTT O +
while O +
leaving O +
expression O +
of O +
wild O -
- O -
type O +
HTT O +
intact O -
. O +

Inhibiting O +
expression O +
of O +
huntingtin O +
( O -
HTT O -
) O +
protein O +
is O +
a O +
promising O +
strategy O +
for O +
treating O +
Huntington O -
's O +
disease O +
( O -
HD O -
) O -
, O +
but O +
indiscriminant O +
inhibition O +
of O +
both O +
wild O -
- O -
type O +
and O +
mutant O +
alleles O +
may O +
lead O +
to O +
toxicity O -
. O +

Allele O -
- O -
selective O +
inhibition O +
of O +
huntingtin O +
expression O +
by O +
switching O +
to O +
an O +
miRNA O -
- O -
like O +
RNAi O +
mechanism O -
. O +

Thus O +
we O +
have O +
identified O +
a O +
miRNA O +
expression O +
signature O +
that O +
can O +
predict O +
GBM O +
patient B-Species +
survival O -
. O +

Cox O +
multivariate O +
analysis O +
with O +
patient B-Species +
age O +
as O +
a O +
covariate O +
on O +
the O +
entire O +
patient B-Species +
set O +
identified O +
risk O +
score O +
based O +
on O +
the O +
10 O +
miRNA O +
expression O +
signature O +
to O +
be O +
an O +
independent O +
predictor O +
of O +
patient B-Species +
survival O +
( O -
HR O +
= O +
1.120 O -
; O +
95 O -
% O +
CI O +
= O +
1.04 O -
- O -
1.20 O -
; O +
p O +
= O +
0.003 O -
) O -
. O +

These O +
findings O +
may O +
have O +
implications O +
in O +
the O +
understanding O +
of O +
gliomagenesis O -
, O +
development O +
of O +
targeted O +
therapy O +
and O +
selection O +
of O +
high O +
risk O +
cancer O +
patients B-Species +
for O +
adjuvant O +
therapy O -
. O +

GBM O +
patients B-Species +
with O +
high O +
risk O +
scores O +
had O +
overall O +
poor O +
survival O +
compared O +
to O +
the O +
patients B-Species +
with O +
low O +
risk O +
scores O -
. O +

Overall O +
survival O +
among O +
the O +
entire O +
patient B-Species +
set O +
was O +
35.0 O -
% O +
at O +
2 O +
years O -
, O +
21.5 O -
% O +
at O +
3 O +
years O -
, O +
18.5 O -
% O +
at O +
4 O +
years O +
and O +
11.8 O -
% O +
at O +
5 O +
years O +
in O +
the O +
low O +
risk O +
group O -
, O +
versus O +
11.0 O -
% O -
, O +
5.5 O -
% O -
, O +
0.0 O +
and O +
0.0 O -
% O +
respectively O +
in O +
the O +
high O +
risk O +
group O +
( O -
HR O +
= O +
2.0 O -
; O +
95 O -
% O +
CI O +
= O +
1.4 O -
- O -
2.8 O -
; O +
p<0.0001 O -
) O -
. O +

To O +
identify O +
a O +
microRNA O +
( O -
miRNA O -
) O +
expression O +
signature O +
that O +
can O +
predict O +
GBM O +
patient B-Species +
survival O -
, O +
we O +
analyzed O +
the O +
miRNA O +
expression O +
data O +
of O +
GBM O +
patients B-Species +
( O -
n O +
= O +
222 O -
) O +
derived O +
from O +
The O +
Cancer O +
Genome O +
Atlas O +
( O -
TCGA O -
) O +
dataset O -
. O +

We O +
divided O +
the O +
patients B-Species +
randomly O +
into O +
training O +
and O +
testing O +
sets O +
with O +
equal O +
number O +
in O +
each O +
group O -
. O +

A O +
Ten O -
- O -
microRNA O +
Expression O +
Signature O +
Predicts O +
Survival O +
in O +
Glioblastoma O -
. O +

Glioblastoma O +
( O -
GBM O -
) O +
is O +
the O +
most O +
common O +
and O +
aggressive O +
primary O +
brain O +
tumor O +
with O +
very O +
poor O +
patient B-Species +
median O +
survival O -
. O +

Of O +
these O +
10 O +
miRNAs O -
, O +
7 O +
were O +
found O +
to O +
be O +
risky O +
miRNAs O +
and O +
3 O +
were O +
found O +
to O +
be O +
protective O -
. O +

This O +
signature O +
was O +
independently O +
validated O +
in O +
the O +
testing O +
set O +
( O -
HR O +
= O +
1.7 O -
; O +
95 O -
% O +
CI O +
= O +
1.1 O -
- O -
2.8 O -
; O +
p O +
= O +
0.002 O -
) O -
. O +

We O +
identified O +
10 O +
significant O +
miRNAs O +
using O +
Cox O +
regression O +
analysis O +
on O +
the O +
training O +
set O +
and O +
formulated O +
a O +
risk O +
score O +
based O +
on O +
the O +
expression O +
signature O +
of O +
these O +
miRNAs O +
that O +
segregated O +
the O +
patients B-Species +
into O +
high O +
and O +
low O +
risk O +
groups O +
with O +
significantly O +
different O +
survival O +
times O +
( O -
hazard O +
ratio O +
[ O -
HR O -
] O +
= O +
2.4 O -
; O +
95 O -
% O +
CI O +
= O +
1.4 O -
- O -
3.8 O -
; O +
p<0.0001 O -
) O -
. O +

Microarray O +
analysis O +
showed O +
differential O +
expression O +
of O +
multiple O +
miRNAs O +
in O +
HIVE O +
compared O +
to O +
control O +
brains O -
. O +

Target O +
prediction O +
and O +
gene O +
ontology O +
enrichment O +
analysis O +
disclosed O +
targeting O +
of O +
several O +
gene O +
families O -
/ O -
biological O +
processes O +
by O +
differentially O +
expressed O +
miRNAs O +
( O -
DEMs O -
) O -
, O +
with O +
cell O +
death O -
- O -
related O +
genes O -
, O +
including O +
caspase-6 O -
, O +
showing O +
a O +
bias O +
toward O +
down O -
- O -
regulated O +
DEMs O -
. O +

Consistent O +
with O +
the O +
miRNA O +
data O -
, O +
HIVE O +
brains O +
exhibited O +
higher O +
levels O +
of O +
caspase-6 O +
transcripts O +
compared O +
with O +
control O +
patients B-Species -
. O +

Immunohistochemical O +
analysis O +
showed O +
localization O +
of O +
the O +
cleaved O +
form O +
of O +
caspase-6 O +
in O +
astrocytes O +
in O +
HIVE O +
brain O +
sections O -
. O +

Exposure O +
of O +
cultured O +
human B-Species +
primary O +
astrocytes O +
to O +
HIV O +
viral O +
protein O +
R O +
( O -
Vpr O -
) O +
induced O +
p53 O +
up O -
- O -
regulation O -
, O +
loss O +
of O +
mitochondrial O +
membrane O +
potential O -
, O +
and O +
caspase-6 O +
activation O +
followed O +
by O +
cell O +
injury O -
. O +

Transgenic B-Species +
mice I-Species -
, O +
expressing O +
Vpr O +
in O +
microglial O +
cells O -
, O +
demonstrated O +
astrocyte O +
apoptosis O +
in O +
brain O -
, O +
which O +
was O +
associated O +
with O +
caspase-6 O +
activation O +
and O +
neurobehavioral O +
abnormalities O -
. O +

Overall O -
, O +
these O +
data O +
point O +
to O +
previously O +
unrecognized O +
alterations O +
in O +
miRNA O +
profile O +
in O +
the O +
brain O +
during O +
HIV O +
infection O -
, O +
which O +
contribute O +
to O +
cell O +
death O +
through O +
dysregulation O +
of O +
cell O +
death O +
machinery O -
. O +

MicroRNA O +
profiling O +
reveals O +
new O +
aspects O +
of O +
HIV O +
neurodegeneration O -
: O +
caspase-6 O +
regulates O +
astrocyte O +
survival O -
. O +

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
small O +
noncoding O +
RNA O +
molecules O -
, O +
which O +
are O +
known O +
to O +
regulate O +
gene O +
expression O +
in O +
physiological O +
and O +
pathological O +
conditions O -
. O +

miRNA O +
profiling O +
was O +
performed O +
using O +
brain O +
tissue O +
from O +
patients B-Species +
with O +
HIV O +
encephalitis O +
( O -
HIVE O -
) O -
, O +
a O +
neuroinflammatory O -
/ O -
degenerative O +
disorder O +
caused O +
by O +
HIV O +
infection O +
of O +
the O +
brain O -
. O +

Language O +
brain O +
dominance O +
in O +
patients B-Species +
with O +
refractory O +
temporal O +
lobe O +
epilepsy O -
: O +
a O +
comparative O +
study O +
between O +
functional O +
magnetic O +
resonance O +
imaging O +
and O +
dichotic O +
listening O +
test O -
. O +

PURPOSE O -
: O +
To O +
identify O +
brain O +
dominance O +
for O +
language O +
functions O +
with O +
DLT O +
and O +
correlate O +
these O +
results O +
with O +
those O +
obtained O +
from O +
fMRI O +
in O +
patients B-Species +
suffering O +
from O +
intractable O +
temporal O +
lobe O +
epilepsy O -
. O +

METHOD O -
: O +
This O +
study O +
reports O +
on O +
13 O +
patients B-Species +
who O +
underwent O +
pre O -
- O -
surgical O +
epileptic O +
evaluation O +
between O +
April O +
and O +
October O +
2004 O +
at O +
the O +
Epilepsy O +
Surgery O +
Program O -
, O +
Hospital O +
Sao O +
Lucas O -
, O +
PUCRS O -
. O +

In O +
DLT O -
, O +
dominance O +
was O +
assessed O +
through O +
a O +
consonant O -
- O -
vowel O +
task O -
, O +
whereas O +
in O +
fMRI O +
patients B-Species +
performed O +
a O +
verb O +
generation O +
task O -
. O +

These O +
findings O +
indicate O +
that O +
DLT O +
( O -
a O +
non O -
- O -
invasive O +
procedure O -
) O +
could O +
be O +
a O +
useful O +
tool O +
to O +
evaluate O +
language O +
brain O +
dominance O +
in O +
pre O -
- O -
surgical O +
epileptic O +
patients B-Species +
as O +
it O +
is O +
cheaper O +
to O +
perform O +
than O +
fMRI O -
. O +

CONCLUSION O -
: O +
DLT O +
was O +
found O +
to O +
significantly O +
correlate O +
with O +
fMRI O -
. O +

RESULTS O -
: O +
Our O +
results O +
identified O +
a O +
correlation O +
between O +
the O +
fMRI O +
lateralization O +
index O +
and O +
the O +
DLT O +
ear O +
predominance O +
index O +
and O +
reply O +
difference O +
index O +
( O -
r=0.6 O -
, O +
p=0.02 O -
; O +
Pearson O +
Correlation O +
Coefficient O -
) O -
, O +
showing O +
positive O +
correlation O +
between O +
results O +
obtained O +
from O +
fMRI O +
and O +
DLT O -
. O +

Our O +
method O +
significantly O +
decreased O +
the O +
duration O +
of O +
hospital O +
admission O +
for O +
monitoring O +
and O +
minimal O +
complications O +
occurred O +
only O +
in O +
8 O -
% O +
of O +
patients B-Species -
. O +

CONCLUSIONS O -
: O +
In O +
conclusion O -
, O +
our O +
method O +
for O +
short O +
VEEG O +
monitoring O +
has O +
a O +
high O +
yield O +
for O +
diagnosis O -
, O +
minimal O +
complications O +
and O +
is O +
cost O +
effective O -
. O +

These O +
qualities O -
, O +
together O +
with O +
good O +
surgery O +
results O +
validate O +
our O +
method O +
for O +
the O +
investigation O +
and O +
treatment O +
of O +
refractory O +
seizure O +
cases O -
. O +

RESULTS O -
: O +
Our O +
monitoring O +
answered O +
the O +
study O +
question O +
in O +
88 O -
% O +
of O +
the O +
patients B-Species -
. O +

We O +
prospectively O +
assessed O +
the O +
yield O +
and O +
safety O +
of O +
the O +
telemetry O +
investigation O +
as O +
well O +
as O +
epilepsy O +
surgery O +
outcomes O -
. O +

Our O +
results O +
changed O +
the O +
management O +
in O +
74 O -
% O +
of O +
cases O +
and O +
potentially O +
improved O +
quality O +
of O +
life O +
by O +
decreasing O +
the O +
AEDs O +
consumption O +
and O +
number O +
of O +
seizures O +
per O +
month O -
. O +

The O +
question O +
was O +
not O +
answered O +
in O +
12 O -
% O +
of O +
cases O +
due O +
to O +
the O +
lack O +
of O +
recorded O +
events O -
. O +

Over O +
all O -
, O +
22 O -
% O +
received O +
epilepsy O +
surgery O +
and O +
became O +
either O +
seizure O +
free O +
or O +
their O +
seizures O +
became O +
non O -
- O -
disabling O -
. O +

Safety O +
and O +
yield O +
of O +
early O +
cessation O +
of O +
AEDs O +
in O +
video O -
- O -
EEG O +
telemetry O +
and O +
outcomes O -
. O +

METHODS O -
: O +
This O +
is O +
a O +
prospective O +
study O +
performed O +
to O +
asses O +
the O +
safety O +
and O +
yield O +
of O +
early O +
discontinuation O +
of O +
antiepileptic O +
drugs O +
( O -
AEDs O -
) O +
in O +
the O +
telemetry O +
unit O -
. O +

BACKGROUND O -
: O +
Video O -
- O -
electroencephalography O +
( O -
VEEG O -
) O +
telemetry O +
is O +
the O +
simultaneous O +
recording O +
of O +
ictal O +
and O +
interictal O +
EEG O +
pattern O +
and O +
paroxysmal O +
behavior O +
to O +
investigate O +
the O +
nature O +
of O +
paroxysmal O +
events O -
. O +

In O +
most O +
cases O +
AEDs O +
( O -
except O +
Phenobarbital O -
) O +
were O +
discontinued O +
in O +
24h O -
. O +

Over O +
a O +
2.5-year O +
period O -
, O +
50 O +
patients B-Species +
that O +
met O +
the O +
indications O +
for O +
VEEG O +
monitoring O +
were O +
admitted O +
by O +
an O +
epileptologist O +
to O +
neuro O -
- O -
observation O +
units O +
with O +
continuous O +
monitoring O -
, O +
nursing O +
coverage O +
and O +
EEG O +
technicians O +
support O +
during O +
working O +
hours O +
and O +
on O -
- O -
call O +
thereafter O -
. O +

The O +
molecular O +
mechanisms O +
that O +
contribute O +
to O +
gliomagenesis O +
have O +
become O +
increasingly O +
clear O +
in O +
recent O +
years O -
, O +
yet O +
much O +
remains O +
to O +
be O +
learned O -
. O +

Gliomas O +
are O +
the O +
most O +
common O +
form O +
of O +
primary O +
brain O +
tumors O +
and O +
are O +
associated O +
with O +
a O +
poor O +
clinical O +
outcome O -
. O +

microRNAs O +
in O +
gliomas O -
: O +
small O +
regulators O +
of O +
a O +
big O +
problem O -
. O +

This O +
is O +
a O +
rapidly O +
evolving O +
field O +
and O +
it O +
is O +
likely O +
that O +
we O +
have O +
only O +
begun O +
to O +
appreciate O +
the O +
involvement O +
of O +
microRNAs O +
in O +
relation O +
to O +
glioma O +
formation O -
, O +
and O +
the O +
therapeutic O +
potential O +
of O +
microRNAs O +
to O +
improve O +
outcome O +
for O +
glioma O +
patients B-Species -
. O +

Here O +
we O +
review O +
the O +
current O +
state O +
of O +
knowledge O +
related O +
to O +
the O +
role O +
of O +
microRNAs O +
in O +
glial O +
tumor O +
development O -
. O +

It O +
is O +
now O +
evident O +
that O +
microRNAs O +
regulate O +
a O +
wide O +
variety O +
of O +
tumorigenic O +
processes O +
including O +
cellular O +
proliferation O -
, O +
differentiation O -
, O +
angiogenesis O -
, O +
invasion O -
, O +
and O +
apoptosis O -
. O +

This O +
is O +
particularly O +
true O +
for O +
the O +
role O +
of O +
microRNAs O +
in O +
gliomagenesis O -
, O +
as O +
an O +
appreciation O +
for O +
the O +
significance O +
of O +
aberrant O +
miRNA O +
expression O +
in O +
human B-Species +
cancer O +
has O +
only O +
emerged O +
in O +
the O +
last O +
5 O +
years O -
. O +

Altered O +
microRNA O +
expression O +
following O +
traumatic O +
spinal O +
cord O +
injury O -
. O +

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
a O +
novel O +
class O +
of O +
small O +
non O -
- O -
coding O +
RNAs O +
that O +
negatively O +
regulate O +
gene O +
expression O +
at O +
the O +
posttranscriptional O +
level O +
by O +
binding O +
to O +
the O +
3 O -
' O +
untranslated O +
region O +
of O +
target O +
mRNAs O +
leading O +
to O +
their O +
translational O +
inhibition O +
or O +
sometimes O +
degradation O -
. O +

We O +
uncovered O +
a O +
previously O +
unknown O +
alteration O +
in O +
temporal O +
expression O +
of O +
a O +
large O +
set O +
of O +
miRNAs O +
following O +
a O +
contusive O +
spinal O +
cord O +
injury O +
( O -
SCI O -
) O +
in O +
adult O +
rats B-Species +
using O +
microarray O +
analysis O -
. O +

These O +
altered O +
miRNAs O +
can O +
be O +
classified O +
into O +
3 O +
categories O -
: O +
( O -
1 O -
) O +
up O -
- O -
regulation O -
, O +
( O -
2 O -
) O +
down O -
- O -
regulation O +
and O +
( O -
3 O -
) O +
an O +
early O +
up O -
- O -
regulation O +
at O +
4 O +
h O +
followed O +
by O +
down O -
- O -
regulation O +
at O +
1 O +
and O +
7 O +
days O +
post O -
- O -
SCI O -
. O +

The O +
bioinformatics O +
analysis O +
indicates O +
that O +
the O +
potential O +
targets O +
for O +
miRNAs O +
altered O +
after O +
SCI O +
include O +
genes O +
encoding O +
components O +
that O +
are O +
involved O +
in O +
the O +
inflammation O -
, O +
oxidation O -
, O +
and O +
apoptosis O +
that O +
are O +
known O +
to O +
play O +
important O +
roles O +
in O +
the O +
pathogenesis O +
of O +
SCI O -
. O +

These O +
findings O +
suggest O +
that O +
abnormal O +
expression O +
of O +
miRNAs O +
may O +
contribute O +
to O +
the O +
pathogenesis O +
of O +
SCI O +
and O +
are O +
potential O +
targets O +
for O +
therapeutic O +
interventions O +
following O +
SCI O -
. O +

Demyelinating O +
process O +
may O +
be O +
the O +
feature O +
of O +
nervous O +
impairment O +
in O +
systemic O +
lupus O +
erythematosus O -
, O +
Behcet O -
's O +
disease O +
( O -
BD O -
) O -
, O +
Sjoegren O -
's O +
syndrome O +
( O -
SS O -
) O -
, O +
systemic O +
sclerosis O +
( O -
SSc O -
) O +
or O +
very O +
rarely O +
other O +
systemic O +
autoimmune O +
diseases O -
. O +

An O +
acute O +
isolated O +
neurological O +
syndrome O -
, O +
as O +
the O +
most O +
common O +
symptom O +
of O +
MS O +
can O +
sometimes O +
be O +
the O +
only O +
feature O +
or O +
even O +
first O +
manifestation O +
of O +
nervous O +
impairment O +
in O +
connective O +
tissue O +
disease O -
, O +
hence O +
presenting O +
the O +
diagnostic O +
problem O -
. O +

Although O +
the O +
white O +
matter O +
abnormalities O +
seen O +
by O +
magnetic O +
resonance O +
imaging O +
may O +
be O +
similar O +
in O +
non O -
- O -
MS O +
autoimmune O +
demyelination O +
and O +
MS O -
, O +
it O +
is O +
the O +
most O +
important O +
diagnostic O +
tool O +
in O +
the O +
differential O +
diagnosis O +
of O +
the O +
mentioned O +
conditions O -
. O +

Investigating O +
the O +
presence O +
of O +
various O +
autoantibodies O +
potentially O +
involved O +
in O +
the O +
pathogenesis O +
of O +
demyelinating O +
lesions O +
as O +
well O +
as O +
cerebrospinal O +
fluid O +
( O -
CSF O -
) O +
analysis O +
can O +
be O +
helpful O -
. O +

Non O -
- O -
MS O +
autoimmune O +
demyelination O -
. O +

Connective O +
tissue O +
diseases O +
can O +
be O +
characterised O +
by O +
central O +
nervous O +
system O +
( O -
CNS O -
) O +
involvement O -
, O +
in O +
some O +
patients B-Species +
manifested O +
by O +
demyelination O +
areas O +
in O +
the O +
white O +
matter O +
of O +
the O +
brain O +
and O +
spinal O +
cord O -
, O +
which O +
are O +
difficult O +
to O +
differentiate O +
from O +
multiple O +
sclerosis O +
( O -
MS O -
) O +
and O +
other O +
demyelinating O +
processes O -
, O +
such O +
as O +
transverse O +
myelitis O +
and O +
optic O +
neuritis O -
. O +

Targeting O +
miRNAs O +
in O +
Alzheimer O -
's O +
disease O -
. O +

These O +
findings O +
identify O +
specific O +
microRNAs O +
as O +
attenuators O +
of O +
growth O +
factor O +
signaling O +
and O +
oncogenesis O -
. O +

In O +
line O +
with O +
roles O +
as O +
suppressors O +
of O +
EGF O +
receptor O +
( O -
EGFR O -
) O +
signaling O -
, O +
we O +
report O +
that O +
the O +
abundance O +
of O +
this O +
early O +
subset O +
of O +
microRNAs O +
is O +
decreased O +
in O +
breast O +
and O +
in O +
brain O +
tumors O +
driven O +
by O +
the O +
EGFR O +
or O +
the O +
closely O +
related O +
HER2 O -
. O +

This O +
step O +
permitted O +
rapid O +
induction O +
of O +
oncogenic O +
transcription O +
factors O -
, O +
such O +
as O +
c O -
- O -
FOS O -
, O +
encoded O +
by O +
immediate O +
early O +
genes O -
. O +

EGF O +
decreases O +
the O +
abundance O +
of O +
microRNAs O +
that O +
restrain O +
oncogenic O +
transcription O +
factors O -
. O +

The O +
earliest O +
event O +
involved O +
a O +
decrease O +
in O +
the O +
abundance O +
of O +
a O +
subset O +
of O +
23 O +
microRNAs O -
. O +

Using O +
genome O -
- O -
wide O +
approaches O -
, O +
we O +
showed O +
that O +
EGF O +
stimulation O +
initiates O +
a O +
coordinated O +
transcriptional O +
program O +
of O +
microRNAs O +
and O +
transcription O +
factors O -
. O +

MicroRNAs O -
, O +
which O +
attenuate O +
gene O +
expression O +
by O +
binding O +
complementary O +
regions O +
in O +
messenger O +
RNAs O -
, O +
are O +
broadly O +
implicated O +
in O +
cancer O -
. O +

Epidermal O +
growth O +
factor O +
( O -
EGF O -
) O +
stimulates O +
cells O +
by O +
launching O +
gene O +
expression O +
programs O +
that O +
are O +
frequently O +
deregulated O +
in O +
cancer O -
. O +

To O +
determine O +
the O +
role O +
of O +
possible O +
pathogenic O +
cofactors O +
such O +
as O +
geographic O -
, O +
ethnic B-Species -
, O +
genetic O -
, O +
and O +
cultural O +
features O -
, O +
further O +
pertinent O +
surveys O +
are O +
required O +
in O +
subtropical O +
northwestern O +
Argentina O -
. O +

Considering O +
the O +
HAM O -
/ O -
TSP O +
cluster O +
described O +
here O +
plus O +
previously O +
reported O +
isolated O +
cases O +
in O +
neighboring O +
Salta O +
Province O -
, O +
we O +
speculate O +
that O +
the O +
Puna O +
Jujeña O +
region O +
and O +
regions O +
in O +
that O +
vicinity O +
would O +
be O +
a O +
microepidemic O +
focus O +
of O +
disease O -
. O +

Therefore O -
, O +
the O +
long O -
- O -
term O +
presence O +
of O +
virus O +
in O +
Jujuy O +
natives O +
may O +
be O +
taken O +
for O +
granted O -
. O +

In O +
contrast O +
to O +
the O +
Andean O +
region O +
of O +
Bolivia O -
, O +
where O +
high O +
HTLV O -
- O -
I O +
seroprevalence O +
is O +
in O +
part O +
attributable O +
to O +
Japanese O +
immigrants O -
, O +
the O +
Jujuy O +
population O +
mainly O +
consists O +
of O +
aborigines O -
, O +
mestizos O -
, O +
and O +
European O +
descendants O -
. O +

No O +
history O +
of O +
risk O +
factors O +
was O +
disclosed O -
, O +
except O +
for O +
a O +
single O +
transfusion O +
in O +
1 O +
patient B-Species -
. O +

Most O +
patients B-Species +
( O -
9 O -
/ O -
11 O -
) O +
were O +
born O +
in O +
Cochinoca O +
Department O -
, O +
located O +
in O +
an O +
Andes O +
highland O +
area O +
called O +
Puna O +
Jujeña O -
, O +
situated O +
at O +
more O +
that O +
3400 O +
m O +
above O +
sea O +
level O -
. O +

Accordingly O -
, O +
a O +
clinically O +
diagnosed O +
and O +
serologically O +
confirmed O +
cluster O +
of O +
cases O +
in O +
1 O +
man B-Species +
and O +
10 O +
women B-Species -
, O +
including O +
2 O +
sisters O -
, O +
is O +
described O +
here O -
. O +

Compared O +
with O +
other O +
regions O +
in O +
Argentina O -
, O +
greater O +
human B-Species +
T O -
- O -
cell O +
lymphotropic O +
virus O +
type O +
I O +
( O -
HTLV O -
- O -
I O -
) O +
seroprevalence O +
has O +
been O +
reported O +
in O +
Jujuy O +
Province O -
, O +
where O +
it O +
reaches O +
2.32 O -
% O +
in O +
the O +
general O +
population O -
, O +
so O +
that O +
a O +
search O +
for O +
HTLV O -
- O -
I O -
- O -
associated O +
myelopathy O -
/ O -
tropical O +
spastic O +
paraparesis O +
( O -
HAM O -
/ O -
TSP O -
) O +
cases O +
deserved O +
to O +
be O +
carried O +
out O -
. O +

A O +
cluster O +
of O +
human B-Species +
T O -
- O -
cell O +
lymphotropic O +
virus O +
type O +
I O -
- O -
associated O +
myelopathy O -
/ O -
tropical O +
spastic O +
paraparesis O +
in O +
Jujuy O -
, O +
Argentina O -
. O +

Atrial O +
fibrillation O +
( O -
AF O -
) O +
is O +
an O +
emerging O +
clinical O +
problem O +
with O +
multifaceted O +
issues O -
: O +
current O +
and O +
expected O +
prevalence O -
, O +
significant O +
morbidity O -
, O +
potentially O +
fatal O +
outcome O +
( O -
e.g. O -
, O +
stroke O -
) O +
and O +
gaps O +
in O +
therapeutic O +
approaches O -
. O +

Targeting O +
the O +
arrhythmogenic O +
substrate O +
in O +
atrial O +
fibrillation O -
: O +
focus O +
on O +
structural O +
remodeling O -
. O +

Although O +
a O +
number O +
of O +
drugs O +
have O +
just O +
come O +
out O +
of O +
the O +
pipeline O +
with O +
promising O +
results O +
( O -
e.g. O -
, O +
dronedarone O -
) O -
, O +
the O +
question O +
arises O +
whether O +
channel O -
- O -
targeted O +
drugs O +
represent O +
the O +
only O +
viable O +
approach O -
. O +

Current O +
anti O -
- O -
arrhythmic O +
strategies O +
not O +
only O +
fail O +
to O +
guarantee O +
effective O +
rhythm O +
control O -
, O +
but O +
also O +
cause O +
" O -
on O +
target O -
" O +
( O -
i.e. O -
, O +
pro O -
- O -
arrhythmia O -
, O +
namely O +
torsade O +
de O +
pointes O -
) O +
and O +
" O -
off O +
target O -
" O +
( O -
i.e. O -
, O +
extra O -
- O -
cardiac O +
toxicities O -
) O +
side O +
effects O -
. O +

Fascinating O +
and O +
innovative O +
strategies O +
have O +
been O +
proposed O +
( O -
e.g. O -
, O +
miRNAs O +
modulation O -
) O -
, O +
but O +
the O +
actual O +
benefit O +
is O +
debated O -
. O +

This O +
review O +
will O +
provide O +
mechanistic O +
insights O +
into O +
structural O +
remodeling O +
and O +
highlight O +
emerging O +
upstream O +
strategies O +
in O +
AF O +
management O -
. O +

A O +
body O +
of O +
evidence O +
has O +
emerged O +
supporting O +
structural O +
remodeling O +
as O +
the O +
main O +
arrhythmogenic O +
substrate O +
perpetuating O +
AF O -
. O +
Fibrosis O -
, O +
inflammation O +
and O +
oxidative O +
stress O +
appear O +
strongly O +
interconnected O +
in O +
the O +
pathogenesis O +
of O +
remodeling O -
- O -
induced O +
abnormalities O -
. O +

Moreover O -
, O +
insights O +
into O +
extracellular O +
matrix O +
network O +
strongly O +
suggested O +
an O +
active O +
cross O -
- O -
talk O +
within O +
the O +
cardiac O +
microenvironment O -
, O +
which O +
should O +
be O +
further O +
investigated O +
as O +
promising O +
" O -
anti O -
- O -
remodeling O -
" O +
approach O -
. O +

Therefore O -
, O +
pharmacological O +
modulation O +
of O +
non O -
- O -
ionic O +
targets O +
( O -
the O +
so O +
called O +
" O -
upstream O -
" O +
therapy O -
) O +
has O +
gained O +
interest O +
as O +
a O +
preventive O +
strategy O +
in O +
AF O -
. O +

At O +
the O +
present O +
state O +
of O +
knowledge O -
, O +
renin O -
- O -
angiotensin O -
- O -
aldosterone O +
system O +
blockers O +
and O +
statins O +
offer O +
evidence O +
for O +
potential O +
clinical O +
exploitation O -
, O +
while O +
several O +
remodeling O -
- O -
targeted O +
therapies O +
have O +
been O +
tested O +
only O +
experimentally O +
or O +
failed O +
when O +
studied O +
for O +
human B-Species +
validation O -
. O +

Epigenetics O +
are O +
defined O -
, O +
in O +
broad O -
- O -
terms O -
, O +
as O +
alterations O +
in O +
gene O +
expression O +
without O +
changes O +
in O +
DNA O +
sequence O -
. O +

Epigenetic O +
changes O +
in O +
gliomas O -
. O +

In O +
this O +
review O -
, O +
we O +
will O +
first O +
describe O +
briefly O +
histone O +
modifications O -
, O +
DNA O +
methylation O +
and O +
miRNAs O +
and O +
the O +
functions O +
of O +
these O +
epigenetic O +
marks O +
during O +
different O +
cellular O +
processes O +
involving O +
DNA O +
metabolism O -
. O +

While O +
histone O +
modifications O +
and O +
DNA O +
methylation O +
are O +
two O +
classical O +
means O +
to O +
regulate O +
gene O +
expression O -
, O +
miRNA O +
has O +
also O +
recently O +
been O +
documented O +
to O +
govern O +
gene O +
expression O +
in O +
normal O +
as O +
well O +
as O +
cancer O +
cells O -
. O +

We O +
expect O +
that O +
novel O +
therapies O +
will O +
be O +
developed O +
to O +
counter O +
epigenetic O +
changes O +
in O +
this O +
deadly O +
disease O -
. O +

We O +
will O +
then O +
highlight O +
some O +
epigenetic O +
changes O +
in O +
glioblastomas O -
, O +
a O +
malignant O +
form O +
of O +
brain O +
tumor O -
, O +
and O +
potential O +
application O +
of O +
epigenetic O +
means O +
for O +
diagnosis O -
, O +
prognosis O -
, O +
and O +
treatment O +
of O +
gliomas O -
. O +

Human B-Species +
brains O +
retain O +
discrete O +
populations O +
of O +
micro O +
RNA O +
( O -
miRNA O -
) O +
species O +
that O +
support O +
homeostatic O +
brain O +
gene O +
expression O +
functions O -
; O +
however O -
, O +
specific O +
miRNA O +
abundance O +
is O +
significantly O +
altered O +
in O +
neurological O +
disorders O +
such O +
as O +
Alzheimer O +
disease O +
( O -
AD O -
) O +
when O +
compared O +
with O +
age O -
- O -
matched O +
controls O -
. O +

An O +
NF O -
- O -
kappaB O -
- O -
sensitive O +
micro O +
RNA-146a O -
- O -
mediated O +
inflammatory O +
circuit O +
in O +
Alzheimer O +
disease O +
and O +
in O +
stressed O +
human B-Species +
brain O +
cells O -
. O +

Up O -
- O -
regulation O +
of O +
miRNA-146a O +
coupled O +
to O +
down O -
- O -
regulation O +
of O +
CFH O +
was O +
observed O +
in O +
AD O +
brain O +
and O +
in O +
interleukin-1beta O -
, O +
Abeta42 O -
, O +
and/or O +
oxidatively O +
stressed O +
human B-Species +
neural O +
( O -
HN O -
) O +
cells O +
in O +
primary O +
culture O -
. O +

Here O +
we O +
provide O +
evidence O +
in O +
AD O +
brains O +
of O +
a O +
specific O +
up O -
- O -
regulation O +
of O +
an O +
NF O -
- O -
kappaB O -
- O -
sensitive O +
miRNA-146a O +
highly O +
complementary O +
to O +
the O +
3'-untranslated O +
region O +
of O +
complement O +
factor O +
H O +
( O -
CFH O -
) O -
, O +
an O +
important O +
repressor O +
of O +
the O +
inflammatory O +
response O +
of O +
the O +
brain O -
. O +

Treatment O +
of O +
stressed O +
HN O +
cells O +
with O +
the O +
NF O -
- O -
kappaB O +
inhibitor O +
pyrollidine O +
dithiocarbamate O +
or O +
the O +
resveratrol O +
analog O +
CAY10512 O +
abrogated O +
this O +
response O -
. O +

Transfection O +
of O +
HN O +
cells O +
using O +
an O +
NF O -
- O -
kappaB O -
- O -
containing O +
pre O -
- O -
miRNA-146a O +
promoter O -
- O -
luciferase O +
reporter O +
construct O +
in O +
stressed O +
HN O +
cells O +
showed O +
significant O +
up O -
- O -
regulation O +
of O +
luciferase O +
activity O +
that O +
paralleled O +
decreases O +
in O +
CFH O +
gene O +
expression O -
. O +

Incubation O +
of O +
an O +
antisense O +
oligonucleotide O +
to O +
miRNA-146a O +
( O -
anti O -
- O -
miRNA-146a O -
; O +
AM-146a O -
) O +
was O +
found O +
to O +
restore O +
CFH O +
expression O +
levels O -
. O +

These O +
data O +
indicate O +
that O +
NF O -
- O -
kappaB O -
- O -
sensitive O +
miRNA-146a O -
- O -
mediated O +
modulation O +
of O +
CFH O +
gene O +
expression O +
may O +
in O +
part O +
regulate O +
an O +
inflammatory O +
response O +
in O +
AD O +
brain O +
and O +
in O +
stressed O +
HN O +
cell O +
models O +
of O +
AD O +
and O +
illustrate O +
the O +
potential O +
for O +
anti O -
- O -
miRNAs O +
as O +
an O +
effective O +
therapeutic O +
strategy O +
against O +
pathogenic O +
inflammatory O +
signaling O -
. O +

The O +
prevalence O +
of O +
neurodegenerative O +
disorders O +
is O +
rising O +
steadily O +
as O +
human B-Species +
life O +
expectancy O +
increases O -
. O +

However O -
, O +
limited O +
knowledge O +
of O +
the O +
molecular O +
basis O +
of O +
disease O +
pathogenesis O +
is O +
a O +
major O +
hurdle O +
in O +
the O +
identification O +
of O +
drug O +
targets O +
and O +
development O +
of O +
therapeutic O +
strategies O +
for O +
these O +
largely O +
incurable O +
disorders O -
. O +

MicroRNAs O -
: O +
novel O +
therapeutic O +
targets O +
in O +
neurodegenerative O +
diseases O -
. O +

Our O +
bioinformatic O +
analysis O +
suggests O +
novel O +
miRNA O -
- O -
target O +
interactions O +
that O +
could O +
potentially O +
influence O +
neurodegeneration O -
. O +

The O +
recent O +
development O +
of O +
molecules O +
that O +
alter O +
miRNA O +
expression O +
promises O +
valuable O +
tools O +
that O +
will O +
enhance O +
the O +
therapeutic O +
potential O +
of O +
miRNAs O -
. O +

Recently O -
, O +
differential O +
expression O +
of O +
endogenous O +
regulatory O +
small O +
RNAs O -
, O +
known O +
as O +
' O -
microRNAs O -
' O +
( O -
miRNAs O -
) O -
, O +
in O +
patients B-Species +
of O +
Alzheimer O -
's O +
disease O -
, O +
Parkinson O -
's O +
disease O +
and O +
models O +
of O +
ataxia O +
suggest O +
that O +
they O +
might O +
have O +
key O +
regulatory O +
roles O +
in O +
neurodegeneration O -
. O +

miRNAs O +
that O +
can O +
target O +
known O +
mediators O +
of O +
neurodegeneration O +
offer O +
potential O +
therapeutic O +
targets O -
. O +

The O +
miR-146a O +
expression O +
was O +
confirmed O +
to O +
be O +
present O +
in O +
reactive O +
astrocytes O -
. O +

In O +
human B-Species +
TLE O +
with O +
hippocampal O +
sclerosis O -
, O +
increased O +
astroglial O +
expression O +
of O +
miR-146a O +
was O +
observed O +
mainly O +
in O +
regions O +
where O +
neuronal O +
cell O +
loss O +
and O +
reactive O +
gliosis O +
occurred O -
. O +

The O +
increased O +
and O +
persistent O +
expression O +
of O +
miR-146a O +
in O +
reactive O +
astrocytes O +
supports O +
the O +
possible O +
involvement O +
of O +
miRNAs O +
in O +
the O +
modulation O +
of O +
the O +
astroglial O +
inflammatory O +
response O +
occurring O +
in O +
TLE O +
and O +
provides O +
a O +
target O +
for O +
future O +
studies O +
aimed O +
at O +
developing O +
strategies O +
against O +
pro O -
- O -
epileptogenic O +
inflammatory O +
signalling O -
. O +

Increasing O +
evidence O +
supports O +
the O +
involvement O +
of O +
inflammatory O +
and O +
immune O +
processes O +
in O +
temporal O +
lobe O +
epilepsy O +
( O -
TLE O -
) O -
. O +

Expression O +
pattern O +
of O +
miR-146a O -
, O +
an O +
inflammation O -
- O -
associated O +
microRNA O -
, O +
in O +
experimental O +
and O +
human B-Species +
temporal O +
lobe O +
epilepsy O -
. O +

We O +
investigated O +
the O +
expression O +
and O +
cellular O +
distribution O +
of O +
miRNA-146a O +
( O -
miR-146a O -
) O +
in O +
a O +
rat B-Species +
model O +
of O +
TLE O +
as O +
well O +
as O +
in O +
human B-Species +
TLE O -
. O +

MicroRNAs O +
( O -
miRNA O -
) O +
represent O +
small O +
regulatory O +
RNA O +
molecules O +
that O +
have O +
been O +
shown O +
to O +
act O +
as O +
negative O +
regulators O +
of O +
gene O +
expression O +
controlling O +
different O +
biological O +
processes O -
, O +
including O +
immune O -
- O -
system O +
homeostasis O +
and O +
function O -
. O +

Prominent O +
upregulation O +
of O +
miR-146a O +
activation O +
was O +
evident O +
at O +
1 O +
week O +
after O +
SE O +
and O +
persisted O +
in O +
the O +
chronic O +
phase O -
. O +

miR-146a O +
analysis O +
in O +
rat B-Species +
hippocampus O +
was O +
performed O +
by O +
polymerase O +
chain O +
reaction O +
and O +
immunocytochemistry O +
at O +
1 O +
week O +
and O +
3 O -
- O -
4 O +
months O +
after O +
induction O +
of O +
status O +
epilepticus O +
( O -
SE O -
) O -
. O +

Regeneration O +
of O +
neuromuscular O +
synapses O -
: O +
action O +
of O +
microRNA-206 O -
. O +

DESIGN O -
: O +
: O +
Cross O -
- O -
sectional O +
study O -
. O +

OBJECTIVE O -
: O +
: O +
To O +
compare O +
presentation O +
of O +
Alzheimer O +
disease O +
( O -
AD O -
) O +
at O +
the O +
time O +
of O +
initial O +
evaluation O +
at O +
a O +
university O +
specialty O +
clinic O +
across O +
three O +
ethnoracial O +
groups O +
in O +
order O +
to O +
understand O +
similarities O +
and O +
differences O +
in O +
the O +
demographic O -
, O +
clinical O -
, O +
cognitive O -
, O +
psychiatric O -
, O +
and O +
biologic O +
features O -
. O +

Ethnoracial O +
differences O +
in O +
the O +
clinical O +
characteristics O +
of O +
Alzheimer O -
's O +
disease O +
at O +
initial O +
presentation O +
at O +
an O +
urban O +
Alzheimer O -
's O +
disease O +
center O -
. O +

The O +
apolipoprotein O +
E-4 O +
genotype O +
was O +
not O +
associated O +
with O +
AD O +
in O +
the O +
Latino O +
cohort O -
. O +

Greater O +
severity O +
of O +
symptoms O +
was O +
not O +
accounted O +
for O +
by O +
a O +
difference O +
in O +
lag O +
time O +
between O +
onset O +
of O +
symptoms O +
and O +
initial O +
evaluation O -
. O +

There O +
was O +
more O +
depression O +
in O +
the O +
Latinos O +
compared O +
with O +
African O +
Americans O +
and O +
WNHs O -
. O +

In O +
particular O -
, O +
the O +
largely O +
immigrant O +
Puerto O +
Rican O +
Latino O +
group O +
had O +
an O +
earlier O +
age O +
of O +
onset O +
of O +
AD O -
, O +
more O +
cognitive O +
impairment O -
, O +
and O +
greater O +
severity O +
of O +
cognitive O +
impairment O +
at O +
the O +
time O +
of O +
initial O +
evaluation O +
in O +
the O +
setting O +
of O +
low O +
average O +
education O +
and O +
socioeconomic O +
status O -
. O +

RESULTS O -
: O +
: O +
Differences O +
among O +
ethnoracial O +
groups O +
were O +
found O +
for O +
nearly O +
all O +
variables O +
of O +
interest O -
. O +

MEASUREMENTS O -
: O +
: O +
Demographic O +
variables O +
and O +
age O +
of O +
onset O +
of O +
AD O -
, O +
as O +
well O +
as O +
cognitive O -
, O +
functional O -
, O +
and O +
mood O +
impairments O +
at O +
the O +
time O +
of O +
initial O +
presentation O +
and O +
frequencies O +
of O +
apolipoprotein O +
E O +
genotypes O -
, O +
were O +
compared O +
across O +
groups O -
. O +

PARTICIPANTS O -
: O +
: O +
A O +
total O +
of O +
1,341 O +
self O -
- O -
identified O +
African O +
American O -
, O +
Latino O +
( O -
primarily O +
of O +
Caribbean O +
origin O -
) O -
, O +
and O +
white O +
non O -
- O -
Hispanic O +
( O -
" O -
WNH O -
" O -
) O +
subjects O +
were O +
recruited O +
from O +
primary O +
care O +
sites O +
or O +
by O +
referral O +
by O +
primary O +
care O +
physicians O -
. O +

Important O +
potential O +
confounds O +
need O +
to O +
be O +
considered O +
and O +
future O +
research O +
comparing O +
immigrant O +
and O +
nonimmigrant O +
Latino O +
groups O +
will O +
be O +
necessary O +
to O +
elucidate O +
the O +
highly O +
significant O +
differences O +
reported O -
. O +

CONCLUSIONS O -
: O +
: O +
Minority O +
groups O +
in O +
Philadelphia O -
, O +
especially O +
Latinos O -
, O +
exhibit O +
a O +
more O +
severe O +
profile O +
of O +
AD O +
at O +
the O +
time O +
of O +
presentation O +
than O +
WNHs O -
. O +

These O +
tumors O +
arise O +
in O +
the O +
cerebellum O +
and O +
may O +
attribute O +
their O +
origins O +
to O +
deregulated O +
proliferation O +
of O +
neural O +
progenitor O +
cells O +
during O +
development O -
. O +

However O -
, O +
only O +
a O +
few O +
studies O +
to O +
date O +
have O +
focused O +
on O +
the O +
role O +
of O +
miRNAs O +
in O +
medulloblastoma O -
, O +
the O +
most O +
common O +
malignant O +
pediatric O +
brain O +
tumor O -
. O +

MiRNA O +
expression O +
profiling O +
of O +
both O +
mouse B-Species +
and O +
human B-Species +
medulloblastomas O +
has O +
led O +
to O +
the O +
identification O +
of O +
signatures O +
correlating O +
with O +
the O +
molecular O +
subgroups O +
of O +
medulloblastoma O -
, O +
tumor O +
diagnosis O +
and O +
response O +
to O +
treatment O -
, O +
as O +
well O +
as O +
novel O +
targets O +
of O +
potential O +
clinical O +
relevance O -
. O +

Understanding O +
the O +
interplay O +
between O +
normal O +
brain O +
development O +
and O +
medulloblastoma O +
pathogenesis O +
is O +
necessary O +
in O +
order O +
for O +
more O +
efficient O -
, O +
less O +
toxic O +
targeted O +
therapies O +
to O +
be O +
developed O +
and O +
implemented O -
. O +

Normal O +
and O +
oncogenic O +
roles O +
for O +
microRNAs O +
in O +
the O +
developing O +
brain O -
. O +

Emerging O +
evidence O +
indicates O +
that O +
miRNAs O +
are O +
key O +
players O +
in O +
mammalian O +
development O +
that O -
, O +
when O +
altered O -
, O +
contribute O +
to O +
tumorigenesis O -
. O +

MicroRNAS O +
( O -
miRNAs O -
) O +
are O +
small O +
endogenous O +
non O -
- O -
coding O +
RNAs O +
that O +
play O +
important O +
roles O +
in O +
many O +
different O +
biological O +
processes O +
including O +
proliferation O -
, O +
differentiation O +
and O +
apoptosis O +
through O +
silencing O +
of O +
target O +
genes O -
. O +

This O +
review O +
summarizes O +
the O +
recent O +
miRNA O +
literature O +
in O +
both O +
medulloblastoma O +
and O +
normal O +
brain O +
development O -
. O +

A O +
miRNA O +
signature O +
of O +
prion O +
induced O +
neurodegeneration O -
. O +

Compelling O +
evidence O +
links O +
miRNAs O +
to O +
the O +
control O +
of O +
neuronal O +
development O +
and O +
differentiation O -
, O +
however O -
, O +
little O +
is O +
known O +
about O +
their O +
role O +
in O +
neurodegeneration O -
. O +

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
small O -
, O +
non O -
- O -
coding O +
RNA O +
molecules O +
which O +
are O +
emerging O +
as O +
key O +
regulators O +
of O +
numerous O +
cellular O +
processes O -
. O +

We O +
determined O +
15 O +
miRNAs O +
were O +
de O -
- O -
regulated O +
during O +
the O +
disease O +
processes O -
; O +
miR-342 O -
- O -
3p O -
, O +
miR-320 O -
, O +
let-7b O -
, O +
miR-328 O -
, O +
miR-128 O -
, O +
miR-139 O -
- O -
5p O +
and O +
miR-146a O +
were O +
over O +
2.5 O +
fold O +
up O -
- O -
regulated O +
and O +
miR-338 O -
- O -
3p O +
and O +
miR-337 O -
- O -
3p O +
over O +
2.5 O +
fold O +
down O -
- O -
regulated O -
. O +

We O +
used O +
microarrays O +
and O +
RT O -
- O -
PCR O +
to O +
profile O +
miRNA O +
expression O +
changes O +
in O +
the O +
brains O +
of O +
mice B-Species +
infected O +
with O +
mouse B-Species -
- O -
adapted O +
scrapie O -
. O +

De O -
- O -
regulation O +
of O +
a O +
unique O +
subset O +
of O +
miRNAs O +
suggests O +
a O +
conserved O -
, O +
disease O -
- O -
specific O +
pattern O +
of O +
differentially O +
expressed O +
miRNAs O +
is O +
associated O +
with O +
prion O -
- O -
induced O +
neurodegeneration O -
. O +

Only O +
one O +
of O +
these O +
miRNAs O -
, O +
miR-128 O -
, O +
has O +
previously O +
been O +
shown O +
to O +
be O +
de O -
- O -
regulated O +
in O +
neurodegenerative O +
disease O -
. O +

Computational O +
analysis O +
predicted O +
numerous O +
potential O +
gene O +
targets O +
of O +
these O +
miRNAs O -
, O +
including O +
119 O +
genes O +
previously O +
determined O +
to O +
be O +
also O +
de O -
- O -
regulated O +
in O +
mouse B-Species +
scrapie O -
. O +

We O +
used O +
a O +
co O -
- O -
ordinated O +
approach O +
to O +
integrate O +
miRNA O +
and O +
mRNA O +
profiling O -
, O +
bioinformatic O +
predictions O +
and O +
biochemical O +
validation O +
to O +
determine O +
miRNA O +
regulated O +
processes O +
and O +
genes O +
potentially O +
involved O +
in O +
disease O +
progression O -
. O +

In O +
particular O -
, O +
a O +
correlation O +
between O +
miRNA O +
expression O +
and O +
putative O +
gene O +
targets O +
involved O +
in O +
intracellular O +
protein O -
- O -
degradation O +
pathways O +
and O +
signaling O +
pathways O +
related O +
to O +
cell O +
death O -
, O +
synapse O +
function O +
and O +
neurogenesis O +
was O +
identified O -
. O +

Type O +
III O +
RNase O +
Dicer O +
is O +
responsible O +
for O +
the O +
maturation O +
and O +
function O +
of O +
microRNA O +
( O -
miRNA O -
) O +
molecules O +
in O +
the O +
cell O -
. O +

Genetic O +
ablation O +
of O +
Dicer O +
in O +
adult O +
forebrain O +
neurons O +
results O +
in O +
abnormal O +
tau O +
hyperphosphorylation O +
and O +
neurodegeneration O -
. O +

Although O +
neuronal O +
loss O +
is O +
observed O +
in O +
the O +
hippocampus O -
, O +
cellular O +
shrinkage O +
is O +
predominant O +
in O +
the O +
cortex O -
. O +

Here O +
we O +
show O +
that O +
the O +
absence O +
of O +
Dicer O +
in O +
the O +
adult O +
forebrain O +
is O +
accompanied O +
by O +
a O +
mixed O +
neurodegenerative O +
phenotype O -
. O +

However O -
, O +
the O +
underlying O +
mechanisms O +
involved O +
in O +
neuronal O +
death O -
, O +
particularly O +
in O +
the O +
adult O +
brain O -
, O +
remain O +
poorly O +
defined O -
. O +

It O +
is O +
now O +
well O -
- O -
documented O +
that O +
Dicer O +
and O +
the O +
fine O -
- O -
tuning O +
of O +
the O +
miRNA O +
gene O +
network O +
are O +
important O +
for O +
neuronal O +
integrity O -
. O +

We O +
further O +
demonstrate O +
that O +
miRNAs O +
belonging O +
to O +
the O +
miR-15 O +
family O +
are O +
potent O +
regulators O +
of O +
ERK1 O +
expression O +
in O +
mouse B-Species +
neuronal O +
cells O +
and O +
co O -
- O -
expressed O +
with O +
ERK1 O -
/ O -
2 O +
in O +
vivo O -
. O +

Finally O -
, O +
we O +
show O +
that O +
miR-15a O +
is O +
specifically O +
downregulated O +
in O +
Alzheimer O -
's O +
disease O +
brain O -
. O +

Interestingly O -
, O +
neuronal O +
degeneration O +
coincides O +
with O +
the O +
hyperphosphorylation O +
of O +
endogenous O +
tau O +
at O +
several O +
epitopes O +
previously O +
associated O +
with O +
neurofibrillary O +
pathology O -
. O +

Transcriptome O +
analysis O +
of O +
enzymes O +
involved O +
in O +
tau O +
phosphorylation O +
identified O +
ERK1 O +
as O +
one O +
of O +
the O +
candidate O +
kinases O +
responsible O +
for O +
this O +
event O +
in O +
vivo O -
. O +

In O +
summary O -
, O +
these O +
results O +
support O +
the O +
hypothesis O +
that O +
changes O +
in O +
the O +
miRNA O +
network O +
may O +
contribute O +
to O +
a O +
neurodegenerative O +
phenotype O +
by O +
affecting O +
tau O +
phosphorylation O -
. O +

MiR-21 O +
can O +
be O +
induced O +
in O +
neurons O +
by O +
prolonged O +
N O -
- O -
methyl O -
- O -
D O -
- O -
aspartic O +
acid O +
receptor O +
stimulation O -
, O +
an O +
excitotoxic O +
process O +
active O +
in O +
HIV O +
and O +
other O +
neurodegenerative O +
diseases O -
. O +

Introduction O +
of O +
miR-21 O +
into O +
human B-Species +
neurons O +
leads O +
to O +
pathological O +
functional O +
defects O -
. O +

Furthermore O -
, O +
we O +
show O +
that O +
miR-21 O +
specifically O +
targets O +
the O +
mRNA O +
of O +
myocyte O +
enhancer O +
factor O +
2C O +
( O -
MEF2C O -
) O -
, O +
a O +
transcription O +
factor O +
crucial O +
for O +
neuronal O +
function O -
, O +
and O +
reduces O +
its O +
expression O -
. O +

MEF2C O +
is O +
dramatically O +
downregulated O +
in O +
neurons O +
of O +
HIV O -
- O -
associated O +
dementia O +
patients B-Species +
as O +
well O +
as O +
monkeys O +
with O +
SIVE O -
. O +

Together O -
, O +
this O +
study O +
elucidates O +
a O +
novel O +
role O +
for O +
miR-21 O +
in O +
the O +
brain O -
, O +
not O +
only O +
as O +
a O +
potential O +
signature O +
of O +
neurological O +
disease O +
but O +
also O +
as O +
a O +
crucial O +
effector O +
of O +
HIV O +
induced O +
neuronal O +
dysfunction O +
and O +
neurodegeneration O -
. O +

MicroRNAs O +
( O -
miRNAs O -
) O +
play O +
important O +
roles O +
in O +
regulating O +
a O +
plethora O +
of O +
physiological O +
and O +
pathophysiogical O +
processes O +
including O +
neurodegeneration O -
. O +

MicroRNA-21 O +
dysregulates O +
the O +
expression O +
of O +
MEF2C O +
in O +
neurons O +
in O +
monkey O +
and O +
human B-Species +
SIV O -
/ O -
HIV O +
neurological O +
disease O -
. O +

In O +
situ O +
hybridization O +
of O +
the O +
diseased O +
brain O +
sections O +
revealed O +
induction O +
of O +
miR-21 O +
in O +
neurons O -
. O +

In O +
both O +
HIV O +
associated O +
dementia O +
in O +
humans B-Species +
and O +
its O +
monkey O +
model O +
SIV O +
encephalitis O +
we O +
find O +
miR-21 O -
, O +
a O +
miRNA O +
largely O +
known O +
for O +
its O +
link O +
to O +
oncogenesis O -
, O +
to O +
be O +
significantly O +
upregulated O +
in O +
the O +
brain O -
. O +

However O -
, O +
by O +
examining O +
pairs O +
in O +
which O +
the O +
significance O +
of O +
the O +
correlation O +
coefficients O +
is O +
modestly O +
relaxed O -
, O +
negative O +
correlations O +
do O +
tend O +
to O +
predict O +
targets O +
and O +
positive O +
correlations O +
tend O +
to O +
predict O +
physically O +
proximate O +
pairs O -
. O +

A O +
subset O +
of O +
high O +
correlation O +
pairs O +
were O +
experimentally O +
validated O +
by O +
over O -
- O -
expressing O +
or O +
suppressing O +
a O +
miRNA O +
and O +
measuring O +
the O +
correlated O +
mRNAs O -
. O +

Most O +
of O +
these O +
highest O +
correlation O +
pairs O +
do O +
not O +
contain O +
sufficiently O +
complementary O +
sequences O +
to O +
predict O +
a O +
target O +
relationship O -
; O +
nor O +
do O +
they O +
lie O +
in O +
physical O +
proximity O +
to O +
each O +
other O -
. O +

From O +
these O +
data O +
sets O -
, O +
we O +
inferred O +
and O +
validated O +
a O +
tumor O +
suppression O +
pathway O +
linked O +
to O +
miR-181c O -
. O +

CONCLUSIONS O -
/ O -
SIGNIFICANCE O -
: O +
Sufficient O +
information O +
exists O +
within O +
a O +
set O +
of O +
tumor O +
samples O +
to O +
detect O +
endogenous O +
correlations O +
between O +
miRNA O +
and O +
mRNA O +
levels O -
. O +

Based O +
on O +
the O +
validations O +
the O +
causal O +
arrow O +
for O +
these O +
correlations O +
is O +
likely O +
to O +
be O +
directed O +
from O +
the O +
miRNAs O +
to O +
the O +
mRNAs O -
. O +

METHODOLOGY O -
/ O -
PRINCIPAL O +
FINDINGS O -
: O +
RNA O +
was O +
extracted O +
from O +
12 O +
human B-Species +
primary O +
brain O +
tumor O +
biopsies O -
. O +

These O +
samples O +
were O +
used O +
to O +
determine O +
genome O -
- O -
wide O +
mRNA O +
expression O +
levels O +
by O +
microarray O +
analysis O +
and O +
a O +
miRNA O +
profile O +
by O +
real O -
- O -
time O +
reverse O +
transcription O +
PCR O -
. O +

Correlation O +
coefficients O +
were O +
determined O +
for O +
all O +
possible O +
mRNA O -
- O -
miRNA O +
pairs O +
and O +
the O +
distribution O +
of O +
these O +
correlations O +
compared O +
to O +
the O +
random O +
distribution O -
. O +

An O +
excess O +
of O +
high O +
positive O +
and O +
negative O +
correlation O +
pairs O +
were O +
observed O +
at O +
the O +
tails O +
of O +
these O +
distributions O -
. O +

BACKGROUND O -
: O +
microRNAs O +
( O -
miRNAs O -
) O +
are O +
approximately O +
21 O +
nucleotide O +
non O -
- O -
coding O +
transcripts O +
capable O +
of O +
regulating O +
gene O +
expression O -
. O +

Detection O +
of O +
a O +
microRNA O +
signal O +
in O +
an O +
in O +
vivo O +
expression O +
set O +
of O +
mRNAs O -
. O +

As O +
a O +
result O -
, O +
translation O +
of O +
the O +
target O +
mRNA O +
is O +
inhibited O +
and O +
the O +
mRNA O +
may O +
be O +
destabilized O -
. O +

The O +
most O +
widely O +
studied O +
mechanism O +
of O +
regulation O +
involves O +
binding O +
of O +
a O +
miRNA O +
to O +
the O +
target O +
mRNA O -
. O +

We O +
asked O +
whether O +
endogenous O +
fluctuations O +
in O +
a O +
set O +
of O +
mRNA O +
and O +
miRNA O +
profiles O +
contain O +
correlated O +
changes O +
that O +
are O +
statistically O +
distinguishable O +
from O +
the O +
many O +
other O +
fluctuations O +
in O +
the O +
data O +
set O -
. O +

The O +
inhibitory O +
effects O +
of O +
miRNAs O +
have O +
been O +
linked O +
to O +
diverse O +
cellular O +
processes O +
including O +
malignant O +
proliferation O -
, O +
apoptosis O -
, O +
development O -
, O +
differentiation O -
, O +
and O +
metabolic O +
processes O -
. O +

METHODOLOGY O -
/ O -
PRINCIPAL O +
FINDINGS O -
: O +
In O +
a O +
screening O +
of O +
MB O +
cell O +
lines O -
, O +
the O +
miRNA O +
miR-199b-5p O +
was O +
seen O +
to O +
be O +
a O +
regulator O +
of O +
the O +
Notch O +
pathway O +
through O +
its O +
targeting O +
of O +
the O +
transcription O +
factor O +
HES1 O -
. O +
Down O -
- O -
regulation O +
of O +
HES1 O +
expression O +
by O +
miR-199b-5p O +
negatively O +
regulates O +
the O +
proliferation O +
rate O +
and O +
anchorage O -
- O -
independent O +
growth O +
of O +
MB O +
cells O -
. O +

MiR-199b-5p O +
over O -
- O -
expression O +
blocks O +
expression O +
of O +
several O +
cancer O +
stem O -
- O -
cell O +
genes O -
, O +
impairs O +
the O +
engrafting O +
potential O +
of O +
MB O +
cells O +
in O +
the O +
cerebellum O +
of O +
athymic O -
/ O -
nude B-Species +
mice I-Species -
, O +
and O +
of O +
particular O +
interest O -
, O +
decreases O +
the O +
MB O +
stem O -
- O -
cell O -
- O -
like O +
( O -
CD133 O -
+ O -
) O +
subpopulation O +
of O +
cells O -
. O +

In O +
our O +
analysis O +
of O +
61 O +
patients B-Species +
with O +
MB O -
, O +
the O +
expression O +
of O +
miR-199b-5p O +
in O +
the O +
non O -
- O -
metastatic O +
cases O +
was O +
significantly O +
higher O +
than O +
in O +
the O +
metastatic O +
cases O +
( O -
P O +
= O +
0.001 O -
) O -
. O +

Correlation O +
with O +
survival O +
for O +
these O +
patients B-Species +
with O +
high O +
levels O +
of O +
miR-199b O +
expression O +
showed O +
a O +
positive O +
trend O +
to O +
better O +
overall O +
survival O +
than O +
for O +
the O +
low O -
- O -
expressing O +
patients B-Species -
. O +

Here O +
we O +
have O +
investigated O +
medulloblastoma O +
tumors O +
( O -
MBs O -
) O -
, O +
which O +
arise O +
from O +
an O +
early O +
impairment O +
of O +
developmental O +
processes O +
in O +
the O +
cerebellum O -
, O +
where O +
Notch O +
signaling O +
is O +
involved O +
in O +
many O +
cell O -
- O -
fate O -
- O -
determining O +
stages O -
. O +

MBs O +
occur O +
bimodally O -
, O +
with O +
the O +
peak O +
incidence O +
seen O +
between O +
3 O -
- O -
4 O +
years O +
and O +
8 O -
- O -
9 O +
years O +
of O +
age O -
, O +
although O +
it O +
can O +
also O +
occur O +
in O +
adults O -
. O +

Notch O +
regulates O +
a O +
subset O +
of O +
the O +
MB O +
cells O +
that O +
have O +
stem O -
- O -
cell O -
- O -
like O +
properties O +
and O +
can O +
promote O +
tumor O +
growth O -
. O +

On O +
the O +
basis O +
of O +
this O +
evidence O -
, O +
we O +
hypothesized O +
that O +
miRNAs O +
targeting O +
the O +
Notch O +
pathway O +
can O +
regulated O +
these O +
phenomena O -
, O +
and O +
can O +
be O +
used O +
in O +
anti O -
- O -
cancer O +
therapies O -
. O +

BACKGROUND O -
: O +
Through O +
negative O +
regulation O +
of O +
gene O +
expression O -
, O +
microRNAs O +
( O -
miRNAs O -
) O +
can O +
function O +
in O +
cancers O +
as O +
oncosuppressors O -
, O +
and O +
they O +
can O +
show O +
altered O +
expression O +
in O +
various O +
tumor O +
types O -
. O +

MicroRNA-199b-5p O +
impairs O +
cancer O +
stem O +
cells O +
through O +
negative O +
regulation O +
of O +
HES1 O +
in O +
medulloblastoma O -
. O +

To O +
date O -
, O +
this O +
is O +
the O +
first O +
report O +
that O +
expression O +
of O +
a O +
miRNA O +
can O +
deplete O +
the O +
tumor O +
stem O +
cells O -
, O +
indicating O +
an O +
interesting O +
therapeutic O +
approach O +
for O +
the O +
targeting O +
of O +
these O +
cells O +
in O +
brain O +
tumors O -
. O +

CONCLUSIONS O -
/ O -
SIGNIFICANCE O -
: O +
Despite O +
advances O +
in O +
our O +
understanding O +
of O +
the O +
pathogenesis O +
of O +
MB O -
, O +
one O -
- O -
third O +
of O +
these O +
patients B-Species +
remain O +
incurable O +
and O +
current O +
treatments O +
can O +
significantly O +
damage O +
long O -
- O -
term O +
survivors O -
. O +

Infection O +
with O +
MB O +
cells O +
in O +
an O +
induced O +
xenograft O +
model O +
in O +
the O +
mouse B-Species +
cerebellum O +
and O +
the O +
use O +
of O +
an O +
adenovirus O +
carrying O +
miR-199b-5p O +
indicate O +
a O +
clinical O +
benefit O +
through O +
this O +
negative O +
influence O +
of O +
miR-199b-5p O +
on O +
tumor O +
growth O +
and O +
on O +
the O +
subset O +
of O +
MB O +
stem O -
- O -
cell O -
- O -
like O +
cells O -
, O +
providing O +
further O +
proof O +
of O +
concept O -
. O +

We O +
further O +
show O +
that O +
in O +
a O +
xenograft O +
model O -
, O +
MB O +
tumor O +
burden O +
can O +
be O +
reduced O -
, O +
indicating O +
the O +
use O +
of O +
miR199b-5p O +
as O +
an O +
adjuvant O +
therapy O +
after O +
surgery O -
, O +
in O +
combination O +
with O +
radiation O +
and O +
chemotherapy O -
, O +
for O +
the O +
improvement O +
of O +
anti O -
- O -
cancer O +
MB O +
therapies O +
and O +
patient B-Species +
quality O +
of O +
life O -
. O +

Here O +
we O +
show O +
that O +
miR-199b-5p O +
expression O +
correlates O +
with O +
metastasis O +
spread O -
, O +
identifying O +
a O +
new O +
molecular O +
marker O +
for O +
a O +
poor O -
- O -
risk O +
class O +
in O +
patients B-Species +
with O +
MB O -
. O +

These O +
data O +
showing O +
the O +
down O -
- O -
regulation O +
of O +
miR-199b-5p O +
in O +
metastatic O +
MBs O +
suggest O +
a O +
potential O +
silencing O +
mechanism O +
through O +
epigenetic O +
or O +
genetic O +
alterations O -
. O +

Furthermore O -
, O +
two O +
cell O +
lines O +
( O -
Med8a O +
and O +
UW228 O -
) O +
showed O +
significant O +
up O -
- O -
regulation O +
of O +
miR-199b-5p O +
upon O +
treatment O -
. O +

Upon O +
induction O +
of O +
de O -
- O -
methylation O +
using O +
5-aza O -
- O -
deoxycytidine O -
, O +
lower O +
miR-199b-5p O +
expression O +
was O +
seen O +
in O +
a O +
panel O +
of O +
MB O +
cell O +
lines O -
, O +
supported O +
an O +
epigenetic O +
mechanism O +
of O +
regulation O -
. O +

Many O +
tools O +
have O +
been O +
developed O +
to O +
help O +
describe O +
the O +
repertoire O +
of O +
miRNAs O +
present O +
at O +
the O +
tissue O +
level O +
in O +
a O +
given O +
sample O -
. O +

To O +
understand O +
how O +
miRNAs O +
contribute O +
to O +
normal O +
biologic O +
functions O +
and O +
disease O +
states O -
, O +
it O +
is O +
critical O +
to O +
understand O +
the O +
miRNAs O +
that O +
are O +
expressed O +
in O +
particular O +
cell O +
types O +
under O +
a O +
range O +
of O +
conditions O -
. O +

Such O +
knowledge O +
is O +
especially O +
important O +
in O +
the O +
nervous O +
system O +
with O +
its O +
many O +
cell O +
types O -
, O +
microscopic O +
heterogeneity O +
with O +
regard O +
to O +
functionally O +
distinct O +
cell O +
groups O -
, O +
and O +
extreme O +
geometrical O +
complexity O +
in O +
cellular O +
shapes O -
. O +

However O -
, O +
tissue O +
level O +
miRNA O +
profiling O +
is O +
inadequate O +
to O +
pinpoint O +
the O +
cellular O +
and O +
sub O -
- O -
cellular O +
distribution O +
of O +
individual O +
miRNAs O -
. O +

In O +
situ O +
hybridization O +
is O +
a O +
necessary O +
experimental O +
complement O +
to O +
microRNA O +
( O -
miRNA O -
) O +
expression O +
profiling O +
in O +
the O +
human B-Species +
brain O -
. O +

However O -
, O +
much O +
remains O +
to O +
be O +
learned O +
in O +
this O +
fast O -
- O -
paced O +
field O -
. O +

MicroRNAs O +
( O -
miRNAs O -
) O +
play O +
fundamental O +
roles O +
in O +
human B-Species +
brain O +
neurochemistry O -
. O +

Thus O -
, O +
in O +
situ O +
hybridization O +
is O +
an O +
important O +
experimental O +
complement O +
to O +
tissue O +
level O +
miRNA O +
expression O +
profiling O -
. O +

We O +
have O +
found O +
that O +
in O +
situ O +
hybridization O +
shows O +
important O +
cerebral O +
cortical O +
lamina O -
- O -
specific O +
patterns O +
of O +
miRNA O +
expression O +
that O +
would O +
be O +
lost O +
on O +
most O +
tissue O +
level O +
expression O +
studies O -
, O +
and O +
these O +
lamina O -
- O -
specific O +
patterns O +
can O +
be O +
directly O +
relevant O +
to O +
human B-Species +
brain O +
disease O -
. O +

Technical O +
and O +
theoretical O +
aspects O +
of O +
this O +
important O +
technique O +
are O +
described O -
, O +
especially O +
those O +
pertinent O +
to O +
studying O +
the O +
human B-Species +
brain O -
. O +

The O +
expression O +
levels O +
of O +
most O +
miRNAs O +
were O +
in O +
accordance O +
with O +
previously O +
published O +
results O +
by O +
microarray O -
. O +

Their O +
frequency O +
distribution O +
was O +
approximately O +
a O +
normal O +
distribution O -
. O +

However O -
, O +
the O +
positive O +
rate O +
was O +
higher O +
than O +
that O +
detected O +
by O +
microarray O -
. O +

[ O -
Profiling O +
of O +
microRNAs O +
in O +
mouse B-Species +
brain O +
with O +
real O -
- O -
time O +
PCR O +
array O -
] O -
. O +

METHODS O -
: O +
Low O +
molecular O +
weight O +
RNA O +
from O +
cerebrum O +
of O +
five O +
C57BL O -
/ O -
6J O +
mice B-Species +
were O +
tailed O +
and O +
reverse O +
transcribed O +
by O +
extended O +
RT O -
- O -
primer O -
. O +

OBJECTIVE O -
: O +
To O +
examine O +
global O +
expression O +
levels O +
of O +
microRNAs O -
( O -
miRNAs O -
) O +
in O +
mouse B-Species +
cerebrum O +
and O +
to O +
provide O +
an O +
important O +
basis O +
for O +
detailed O +
studies O +
of O +
individual O +
miRNAs O -
, O +
their O +
target O +
genes O -
, O +
the O +
miRNA O -
- O -
related O +
regulatory O +
networks O +
in O +
the O +
mammalian O +
central O +
nervous O +
system O -
, O +
and O +
their O +
implications O +
in O +
diseases O -
. O +

PCR O +
was O +
carried O +
out O +
at O +
different O +
annealing O +
temperatures O +
using O +
a O +
gradient O +
real O -
- O -
time O +
PCR O +
instrument O -
. O +

miRNA O +
primers O +
were O +
carefully O +
designed O +
and O +
arrayed O +
on O +
plates O +
according O +
to O +
the O +
Tm O +
of O +
each O +
primer O -
. O +

RESULTS O -
: O +
Among O +
the O +
285 O +
miRNAs O +
detected O -
, O +
260 O +
were O +
positive O +
with O +
varying O +
abundance O -
. O +

The O +
relative O +
expression O +
level O +
of O +
each O +
miRNA O +
was O +
calculated O +
using O +
5sRNA O +
for O +
normalization O -
. O +

Clusters O +
of O +
proximal O +
miRNAs O +
were O +
similar O +
or O +
quite O +
different O +
in O +
abundance O -
. O +

miRNAs O +
originating O +
from O +
the O +
same O +
hairpin O +
precursors O +
expressed O +
at O +
similar O +
or O +
significantly O +
different O +
levels O -
. O +

It O +
is O +
suggested O +
that O +
the O +
fate O +
of O +
miRNA O +
after O +
transcription O +
determined O +
their O +
abundance O -
. O +

CONCLUSION O -
: O +
Using O +
the O +
RNA O -
- O -
tailing O +
and O +
primer O -
- O -
extension O +
PCR O +
array O +
method O -
, O +
we O +
obtained O +
expression O +
profile O +
of O +
miRNA O +
in O +
mouse B-Species +
cerebrum O -
, O +
especially O +
the O +
relative O +
expression O +
data O +
of O +
many O +
low O +
abundant O +
miRNA O +
in O +
mouse B-Species +
cerebrum O -
, O +
which O +
will O +
be O +
of O +
special O +
help O +
for O +
studying O +
the O +
fine O -
- O -
tuning O +
function O +
of O +
low O -
- O -
level O +
miRNAs O -
. O +

Furthermore O -
, O +
methods O +
to O +
profile O +
miRNAs O +
from O +
formalin O -
- O -
fixed O -
, O +
paraffin O -
- O -
embedded O +
( O -
FFPE O -
) O +
archival O +
tissues O +
or O +
to O +
study O +
their O +
cellular O +
and O +
subcellular O +
localization O +
in O +
FFPE O +
tissues O +
have O +
been O +
lacking O -
. O +

Here O +
we O +
report O +
the O +
coordinated O +
miRNA O +
expression O +
analysis O +
from O +
the O +
tissue O +
level O +
to O +
the O +
subcellular O +
level O -
, O +
using O +
the O +
RAKE O +
( O -
RNA O -
- O -
primed O -
, O +
array O -
- O -
based O -
, O +
Klenow O +
Enzyme O -
) O +
miRNA O +
microarray O +
platform O +
in O +
conjunction O +
with O +
Locked O +
Nucleic O +
Acid O +
( O -
LNA O -
) O -
-based O +
in O +
situ O +
hybridization O +
( O -
LNA O -
- O -
ISH O -
) O +
on O +
archival O +
FFPE O +
human B-Species +
brains O +
and O +
oligodendroglial O +
tumors O -
. O +

The O +
ability O +
to O +
profile O +
miRNAs O +
from O +
archival O +
tissues O +
at O +
the O +
tissue O +
level O -
, O +
by O +
RAKE O +
microarrays O -
, O +
and O +
at O +
the O +
cellular O +
level O +
by O +
LNA O -
- O -
ISH O -
, O +
will O +
accelerate O +
studies O +
of O +
miRNAs O +
in O +
human B-Species +
diseases O -
. O +

RAKE O +
and O +
LNA O -
- O -
ISH O +
reveal O +
microRNA O +
expression O +
and O +
localization O +
in O +
archival O +
human B-Species +
brain O -
. O +

microRNAs O +
( O -
miRNAs O -
) O +
are O +
small O +
( O -
approximately O +
22 O +
nucleotide O -
) O +
regulatory O +
RNAs O +
which O +
play O +
fundamental O +
roles O +
in O +
many O +
biological O +
processes O -
. O +

Recent O +
studies O +
have O +
shown O +
that O +
the O +
expression O +
of O +
many O +
miRNAs O +
is O +
altered O +
in O +
various O +
human B-Species +
tumors O +
and O +
some O +
miRNAs O +
may O +
function O +
as O +
oncogenes O +
or O +
tumor O +
suppressor O +
genes O -
. O +

However O -
, O +
with O +
the O +
exception O +
of O +
glioblastoma O +
multiforme O -
, O +
the O +
expression O +
of O +
miRNAs O +
in O +
brain O +
tumors O +
is O +
unknown O -
. O +

Thus O +
we O +
have O +
identified O +
the O +
miRNA O +
expression O +
signature O +
for O +
malignant O +
astrocytoma O -
, O +
in O +
particular O +
glioblastoma O -
, O +
and O +
showed O +
the O +
miRNA O +
involvement O +
and O +
their O +
importance O +
in O +
astrocytoma O +
development O -
. O +

Inhibition O +
of O +
two O +
glioblastoma O -
- O -
upregulated O +
miRNAs O +
( O -
miR-21 O +
and O +
miR-23a O -
) O +
and O +
exogenous O +
overexpression O +
of O +
two O +
glioblastoma O -
- O -
downregulated O +
miRNAs O +
( O -
miR-218 O +
and O +
miR-219 O -
- O -
5p O -
) O +
resulted O +
in O +
reduced O +
soft O +
agar O +
colony O +
formation O +
but O +
showed O +
varying O +
effects O +
on O +
cell O +
proliferation O +
and O +
chemosensitivity O -
. O +

Among O +
them O -
, O +
glioblastoma O +
is O +
the O +
most O +
common O +
primary O +
brain O +
tumor O +
with O +
dismal O +
responses O +
to O +
all O +
therapeutic O +
modalities O -
. O +

Malignant O +
astrocytoma O +
includes O +
anaplastic O +
astrocytoma O +
( O -
grade O +
III O -
) O +
and O +
glioblastoma O +
( O -
grade O +
IV O -
) O -
. O +

Genome O -
- O -
wide O +
expression O +
profiling O +
identifies O +
deregulated O +
miRNAs O +
in O +
malignant O +
astrocytoma O -
. O +

The O +
differential O +
expression O +
pattern O +
of O +
nine O +
miRNAs O +
was O +
further O +
validated O +
by O +
real O -
- O -
time O +
RT O -
- O -
PCR O +
on O +
an O +
independent O +
set O +
of O +
malignant O +
astrocytomas O +
( O -
n=72 O -
) O +
and O +
normal O +
samples O +
( O -
n=7 O -
) O -
. O +

More O +
importantly O -
, O +
we O +
identified O +
a O +
most O +
discriminatory O +
23-miRNA O +
expression O +
signature O -
, O +
by O +
using O +
PAM O -
, O +
which O +
precisely O +
distinguished O +
glioblastoma O +
from O +
anaplastic O +
astrocytoma O +
with O +
an O +
accuracy O +
of O +
95 O -
% O -
. O +

We O +
identified O +
several O +
differentially O +
regulated O +
miRNAs O +
between O +
these O +
groups O -
, O +
which O +
could O +
differentiate O +
glioma O +
grades O +
and O +
normal O +
brain O +
as O +
recognized O +
by O +
PCA O -
. O +

We O +
performed O +
a O +
large O -
- O -
scale O -
, O +
genome O -
- O -
wide O +
microRNA O +
( O -
miRNA O -
) O +
( O -
n=756 O -
) O +
expression O +
profiling O +
of O +
26 O +
glioblastoma O -
, O +
13 O +
anaplastic O +
astrocytoma O +
and O +
7 O +
normal O +
brain O +
samples O +
with O +
an O +
aim O +
to O +
find O +
deregulated O +
miRNA O +
in O +
malignant O +
astrocytoma O -
. O +

Our O +
findings O +
suggest O +
a O +
functional O +
collaboration O +
between O +
the O +
miR-17 O +
approximately O +
92 O +
cluster O +
and O +
the O +
SHH O +
signaling O +
pathway O +
in O +
the O +
development O +
of O +
MBs O +
in O +
mouse B-Species +
and O +
man B-Species -
. O +

Analysis O +
of O +
human B-Species +
MBs O +
demonstrated O +
that O +
3 O +
miR-17 O +
approximately O +
92 O +
cluster O +
miRNAs O +
( O -
miR-92 O -
, O +
miR-19a O -
, O +
and O +
miR-20 O -
) O +
were O +
also O +
overexpressed O +
in O +
human B-Species +
MBs O +
with O +
a O +
constitutively O +
activated O +
Sonic O +
Hedgehog O +
( O -
SHH O -
) O +
signaling O +
pathway O -
, O +
but O +
not O +
in O +
other O +
forms O +
of O +
the O +
disease O -
. O +

To O +
test O +
whether O +
the O +
miR-17 O +
approximately O +
92 O +
cluster O +
could O +
promote O +
MB O +
formation O -
, O +
we O +
enforced O +
expression O +
of O +
these O +
miRNAs O +
in O +
GNPs O +
isolated O +
from O +
cerebella O +
of O +
postnatal O +
( O -
P O -
) O +
day O +
P6 O +
Ink4c- O -
/ O -
- O -
; O +
Ptch1+ O -
/ O -
- O +
mice B-Species -
. O +

These O -
, O +
but O +
not O +
similarly O +
engineered O +
cells O +
from O +
Ink4c- O -
/ O -
- O -
; O +
p53- O -
/ O -
- O +
mice B-Species -
, O +
formed O +
MBs O +
in O +
orthotopic O +
transplants O +
with O +
complete O +
penetrance O -
. O +

Interestingly O -
, O +
orthotopic O +
mouse B-Species +
tumors O +
ectopically O +
expressing O +
miR-17 O +
approximately O +
92 O +
lost O +
expression O +
of O +
the O +
wild O -
- O -
type O +
Ptch1 O +
allele O -
. O +

Some O +
are O +
thought O +
to O +
originate O +
from O +
cerebellar O +
granule O +
neuron O +
progenitors O +
( O -
GNPs O -
) O +
that O +
fail O +
to O +
undergo O +
normal O +
cell O +
cycle O +
exit O +
and O +
differentiation O -
. O +

Because O +
microRNAs O +
regulate O +
numerous O +
aspects O +
of O +
cellular O +
physiology O +
and O +
development O -
, O +
we O +
reasoned O +
that O +
alterations O +
in O +
miRNA O +
expression O +
might O +
contribute O +
to O +
MB O -
. O +
We O +
tested O +
this O +
hypothesis O +
using O +
2 O +
spontaneous O +
mouse B-Species +
MB O +
models O +
with O +
specific O +
initiating O +
mutations O -
, O +
Ink4c- O -
/ O -
- O -
; O +
Ptch1+ O -
/ O -
- O +
and O +
Ink4c- O -
/ O -
- O -
; O +
p53- O -
/ O -
- O -
. O +

We O +
found O +
that O +
26 O +
miRNAs O +
showed O +
increased O +
expression O +
and O +
24 O +
miRNAs O +
showed O +
decreased O +
expression O +
in O +
proliferating O +
mouse B-Species +
GNPs O +
and O +
MBs O +
relative O +
to O +
mature O +
mouse B-Species +
cerebellum O -
, O +
regardless O +
of O +
genotype O -
. O +

Among O +
the O +
26 O +
overexpressed O +
miRNAs O -
, O +
9 O +
were O +
encoded O +
by O +
the O +
miR-17 O +
approximately O +
92 O +
cluster O +
family O -
, O +
a O +
group O +
of O +
microRNAs O +
implicated O +
as O +
oncogenes O +
in O +
several O +
tumor O +
types O -
. O +

The O +
miR-17~92 O +
cluster O +
collaborates O +
with O +
the O +
Sonic O +
Hedgehog O +
pathway O +
in O +
medulloblastoma O -
. O +

Medulloblastomas O +
( O -
MBs O -
) O +
are O +
the O +
most O +
common O +
brain O +
tumors O +
in O +
children B-Species -
. O +

Since O +
over O -
- O -
expression O +
of O +
human B-Species +
SNCA O +
( O -
hSNCA O -
) O +
leads O +
to O +
death O +
of O +
dopaminergic O +
( O -
DA O -
) O +
neurons O +
in O +
human B-Species -
, O +
rodent O +
and O +
fly O +
brain O -
, O +
hSNCA O +
gene O +
silencing O +
may O +
reduce O +
levels O +
of O +
toxic O +
forms O +
of O +
SNCA O +
and O +
ameliorate O +
degeneration O +
of O +
DA O +
neurons O +
in O +
PD O -
. O +

Alpha O -
- O -
synuclein O +
( O -
SNCA O -
) O -
, O +
an O +
abundantly O +
expressed O +
presynaptic O +
protein O -
, O +
is O +
implicated O +
in O +
Parkinson O -
's O +
disease O +
( O -
PD O -
) O -
. O +

A O +
microRNA O +
embedded O +
AAV O +
alpha O -
- O -
synuclein O +
gene O +
silencing O +
vector O +
for O +
dopaminergic O +
neurons O -
. O +

Our O +
in O +
vitro O +
data O +
suggest O +
that O +
this O +
miRNA O -
- O -
embedded O +
silencing O +
vector O +
may O +
be O +
ideal O +
for O +
chronic O +
in O +
vivo O +
SNCA O +
gene O +
silencing O +
in O +
DA O +
neurons O -
. O +

However O -
, O +
the O +
mir30 O +
embedded O +
vector O +
was O +
significantly O +
less O +
toxic O +
to O +
both O +
PC12 O +
and O +
SH O -
- O -
SY5Y O +
cells O -
. O +

In O +
DA O +
PC12 O +
cells O -
, O +
neither O +
vector O +
decreased O +
expression O +
of O +
rat B-Species +
SNCA O -
, O +
tyrosine O +
hydroxylase O +
( O -
TH O -
) O -
, O +
dopamine O +
transporter O +
( O -
DAT O -
) O +
or O +
the O +
vesicular O +
monoamine O +
transporter O +
( O -
VMAT O -
) O -
. O +

Both O +
vectors O +
silenced O +
hSNCA O +
to O +
the O +
same O +
extent O +
in O +
293 O -
T O +
cells O +
transfected O +
with O +
hSNCA O -
. O +

The O +
same O +
hSNCA O +
silencing O +
sequence O +
( O -
shRNA O -
) O +
was O +
used O +
in O +
both O +
vectors O -
, O +
but O +
in O +
one O +
vector O -
, O +
the O +
shRNA O +
was O +
embedded O +
in O +
a O +
microRNA O +
backbone O +
and O +
driven O +
by O +
a O +
pol O +
II O +
promoter O -
, O +
and O +
in O +
the O +
other O +
the O +
shRNA O +
was O +
not O +
embedded O +
in O +
a O +
microRNA O +
and O +
was O +
driven O +
by O +
a O +
pol O +
III O +
promoter O -
. O +

To O +
begin O +
to O +
develop O +
a O +
gene O +
therapy O +
for O +
PD O +
based O +
on O +
hSNCA O +
gene O +
silencing O -
, O +
two O +
AAV O +
gene O +
silencing O +
vectors O +
were O +
designed O -
, O +
and O +
tested O +
for O +
efficiency O +
and O +
specificity O +
of O +
silencing O -
, O +
as O +
well O +
as O +
toxicity O +
in O +
vitro O -
. O +

Taken O +
together O -
, O +
induction O +
of O +
microRNA O +
expression O +
in O +
BMC O +
may O +
contribute O +
to O +
the O +
aberrant O +
systemic O +
decline O +
in O +
mRNA O +
levels O +
in O +
sporadic O +
AD O -
. O +

MicroRNA O +
expression O +
in O +
Alzheimer O +
blood O +
mononuclear O +
cells O -
. O +

Various O +
coding O +
genes O +
representing O +
multiple O +
functional O +
categories O +
are O +
downregulated O +
in O +
blood O +
mononuclear O +
cells O +
( O -
BMC O -
) O +
of O +
patients B-Species +
with O +
sporadic O +
Alzheimer O +
disease O +
( O -
AD O -
) O -
. O +

Noncoding O +
microRNAs O +
( O -
miRNA O -
) O +
regulate O +
gene O +
expression O +
by O +
degrading O +
messages O +
or O +
inhibiting O +
translation O -
. O +

Using O +
BMC O +
as O +
a O +
paradigm O +
for O +
the O +
study O +
of O +
systemic O +
alterations O +
in O +
AD O -
, O +
we O +
investigated O +
whether O +
peripheral O +
miRNA O +
expression O +
is O +
altered O +
in O +
this O +
condition O -
. O +

MicroRNA O +
levels O +
were O +
assessed O +
using O +
the O +
microRNA O +
microarray O +
( O -
MMChip O -
) O +
containing O +
462 O +
human B-Species +
miRNA O -
, O +
and O +
the O +
results O +
validated O +
by O +
real O +
time O +
PCR O -
. O +

Sixteen O +
AD O +
patients B-Species +
and O +
sixteen O +
normal O +
elderly O +
controls O +
( O -
NEC O -
) O +
were O +
matched O +
for O +
ethnicity O -
, O +
age O -
, O +
gender O +
and O +
education O -
. O +

The O +
expression O +
of O +
several O +
BMC O +
miRNAs O +
was O +
found O +
to O +
increase O +
in O +
AD O +
relative O +
to O +
NEC O +
levels O -
, O +
and O +
may O +
differ O +
between O +
AD O +
subjects O +
bearing O +
one O +
or O +
two O +
APOE4 O +
alleles O -
. O +

As O +
compared O +
to O +
NEC O -
, O +
miRNAs O +
significantly O +
upregulated O +
in O +
AD O +
subjects O +
and O +
confirmed O +
by O +
qPCR O +
were O +
miR-34a O +
and O +
181b O -
. O +

Predicted O +
target O +
genes O +
downregulated O +
in O +
Alzheimer O +
BMC O +
that O +
correlated O +
with O +
the O +
upregulated O +
miRNAs O +
were O +
largely O +
represented O +
in O +
the O +
functional O +
categories O +
of O +
Transcription O -
/ O -
Translation O +
and O +
Synaptic O +
Activity O -
. O +

Several O +
miRNAs O +
targeting O +
the O +
same O +
genes O +
were O +
within O +
the O +
functional O +
category O +
of O +
Injury O +
response O -
/ O -
Redox O +
homeostasis O -
. O +

Despite O +
the O +
small O +
sample O +
available O -
, O +
we O +
can O +
show O +
that O +
this O +
approach O +
permits O +
identification O +
of O +
meaningful O +
structures O -
, O +
in O +
particular O +
two O +
polycistronic O +
miRNA O +
genes O +
related O +
to O +
transcriptional O +
activity O +
and O +
likely O +
to O +
be O +
relevant O +
in O +
the O +
discrimination O +
between O +
gliosarcomas O +
and O +
other O +
brain O +
tumors O -
. O +

Our O +
intention O +
is O +
to O +
identify O +
structures O +
that O +
contain O +
information O +
from O +
both O +
mRNAs O +
and O +
miRNAs O -
, O +
and O +
that O +
can O +
explain O +
the O +
complexity O +
of O +
the O +
data O -
. O +

RESULTS O -
: O +
We O +
use O +
Factor O +
Analysis O +
coupled O +
with O +
pre O -
- O -
established O +
knowledge O +
as O +
a O +
theoretical O +
base O +
to O +
achieve O +
this O +
goal O -
. O +

We O +
analyzed O +
one O +
of O +
the O +
( O -
currently O -
) O +
few O +
datasets O +
that O +
provide O +
both O +
transcriptional O +
and O +
post O -
- O -
transcriptional O +
data O +
of O +
the O +
same O +
samples O +
to O +
investigate O +
the O +
possibility O +
to O +
extract O +
more O +
information O -
, O +
using O +
a O +
joint O +
analysis O +
approach O -
. O +

CONCLUSIONS O -
: O +
This O +
suggests O +
the O +
need O +
to O +
develop O +
methodologies O +
to O +
simultaneously O +
mine O +
information O +
from O +
different O +
levels O +
of O +
biological O +
organization O -
, O +
rather O +
than O +
linking O +
separate O +
analyses O +
performed O +
in O +
parallel O -
. O +

However O -
, O +
to O +
date O -
, O +
most O +
computational O +
and O +
algorithmic O +
efforts O +
have O +
been O +
directed O +
at O +
mining O +
data O +
from O +
each O +
of O +
these O +
molecular O +
levels O +
( O -
genomic O -
, O +
transcriptional O -
, O +
etc O -
. O -
) O +
separately O -
. O +

In O +
view O +
of O +
the O +
rapid O +
advances O +
in O +
technology O +
( O -
new O +
generation O +
sequencing O -
, O +
high O -
- O -
throughput O +
proteomics O -
) O +
it O +
is O +
important O +
to O +
address O +
the O +
problem O +
of O +
analyzing O +
these O +
data O +
as O +
a O +
whole O -
, O +
i.e. O +
preserving O +
the O +
emergent O +
properties O +
that O +
appear O +
in O +
the O +
cellular O +
system O +
when O +
all O +
molecular O +
levels O +
are O +
interacting O -
. O +

Joint O +
analysis O +
of O +
transcriptional O +
and O +
post- O +
transcriptional O +
brain O +
tumor O +
data O -
: O +
searching O +
for O +
emergent O +
properties O +
of O +
cellular O +
systems O -
. O +

UNLABELLED O -
: O +
ABSTRACT O -
: O +
BACKGROUND O -
: O +
Advances O +
in O +
biotechnology O +
offer O +
a O +
fast O +
growing O +
variety O +
of O +
high O -
- O -
throughput O +
data O +
for O +
screening O +
molecular O +
activities O +
of O +
genomic O -
, O +
transcriptional O -
, O +
post O -
- O -
transcriptional O +
and O +
translational O +
observations O -
. O +

To O +
investigate O +
noncoding O +
tiny O +
microRNA O +
mediated O +
gene O +
regulation O -
, O +
miRanda O +
( O -
version O +
1.0b O -
) O +
was O +
used O +
to O +
predict O +
human B-Species +
miRNA O +
target O +
sites O +
on O +
selected O +
29 O +
genes O +
related O +
to O +
PD O -
. O +
To O +
verify O +
output O +
generated O +
from O +
miRanda O -
, O +
a O +
similar O +
analysis O +
was O +
performed O +
only O +
for O +
microRNA O +
target O +
sites O +
in O +
3'UTR O +
using O +
TargetScan O +
( O -
version O +
5.1 O -
) O -
. O +

Data O +
extracted O +
by O +
miRanda O +
elucidates O +
the O +
mode O +
of O +
microRNA O +
action O +
based O +
on O +
the O +
location O +
of O +
target O +
sites O +
in O +
the O +
Parkinson O +
genes O -
. O +

Sites O +
prone O +
to O +
action O +
of O +
multiple O +
miRNAs O +
were O +
identified O +
as O +
" O -
hot O +
spots O -
. O -
" O +

Important O +
properties O +
of O +
each O +
miRNA O +
including O +
multiplicity O +
and O +
cooperativity O +
appear O +
to O +
contribute O +
towards O +
a O +
complex O +
interplay O +
between O +
miRNAs O +
and O +
their O +
targets O -
. O +

Two O +
sets O +
of O +
predicted O +
results O +
were O +
explored O +
for O +
the O +
occurrence O +
of O +
target O +
sites O +
of O +
112 O +
miRNAs O +
expressed O +
in O +
midbrain O -
. O +

Overall O -
, O +
convergence O +
of O +
results O +
predicted O +
by O +
two O +
algorithms O +
revealed O +
that O +
48 O +
target O +
sites O +
for O +
midbrain O -
- O -
specific O +
miRNA O +
occur O +
in O +
close O +
proximity O +
in O +
9 O +
genes O -
. O +

This O +
study O +
will O +
pave O +
a O +
way O +
for O +
selection O +
of O +
potential O +
miRNA O +
candidates O +
for O +
Parkinson O -
's O +
disease O -
- O -
related O +
genes O +
for O +
quick O +
therapeutic O +
applications O +
and O +
diagnosis O -
. O +

Parkinson O -
's O +
disease O +
( O -
PD O -
) O +
is O +
a O +
complex O +
multigenic O +
neurodisorder O +
frequently O +
occurring O +
in O +
elderly O +
persons O -
. O +

Interaction O +
map O +
and O +
selection O +
of O +
microRNA O +
targets O +
in O +
Parkinson O -
's O +
disease O -
- O -
related O +
genes O -
. O +

These O +
studies O +
suggest O +
that O +
miRNAs O +
may O +
be O +
important O +
for O +
neuronal O +
survival O +
in O +
the O +
context O +
of O +
human B-Species +
neurodegenerative O +
disease O -
. O +

These O +
studies O +
provide O +
the O +
foundation O +
to O +
define O +
the O +
miRNAs O +
involved O +
in O +
neurodegenerative O +
disease O -
, O +
and O +
the O +
biological O +
pathways O +
affected O -
. O +

These O +
studies O +
showed O +
that O +
upregulation O +
of O +
ban O +
mitigates O +
degeneration O +
induced O +
by O +
the O +
pathogenic O +
polyglutamine O +
( O -
polyQ O -
) O +
protein O +
Ataxin-3 O -
, O +
which O +
is O +
mutated O +
in O +
the O +
human B-Species +
polyglutamine O +
disease O +
spinocerebellar O +
ataxia O +
type O +
3 O +
( O -
SCA3 O -
) O -
. O +

To O +
address O +
the O +
broader O +
role O +
for O +
miRNAs O +
in O +
neuroprotection O -
, O +
we O +
also O +
showed O +
that O +
loss O +
of O +
all O +
miRNAs O -
, O +
by O +
dicer O +
mutation O -
, O +
dramatically O +
enhances O +
pathogenic O +
polyQ O +
protein O +
toxicity O +
in O +
flies O +
and O +
in O +
human B-Species +
HeLa O +
cells O -
. O +

A O +
new O +
role O +
for O +
microRNA O +
pathways O -
: O +
modulation O +
of O +
degeneration O +
induced O +
by O +
pathogenic O +
human B-Species +
disease O +
proteins O -
. O +

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
small O +
noncoding O +
RNAs O +
that O +
regulate O +
the O +
expression O +
of O +
target O +
transcript O +
mRNAs O -
. O +

Many O +
miRNAs O +
have O +
been O +
defined O -
, O +
however O +
their O +
roles O +
and O +
the O +
processes O +
influenced O +
by O +
miRNA O +
pathways O +
are O +
still O +
being O +
elucidated O -
. O +

A O +
role O +
for O +
miRNAs O +
in O +
development O +
and O +
cancer O +
has O +
been O +
described O -
. O +

We O +
recently O +
isolated O +
the O +
miRNA O +
bantam O +
( O -
ban O -
) O +
in O +
a O +
genetic O +
screen O +
for O +
modulators O +
of O +
pathogenicity O +
of O +
a O +
human B-Species +
neurodegenerative O +
disease O +
model O +
in O +
Drosophila O -
. O +

CONCLUSIONS O -
/ O -
SIGNIFICANCE O -
: O +
We O +
provide O +
a O +
list O +
of O +
ten O +
miRNA O +
loci O +
potentially O +
involved O +
in O +
the O +
development O +
of O +
blood O +
cancer O +
or O +
brain O +
tumors O -
. O +

There O +
is O +
independent O +
experimental O +
support O +
from O +
other O +
studies O +
for O +
the O +
involvement O +
of O +
miRNAs O +
from O +
at O +
least O +
three O +
CIS O -
- O -
associated O +
miRNA O +
loci O +
in O +
cancer O +
development O -
. O +

CIS O -
- O -
associated O +
miRNAs O +
on O +
average O +
are O +
more O +
conserved O +
in O +
vertebrates O +
than O +
miRNAs O +
associated O +
with O +
non O -
- O -
CIS O +
inserts O +
and O +
their O +
human B-Species +
homologs O +
are O +
also O +
located O +
in O +
regions O +
perturbed O +
in O +
cancer O -
. O +

In O +
addition O +
we O +
show O +
that O +
miRNA O +
genes O +
are O +
enriched O +
around O +
promoter O +
and/or O +
terminator O +
regions O +
of O +
RefSeq O +
genes O +
in O +
both O +
mouse B-Species +
and O +
human B-Species -
. O +

Ten O +
CIS O -
- O -
associated O +
miRNA O +
loci O +
containing O +
22 O +
miRNAs O +
are O +
located O +
within O +
10 O +
kb O +
of O +
known O +
CIS O +
insertions O -
. O +

Only O +
one O +
CIS O -
- O -
associated O +
miRNA O +
locus O +
overlaps O +
a O +
RefSeq O +
protein O -
- O -
coding O +
gene O +
and O +
six O +
loci O +
are O +
located O +
more O +
than O +
10 O +
kb O +
from O +
any O +
RefSeq O +
gene O -
. O +

METHODOLOGY O -
/ O -
PRINCIPAL O +
FINDINGS O -
: O +
Using O +
a O +
public O +
database O +
of O +
mapped O +
retroviral O +
insertion O +
sites O +
from O +
various O +
mouse B-Species +
models O +
of O +
cancer O +
we O +
demonstrate O +
that O +
MLV O -
- O -
derived O +
retroviral O +
inserts O +
are O +
enriched O +
in O +
close O +
proximity O +
to O +
mouse B-Species +
miRNA O +
loci O -
. O +

Clustered O +
inserts O +
from O +
cancer O -
- O -
associated O +
regions O +
( O -
Common O +
Integration O +
Sites O -
, O +
CIS O -
) O +
have O +
a O +
higher O +
association O +
with O +
miRNAs O +
than O +
non O -
- O -
clustered O +
inserts O -
. O +

BACKGROUND O -
: O +
MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
short O +
non O -
- O -
coding O +
RNAs O +
that O +
regulate O +
differentiation O +
and O +
development O +
in O +
many O +
organisms O +
and O +
play O +
an O +
important O +
role O +
in O +
cancer O -
. O +

Orthologous O +
microRNA O +
genes O +
are O +
located O +
in O +
cancer O -
- O -
associated O +
genomic O +
regions O +
in O +
human B-Species +
and O +
mouse B-Species -
. O +

Paired O +
Student O -
's O +
" O -
t O -
" O +
test O +
was O +
applied O +
to O +
the O +
scores O +
and O +
no O +
significant O +
difference O +
was O +
found O +
( O -
p O +
= O +
0.315 O -
) O -
. O +

In O +
the O +
postoperative O +
period O +
the O +
mean O +
MMSE O +
score O +
was O +
28.40 O +
( O -
SD O -
, O +
1.46 O -
) O -
. O +

METHOD O -
: O +
A O +
consecutive O +
series O +
of O +
40 O +
patients B-Species +
who O +
underwent O +
microsurgical O +
clipping O +
for O +
UIA O +
were O +
studied O -
. O +

The O +
cognitive O +
assessment O +
( O -
Mini O +
Mental O +
State O +
Examination O -
, O +
MMSE O -
) O +
was O +
performed O +
immediately O +
before O +
and O +
at O +
least O +
one O +
month O +
after O +
surgery O -
. O +

Paired O +
Student O -
's O +
" O -
t O -
" O +
test O +
and O +
analysis O +
of O +
variance O +
( O -
ANOVA O -
) O +
were O +
used O +
for O +
statistical O +
purposes O -
. O +

RESULTS O -
: O +
The O +
mean O +
MMSE O +
score O +
in O +
the O +
preoperative O +
analysis O +
was O +
28.12 O +
( O -
SD O -
, O +
1.34 O -
) O -
. O +

Microsurgical O +
clipping O +
in O +
forty O +
patients B-Species +
with O +
unruptured O +
anterior O +
cerebral O +
circulation O +
aneurysms O -
: O +
an O +
investigation O +
into O +
cognitive O +
outcome O -
. O +

OBJECTIVE O -
: O +
It O +
is O +
a O +
consensus O +
that O +
most O +
unruptured O +
intracranial O +
aneurysms O +
( O -
UIA O -
) O +
can O +
be O +
treated O +
with O +
acceptably O +
low O +
morbidity O -
. O +

However O -
, O +
some O +
studies O +
recently O +
reported O +
postoperative O +
cognitive O +
impairment O -
, O +
suggesting O +
that O +
it O +
could O +
be O +
attributable O +
to O +
surgical O +
damage O -
. O +

Our O +
goal O +
is O +
to O +
evaluate O +
cognitive O +
function O +
before O +
and O +
after O +
microsurgical O +
clipping O +
in O +
patients B-Species +
with O +
UIA O -
. O +

ANOVA O +
did O +
not O +
find O +
independent O +
associations O +
between O +
MMSE O +
scores O +
and O +
age O -
, O +
hypertension O -
, O +
smoking O -
, O +
dyslipidemia O -
, O +
education O -
, O +
aneurysm O +
location O -
, O +
number O -
, O +
laterality O +
or O +
size O -
. O +

CONCLUSION O -
: O +
The O +
present O +
study O +
suggests O +
that O +
microsurgical O +
clipping O +
for O +
UIA O +
does O +
not O +
result O +
in O +
major O +
cognitive O +
dysfunction O +
as O +
determined O +
by O +
the O +
MMSE O -
. O +

MicroRNA O +
miR-133b O +
is O +
essential O +
for O +
functional O +
recovery O +
after O +
spinal O +
cord O +
injury O +
in O +
adult O +
zebrafish B-Species -
. O +

MicroRNAs O +
( O -
miRNAs O -
) O +
play O +
important O +
roles O +
during O +
development O +
and O +
also O +
in O +
adult O +
organisms O +
by O +
regulating O +
the O +
expression O +
of O +
multiple O +
target O +
genes O -
. O +

Here O -
, O +
we O +
studied O +
the O +
function O +
of O +
miR-133b O +
during O +
zebrafish B-Species +
spinal O +
cord O +
regeneration O +
and O +
show O +
upregulation O +
of O +
miR-133b O +
expression O +
in O +
regenerating O +
neurons O +
of O +
the O +
brainstem O +
after O +
transection O +
of O +
the O +
spinal O +
cord O -
. O +

miR-133b O +
has O +
been O +
shown O +
to O +
promote O +
tissue O +
regeneration O +
in O +
other O +
tissue O -
, O +
but O +
its O +
ability O +
to O +
do O +
so O +
in O +
the O +
nervous O +
system O +
has O +
yet O +
to O +
be O +
tested O -
. O +

Inhibition O +
of O +
miR-133b O +
expression O +
by O +
antisense O +
morpholino O +
( O -
MO O -
) O +
application O +
resulted O +
in O +
impaired O +
locomotor O +
recovery O +
and O +
reduced O +
regeneration O +
of O +
axons O +
from O +
neurons O +
in O +
the O +
nucleus O +
of O +
the O +
medial O +
longitudinal O +
fascicle O -
, O +
superior O +
reticular O +
formation O +
and O +
intermediate O +
reticular O +
formation O -
. O +

miR-133b O +
targets O +
the O +
small O +
GTPase O +
RhoA O -
, O +
which O +
is O +
an O +
inhibitor O +
of O +
axonal O +
growth O -
, O +
as O +
well O +
as O +
other O +
neurite O +
outgrowth O -
- O -
related O +
molecules O -
. O +

Our O +
results O +
indicate O +
that O +
miR-133b O +
is O +
an O +
important O +
determinant O +
in O +
spinal O +
cord O +
regeneration O +
of O +
adult O +
zebrafish B-Species +
through O +
reduction O +
in O +
RhoA O +
protein O +
levels O +
by O +
direct O +
interaction O +
with O +
its O +
mRNA O -
. O +

While O +
RhoA O +
has O +
been O +
studied O +
as O +
a O +
therapeutic O +
target O +
in O +
spinal O +
cord O +
injury O -
, O +
this O +
is O +
the O +
first O +
demonstration O +
of O +
endogenous O +
regulation O +
of O +
RhoA O +
by O +
a O +
microRNA O +
that O +
is O +
required O +
for O +
spinal O +
cord O +
regeneration O +
in O +
zebrafish B-Species -
. O +

The O +
ability O +
of O +
miR-133b O +
to O +
suppress O +
molecules O +
that O +
inhibit O +
axon O +
regrowth O +
may O +
underlie O +
the O +
capacity O +
for O +
adult O +
zebrafish B-Species +
to O +
recover O +
locomotor O +
function O +
after O +
spinal O +
cord O +
injury O -
. O +

As O +
a O +
genetically O +
complex O +
disease O -
, O +
dysregulation O +
of O +
miRNA O +
expression O +
might O +
be O +
a O +
feature O +
of O +
autism O +
spectrum O +
disorders O +
( O -
ASDs O -
) O -
. O +

Using O +
multiplex O +
quantitative O +
polymerase O +
chain O +
reaction O +
( O -
PCR O -
) O -
, O +
we O +
compared O +
the O +
expression O +
of O +
466 O +
human B-Species +
miRNAs O +
from O +
postmortem O +
cerebellar O +
cortex O +
tissue O +
of O +
individuals O +
with O +
ASD O +
( O -
n O +
= O +
13 O -
) O +
and O +
a O +
control O +
set O +
of O +
non O -
- O -
autistic O +
cerebellar O +
samples O +
( O -
n O +
= O +
13 O -
) O -
. O +

microRNAs O +
( O -
miRNAs O -
) O +
are O +
approximately O +
21 O +
nt O +
transcripts O +
capable O +
of O +
regulating O +
the O +
expression O +
of O +
many O +
mRNAs O +
and O +
are O +
abundant O +
in O +
the O +
brain O -
. O +

miRNAs O +
have O +
a O +
role O +
in O +
several O +
complex O +
diseases O +
including O +
cancer O +
as O +
well O +
as O +
some O +
neurological O +
diseases O +
such O +
as O +
Tourette O -
's O +
syndrome O +
and O +
Fragile O +
x O +
syndrome O -
. O +

To O +
validate O +
the O +
finding O -
, O +
we O +
reversed O +
the O +
analysis O +
and O +
compared O +
each O +
non O -
- O -
autism O +
control O +
to O +
a O +
single O +
mean O +
value O +
for O +
each O +
miRNA O +
across O +
all O +
autism O +
cases O -
. O +

In O +
this O +
analysis O -
, O +
the O +
number O +
of O +
dysregulated O +
miRNAs O +
fell O +
from O +
28 O +
to O +
9 O +
miRNAs O -
. O +

While O +
most O +
miRNAs O +
levels O +
showed O +
little O +
variation O +
across O +
all O +
samples O +
suggesting O +
that O +
autism O +
does O +
not O +
induce O +
global O +
dysfunction O +
of O +
miRNA O +
expression O -
, O +
some O +
miRNAs O +
among O +
the O +
autistic O +
samples O +
were O +
expressed O +
at O +
significantly O +
different O +
levels O +
compared O +
to O +
the O +
mean O +
control O +
value O -
. O +

Twenty O -
- O -
eight O +
miRNAs O +
were O +
expressed O +
at O +
significantly O +
different O +
levels O +
compared O +
to O +
the O +
non O -
- O -
autism O +
control O +
set O +
in O +
at O +
least O +
one O +
of O +
the O +
autism O +
samples O -
. O +

Among O +
the O +
predicted O +
targets O +
of O +
dysregulated O +
miRNAs O +
are O +
genes O +
that O +
are O +
known O +
genetic O +
causes O +
of O +
autism O +
such O +
Neurexin O +
and O +
SHANK3 O -
. O +

Heterogeneous O +
dysregulation O +
of O +
microRNAs O +
across O +
the O +
autism O +
spectrum O -
. O +

This O +
study O +
finds O +
that O +
altered O +
miRNA O +
expression O +
levels O +
are O +
observed O +
in O +
postmortem O +
cerebellar O +
cortex O +
from O +
autism O +
patients B-Species -
, O +
a O +
finding O +
which O +
suggests O +
that O +
dysregulation O +
of O +
miRNAs O +
may O +
contribute O +
to O +
autism O +
spectrum O +
phenotype O -
. O +

A O +
tight O +
correlation O +
between O +
these O +
miRNAs O +
and O +
APP O +
was O +
found O +
during O +
brain O +
development O +
and O +
in O +
differentiating O +
neurons O -
. O +

We O +
thus O +
identify O +
miRNAs O +
as O +
novel O +
endogenous O +
regulators O +
of O +
APP O +
expression O -
, O +
suggesting O +
that O +
variations O +
in O +
miRNA O +
expression O +
could O +
contribute O +
to O +
changes O +
in O +
APP O +
expression O +
in O +
the O +
brain O +
during O +
development O +
and O +
disease O -
. O +

This O +
possibility O +
is O +
further O +
corroborated O +
by O +
the O +
observation O +
that O +
a O +
statistically O +
significant O +
decrease O +
in O +
miR-106b O +
expression O +
was O +
found O +
in O +
sporadic O +
AD O +
patients B-Species -
. O +

MicroRNA O +
regulation O +
of O +
Alzheimer O -
's O +
Amyloid O +
precursor O +
protein O +
expression O -
. O +

Gene O +
dosage O +
effects O +
of O +
Amyloid O +
precursor O +
protein O +
( O -
APP O -
) O +
can O +
cause O +
familial O +
AD O -
. O +
Recent O +
evidence O +
suggest O +
that O +
microRNA O +
( O -
miRNA O -
) O +
pathways O -
, O +
implicated O +
in O +
gene O +
transcriptional O +
control O -
, O +
could O +
be O +
involved O +
in O +
the O +
development O +
of O +
sporadic O +
Alzheimer O -
's O +
disease O +
( O -
AD O -
) O -
. O +

We O +
therefore O +
investigated O +
whether O +
miRNAs O +
could O +
participate O +
in O +
the O +
regulation O +
of O +
APP O +
gene O +
expression O -
. O +

We O +
show O +
that O +
miRNAs O +
belonging O +
to O +
the O +
miR-20a O +
family O +
( O -
that O +
is O -
, O +
miR-20a O -
, O +
miR-17 O -
- O -
5p O +
and O +
miR-106b O -
) O +
could O +
regulate O +
APP O +
expression O +
in O +
vitro O +
and O +
at O +
the O +
endogenous O +
level O +
in O +
neuronal O +
cell O +
lines O -
. O +

We O +
concluded O +
that O +
patients B-Species +
with O +
partial O +
recurrent O +
seizures O +
of O +
temporal O +
origin O +
have O +
poor O +
subjective O +
sleep O +
quality O +
that O +
improves O +
significantly O +
after O +
epilepsy O +
surgery O -
. O +

ESS O +
and O +
PSQI O +
scores O +
were O +
also O +
analyzed O +
by O +
gender O -
, O +
antiepileptic O +
drug O +
class O -
, O +
age O -
, O +
and O +
seizure O +
frequency O -
, O +
with O +
no O +
significant O +
differences O -
. O +

Global O +
PSQI O +
was O +
high O +
( O -
mean=5.65 O +
SD=3.71 O -
) O +
before O +
the O +
surgical O +
procedure O +
( O -
P<0.001 O -
) O -
. O +

Two O +
questionnaires O +
were O +
used O +
to O +
assess O +
daytime O +
sleepiness O +
( O -
Epworth O +
Sleepiness O +
Scale O +
[ O -
ESS O -
] O -
) O +
and O +
sleep O +
quality O +
( O -
Pittsburgh O +
Sleep O +
Quality O +
Index O +
[ O -
PSQI O -
] O -
) O -
. O +

PSQI O +
evaluation O +
revealed O +
higher O +
and O +
statistically O +
significant O +
scores O +
in O +
three O +
components O +
as O +
well O +
as O +
in O +
the O +
global O +
score O -
, O +
when O +
analyzed O +
by O +
predominance O +
of O +
daytime O +
or O +
nocturnal O +
seizures O -
. O +

Evaluation O +
of O +
sleep O +
quality O +
in O +
patients B-Species +
with O +
refractory O +
seizures O +
who O +
undergo O +
epilepsy O +
surgery O -
. O +

The O +
aim O +
of O +
the O +
study O +
was O +
to O +
evaluate O +
excessive O +
daytime O +
sleepiness O +
and O +
subjective O +
sleep O +
quality O +
in O +
patients B-Species +
who O +
undergo O +
epilepsy O +
surgery O +
for O +
treatment O +
of O +
refractory O +
partial O +
seizures O -
. O +

Forty O -
- O -
eight O +
patients B-Species +
were O +
enrolled O +
in O +
this O +
research O +
study O -
. O +

All O +
of O +
them O +
were O +
evaluated O +
2 O +
days O +
before O +
and O +
3 O +
months O +
after O +
the O +
surgery O -
. O +

Here O -
, O +
we O +
investigated O +
the O +
possibility O +
that O +
IFN O -
- O -
beta O +
may O +
induce O +
or O +
downregulate O +
cellular O +
microRNAs O +
( O -
miRNA O -
) O +
in O +
human B-Species +
neoplasms O +
and O +
thereby O +
use O +
the O +
RNA O +
interference O +
system O +
to O +
show O +
antitumor O +
effects O -
. O +

Because O +
of O +
its O +
known O +
connection O +
to O +
glioma O +
biology O -
, O +
we O +
focused O +
on O +
miR-21 O +
among O +
seven O +
miRNAs O +
influenced O +
by O +
IFN O -
- O -
beta O -
. O +

The O +
modulation O +
of O +
microRNAs O +
by O +
type O +
I O +
IFN O +
through O +
the O +
activation O +
of O +
signal O +
transducers O +
and O +
activators O +
of O +
transcription O +
3 O +
in O +
human B-Species +
glioma O -
. O +

Type O +
I O +
IFNs O +
are O +
involved O +
in O +
double O -
- O -
stranded O +
RNA O +
responses O -
. O +

The O +
levels O +
of O +
primary O +
miR-21 O +
gene O +
transcripts O -
, O +
precursor O +
miR-21 O -
, O +
and O +
mature O +
miR-21 O +
decreased O +
6 O +
hours O +
after O +
the O +
addition O +
of O +
IFN O -
- O -
beta O -
, O +
indicating O +
that O +
the O +
reduction O +
in O +
miR-21 O +
levels O +
was O +
due O +
to O +
transcriptional O +
suppression O -
. O +

We O +
did O +
reporter O +
assays O +
to O +
elucidate O +
the O +
IFN O -
- O -
beta O -
- O -
mediated O +
suppression O +
of O +
miR-21 O -
; O +
the O +
addition O +
of O +
signal O +
transducers O +
and O +
activators O +
of O +
transcription O +
3 O +
( O -
STAT3 O -
) O -
-expressing O +
vectors O +
induced O +
the O +
IFN O -
- O -
beta O -
- O -
mediated O +
suppression O +
of O +
miR-21 O -
, O +
whereas O +
STAT3-inhibiting O +
agents O +
inhibited O +
the O +
miR-21 O +
suppression O -
. O +

We O +
analyzed O +
the O +
effect O +
of O +
IFN O -
- O -
beta O +
treatment O +
on O +
miR-21 O +
expression O +
in O +
glioma O +
cells O +
and O +
intracranial O +
glioma O +
xenografts O -
. O +

IFN O -
- O -
beta O +
treatment O +
reduced O +
miR-21 O +
expression O +
in O +
glioma O +
cells O +
markedly O -
, O +
and O +
IFN O -
- O -
beta O +
administration O +
suppressed O +
the O +
growth O +
of O +
glioma O -
- O -
initiating O +
cell O -
- O -
derived O +
intracranial O +
tumors O -
. O +

Thus O -
, O +
the O +
results O +
of O +
our O +
study O +
show O +
that O +
the O +
downregulation O +
of O +
miR-21 O +
contributes O +
to O +
the O +
antitumor O +
effects O +
of O +
IFN O -
- O -
beta O +
and O +
that O +
miR-21 O +
expression O +
is O +
negatively O +
regulated O +
by O +
STAT3 O +
activation O -
. O +

These O +
results O +
highlight O +
the O +
importance O +
of O +
understanding O +
the O +
transcriptional O +
regulation O +
of O +
the O +
miRNAs O +
involved O +
in O +
oncogenesis O -
. O +

This O +
work O +
represents O +
the O +
first O +
experimental O +
study O +
showing O +
that O +
an O +
miR-30-based O +
shRNA O +
construct O +
prevents O +
Oas1 O +
pathway O +
associated O +
off O -
- O -
target O +
effects O -
, O +
which O +
we O +
consider O +
as O +
an O +
essential O +
prerequisite O +
for O +
shRNA O +
use O +
in O +
future O +
gene O +
therapeutic O +
approaches O -
. O +

Modification O +
of O +
the O +
shRNA O +
construct O +
by O +
implementing O +
features O +
of O +
the O +
naturally O +
occurring O +
microRNA-30 O +
( O -
miR-30 O -
) O +
precursor O +
avoided O +
Oas1 O +
induction O +
in O +
transduced O +
primary O +
cultures O -
, O +
whereby O +
modification O +
of O +
the O +
passenger O +
strand O +
seems O +
to O +
be O +
a O +
crucial O +
feature O +
to O +
circumvent O +
interferon O -
- O -
stimulated O +
gene O +
expression O -
. O +

We O +
found O +
that O +
lentiviral O +
vector O +
( O -
LV O -
) O -
-mediated O +
expression O +
of O +
shRNAs O +
in O +
primary O +
cortical O +
cultures O +
resulted O +
in O +
strong O +
expression O +
of O +
the O +
interferon O -
- O -
stimulated O +
gene O +
oligoadenylate O +
synthetase O +
1 O +
( O -
Oas1 O -
) O -
, O +
which O +
was O +
accompanied O +
by O +
accelerated O +
apoptosis O +
and O +
substantial O +
net O +
neuron O +
loss O -
. O +

Prevention O +
of O +
interferon O -
- O -
stimulated O +
gene O +
expression O +
using O +
microRNA O -
- O -
designed O +
hairpins O -
. O +

However O -
, O +
growing O +
evidence O +
exists O +
that O +
the O +
expression O +
of O +
short O +
hairpin O +
RNAs O +
( O -
shRNAs O -
) O +
can O +
trigger O +
cellular O +
immune O +
response O +
resulting O +
in O +
unspecific O +
cellular O +
phenotypes O +
and O +
severe O +
side O +
effects O -
. O +

RNA O +
interference O +
allows O +
selective O +
gene O +
silencing O -
, O +
and O +
is O +
widely O +
used O +
for O +
functional O +
analysis O +
of O +
individual O +
genes O +
in O +
vertebrate O +
cells O +
and O +
represents O +
an O +
attractive O +
therapeutic O +
option O +
for O +
treating O +
central O +
nervous O +
system O +
diseases O -
. O +

The O +
basis O +
for O +
the O +
younger O +
age O +
at O +
symptom O +
onset O +
remains O +
obscure O -
. O +

CONCLUSIONS O -
: O +
An O +
earlier O +
age O +
at O +
symptom O +
onset O +
suggests O +
that O +
US O +
mainland O +
Latino O +
individuals O +
may O +
experience O +
an O +
increased O +
burden O +
of O +
AD O +
compared O +
with O +
Anglo O +
individuals O -
. O +

OBJECTIVE O -
: O +
To O +
compare O +
the O +
age O +
at O +
AD O +
symptom O +
onset O +
in O +
Latino O +
and O +
Anglo O +
individuals O -
. O +

BACKGROUND O -
: O +
Latino O +
individuals O +
are O +
the O +
largest O +
minority O +
group O +
and O +
the O +
fastest O +
growing O +
population O +
group O +
in O +
the O +
United O +
States O -
, O +
yet O +
there O +
are O +
few O +
studies O +
comparing O +
the O +
clinical O +
features O +
of O +
Alzheimer O +
disease O +
( O -
AD O -
) O +
in O +
this O +
population O +
with O +
those O +
found O +
in O +
Anglo O +
( O -
white O +
non O -
- O -
Latino O -
) O +
patients B-Species -
. O +

Earlier O +
onset O +
of O +
Alzheimer O +
disease O +
symptoms O +
in O +
latino O +
individuals O +
compared O +
with O +
anglo O +
individuals O -
. O +

RESULTS O -
: O +
After O +
adjusting O +
for O +
center O -
, O +
sex O -
, O +
and O +
years O +
of O +
education O -
, O +
Latino O +
patients B-Species +
had O +
a O +
mean O +
age O +
at O +
symptom O +
onset O +
6.8 O +
years O +
earlier O +
( O -
95 O -
% O +
confidence O +
interval O -
, O +
3.5 O -
- O -
10.3 O +
years O +
earlier O -
) O +
than O +
Anglo O +
patients B-Species -
. O +

PATIENTS B-Species -
: O +
We O +
evaluated O +
119 O +
Latino O +
and O +
55 O +
Anglo O +
patients B-Species +
who O +
had O +
a O +
diagnosis O +
of O +
AD O -
. O +
MAIN O +
OUTCOME O +
MEASURE O -
: O +
Age O +
at O +
symptom O +
onset O -
. O +

SETTING O -
: O +
Five O +
National O +
Institute O +
on O +
Aging O -
- O -
sponsored O +
Alzheimer O -
's O +
Disease O +
Centers O +
with O +
experience O +
evaluating O +
Spanish O -
- O -
speaking O +
individuals O -
. O +

DESIGN O -
: O +
Cross O -
- O -
sectional O +
assessment O +
using O +
standardized O +
methods O +
to O +
collect O +
and O +
compare O +
age O +
at O +
AD O +
symptom O +
onset O -
, O +
demographic O +
variables O -
, O +
and O +
medical O +
variables O -
. O +

In O +
a O +
well O -
- O -
characterized O +
Belgian O +
group O +
of O +
358 O +
AD O +
patients B-Species +
and O +
462 O +
controls O -
, O +
we O +
examined O +
whether O +
genetic O +
variability O +
in O +
microRNA O +
( O -
miRNA O -
) O +
binding O +
sites O +
of O +
APP O +
and O +
BACE1 O +
or O +
in O +
associated O +
miRNAs O +
influenced O +
risk O +
for O +
AD O -
. O +
Direct O +
sequencing O +
identified O +
six O +
variants O +
in O +
the O +
3 O -
' O +
untranslated O +
region O +
( O -
UTR O -
) O +
of O +
APP O +
and O +
29 O +
variants O +
in O +
the O +
3 O -
' O +
UTR O +
of O +
BACE1 O -
, O +
of O +
which O +
few O +
variants O +
were O +
restricted O +
to O +
patients B-Species -
: O +
in O +
APP O -
; O +
4 O +
variants O +
in O +
6 O +
patients B-Species +
( O +
approximately O +
2 O -
% O -
) O +
and O +
in O +
BACE1 O -
; O +
7 O +
variants O +
in O +
11 O +
patients B-Species +
( O +
approximately O +
3.5 O -
% O -
) O -
. O +

Expression O +
levels O +
of O +
the O +
amyloid O +
precursor O +
protein O +
( O -
APP O -
) O +
and O +
beta O -
- O -
site O +
amyloid O +
( O -
Abeta O -
) O +
cleaving O +
enzyme O +
1 O +
( O -
BACE1 O -
) O +
have O +
been O +
implicated O +
in O +
Alzheimer O +
disease O +
( O -
AD O -
) O +
progression O -
. O +

APP O +
and O +
BACE1 O +
miRNA O +
genetic O +
variability O +
has O +
no O +
major O +
role O +
in O +
risk O +
for O +
Alzheimer O +
disease O -
. O +

Further O +
genetic O +
screening O +
of O +
the O +
miR-29 O +
cluster O +
encoding O +
the O +
miR-29a O -
/ O -
b-1 O +
genes O +
showed O +
10 O +
variants O +
in O +
close O +
proximity O +
of O +
this O +
cluster O -
. O +

Association O +
studies O +
using O +
all O +
common O +
variants O +
detected O +
in O +
the O +
3 O -
' O +
UTR O +
of O +
BACE1 O +
and O +
the O +
miR-29 O +
gene O +
cluster O +
did O +
not O +
identify O +
an O +
association O +
with O +
AD O +
risk O -
. O +

However O -
, O +
we O +
did O +
observe O +
statistical O +
interaction O +
between O +
rs535860 O +
( O -
BACE1 O +
3 O -
' O +
UTR O -
) O +
and O +
rs34772568 O +
( O -
near O +
miR29a O -
; O +
odds O +
ratio O +
[ O -
OR O -
] O -
( O -
interaction O -
) O -
, O +
0.4 O -
; O +
95 O -
% O +
confidence O +
interval O +
[ O -
CI O -
] O -
, O +
0.17 O -
- O -
0.96 O -
; O +
P=0.033 O -
) O -
. O +

While O +
the O +
exact O +
role O +
of O +
the O +
patient B-Species -
- O -
specific O +
miRNA O +
variants O +
within O +
the O +
3 O -
' O +
UTR O +
region O +
of O +
APP O +
and O +
BACE1 O +
demands O +
further O +
analyses O -
, O +
this O +
study O +
does O +
not O +
support O +
a O +
major O +
contribution O +
of O +
miRNA O +
genetic O +
variability O +
to O +
AD O +
pathogenesis O -
. O +

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
small O -
, O +
noncoding O +
RNAs O +
that O +
play O +
a O +
critical O +
role O +
in O +
developmental O +
and O +
physiological O +
processes O +
and O +
are O +
implicated O +
in O +
the O +
pathogenesis O +
of O +
several O +
human B-Species +
diseases O -
, O +
including O +
cancer O -
. O +

Downregulation O +
of O +
Pdcd4 O +
by O +
mir-21 O +
facilitates O +
glioblastoma O +
proliferation O +
in O +
vivo O -
. O +

In O +
this O +
study O -
, O +
we O +
examined O +
the O +
role O +
of O +
oncogenic O +
mir-21 O +
in O +
the O +
pathogenesis O +
of O +
glioblastoma O -
, O +
the O +
most O +
aggressive O +
form O +
of O +
primary O +
brain O +
tumor O -
. O +

They O +
function O +
by O +
regulating O +
target O +
gene O +
expression O +
post O -
- O -
transcriptionally O -
. O +

We O +
demonstrate O +
that O +
downregulation O +
of O +
mir-21 O +
in O +
glioblastoma O -
- O -
derived O +
cell O +
lines O +
results O +
in O +
increased O +
expression O +
of O +
its O +
target O -
, O +
programmed O +
cell O +
death O +
4 O +
( O -
Pdcd4 O -
) O -
, O +
a O +
known O +
tumor O -
- O -
suppressor O +
gene O -
. O +

We O +
have O +
previously O +
reported O +
that O +
mir-21 O +
is O +
expressed O +
at O +
higher O +
levels O +
in O +
primary O +
glioblastoma O -
- O -
tissue O +
and O +
glioblastoma O -
- O -
derived O +
cell O +
lines O +
than O +
in O +
normal O +
brain O +
tissue O -
. O +

Using O +
a O +
glioblastoma O +
xenograft O +
model O +
in O +
immune O -
- O -
deficient O +
nude B-Species +
mice I-Species -
, O +
we O +
observe O +
that O +
glioblastoma O -
- O -
derived O +
cell O +
lines O +
in O +
which O +
mir-21 O +
levels O +
are O +
downregulated O +
or O +
Pdcd4 O +
is O +
over O -
- O -
expressed O +
exhibit O +
decreased O +
tumor O +
formation O +
and O +
growth O -
. O +

In O +
addition O -
, O +
our O +
data O +
indicate O +
that O +
either O +
downregulation O +
of O +
mir-21 O +
or O +
overexpression O +
of O +
its O +
target O -
, O +
Pdcd4 O -
, O +
in O +
glioblastoma O -
- O -
derived O +
cell O +
lines O +
leads O +
to O +
decreased O +
proliferation O -
, O +
increased O +
apoptosis O -
, O +
and O +
decreased O +
colony O +
formation O +
in O +
soft O +
agar O -
. O +

Significantly O -
, O +
tumors O +
grow O +
when O +
the O +
glioblastoma O -
- O -
derived O +
cell O +
lines O +
are O +
transfected O +
with O +
anti O -
- O -
mir-21 O +
and O +
siRNA O +
to O +
Pdcd4 O -
, O +
confirming O +
that O +
the O +
tumor O +
growth O +
is O +
specifically O +
regulated O +
by O +
Pdcd4 O -
. O +

These O +
critical O +
in O +
vivo O +
findings O +
demonstrate O +
an O +
important O +
functional O +
linkage O +
between O +
mir-21 O +
and O +
Pdcd4 O +
and O +
further O +
elucidate O +
the O +
molecular O +
mechanisms O +
by O +
which O +
the O +
known O +
high O +
level O +
of O +
mir-21 O +
expression O +
in O +
glioblastoma O +
can O +
attribute O +
to O +
tumorigenesis O -
-- O -
namely O -
, O +
inhibition O +
of O +
Pdcd4 O +
and O +
its O +
tumor O -
- O -
suppressive O +
functions O -
. O +

We O +
conclude O +
that O +
miR-17 O -
/ O -
92 O +
is O +
a O +
positive O +
effector O +
of O +
Shh O -
- O -
mediated O +
proliferation O +
and O +
that O +
aberrant O +
expression O -
/ O -
amplification O +
of O +
this O +
miR O +
confers O +
a O +
growth O +
advantage O +
to O +
medulloblastomas O -
. O +

Ectopic O +
miR-17 O -
/ O -
92 O +
expression O +
in O +
CGNPs O +
synergized O +
with O +
exogenous O +
Shh O +
to O +
increase O +
proliferation O +
and O +
also O +
enabled O +
them O +
to O +
proliferate O +
in O +
the O +
absence O +
of O +
Shh O -
. O +

In O +
CGNPs O -
, O +
the O +
Shh O +
effector O +
N O -
- O -
myc O -
, O +
but O +
not O +
Gli1 O -
, O +
induced O +
miR-17 O -
/ O -
92 O +
expression O -
. O +

Consistent O +
with O +
its O +
regulation O +
by O +
Shh O -
, O +
we O +
observed O +
that O +
Shh O +
treatment O +
of O +
primary O +
cerebellar O +
granule O +
neuron O +
precursors O +
( O -
CGNP O -
) O -
, O +
proposed O +
cells O +
of O +
origin O +
for O +
the O +
Shh O -
- O -
associated O +
medulloblastomas O -
, O +
resulted O +
in O +
increased O +
miR-17 O -
/ O -
92 O +
expression O -
. O +

Medulloblastomas O +
in O +
which O +
miR-17 O -
/ O -
92 O +
was O +
up O -
- O -
regulated O +
also O +
had O +
elevated O +
levels O +
of O +
MYC O -
/ O -
MYCN O +
expression O -
. O +

Expression O +
of O +
miR-17 O -
/ O -
92 O +
was O +
highest O +
in O +
the O +
subgroup O +
of O +
medulloblastomas O +
associated O +
with O +
activation O +
of O +
the O +
sonic O +
hedgehog O +
( O -
Shh O -
) O +
signaling O +
pathway O +
compared O +
with O +
other O +
subgroups O +
of O +
medulloblastoma O -
. O +

Profiling O +
the O +
expression O +
of O +
427 O +
mature O +
microRNAs O +
( O -
miRNA O -
) O +
in O +
a O +
series O +
of O +
90 O +
primary O +
human B-Species +
medulloblastomas O +
revealed O +
that O +
components O +
of O +
the O +
miR-17 O -
/ O -
92 O +
polycistron O +
are O +
the O +
most O +
highly O +
up O -
- O -
regulated O +
miRNAs O +
in O +
medulloblastoma O -
. O +

We O +
identified O +
recurrent O +
amplification O +
of O +
the O +
miR-17 O -
/ O -
92 O +
polycistron O +
proto O -
- O -
oncogene O +
in O +
6 O -
% O +
of O +
pediatric O +
medulloblastomas O +
by O +
high O -
- O -
resolution O +
single O -
- O -
nucleotide O +
polymorphism O +
genotyping O +
arrays O +
and O +
subsequent O +
interphase O +
fluorescence O +
in O +
situ O +
hybridization O +
on O +
a O +
human B-Species +
medulloblastoma O +
tissue O +
microarray O -
. O +

Medulloblastoma O +
is O +
the O +
most O +
common O +
malignant O +
pediatric O +
brain O +
tumor O -
, O +
and O +
mechanisms O +
underlying O +
its O +
development O +
are O +
poorly O +
understood O -
. O +

The O +
miR-17 O -
/ O -
92 O +
polycistron O +
is O +
up O -
- O -
regulated O +
in O +
sonic O +
hedgehog O -
- O -
driven O +
medulloblastomas O +
and O +
induced O +
by O +
N O -
- O -
myc O +
in O +
sonic O +
hedgehog O -
- O -
treated O +
cerebellar O +
neural O +
precursors O -
. O +

New O +
insights O +
into O +
non O -
- O -
coding O +
RNA O +
networks O +
in O +
Huntington O -
's O +
disease O -
. O +

MicroRNA O +
regulation O +
of O +
IFN O -
- O -
beta O +
protein O +
expression O -
: O +
rapid O +
and O +
sensitive O +
modulation O +
of O +
the O +
innate O +
immune O +
response O -
. O +

In O +
primary O +
primate O +
macrophages O -
, O +
the O +
main O +
cell O +
type O +
implicated O +
in O +
HIV O +
and O +
SIV O +
infection O +
in O +
the O +
CNS O -
, O +
specific O +
miRNAs O +
reduce O -
, O +
whereas O +
miRNA O +
inhibitors O +
enhance O -
, O +
IFN O -
- O -
beta O +
protein O +
production O -
. O +

The O +
potential O +
biologic O +
significance O +
of O +
this O +
regulation O +
is O +
supported O +
by O +
evidence O +
of O +
an O +
apparent O +
negative O +
feedback O +
loop O -
, O +
with O +
increased O +
expression O +
of O +
three O +
IFN O -
- O -
beta O -
- O -
regulating O +
miRNAs O +
by O +
primate O +
macrophages O +
exposed O +
to O +
recombinant O +
IFN O -
- O -
beta O +
or O +
stimulated O +
to O +
produce O +
IFN O -
- O -
beta O -
. O +

Thus O -
, O +
miRNAs O +
may O +
contribute O +
significantly O +
to O +
the O +
regulation O +
of O +
IFN O -
- O -
beta O +
in O +
innate O +
immune O +
responses O -
. O +

IFN O -
- O -
beta O +
production O +
is O +
an O +
inaugural O +
event O +
in O +
the O +
innate O +
immune O +
response O +
to O +
viral O +
infections O -
, O +
with O +
relatively O +
small O +
fold O +
changes O +
in O +
IFN O -
- O -
beta O +
expression O +
resulting O +
in O +
the O +
activation O +
of O +
important O +
antiviral O +
signaling O +
cascades O -
. O +

In O +
our O +
rapid O +
SIV O -
/ O -
macaque O +
model O +
of O +
HIV O +
encephalitis O -
, O +
the O +
virus O +
enters O +
the O +
CNS O +
within O +
4 O +
d O +
of O +
infection O -
, O +
accompanied O +
by O +
a O +
marked O +
IFN O -
- O -
beta O +
response O +
that O +
wanes O +
as O +
SIV O +
replication O +
is O +
controlled O -
. O +

The O +
centrality O +
of O +
IFN O -
- O -
beta O +
to O +
the O +
innate O +
antiviral O +
response O +
in O +
the O +
CNS O +
combines O +
with O +
the O +
potential O +
inflammatory O +
damage O +
associated O +
with O +
long O -
- O -
term O +
activation O +
of O +
this O +
pathway O +
to O +
suggest O +
that O +
IFN O -
- O -
beta O +
may O +
be O +
subject O +
to O +
regulatory O +
fine O -
- O -
tuning O +
in O +
addition O +
to O +
well O -
- O -
established O +
transcriptional O +
and O +
message O +
stability O +
mechanisms O +
of O +
regulation O -
. O +

In O +
this O +
paper O -
, O +
we O +
present O +
for O +
the O +
first O +
time O +
evidence O +
that O +
microRNAs O +
( O -
miRNAs O -
) O -
, O +
including O +
miR-26a O -
, O +
-34a O -
, O +
-145 O -
, O +
and O +
let-7b O -
, O +
may O +
directly O +
regulate O +
IFN O -
- O -
beta O +
in O +
human B-Species +
and O +
macaque O +
cells O -
. O +

Plasma O +
miRNAs O +
should O +
be O +
investigated O +
further O +
as O +
leading O +
indicators O +
of O +
HIV O +
diseases O +
as O +
early O +
as O +
acute O +
infection O -
. O +

CONCLUSION O -
: O +
: O +
Acute O -
- O -
phase O +
differential O +
expression O +
of O +
plasma O +
miRNAs O +
predicts O +
CNS O +
disease O +
and O +
suggests O +
that O +
CNS O +
damage O +
or O +
predisposition O +
to O +
disease O +
progression O +
begins O +
in O +
the O +
earliest O +
phase O +
of O +
infection O -
. O +

At O +
least O +
six O +
miRNAs O +
were O +
significantly O +
differentially O +
expressed O +
in O +
individuals O +
with O +
severe O +
versus O +
no O +
CNS O +
disease O -
; O +
in O +
an O +
unweighted O +
expression O +
test O -
, O +
they O +
predicted O +
CNS O +
disease O -
. O +

miRNAs O +
tracked O +
with O +
viral O +
load O +
and O +
platelet O +
count O +
were O +
also O +
predictors O +
of O +
CNS O +
disease O -
. O +

OBJECTIVE O -
: O +
: O +
Plasma O +
microRNAs O +
( O -
miRNAs O -
) O +
are O +
modulated O +
during O +
disease O +
and O +
are O +
emerging O +
biomarkers O -
; O +
they O +
have O +
not O +
been O +
characterized O +
in O +
HIV O +
infection O -
. O +

A O +
plasma O +
microRNA O +
signature O +
of O +
acute O +
lentiviral O +
infection O -
: O +
biomarkers O +
of O +
central O +
nervous O +
system O +
disease O -
. O +

miRNA O +
expression O +
was O +
compared O +
with O +
levels O +
of O +
cytokines O -
, O +
virus O -
, O +
and O +
plasma O +
platelet O +
count O -
. O +

METHODS O -
: O +
: O +
Plasma O +
miRNA O +
expression O +
profiles O +
were O +
determined O +
by O +
TaqMan O +
low O -
- O -
density O +
array O +
for O +
six O +
individuals O -
. O +

DESIGN O -
: O +
: O +
Plasma O +
samples O +
were O +
obtained O +
before O +
inoculation O +
and O +
10 O +
days O +
after O +
inoculation O +
from O +
SIV O -
- O -
infected O +
macaques B-Species -
. O +

Using O +
our O +
macaque O -
/ O -
simian O +
immunodeficiency O +
virus O +
( O -
SIV O -
) O +
model O +
of O +
HIV O -
, O +
we O +
sought O +
to O +
identify O +
a O +
plasma O +
miRNA O +
profile O +
of O +
acute O +
lentiviral O +
infection O -
, O +
evaluate O +
its O +
relationship O +
with O +
known O +
cellular O +
and O +
viral O +
determinants O +
of O +
lentivirus O -
- O -
associated O +
central O +
nervous O +
system O +
( O -
CNS O -
) O +
disease O -
, O +
and O +
explore O +
the O +
potential O +
of O +
miRNAs O +
to O +
predict O +
CNS O +
disease O -
. O +

Several O +
differentially O +
expressed O +
miRNAs O +
correlated O +
with O +
CNS O +
disease O -
- O -
associated O +
cytokines O +
interleukin-6 O +
and O +
CCL2 O +
and O +
included O +
predicted O +
and/or O +
validated O +
regulators O +
of O +
the O +
corresponding O +
mRNAs O -
. O +

RESULTS O -
: O +
: O +
A O +
45-miRNA O +
signature O +
of O +
acute O +
infection O +
( O -
differential O +
expression O +
with O +
P O +
< O +
0.05 O +
after O +
multiple O +
comparison O +
correction O -
) O +
classified O +
plasma O +
as O +
infected O +
or O +
not O -
. O +

Nineteen O +
individuals O +
were O +
used O +
to O +
validate O +
a O +
disease O +
prediction O +
test O -
. O +

miRNA O +
results O +
were O +
confirmed O +
by O +
single O +
miRNA O -
- O -
specific O +
assays O +
for O +
10 O +
macaques B-Species -
. O +

Identification O +
of O +
miRNA O +
changes O +
in O +
Alzheimer O -
's O +
disease O +
brain O +
and O +
CSF O +
yields O +
putative O +
biomarkers O +
and O +
insights O +
into O +
disease O +
pathways O -
. O +

MicroRNAs O +
have O +
essential O +
functional O +
roles O +
in O +
brain O +
development O +
and O +
neuronal O +
specification O +
but O +
their O +
roles O +
in O +
neurodegenerative O +
diseases O +
such O +
as O +
Alzheimer O -
's O +
disease O +
( O -
AD O -
) O +
is O +
unknown O -
. O +

Using O +
a O +
sensitive O +
qRT O -
- O -
PCR O +
platform O +
we O +
identified O +
regional O +
and O +
stage O -
- O -
specific O +
deregulation O +
of O +
miRNA O +
expression O +
in O +
AD O +
patient B-Species +
brains O -
. O +

We O +
used O +
experimental O +
validation O +
in O +
addition O +
to O +
literature O +
to O +
reveal O +
how O +
the O +
deregulated O +
brain O +
microRNAs O +
are O +
biomarkers O +
for O +
known O +
and O +
novel O +
pathways O +
in O +
AD O +
pathogenesis O +
related O +
to O +
amyloid O +
processing O -
, O +
neurogenesis O -
, O +
insulin O +
resistance O -
, O +
and O +
innate O +
immunity O -
. O +

We O +
additionally O +
recovered O +
miRNAs O +
from O +
cerebrospinal O +
fluid O +
and O +
discovered O +
AD O -
- O -
specific O +
miRNA O +
changes O +
consistent O +
with O +
their O +
role O +
as O +
potential O +
biomarkers O +
of O +
disease O -
. O +

Regulation O +
of O +
oligodendrocyte O +
differentiation O +
and O +
myelination O -
. O +

These O +
recent O +
advances O +
provide O +
new O +
insight O +
into O +
how O +
remyelination O +
may O +
be O +
stimulated O +
in O +
demyelinating O +
disorders O +
such O +
as O +
multiple O +
sclerosis O -
. O +

Studies O +
have O +
also O +
demonstrated O +
an O +
unexpected O +
level O +
of O +
plasticity O +
of O +
myelin O +
in O +
the O +
adult O +
CNS O -
. O +

Recent O +
results O +
have O +
greatly O +
advanced O +
this O +
understanding O -
, O +
identifying O +
new O +
transcriptional O +
regulators O +
of O +
myelin O +
gene O +
expression O -
, O +
elucidating O +
vital O +
roles O +
for O +
microRNAs O +
in O +
controlling O +
myelination O -
, O +
and O +
clarifying O +
the O +
extracellular O +
signaling O +
mechanisms O +
that O +
orchestrate O +
the O +
development O +
of O +
myelin O -
. O +

Despite O +
the O +
importance O +
of O +
myelin O +
for O +
the O +
rapid O +
conduction O +
of O +
action O +
potentials O -
, O +
the O +
molecular O +
bases O +
of O +
oligodendrocyte O +
differentiation O +
and O +
central O +
nervous O +
system O +
( O -
CNS O -
) O +
myelination O +
are O +
still O +
incompletely O +
understood O -
. O +

In O +
sum O -
, O +
our O +
results O +
suggest O +
that O +
specific O +
miRNAs O +
are O +
involved O +
in O +
the O +
fine O -
- O -
tuning O +
of O +
APP O +
alternative O +
splicing O +
in O +
neurons O -
. O +

Finally O -
, O +
we O +
show O +
that O +
miR-124 O +
is O +
down O -
- O -
regulated O +
in O +
AD O +
brain O -
. O +

Furthermore O -
, O +
PTBP1 O +
levels O +
correlate O +
with O +
the O +
presence O +
of O +
APP O +
exons O +
7 O +
and O +
8 O -
, O +
while O +
PTBP2 O +
levels O +
correlate O +
with O +
the O +
skipping O +
of O +
these O +
exons O +
during O +
neuronal O +
differentiation O -
. O +

Similar O +
results O +
were O +
obtained O +
by O +
depletion O +
of O +
endogenous O +
polypyrimidine O +
tract O +
binding O +
protein O +
1 O +
( O -
PTBP1 O -
) O +
in O +
cells O -
, O +
a O +
recognized O +
miR-124 O +
target O +
gene O -
. O +

In O +
vivo O +
regulation O +
of O +
amyloid O +
precursor O +
protein O +
neuronal O +
splicing O +
by O +
microRNAs O -
. O +

The O +
β O -
- O -
amyloid O +
peptide O +
that O +
accumulate O +
in O +
Alzheimer O -
's O +
disease O +
( O -
AD O -
) O +
brain O +
derive O +
from O +
proteolytic O +
processing O +
of O +
the O +
amyloid O +
precursor O +
protein O +
( O -
APP O -
) O -
. O +

Here O -
, O +
we O +
present O +
evidence O +
that O -
, O +
besides O +
APP O +
expression O +
regulation O -
, O +
miRNAs O +
are O +
equally O +
involved O +
in O +
the O +
regulation O +
of O +
neuronal O +
APP O +
mRNA O +
alternative O +
splicing O -
. O +

Lack O +
of O +
miRNAs O +
in O +
post O -
- O -
mitotic O +
neurons O +
in O +
vivo O +
is O +
associated O +
with O +
APP O +
exons O +
7 O +
and O +
8 O +
inclusion O -
, O +
while O +
ectopic O +
expression O +
of O +
miR-124 O -
, O +
an O +
abundant O +
neuronal O -
- O -
specific O +
miRNA O -
, O +
reversed O +
these O +
effects O +
in O +
cultured O +
neurons O -
. O +

Recent O +
evidence O +
suggest O +
that O +
microRNAs O +
( O -
miRNAs O -
) O +
participate O +
in O +
the O +
post O -
- O -
transcriptional O +
regulation O +
of O +
APP O +
expression O -
. O +

Because O +
gene O +
dosage O +
effects O +
of O +
the O +
APP O +
gene O +
can O +
cause O +
genetic O +
AD O -
, O +
dysregulation O +
of O +
the O +
miRNA O +
network O +
could O +
contribute O +
significantly O +
to O +
disease O -
. O +

Since O +
abnormal O +
neuronal O +
splicing O +
of O +
APP O +
affects O +
β O -
- O -
amyloid O +
peptide O +
production O -
, O +
these O +
results O +
could O +
contribute O +
to O +
the O +
understanding O +
of O +
the O +
implication O +
of O +
miRNAs O +
in O +
brain O +
health O +
and O +
disease O -
. O +

miR-182 O +
as O +
a O +
prognostic O +
marker O +
for O +
glioma O +
progression O +
and O +
patient B-Species +
survival O -
. O +

Taken O +
together O -
, O +
our O +
results O +
suggest O +
that O +
miR-182 O +
could O +
be O +
a O +
valuable O +
marker O +
of O +
glioma O +
progression O +
and O +
that O +
high O +
miR-182 O +
expression O +
is O +
associated O +
with O +
poor O +
overall O +
survival O +
in O +
patients B-Species +
with O +
malignant O +
glioma O -
. O +

Moreover O -
, O +
the O +
correlations O +
of O +
miR-182 O +
level O +
with O +
the O +
clinical O +
features O +
of O +
glioma O +
suggested O +
in O +
the O +
in O +
situ O +
hybridization O +
analysis O +
were O +
further O +
verified O +
by O +
the O +
real O -
- O -
time O +
RT O -
- O -
PCR O +
analysis O -
. O +

The O +
cumulative O +
5-year O +
survival O +
rate O +
of O +
glioma O +
patients B-Species +
was O +
51.54 O -
% O +
( O -
95 O -
% O +
confidence O +
interval O -
, O +
0.435 O +
to O +
0.596 O -
) O +
in O +
the O +
low O +
miR-182-expression O +
group O -
, O +
whereas O +
it O +
was O +
only O +
7.23 O -
% O +
( O -
95 O -
% O +
confidence O +
interval O -
, O +
0.027 O +
to O +
0.118 O -
) O +
in O +
the O +
high O +
miR-182-expression O +
group O +
( O -
P O +
= O +
0.001 O -
) O -
, O +
and O +
multivariate O +
Cox O +
regression O +
analysis O +
indicated O +
that O +
miR-182 O +
expression O +
was O +
an O +
independent O +
prognostic O +
indicator O +
for O +
the O +
survival O +
of O +
glioma O +
patients B-Species -
. O +

Statistical O +
analysis O +
revealed O +
a O +
significant O +
correlation O +
between O +
miR-182 O +
expression O +
and O +
World O +
Health O +
Organization O +
glioma O +
grading O +
( O -
P O +
< O +
0.001 O -
) O -
. O +

Elevated O +
expression O +
of O +
miR-182 O +
was O +
further O +
identified O +
by O +
in O +
situ O +
hybridization O +
in O +
248 O +
of O +
253 O +
( O -
98 O -
% O -
) O +
archived O +
human B-Species +
glioma O +
biopsies O +
tested O -
. O +

Quantitative O +
PCR O +
analysis O +
showed O +
that O +
miR-182 O +
was O +
significantly O +
increased O +
by O +
up O +
to O +
32-fold O +
in O +
glioma O +
tumors O +
compared O +
with O +
the O +
adjacent O +
nontumor O +
brain O +
tissues O +
obtained O +
from O +
the O +
same O +
patient B-Species -
. O +

We O +
report O +
that O +
the O +
expression O +
level O +
of O +
miR-182 O +
was O +
markedly O +
up O -
- O -
regulated O +
in O +
glioma O +
cell O +
lines O +
and O +
in O +
human B-Species +
primary O +
glioma O +
specimens O -
. O +

Accumulating O +
evidence O +
indicates O +
that O +
miRNA O +
expression O +
can O +
be O +
used O +
as O +
a O +
diagnostic O +
and O +
prognostic O +
marker O +
for O +
human B-Species +
cancers O -
. O +

A O +
greater O +
understanding O +
of O +
aberrant O +
miRNA O +
expression O +
in O +
pediatric O +
brain O +
tumors O +
may O +
aid O +
in O +
the O +
development O +
of O +
novel O +
therapies O -
. O +

The O +
characterization O +
of O +
tumor O -
- O -
specific O +
miRNA O +
signatures O +
may O +
aid O +
in O +
the O +
discovery O +
of O +
biomarkers O +
with O +
diagnostic O +
or O +
prognostic O +
utility O -
. O +

The O +
present O +
study O +
provides O +
an O +
initial O +
survey O +
of O +
miRNA O +
expression O +
in O +
pediatric O +
central O +
nervous O +
system O +
( O -
CNS O -
) O +
malignancies O +
including O +
atypical O +
teratoid O -
/ O -
rhabdoid O +
tumor O -
, O +
ependymoma O -
, O +
glioblastoma O -
, O +
medulloblastoma O -
, O +
and O +
pilocytic O +
astrocytoma O -
. O +

PROCEDURE O -
: O +
MicroRNA O +
expression O +
in O +
pediatric O +
brain O +
tumors O +
and O +
normal O +
tissue O +
controls O +
was O +
examined O +
by O +
microarray O -
. O +

BACKGROUND O -
: O +
A O +
better O +
understanding O +
of O +
pediatric O +
brain O +
tumor O +
biology O +
is O +
needed O +
to O +
assist O +
in O +
the O +
development O +
of O +
less O +
toxic O +
therapies O +
and O +
to O +
provide O +
better O +
markers O +
for O +
disease O +
stratification O -
. O +

MicroRNAs O +
( O -
miRNA O -
) O +
may O +
play O +
a O +
significant O +
role O +
in O +
brain O +
tumor O +
biology O -
. O +

When O +
further O +
examined O +
by O +
qRT O -
- O -
PCR O -
, O +
these O +
miRNAs O +
demonstrated O +
differential O +
expression O +
that O +
significantly O +
correlated O +
with O +
the O +
microarray O +
findings O -
. O +

Distinctive O +
miRNA O +
expression O +
profiles O +
were O +
also O +
observed O +
in O +
the O +
different O +
pediatric O +
brain O +
tumor O +
types O -
. O +

Three O +
aberrantly O +
expressed O +
miRNAs O +
were O +
further O +
studied O +
in O +
a O +
larger O +
cohort O +
by O +
quantitative O +
real O -
- O -
time O +
PCR O +
( O -
qRT O -
- O -
PCR O -
) O -
. O +

RESULTS O -
: O +
MicroRNA-129 O -
, O +
miR-142 O -
- O -
5p O -
, O +
and O +
miR-25 O +
were O +
differentially O +
expressed O +
in O +
every O +
pediatric O +
brain O +
tumor O +
type O +
compared O +
to O +
normal O +
tissue O +
controls O +
as O +
measured O +
by O +
microarray O -
. O +

CONCLUSIONS O -
: O +
MicroRNAs O +
are O +
differentially O +
expressed O +
between O +
pediatric O +
CNS O +
neoplasms O +
and O +
normal O +
tissue O +
suggesting O +
that O +
they O +
may O +
play O +
a O +
significant O +
role O +
in O +
oncogenesis O -
. O +

Survey O +
of O +
MicroRNA O +
expression O +
in O +
pediatric O +
brain O +
tumors O -
. O +

Recently O -
, O +
we O +
have O +
found O +
that O +
microRNA O +
( O -
miRNA O -
) O +
miR-145 O +
is O +
the O +
most O +
abundant O +
miRNA O +
in O +
normal O +
vascular O +
walls O +
and O +
in O +
freshly O +
isolated O +
VSMCs O -
; O +
however O -
, O +
the O +
role O +
of O +
miR-145 O +
in O +
VSMC O +
phenotypic O +
modulation O +
and O +
vascular O +
diseases O +
is O +
currently O +
unknown O -
. O +

Phenotypic O +
modulation O +
of O +
vascular O +
smooth O +
muscle O +
cells O +
( O -
VSMCs O -
) O +
plays O +
a O +
critical O +
role O +
in O +
the O +
pathogenesis O +
of O +
a O +
variety O +
of O +
proliferative O +
vascular O +
diseases O -
. O +

More O +
importantly O -
, O +
both O +
in O +
cultured O +
rat B-Species +
VSMCs O +
in O +
vitro O +
and O +
in O +
balloon O -
- O -
injured O +
rat B-Species +
carotid O +
arteries O +
in O +
vivo O -
, O +
we O +
demonstrate O +
that O +
the O +
noncoding O +
RNA O +
miR-145 O +
is O +
a O +
novel O +
phenotypic O +
marker O +
and O +
a O +
novel O +
phenotypic O +
modulator O +
of O +
VSMCs O -
. O +

Here O +
we O +
find O +
that O +
miR-145 O +
is O +
selectively O +
expressed O +
in O +
VSMCs O +
of O +
the O +
vascular O +
wall O +
and O +
its O +
expression O +
is O +
significantly O +
downregulated O +
in O +
the O +
vascular O +
walls O +
with O +
neointimal O +
lesion O +
formation O +
and O +
in O +
cultured O +
dedifferentiated O +
VSMCs O -
. O +

MicroRNA-145 O -
, O +
a O +
novel O +
smooth O +
muscle O +
cell O +
phenotypic O +
marker O +
and O +
modulator O -
, O +
controls O +
vascular O +
neointimal O +
lesion O +
formation O -
. O +

These O +
novel O +
findings O +
may O +
have O +
extensive O +
implications O +
for O +
the O +
diagnosis O +
and O +
therapy O +
of O +
a O +
variety O +
of O +
proliferative O +
vascular O +
diseases O -
. O +

We O +
have O +
further O +
identified O +
that O +
miR-145-mediated O +
phenotypic O +
modulation O +
of O +
VSMCs O +
is O +
through O +
its O +
target O +
gene O +
KLF5 O +
and O +
its O +
downstream O +
signaling O +
molecule O -
, O +
myocardin O -
. O +

VSMC O +
differentiation O +
marker O +
genes O +
such O +
as O +
SM O +
alpha O -
- O -
actin O -
, O +
calponin O -
, O +
and O +
SM O -
- O -
MHC O +
are O +
upregulated O +
by O +
premiR-145 O +
or O +
adenovirus O +
expressing O +
miR-145 O +
( O -
Ad O -
- O -
miR-145 O -
) O +
but O +
are O +
downregulated O +
by O +
the O +
miR-145 O +
inhibitor O +
2'OMe O -
- O -
miR-145 O -
. O +

We O +
conclude O +
that O +
miR-145 O +
is O +
a O +
novel O +
VSMC O +
phenotypic O +
marker O +
and O +
modulator O +
that O +
is O +
able O +
of O +
controlling O +
vascular O +
neointimal O +
lesion O +
formation O -
. O +

Finally O -
, O +
restoration O +
of O +
miR-145 O +
in O +
balloon O -
- O -
injured O +
arteries O +
via O +
Ad O -
- O -
miR-145 O +
inhibits O +
neointimal O +
growth O -
. O +

In O +
this O +
review O -
, O +
we O +
summarise O +
the O +
current O +
knowledge O +
of O +
miR-21 O +
functions O +
in O +
human B-Species +
disease O -
, O +
with O +
an O +
emphasis O +
on O +
its O +
regulation O -
, O +
oncogenic O +
role O -
, O +
targets O +
in O +
human B-Species +
cancers O -
, O +
potential O +
as O +
a O +
disease O +
biomarker O +
and O +
novel O +
therapeutic O +
target O +
in O +
oncology O -
. O +

However O -
, O +
an O +
miR-21 O +
knockout O +
mouse B-Species +
has O +
not O +
yet O +
been O +
generated O -
, O +
and O +
the O +
data O +
about O +
miR-21 O +
functions O +
in O +
normal O +
cells O +
are O +
still O +
very O +
limited O -
. O +

Since O +
its O +
identification O +
3 O +
years O +
ago O +
as O +
the O +
miRNA O +
most O +
commonly O +
and O +
strongly O +
up O -
- O -
regulated O +
in O +
human B-Species +
brain O +
tumour O +
glioblastoma O +
[ O -
1 O -
] O -
, O +
miR-21 O +
has O +
attracted O +
the O +
attention O +
of O +
researchers O +
in O +
various O +
fields O -
, O +
such O +
as O +
development O -
, O +
oncology O -
, O +
stem O +
cell O +
biology O +
and O +
aging O -
, O +
becoming O +
one O +
of O +
the O +
most O +
studied O +
miRNAs O -
, O +
along O +
with O +
let-7 O -
, O +
miR-17 O -
- O -
92 O +
cluster O +
( O -
' O -
oncomir-1 O -
' O -
) O -
, O +
miR-155 O +
and O +
a O +
few O +
others O -
. O +

Particular O +
miRNAs O +
emerge O +
as O +
principal O +
regulators O +
that O +
control O +
major O +
cell O +
functions O +
in O +
various O +
physiological O +
and O +
pathophysiological O +
settings O -
. O +

miR-21 O -
: O +
a O +
small O +
multi O -
- O -
faceted O +
RNA O -
. O +

More O +
than O +
1000 O +
microRNAs O +
( O -
miRNAs O -
) O +
are O +
expressed O +
in O +
human B-Species +
cells O -
, O +
some O +
tissue O +
or O +
cell O +
type O +
specific O -
, O +
others O +
considered O +
as O +
house O -
- O -
keeping O +
molecules O -
. O +

Functions O +
and O +
direct O +
mRNA O +
targets O +
for O +
some O +
miRNAs O +
have O +
been O +
relatively O +
well O +
studied O +
over O +
the O +
last O +
years O -
. O +

Every O +
miRNA O +
potentially O +
regulates O +
the O +
expression O +
of O +
numerous O +
protein O -
- O -
coding O +
genes O +
( O -
tens O +
to O +
hundreds O -
) O -
, O +
but O +
it O +
has O +
become O +
increasingly O +
clear O +
that O +
not O +
all O +
miRNAs O +
are O +
equally O +
important O -
; O +
diverse O +
high O -
- O -
throughput O +
screenings O +
of O +
various O +
systems O +
have O +
identified O +
a O +
limited O +
number O +
of O +
key O +
functional O +
miRNAs O +
over O +
and O +
over O +
again O -
. O +

MicroRNAs O +
and O +
regenerative O +
medicine O -
. O +

Recently O -
, O +
researchers O +
have O +
demonstrated O +
the O +
crucial O +
roles O +
of O +
microRNAs O -
, O +
not O +
only O +
in O +
the O +
differentiation O +
and O +
proliferation O +
of O +
stem O +
cells O -
, O +
which O +
have O +
a O +
key O +
function O +
in O +
the O +
regeneration O +
and O +
transplantation O +
of O +
organs O -
, O +
but O +
also O +
in O +
oncogenesis O -
. O +

In O +
this O +
paper O -
, O +
we O +
review O +
the O +
prospects O +
of O +
microRNAs O +
as O +
future O +
therapies O +
in O +
regenerative O +
medicine O -
. O +

The O +
combination O +
of O +
microRNAs O +
and O +
regenerative O +
medicine O +
is O +
an O +
emerging O +
interdisciplinary O +
medical O +
field O +
that O +
can O +
yield O +
exciting O +
new O +
possibilities O +
for O +
clinical O +
medicine O -
. O +

MicroRNAs O -
, O +
identified O +
only O +
relatively O +
recently O -
, O +
are O +
regulators O +
of O +
gene O +
expression O +
with O +
potential O +
medical O +
benefits O -
. O +

Further O -
, O +
microRNAs O +
have O +
been O +
indicated O +
to O +
be O +
involved O +
in O +
diverse O +
biological O +
processes O -
, O +
suggesting O +
the O +
potential O +
role O +
of O +
these O +
molecules O +
in O +
the O +
treatment O +
of O +
diseases O -
. O +

Several O +
lines O +
of O +
indirect O +
evidence O +
show O +
that O +
the O +
initiation O +
and O +
maintenance O +
of O +
cancer O +
stem O +
cells O +
might O +
also O +
be O +
under O +
the O +
control O +
of O +
microRNAs O -
. O +

Expression O +
levels O +
of O +
select O +
protein O -
- O -
coding O +
genes O +
and O +
miRNAs O +
could O +
classify O +
an O +
independent O +
set O +
of O +
medulloblastomas O -
. O +

Twelve O +
of O +
31 O +
medulloblastomas O +
were O +
found O +
to O +
overexpress O +
genes O +
belonging O +
to O +
the O +
canonical O +
WNT O +
signaling O +
pathway O +
and O +
carry O +
a O +
mutation O +
in O +
CTNNB1 O +
gene O -
. O +

In O +
order O +
to O +
get O +
a O +
better O +
understanding O +
of O +
medulloblastoma O +
biology O -
, O +
miRNA O +
profiling O +
of O +
medulloblastomas O +
was O +
carried O +
out O +
in O +
parallel O +
with O +
expression O +
profiling O +
of O +
protein O -
- O -
coding O +
genes O -
. O +

MATERIALS O +
AND O +
METHODS O -
: O +
miRNA O +
profiling O +
of O +
medulloblastomas O +
was O +
carried O +
out O +
using O +
Taqman O +
Low O +
Density O +
Array O +
v O +
1.0 O +
having O +
365 O +
human B-Species +
microRNAs O -
. O +

In O +
parallel O -
, O +
genome O -
- O -
wide O +
expression O +
profiling O +
of O +
protein O -
- O -
coding O +
genes O +
was O +
carried O +
out O +
using O +
Affymetrix O +
gene O +
1.0 O +
ST O +
arrays O -
. O +

RESULTS O -
: O +
Both O +
the O +
profiling O +
studies O +
identified O +
four O +
molecular O +
subtypes O +
of O +
medulloblastomas O -
. O +

Distinctive O +
microRNA O +
signature O +
of O +
medulloblastomas O +
associated O +
with O +
the O +
WNT O +
signaling O +
pathway O -
. O +

AIM O -
: O +
Medulloblastoma O +
is O +
a O +
malignant O +
brain O +
tumor O +
that O +
occurs O +
predominantly O +
in O +
children B-Species -
. O +

Current O +
risk O +
stratification O +
based O +
on O +
clinical O +
parameters O +
is O +
inadequate O +
for O +
accurate O +
prognostication O -
. O +

MicroRNA O +
expression O +
is O +
known O +
to O +
be O +
deregulated O +
in O +
various O +
cancers O +
and O +
has O +
been O +
found O +
to O +
be O +
useful O +
in O +
predicting O +
tumor O +
behavior O -
. O +

A O +
number O +
of O +
miRNAs O +
like O +
miR-193a O -
, O +
miR-224 O -
/ O -
miR-452 O +
cluster O -
, O +
miR-182 O -
/ O -
miR-183 O -
/ O -
miR-96 O +
cluster O -
, O +
and O +
miR-148a O +
having O +
potential O +
tumor O -
/ O -
metastasis O +
suppressive O +
activity O +
were O +
found O +
to O +
be O +
overexpressed O +
in O +
the O +
WNT O +
signaling O +
associated O +
medulloblastomas O -
. O +

CONCLUSION O -
: O +
Expression O +
level O +
of O +
tumor O -
/ O -
metastasis O +
suppressive O +
miRNAs O +
in O +
the O +
WNT O +
signaling O +
associated O +
medulloblastomas O +
is O +
likely O +
to O +
determine O +
their O +
response O +
to O +
treatment O -
, O +
and O +
thus O -
, O +
these O +
miRNAs O +
would O +
be O +
important O +
biomarkers O +
for O +
risk O +
stratification O +
within O +
the O +
WNT O +
signaling O +
associated O +
medulloblastomas O -
. O +

Exogenous O +
expression O +
of O +
miR-193a O +
and O +
miR-224 O -
, O +
two O +
miRNAs O +
that O +
have O +
the O +
highest O +
WNT O +
pathway O +
specific O +
upregulation O -
, O +
was O +
found O +
to O +
inhibit O +
proliferation O -
, O +
increase O +
radiation O +
sensitivity O +
and O +
reduce O +
anchorage O -
- O -
independent O +
growth O +
of O +
medulloblastoma O +
cells O -
. O +

MicroRNAs O +
in O +
CNS O +
injury O -
: O +
potential O +
roles O +
and O +
therapeutic O +
implications O -
. O +

We O +
now O +
report O +
clinical O +
and O +
genetic O +
findings O +
in O +
nine O +
additional O +
European O +
families O +
with O +
myoclonus O -
- O -
dystonia O +
syndrome O -
. O +

Mutations O +
in O +
the O +
gene O +
for O +
epsilon O -
- O -
sarcoglycan O +
( O -
SGCE O -
) O +
have O +
been O +
found O +
to O +
cause O +
myoclonus O -
- O -
dystonia O +
syndrome O -
. O +

Six O +
novel O +
and O +
one O +
previously O +
known O +
heterozygous O +
SGCE O +
mutations O +
were O +
identified O -
. O +

The O +
clinical O +
presentation O +
in O +
24 O +
affecteds O +
was O +
homogeneous O +
with O +
myoclonus O +
predominantly O +
of O +
neck O +
and O +
upper O +
limbs O +
in O +
23 O +
of O +
them O +
and O +
dystonia O -
, O +
presenting O +
as O +
cervical O +
dystonia O +
and/or O +
writer O -
's O +
cramp O -
, O +
in O +
13 O +
cases O -
. O +

SGCE O +
deficiency O +
seems O +
to O +
be O +
the O +
common O +
pathogenetic O +
mechanism O +
in O +
myoclonus O -
- O -
dystonia O +
syndrome O -
. O +

Myoclonus O -
- O -
dystonia O +
syndrome O -
: O +
epsilon O -
- O -
sarcoglycan O +
mutations O +
and O +
phenotype O -
. O +

Ameliorating O +
amyotrophic O +
lateral O +
sclerosis O -
. O +

This O +
review O +
summarizes O +
recent O +
findings O +
of O +
miRNA O +
study O +
in O +
brain O +
tumors O -
. O +

Several O +
deregulated O +
miRNAs O +
uncovered O +
in O +
glioblastomas O +
and O +
medulloblastomas O +
have O +
their O +
gene O +
targets O +
and O +
the O +
associated O +
genetic O +
pathways O +
identified O -
. O +

Moreover O -
, O +
specific O +
miRNA O +
subsets O +
may O +
have O +
potential O +
diagnostic O +
and O +
prognostic O +
values O +
in O +
some O +
brain O +
tumors O -
. O +

Expression O +
profiling O +
has O +
unveiled O +
miRNA O +
signatures O +
that O +
not O +
only O +
distinguish O +
brain O +
tumors O +
from O +
normal O +
tissues O -
, O +
but O +
can O +
also O +
differentiate O +
histotypes O +
or O +
molecular O +
subtypes O +
with O +
altered O +
genetic O +
pathways O -
. O +

Recent O +
years O +
have O +
seen O +
considerable O +
progress O +
in O +
miRNA O +
research O +
in O +
brain O +
tumors O -
, O +
particularly O +
in O +
glioblastomas O +
and O +
medulloblastomas O -
, O +
providing O +
novel O +
insights O +
into O +
the O +
pathogenesis O +
of O +
these O +
malignant O +
lesions O -
. O +

Emerging O +
evidence O +
indicates O +
that O +
miRNAs O +
play O +
an O +
important O +
role O +
in O +
the O +
development O +
of O +
human B-Species +
cancers O -
, O +
with O +
their O +
deregulation O +
resulting O +
in O +
altered O +
activity O +
of O +
downstream O +
tumor O +
suppressors O -
, O +
oncogenes O +
and O +
other O +
signaling O +
molecules O -
. O +

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
short O +
non O -
- O -
protein O -
- O -
coding O +
RNAs O +
that O +
function O +
as O +
key O +
regulators O +
of O +
diverse O +
biological O +
processes O +
through O +
negative O +
control O +
on O +
gene O +
expression O +
at O +
the O +
post O -
- O -
transcriptional O +
level O -
. O +

Oncogenic O +
role O +
of O +
microRNAs O +
in O +
brain O +
tumors O -
. O +

Pathway O +
analyses O +
showed O +
that O +
majority O +
of O +
these O +
miRNAs O +
are O +
involved O +
in O +
the O +
neuronal O +
development O +
and O +
function O -
. O +

In O +
this O +
study O -
, O +
we O +
report O +
for O +
the O +
first O +
time O +
that O +
VEEV O +
infection O +
in O +
mice B-Species +
brain O +
causes O +
modulation O +
of O +
miRNA O +
expression O -
. O +

Target O +
gene O +
prediction O +
of O +
the O +
modulated O +
miRNAs O +
correlates O +
with O +
our O +
recently O +
reported O +
mRNA O +
expression O +
in O +
VEEV O +
infected O +
mice B-Species +
brain O -
. O +

Recent O +
studies O +
have O +
shown O +
that O +
cellular O +
miRNA O +
plays O +
a O +
very O +
important O +
role O +
in O +
the O +
pathogenesis O +
of O +
viral O +
infection O -
. O +

MicroRNAs O +
( O -
miRNA O -
) O +
are O +
small O +
RNA O +
( O -
approximately O +
22nts O -
) O +
molecules O +
that O +
are O +
expressed O +
endogenously O +
in O +
cells O +
and O +
play O +
an O +
important O +
role O +
in O +
regulating O +
gene O +
expression O -
. O +

VEEV O +
is O +
infectious O +
in O +
aerosol O +
form O +
and O +
is O +
a O +
potential O +
biothreat O +
agent O -
. O +

Venezuelan O +
equine O +
encephalitis O +
virus O +
( O -
VEEV O -
) O +
is O +
an O +
RNA O +
virus O +
and O +
is O +
a O +
member O +
of O +
the O +
genus O +
Alphavirus O +
in O +
the O +
family O +
Togaviridae O -
. O +

Analysis O +
of O +
microRNAs O +
induced O +
by O +
Venezuelan O +
equine O +
encephalitis O +
virus O +
infection O +
in O +
mouse B-Species +
brain O -
. O +

Additionally O -
, O +
a O +
control O +
shRNA O +
containing O +
mismatches O +
also O +
induced O +
toxicity O -
, O +
although O +
it O +
did O +
not O +
reduce O +
HDh O +
mRNA O +
expression O -
. O +

Interestingly O -
, O +
the O +
toxic O +
shRNAs O +
generated O +
higher O +
antisense O +
RNA O +
levels O -
, O +
compared O +
with O +
the O +
nontoxic O +
shRNA O -
. O +

These O +
results O +
demonstrate O +
that O +
the O +
robust O +
levels O +
of O +
antisense O +
RNAs O +
emerging O +
from O +
shRNA O +
expression O +
systems O +
can O +
be O +
problematic O +
in O +
the O +
mouse B-Species +
brain O -
. O +

Importantly O -
, O +
when O +
sequences O +
that O +
were O +
toxic O +
in O +
the O +
context O +
of O +
shRNAs O +
were O +
placed O +
into O +
artificial O +
microRNA O +
( O -
miRNA O -
) O +
expression O +
systems O -
, O +
molecular O +
and O +
neuropathological O +
readouts O +
of O +
neurotoxicity O +
were O +
significantly O +
attenuated O +
without O +
compromising O +
mouse B-Species +
HDh O +
silencing O +
efficacy O -
. O +

Artificial O +
miRNAs O +
mitigate O +
shRNA O -
- O -
mediated O +
toxicity O +
in O +
the O +
brain O -
: O +
implications O +
for O +
the O +
therapeutic O +
development O +
of O +
RNAi O -
. O +

Huntington O -
's O +
disease O +
( O -
HD O -
) O +
is O +
a O +
fatal O -
, O +
dominant O +
neurodegenerative O +
disease O +
caused O +
by O +
a O +
polyglutamine O +
repeat O +
expansion O +
in O +
exon O +
1 O +
of O +
the O +
HD O +
gene O -
, O +
which O +
encodes O +
the O +
huntingtin O +
protein O -
. O +

We O +
and O +
others O +
have O +
shown O +
that O +
RNAi O +
is O +
a O +
candidate O +
therapy O +
for O +
HD O +
because O +
expression O +
of O +
inhibitory O +
RNAs O +
targeting O +
mutant O +
human B-Species +
HD O +
transgenes O +
improved O +
neuropathology O +
and O +
behavioral O +
deficits O +
in O +
HD O +
mouse B-Species +
models O -
. O +

Here O -
, O +
we O +
developed O +
shRNAs O +
targeting O +
conserved O +
sequences O +
in O +
human B-Species +
HD O +
and O +
mouse B-Species +
HD O +
homolog O +
( O -
HDh O -
) O +
mRNAs O +
to O +
initiate O +
preclinical O +
testing O +
in O +
a O +
knockin O +
mouse B-Species +
model O +
of O +
HD O -
. O +

We O +
screened O +
35 O +
shRNAs O +
in O +
vitro O +
and O +
subsequently O +
narrowed O +
our O +
focus O +
to O +
three O +
candidates O +
for O +
in O +
vivo O +
testing O -
. O +

Unexpectedly O -
, O +
two O +
active O +
shRNAs O +
induced O +
significant O +
neurotoxicity O +
in O +
mouse B-Species +
striatum O -
, O +
although O +
HDh O +
mRNA O +
expression O +
was O +
reduced O +
to O +
similar O +
levels O +
by O +
all O +
three O -
. O +

Thus O -
, O +
miRNA O -
- O -
based O +
approaches O +
may O +
provide O +
more O +
appropriate O +
biological O +
tools O +
for O +
expressing O +
inhibitory O +
RNAs O +
in O +
the O +
brain O -
, O +
the O +
implications O +
of O +
which O +
are O +
crucial O +
to O +
the O +
development O +
of O +
RNAi O +
for O +
both O +
basic O +
biological O +
and O +
therapeutic O +
applications O -
. O +

These O +
findings O +
call O +
attention O +
to O +
the O +
potential O +
of O +
microRNAs O +
to O +
provide O +
etiologic O +
insights O +
as O +
well O +
as O +
to O +
serve O +
as O +
both O +
diagnostic O +
markers O +
and O +
therapeutic O +
targets O +
for O +
many O +
different O +
tumor O +
types O -
. O +

Our O +
results O +
provide O +
evidence O +
that O +
microRNA O +
expression O +
patterns O +
may O +
mark O +
specific O +
biological O +
characteristics O +
of O +
tumors O +
and/or O +
mediate O +
biological O +
activities O +
important O +
for O +
the O +
pathobiology O +
of O +
malignant O +
tumors O -
. O +

Agglomerative O +
hierarchical O +
clustering O +
analysis O +
of O +
microRNA O +
expression O +
revealed O +
four O +
groups O +
among O +
the O +
NCI-60 O +
cell O +
lines O +
consisting O +
of O +
hematologic O -
, O +
colon O -
, O +
central O +
nervous O +
system O -
, O +
and O +
melanoma O +
tumor O -
- O -
derived O +
cell O +
lines O +
clustered O +
in O +
a O +
manner O +
that O +
reflected O +
their O +
tissue O +
of O +
origin O -
. O +

Most O +
microRNAs O +
were O +
expressed O +
at O +
lower O +
levels O +
in O +
tumor O -
- O -
derived O +
cell O +
lines O +
compared O +
with O +
the O +
corresponding O +
normal O +
tissue O -
. O +

We O +
also O +
identified O +
specific O +
microRNA O +
expression O +
patterns O +
that O +
correlated O +
with O +
the O +
proliferation O +
indices O +
of O +
the O +
NCI-60 O +
cell O +
lines O -
, O +
and O +
we O +
developed O +
evidence O +
for O +
the O +
identification O +
of O +
specific O +
microRNAs O +
as O +
candidate O +
oncogenes O +
and O +
tumor O +
suppressor O +
genes O +
in O +
different O +
tumor O +
types O -
. O +

We O +
identified O +
specific O +
subsets O +
of O +
microRNAs O +
that O +
provide O +
candidate O +
molecular O +
signatures O +
characteristic O +
of O +
the O +
tumor O -
- O -
derived O +
cell O +
lines O +
belonging O +
to O +
these O +
four O +
clusters O -
. O +

They O +
play O +
a O +
critical O +
role O +
in O +
developmental O +
and O +
physiologic O +
processes O +
and O +
are O +
implicated O +
in O +
the O +
pathogenesis O +
of O +
several O +
human B-Species +
diseases O +
including O +
cancer O -
. O +

MicroRNAs O +
are O +
small O +
noncoding O +
RNAs O +
that O +
function O +
by O +
regulating O +
target O +
gene O +
expression O +
posttranscriptionally O -
. O +

To O +
quantify O +
microRNA O +
expression O -
, O +
we O +
employed O +
a O +
highly O +
sensitive O +
technique O +
that O +
uses O +
stem O -
- O -
loop O +
primers O +
for O +
reverse O +
transcription O +
followed O +
by O +
real O -
- O -
time O +
PCR O -
. O +

We O +
examined O +
the O +
expression O +
profiles O +
of O +
241 O +
human B-Species +
microRNAs O +
in O +
normal O +
tissues O +
and O +
the O +
NCI-60 O +
panel O +
of O +
human B-Species +
tumor O -
- O -
derived O +
cell O +
lines O -
. O +

Characterization O +
of O +
microRNA O +
expression O +
levels O +
and O +
their O +
biological O +
correlates O +
in O +
human B-Species +
cancer O +
cell O +
lines O -
. O +

Predictive O +
miRNAs O +
could O +
be O +
potentially O +
useful O +
diagnostic O +
markers O -
, O +
improving O +
the O +
classification O +
of O +
pituitary O +
adenomas O -
. O +

Several O +
of O +
the O +
identified O +
miRNAs O +
are O +
involved O +
in O +
cell O +
proliferation O +
and O +
apoptosis O -
, O +
suggesting O +
that O +
their O +
deregulated O +
expression O +
may O +
be O +
involved O +
in O +
pituitary O +
tumorigenesis O -
. O +

Identification O +
of O +
differentially O +
expressed O +
microRNAs O +
by O +
microarray O -
: O +
a O +
possible O +
role O +
for O +
microRNA O +
genes O +
in O +
pituitary O +
adenomas O -
. O +

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
small O +
non O -
- O -
coding O +
RNAs O +
that O +
control O +
gene O +
expression O +
by O +
targeting O +
mRNA O -
. O +

It O +
has O +
been O +
demonstrated O +
that O +
miRNA O +
expression O +
is O +
altered O +
in O +
many O +
human B-Species +
cancers O -
, O +
suggesting O +
that O +
they O +
may O +
play O +
a O +
role O +
in O +
human B-Species +
neoplasia O -
. O +

To O +
determine O +
whether O +
miRNA O +
expression O +
is O +
altered O +
in O +
pituitary O +
adenomas O -
, O +
we O +
analyzed O +
the O +
entire O +
miRNAome O +
in O +
32 O +
pituitary O +
adenomas O +
and O +
in O +
6 O +
normal O +
pituitary O +
samples O +
by O +
microarray O +
and O +
by O +
Real O -
- O -
Time O +
PCR O -
. O +

Here O -
, O +
we O +
show O +
that O +
30 O +
miRNAs O +
are O +
differentially O +
expressed O +
between O +
normal O +
pituitary O +
and O +
pituitary O +
adenomas O -
. O +

Moreover O -
, O +
24 O +
miRNAs O +
were O +
identified O +
as O +
a O +
predictive O +
signature O +
of O +
pituitary O +
adenoma O +
and O +
29 O +
miRNAs O +
were O +
able O +
to O +
predict O +
pituitary O +
adenoma O +
histotype O -
. O +

miRNA O +
expression O +
could O +
differentiate O +
micro- O +
from O +
macro O -
- O -
adenomas O +
and O +
treated O +
from O +
non O -
- O -
treated O +
patient B-Species +
samples O -
. O +

Recent O +
evidence O +
suggests O +
that O +
both O +
development O +
and O +
proper O +
function O +
of O +
central O +
nervous O +
system O +
require O +
intricate O +
spatiotemporal O +
expression O +
of O +
a O +
wide O +
repertoire O +
of O +
small O +
regulatory O +
RNAs O -
. O +

Increasingly O +
complex O +
networks O +
of O +
small O +
RNAs O +
act O +
through O +
RNA O +
interference O +
pathway O +
to O +
regulate O +
gene O +
expression O -
. O +

Small O +
regulatory O +
RNAs O +
in O +
neurodevelopmental O +
disorders O -
. O +

Here O -
, O +
we O +
will O +
review O +
recent O +
progress O +
made O +
toward O +
understanding O +
roles O +
of O +
small O +
regulatory O +
RNAs O +
in O +
neurodevelopmental O +
disorders O +
and O +
discuss O +
the O +
potential O +
involvement O +
of O +
newly O +
discovered O +
classes O +
of O +
small O +
RNAs O +
in O +
these O +
disorders O -
. O +

Misregulation O +
of O +
these O +
small O +
regulatory O +
RNAs O +
could O +
contribute O +
to O +
the O +
abnormalities O +
in O +
brain O +
development O +
that O +
are O +
associated O +
with O +
neurodevelopmental O +
disorders O -
. O +

Comparison O +
of O +
mouse B-Species +
cerebellar O +
development O +
and O +
medulloblastoma O +
demonstrates O +
a O +
shared O +
miRNA O -
- O -
mRNA O +
co O -
- O -
expression O +
program O +
for O +
brain O -
- O -
specific O +
neurologic O +
processes O +
such O +
as O +
synaptic O +
transmission O +
and O +
exocytosis O -
, O +
in O +
which O +
miRNA O +
target O +
expression O +
increases O +
with O +
the O +
accumulation O +
of O +
multiple O +
miRNAs O +
in O +
developing O +
cerebellum O +
and O +
decreases O +
with O +
the O +
loss O +
of O +
these O +
miRNAs O +
in O +
brain O +
tumors O -
. O +

These O +
findings O +
demonstrate O +
the O +
context O -
- O -
dependence O +
of O +
miRNA O -
- O -
mRNA O +
co O -
- O -
expression O -
. O +

Although O +
miRNAs O +
in O +
general O +
suppress O +
target O +
mRNA O +
messages O -
, O +
many O +
predicted O +
miRNA O +
targets O +
demonstrate O +
a O +
significantly O +
higher O +
level O +
of O +
co O -
- O -
expression O +
than O +
non O -
- O -
target O +
genes O +
in O +
developing O +
cerebellum O -
. O +

This O +
phenomenon O +
is O +
tissue O +
specific O +
since O +
it O +
is O +
not O +
observed O +
in O +
developing O +
lungs O -
. O +

Towards O +
that O +
goal O -
, O +
we O +
examined O +
miRNA O -
- O -
mRNA O +
interactions O +
by O +
measuring O +
miRNA O +
and O +
mRNA O +
in O +
the O +
same O +
tissue O +
during O +
development O +
and O +
also O +
in O +
malignant O +
conditions O -
. O +

We O +
identified O +
significant O +
miRNA O -
- O -
mediated O +
biological O +
process O +
categories O +
in O +
developing O +
mouse B-Species +
cerebellum O +
and O +
lung O +
using O +
non O -
- O -
targeted O +
mRNA O +
expression O +
as O +
the O +
negative O +
control O -
. O +

Tissue O +
and O +
process O +
specific O +
microRNA O -
- O -
mRNA O +
co O -
- O -
expression O +
in O +
mammalian O +
development O +
and O +
malignancy O -
. O +

An O +
association O +
between O +
enrichment O +
and O +
depletion O +
of O +
microRNA O +
( O -
miRNA O -
) O +
binding O +
sites O -
, O +
3 O -
' O +
UTR O +
length O -
, O +
and O +
mRNA O +
expression O +
has O +
been O +
demonstrated O +
in O +
various O +
developing O +
tissues O +
and O +
tissues O +
from O +
different O +
mature O +
organs O -
; O +
but O +
functional O -
, O +
context O -
- O -
dependent O +
miRNA O +
regulations O +
have O +
yet O +
to O +
be O +
elucidated O -
. O +

These O +
concepts O +
will O +
be O +
explored O +
in O +
this O +
article O -
. O +

This O +
encourages O +
the O +
idea O +
that O +
certain O +
miRs O +
allow O +
continued O +
tumor O +
growth O +
through O +
the O +
suppression O +
of O +
differentiation O +
and O +
the O +
maintenance O +
of O +
the O +
stem O +
cell O -
- O -
like O +
properties O +
of O +
tumor O +
cells O -
. O +

At O +
the O +
same O +
time O -
, O +
it O +
has O +
become O +
clear O +
that O +
one O +
of O +
the O +
major O +
roles O +
that O +
microRNAs O +
play O +
is O +
in O +
the O +
regulation O +
of O +
stem O +
cell O +
biology O -
, O +
differentiation O -
, O +
and O +
cell O +
' O -
identity O -
' O -
. O +

Recent O +
data O +
draw O +
close O +
parallels O +
between O +
cancer O -
, O +
including O +
glial O +
brain O +
tumors O -
, O +
and O +
the O +
biology O +
of O +
stem O +
and O +
progenitor O +
cells O -
. O +

Interestingly O -
, O +
initial O +
studies O +
in O +
the O +
incurable O +
brain O +
tumor O +
glioblastoma O +
multiforme O +
strongly O +
suggest O +
that O +
microRNAs O +
involved O +
in O +
neural O +
development O +
play O +
a O +
role O +
in O +
this O +
disease O -
. O +

For O +
example O -
, O +
microRNAs O +
have O +
been O +
increasingly O +
implicated O +
in O +
the O +
regulation O +
of O +
neural O +
differentiation O -
. O +

MicroRNAs O +
and O +
glioblastoma O -
; O +
the O +
stem O +
cell O +
connection O -
. O +

MiRNAs O +
may O +
be O +
a O +
new O +
therapeutic O +
target O +
for O +
proliferative O +
vascular O +
diseases O +
such O +
as O +
atherosclerosis O -
, O +
postangioplasty O +
restenosis O -
, O +
transplantation O +
arteriopathy O -
, O +
and O +
stroke O -
. O +

The O +
results O +
suggest O +
that O +
miRNAs O +
are O +
novel O +
regulatory O +
RNAs O +
for O +
neointimal O +
lesion O +
formation O -
. O +

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
a O +
recently O +
discovered O +
class O +
of O +
endogenous O -
, O +
small O -
, O +
noncoding O +
RNAs O +
that O +
regulate O +
about O +
30 O -
% O +
of O +
the O +
encoding O +
genes O +
of O +
the O +
human B-Species +
genome O -
. O +

MicroRNA O +
expression O +
signature O +
and O +
antisense O -
- O -
mediated O +
depletion O +
reveal O +
an O +
essential O +
role O +
of O +
MicroRNA O +
in O +
vascular O +
neointimal O +
lesion O +
formation O -
. O +

Western O +
blot O +
analysis O +
demonstrated O +
that O +
PTEN O +
and O +
Bcl-2 O +
were O +
involved O +
in O +
miR-21-mediated O +
cellular O +
effects O -
. O +

MiR-21-mediated O +
cellular O +
effects O +
were O +
further O +
confirmed O +
in O +
vivo O +
in O +
balloon O -
- O -
injured O +
rat B-Species +
carotid O +
arteries O -
. O +

Depletion O +
of O +
miR-21 O +
resulted O +
in O +
decreased O +
cell O +
proliferation O +
and O +
increased O +
cell O +
apoptosis O +
in O +
a O +
dose O -
- O -
dependent O +
manner O -
. O +

In O +
vitro O -
, O +
the O +
expression O +
level O +
of O +
miR-21 O +
in O +
dedifferentiated O +
vascular O +
smooth O +
muscle O +
cells O +
was O +
significantly O +
higher O +
than O +
that O +
in O +
fresh O +
isolated O +
differentiated O +
cells O -
. O +

Modulating O +
an O +
aberrantly O +
overexpressed O +
miRNA O -
, O +
miR-21 O -
, O +
via O +
antisense O -
- O -
mediated O +
depletion O +
( O -
knock O -
- O -
down O -
) O +
had O +
a O +
significant O +
negative O +
effect O +
on O +
neointimal O +
lesion O +
formation O -
. O +

The O +
aberrantly O +
expressed O +
miRNAs O +
were O +
further O +
confirmed O +
by O +
Northern O +
blot O +
and O +
quantitative O +
real O -
- O -
time O +
polymerase O +
chain O +
reaction O -
. O +

Using O +
microarray O +
analysis O -
, O +
we O +
demonstrated O +
for O +
the O +
first O +
time O +
that O +
miRNAs O +
are O +
aberrantly O +
expressed O +
in O +
the O +
vascular O +
walls O +
after O +
balloon O +
injury O -
. O +

However O -
, O +
the O +
role O +
of O +
miRNAs O +
in O +
vascular O +
disease O +
is O +
currently O +
completely O +
unknown O -
. O +

MicroRNA-223 O +
expression O +
in O +
neutrophils O +
in O +
the O +
early O +
phase O +
of O +
secondary O +
damage O +
after O +
spinal O +
cord O +
injury O -
. O +

MicroRNA O +
( O -
miR O -
) O -
s O +
are O +
short O +
non O -
- O -
coding O +
RNAs O +
that O +
suppress O +
the O +
translation O +
of O +
target O +
genes O -
, O +
and O +
play O +
an O +
important O +
role O +
in O +
gene O +
regulation O -
. O +

Despite O +
this O +
prominence O -
, O +
there O +
are O +
few O +
reports O +
that O +
refer O +
to O +
the O +
expression O +
of O +
miRs O +
after O +
spinal O +
cord O +
injury O +
( O -
SCI O -
) O -
. O +

Previously O -
, O +
we O +
reported O +
on O +
miR-223 O +
expression O +
after O +
SCI O +
in O +
mice B-Species -
. O +

The O +
purpose O +
of O +
this O +
study O +
is O +
to O +
reveal O +
the O +
distribution O +
of O +
miR-223 O +
and O +
identify O +
the O +
cells O +
that O +
express O +
miR-223 O +
in O +
the O +
injured O +
spinal O +
cord O -
. O +

Quantitative O +
polymerase O +
chain O +
reaction O +
analysis O +
revealed O +
high O +
expression O +
of O +
miR-223 O +
at O +
12h O +
after O +
SCI O -
. O +
Double O +
staining O +
of O +
in O +
situ O +
hybridization O +
and O +
immunohistochemistry O +
showed O +
that O +
the O +
signals O +
of O +
miR-223 O +
merged O +
with O +
Gr-1 O +
positive O +
neutrophils O -
. O +

Our O +
data O +
indicate O +
that O +
miR-223 O +
might O +
regulate O +
neutrophils O +
in O +
the O +
early O +
phase O +
after O +
SCI O -
. O +

Point O +
mutations O +
in O +
exon O +
1 O +
of O +
the O +
NR4A2 O +
gene O +
are O +
not O +
a O +
major O +
cause O +
of O +
familial O +
Parkinson O -
's O +
disease O -
. O +

Our O +
results O +
suggest O +
that O +
miR-124a O +
may O +
play O +
a O +
role O +
in O +
GBM O +
migration O -
, O +
and O +
that O +
targeted O +
delivery O +
of O +
miR-124a O +
may O +
be O +
a O +
novel O +
inhibitor O +
of O +
GBM O +
invasion O -
. O +

Glioblastoma O +
( O -
GBM O -
) O +
represents O +
a O +
formidable O +
clinical O +
challenge O +
for O +
both O +
patients B-Species +
and O +
treating O +
physicians O -
. O +

Due O +
to O +
better O +
local O +
treatments O +
and O +
prolonged O +
patient B-Species +
survival O -
, O +
remote O +
recurrences O +
are O +
increasingly O +
observed O -
, O +
underpinning O +
the O +
importance O +
of O +
targeting O +
tumour O +
migration O +
and O +
attachment O -
. O +

Aberrant O +
expression O +
of O +
microRNA O +
( O -
miRNA O -
) O +
is O +
commonly O +
associated O +
with O +
cancer O +
and O +
loss O +
of O +
miR-124a O +
has O +
previously O +
been O +
implicated O +
to O +
function O +
as O +
a O +
tumour O +
suppressor O -
. O +

The O +
assessment O +
of O +
miR-124a O +
in O +
clinical O +
specimens O +
has O +
been O +
limited O +
and O +
a O +
potential O +
role O +
in O +
migration O +
and O +
invasion O +
has O +
been O +
unexplored O +
until O +
now O -
. O +

We O +
measured O +
the O +
expression O +
levels O +
of O +
mature O +
miR-124a O +
in O +
a O +
retrospective O +
series O +
of O +
119 O +
cases O +
of O +
histologically O +
confirmed O +
GBM O +
and O +
found O +
its O +
expression O +
was O +
markedly O +
lower O +
in O +
over O +
80 O -
% O +
of O +
the O +
GBM O +
clinical O +
specimens O +
compared O +
to O +
normal O +
brain O +
tissue O -
. O +

The O +
level O +
of O +
reduction O +
in O +
the O +
clinical O +
cohort O +
varied O +
significantly O +
and O +
patients B-Species +
with O +
lower O +
than O +
the O +
average O +
miR-124a O +
expression O +
levels O +
displayed O +
shorter O +
survival O +
times O -
. O +

Endogenous O +
miR-124a O +
expression O +
and O +
the O +
protein O +
expression O +
of O +
three O +
of O +
its O +
targets O -
; O +
IQ O +
motif O +
containing O +
GTPase O +
activating O +
protein O +
1 O +
( O -
IQGAP1 O -
) O -
, O +
laminin O +
γ1 O +
( O -
LAMC1 O -
) O +
and O +
integrin O +
β1 O +
( O -
ITGB1 O -
) O +
were O +
significantly O +
reciprocally O +
associated O +
in O +
the O +
majority O +
of O +
the O +
clinical O +
cases O -
. O +

We O +
confirmed O +
this O +
association O +
in O +
our O +
in O +
vitro O +
model O -
. O +

miR-124a O +
is O +
frequently O +
down O -
- O -
regulated O +
in O +
glioblastoma O +
and O +
is O +
involved O +
in O +
migration O +
and O +
invasion O -
. O +

Functionally O -
, O +
the O +
ectopic O +
expression O +
of O +
mature O +
miR-124a O +
in O +
a O +
GBM O +
cell O +
line O +
resulted O +
in O +
significant O +
inhibition O +
of O +
migration O +
and O +
invasion O -
, O +
demonstrating O +
a O +
role O +
for O +
miR-124a O +
in O +
promoting O +
tumour O +
invasiveness O -
. O +

In O +
a O +
pilot O +
study O +
we O +
could O +
show O +
that O +
hsa O -
- O -
miR-342 O -
- O -
3p O +
was O +
also O +
upregulated O +
in O +
brain O +
samples O +
of O +
human B-Species +
type O +
1 O +
and O +
type O +
2 O +
sporadic O +
CJD O -
. O +

Our O +
study O +
revealed O +
significant O +
upregulation O +
of O +
hsa O -
- O -
miR-342 O -
- O -
3p O +
and O +
hsa O -
- O -
miR-494 O +
in O +
the O +
brains O +
of O +
BSE O -
- O -
infected O +
macaques O +
compared O +
to O +
non O -
- O -
infected O +
animals O -
. O +

Shock O -
- O -
frozen O +
brain O +
sections O +
of O +
six O +
BSE O -
- O -
infected O +
and O +
five O +
non O -
- O -
infected O +
macaques O +
were O +
used O +
to O +
validate O +
regulated O +
miRNA O +
candidates O +
by O +
two O +
independent O +
qRT O -
- O -
PCR O -
- O -
based O +
methods O -
. O +

We O +
have O +
applied O +
miRNA O -
- O -
microarrays O +
to O +
identify O +
deregulated O +
miRNA O +
candidates O +
in O +
brains O +
of O +
BSE O -
- O -
infected O +
macaques O -
. O +

Therefore O -
, O +
we O +
hypothesized O +
that O +
miRNAs O +
are O +
also O +
regulated O +
in O +
response O +
to O +
human B-Species +
prion O +
disease O -
. O +

Among O +
other O +
functions O +
they O +
contribute O +
to O +
neuronal O +
development O +
and O +
survival O -
. O +

Recently O -
, O +
the O +
lack O +
of O +
miRNA O +
processing O +
has O +
been O +
shown O +
to O +
promote O +
neurodegeneration O +
and O +
deregulation O +
of O +
several O +
miRNAs O +
has O +
been O +
reported O +
to O +
be O +
associated O +
with O +
Scrapie O +
in O +
mice B-Species -
. O +

ABSTRACT O -
: O +
The O +
aim O +
of O +
our O +
study O +
was O +
to O +
analyze O +
the O +
differential O +
expression O +
of O +
miRNAs O +
in O +
the O +
brains O +
of O +
BSE O -
- O -
infected O +
cynomolgus O +
macaques O +
as O +
a O +
model O +
for O +
Creutzfeldt O -
- O -
Jakob O +
disease O +
( O -
CJD O -
) O -
. O +

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
small O +
noncoding O +
RNAs O +
regulating O +
gene O +
expression O +
by O +
mRNA O +
targeting O -
. O +

Upregulation O +
of O +
miRNA O +
hsa O -
- O -
miR-342 O -
- O -
3p O +
in O +
experimental O +
and O +
idiopathic O +
prion O +
disease O -
. O +

With O +
respect O +
to O +
the O +
reported O +
regulation O +
of O +
this O +
miRNA O +
in O +
Scrapie O -
- O -
infected O +
mice B-Species -
, O +
we O +
propose O +
that O +
upregulation O +
of O +
hsa O -
- O -
miR-342 O -
- O -
3p O +
may O +
be O +
a O +
general O +
phenomenon O +
in O +
late O +
stage O +
prion O +
disease O +
and O +
might O +
be O +
used O +
as O +
a O +
novel O +
marker O +
for O +
animal O +
and O +
human B-Species +
TSEs O -
. O +

A O +
specific O +
miRNA O +
signature O +
in O +
the O +
peripheral O +
blood O +
of O +
glioblastoma O +
patients B-Species -
. O +

Biomarkers O +
for O +
the O +
disease O +
would O +
be O +
desirable O +
in O +
order O +
to O +
allow O +
for O +
an O +
early O +
detection O +
of O +
tumor O +
progression O +
or O +
to O +
indicate O +
rapidly O +
growing O +
tumor O +
subtypes O +
requiring O +
more O +
intensive O +
therapy O -
. O +

The O +
prognosis O +
of O +
patients B-Species +
afflicted O +
by O +
glioblastoma O +
remains O +
poor O -
. O +

To O +
this O +
end O -
, O +
miRNA O +
profiles O +
from O +
the O +
blood O +
of O +
20 O +
patients B-Species +
with O +
glioblastoma O +
and O +
20 O +
age- O +
and O +
sex O -
- O -
matched O +
healthy O +
controls O +
were O +
compared O -
. O +

In O +
this O +
study O -
, O +
we O +
investigated O +
whether O +
a O +
blood O -
- O -
derived O +
specific O +
miRNA O +
fingerprint O +
can O +
be O +
defined O +
in O +
patients B-Species +
with O +
glioblastoma O -
. O +

Of O +
these O -
, O +
two O +
candidates O -
, O +
miR-128 O +
( O -
up O -
- O -
regulated O -
) O +
and O +
miR-342 O -
- O -
3p O +
( O -
down O -
- O -
regulated O -
) O -
, O +
remained O +
significant O +
after O +
correcting O +
for O +
multiple O +
testing O +
by O +
Benjamini O -
- O -
Hochberg O +
adjustment O +
with O +
a O +
p O -
- O -
value O +
of O +
0.025 O -
. O +

Of O +
1158 O +
tested O +
miRNAs O -
, O +
52 O +
were O +
significantly O +
deregulated O -
, O +
as O +
assessed O +
by O +
unadjusted O +
Student O -
's O +
t O -
- O -
test O +
at O +
an O +
alpha O +
level O +
of O +
0.05 O -
. O +

The O +
altered O +
expression O +
of O +
these O +
two O +
biomarkers O +
was O +
confirmed O +
in O +
a O +
second O +
cohort O +
of O +
glioblastoma O +
patients B-Species +
and O +
healthy O +
controls O +
by O +
real O -
- O -
time O +
PCR O +
and O +
validated O +
for O +
patients B-Species +
who O +
had O +
received O +
neither O +
radio- O +
nor O +
chemotherapy O +
and O +
for O +
patients B-Species +
who O +
had O +
their O +
glioblastomas O +
resected O +
more O +
than O +
6 O +
months O +
ago O -
. O +

Moreover O -
, O +
using O +
machine O +
learning O -
, O +
a O +
comprehensive O +
miRNA O +
signature O +
was O +
obtained O +
that O +
allowed O +
for O +
the O +
discrimination O +
between O +
blood O +
samples O +
of O +
glioblastoma O +
patients B-Species +
and O +
healthy O +
controls O +
with O +
an O +
accuracy O +
of O +
81 O -
% O +
[ O -
95 O -
% O +
confidence O +
interval O +
( O -
CI O -
) O +
78 O -
- O -
84 O -
% O -
] O -
, O +
specificity O +
of O +
79 O -
% O +
( O -
95 O -
% O +
CI O +
75 O -
- O -
83 O -
% O -
) O +
and O +
sensitivity O +
of O +
83 O -
% O +
( O -
95 O -
% O +
CI O +
71 O -
- O -
85 O -
% O -
) O -
. O +

In O +
summary O -
, O +
our O +
proof O -
- O -
of O -
- O -
concept O +
study O +
demonstrates O +
that O +
blood O -
- O -
derived O +
glioblastoma O -
- O -
associated O +
characteristic O +
miRNA O +
fingerprints O +
may O +
be O +
suitable O +
biomarkers O +
and O +
warrant O +
further O +
exploration O -
. O +

Knockdown O +
of O +
miR-21 O +
in O +
cultured O +
glioblastoma O +
cells O +
triggers O +
activation O +
of O +
caspases O +
and O +
leads O +
to O +
increased O +
apoptotic O +
cell O +
death O -
. O +

Our O +
studies O +
show O +
markedly O +
elevated O +
miR-21 O +
levels O +
in O +
human B-Species +
glioblastoma O +
tumor O +
tissues O -
, O +
early O -
- O -
passage O +
glioblastoma O +
cultures O -
, O +
and O +
in O +
six O +
established O +
glioblastoma O +
cell O +
lines O +
( O -
A172 O -
, O +
U87 O -
, O +
U373 O -
, O +
LN229 O -
, O +
LN428 O -
, O +
and O +
LN308 O -
) O +
compared O +
with O +
nonneoplastic O +
fetal O +
and O +
adult O +
brain O +
tissues O +
and O +
compared O +
with O +
cultured O +
nonneoplastic O +
glial O +
cells O -
. O +

Our O +
data O +
suggest O +
that O +
aberrantly O +
expressed O +
miR-21 O +
may O +
contribute O +
to O +
the O +
malignant O +
phenotype O +
by O +
blocking O +
expression O +
of O +
critical O +
apoptosis O -
- O -
related O +
genes O -
. O +

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
small O +
noncoding O +
RNA O +
molecules O +
that O +
regulate O +
protein O +
expression O +
by O +
targeting O +
the O +
mRNA O +
of O +
protein O -
- O -
coding O +
genes O +
for O +
either O +
cleavage O +
or O +
repression O +
of O +
translation O -
. O +

MicroRNA-21 O +
is O +
an O +
antiapoptotic O +
factor O +
in O +
human B-Species +
glioblastoma O +
cells O -
. O +

Here O +
we O +
show O +
that O +
the O +
highly O +
malignant O +
human B-Species +
brain O +
tumor O -
, O +
glioblastoma O -
, O +
strongly O +
over O -
- O -
expresses O +
a O +
specific O +
miRNA O -
, O +
miR-21 O -
. O +

The O +
roles O +
of O +
miRNAs O +
in O +
lineage O +
determination O +
and O +
proliferation O +
as O +
well O +
as O +
the O +
location O +
of O +
several O +
miRNA O +
genes O +
at O +
sites O +
of O +
translocation O +
breakpoints O +
or O +
deletions O +
has O +
led O +
to O +
the O +
speculation O +
that O +
miRNAs O +
could O +
be O +
important O +
factors O +
in O +
the O +
development O +
or O +
maintenance O +
of O +
the O +
neoplastic O +
state O -
. O +

The O +
study O +
of O +
this O +
novel O +
layer O +
of O +
gene O +
regulation O +
therefore O +
promises O +
to O +
enrich O +
our O +
knowledge O +
of O +
brain O +
function O +
and O +
pathology O -
. O +

MiRNAs O +
function O +
at O +
all O +
stages O +
of O +
neuronal O +
development O -
, O +
ranging O +
from O +
the O +
initial O +
specification O +
of O +
neuronal O +
cell O +
types O +
to O +
the O +
formation O +
and O +
plasticity O +
of O +
synaptic O +
connections O +
between O +
individual O +
neurons O -
. O +

Moreover O -
, O +
links O +
between O +
miRNA O +
dysfunction O +
and O +
neurological O +
diseases O +
become O +
more O +
and O +
more O +
apparent O -
. O +

The O +
development O +
and O +
function O +
of O +
the O +
nervous O +
system O +
is O +
orchestrated O +
by O +
a O +
plethora O +
of O +
gene O +
regulatory O +
mechanisms O -
. O +

MicroRNAs O +
( O -
miRNAs O -
) O -
, O +
an O +
abundant O +
class O +
of O +
small O +
non O -
- O -
coding O +
RNAs O -
, O +
are O +
emerging O +
as O +
important O +
post O -
- O -
transcriptional O +
regulators O +
of O +
gene O +
expression O +
in O +
the O +
brain O -
. O +

MicroRNA O +
function O +
in O +
neuronal O +
development O -
, O +
plasticity O +
and O +
disease O -
. O +

METHODS O -
: O +
We O +
prospectively O +
collected O +
surgical O +
outcome O +
data O +
for O +
2 O +
to O +
11 O +
years O +
for O +
134 O +
consecutive O +
patients B-Species +
who O +
specifically O +
had O +
MTLE O +
and O +
unilateral O +
HS O -
, O +
according O +
to O +
magnetic O +
resonance O +
imaging O +
( O -
MRI O -
) O +
and O +
confirmed O +
by O +
histopathology O -
. O +

PURPOSE O -
: O +
Surgical O +
results O +
in O +
patients B-Species +
with O +
mesial O +
temporal O +
lobe O +
epilepsy O +
due O +
to O +
hippocampal O +
sclerosis O +
( O -
MTLE O -
/ O -
HS O -
) O +
are O +
often O +
reported O +
in O +
conjunction O +
with O +
other O +
etiologies O +
of O +
TLE O -
. O +

Survival O +
analysis O +
of O +
the O +
surgical O +
outcome O +
of O +
temporal O +
lobe O +
epilepsy O +
due O +
to O +
hippocampal O +
sclerosis O -
. O +

Of O +
the O +
patients B-Species +
tested O -
, O +
26 O -
% O +
of O +
those O +
operated O +
on O +
the O +
left O +
side O +
and O +
22 O -
% O +
of O +
those O +
operated O +
on O +
the O +
right O +
had O +
postoperative O +
decline O +
of O +
> O -
1 O +
SD O +
in O +
verbal O +
or O +
visual O +
memory O -
, O +
respectively O -
. O +

CONCLUSIONS O -
: O +
High O +
rates O +
of O +
seizure O +
freedom O +
can O +
be O +
obtained O +
and O +
remain O +
stable O +
over O +
the O +
years O +
in O +
patients B-Species +
operated O +
on O +
for O +
unilateral O +
MTLE O -
/ O -
HS O -
, O +
even O +
in O +
countries O +
with O +
limited O +
resources O -
. O +

RESULTS O -
: O +
Kaplan O -
- O -
Meier O +
estimates O +
of O +
complete O +
seizure O +
freedom O +
( O -
Engel O -
's O +
class O +
IA O -
) O +
for O +
years O +
1 O -
, O +
2 O -
, O +
5 O -
, O +
and O +
10 O +
were O +
85 O -
% O -
, O +
77 O -
% O -
, O +
74 O -
% O -
, O +
and O +
66 O -
% O -
, O +
and O +
of O +
Engel O -
's O +
class O +
I O +
were O +
89 O -
% O -
, O +
86 O -
% O -
, O +
83 O -
% O -
, O +
and O +
81 O -
% O -
. O +

Only O +
nine O +
( O -
6.7 O -
% O -
) O +
patients B-Species +
had O +
outcome O +
classes O +
III O +
or O +
IV O +
at O +
any O +
point O +
during O +
follow O -
- O -
up O -
. O +

Sixty O -
- O -
five O +
had O +
postoperative O +
neuropsychological O +
testing O -
. O +

Outcome O +
was O +
analyzed O +
by O +
using O +
Engel O -
's O +
classification O +
( O -
a O -
) O +
through O +
Kaplan O -
- O -
Meier O +
estimated O +
survival O +
curves O +
( O -
as O +
a O +
function O +
of O +
the O +
time O +
to O +
seizure O +
recurrence O -
) O -
, O +
( O -
b O -
) O +
as O +
percentage O +
of O +
patients B-Species +
in O +
each O +
outcome O +
class O +
on O +
a O +
yearly O +
basis O -
, O +
and O +
( O -
c O -
) O +
at O +
the O +
last O +
updated O +
follow O -
- O -
up O -
. O +

The O +
clinical O +
relevance O +
of O +
our O +
findings O +
was O +
evaluated O +
in O +
HIV O -
- O -
encephalitis O +
( O -
HIVE O -
) O +
brain O +
samples O +
in O +
which O +
decreased O +
levels O +
of O +
MCP-2 O +
and O +
increased O +
levels O +
of O +
mir-146a O +
were O +
observed O -
, O +
suggesting O +
a O +
role O +
for O +
mir-146a O +
in O +
the O +
maintenance O +
of O +
HIV O -
- O -
mediated O +
chronic O +
inflammation O +
of O +
the O +
brain O -
. O +

We O +
further O +
show O +
that O +
CCL8 O -
/ O -
MCP-2 O +
is O +
a O +
target O +
for O +
mir-146a O +
in O +
HIV-1 O +
infected O +
microglia O -
, O +
as O +
overexpression O +
of O +
mir-146a O +
prevented O +
HIV O -
- O -
induced O +
secretion O +
of O +
MCP-2 O +
chemokine O -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
have O +
analyzed O +
changes O +
in O +
the O +
expression O +
of O +
mir-146a O +
in O +
primary O +
human B-Species +
fetal O +
microglial O +
cells O +
upon O +
infection O +
with O +
HIV-1 O +
and O +
found O +
increased O +
expression O +
of O +
mir-146a O -
. O +

MicroRNA O -
- O -
mediated O +
regulation O +
of O +
gene O +
expression O +
appears O +
to O +
be O +
involved O +
in O +
a O +
variety O +
of O +
cellular O +
processes O -
, O +
including O +
development O -
, O +
differentiation O -
, O +
proliferation O -
, O +
and O +
apoptosis O -
. O +

CCL8 O -
/ O -
MCP-2 O +
is O +
a O +
target O +
for O +
mir-146a O +
in O +
HIV-1-infected O +
human O +
microglial O +
cells O -
. O +

Among O +
the O +
predicted O +
gene O +
targets O +
for O +
mir-146a O -
, O +
the O +
chemokine O +
CCL8 O -
/ O -
MCP-2 O +
is O +
a O +
ligand O +
for O +
the O +
CCR5 O +
chemokine O +
receptor O +
and O +
a O +
potent O +
inhibitor O +
of O +
CD4 O -
/ O -
CCR5-mediated O +
HIV-1 O +
entry O +
and O +
replication O -
. O +

Mir-146a O +
is O +
thought O +
to O +
be O +
involved O +
in O +
the O +
regulation O +
of O +
the O +
innate O +
immune O +
response O -
, O +
and O +
its O +
expression O +
is O +
increased O +
in O +
tissues O +
associated O +
with O +
chronic O +
inflammation O -
. O +

Key O +
microRNAs O +
have O +
been O +
identified O +
as O +
essential O +
for O +
a O +
variety O +
of O +
cellular O +
events O +
including O +
cell O +
lineage O +
determination O -
, O +
proliferation O -
, O +
apoptosis O -
, O +
DNA O +
repair O -
, O +
and O +
cytoskeletal O +
organization O -
; O +
most O -
, O +
if O +
not O +
all O -
, O +
acting O +
to O +
fine O -
- O -
tune O +
gene O +
expression O +
at O +
the O +
post O -
- O -
transcriptional O +
level O +
in O +
a O +
host O +
of O +
cellular O +
signaling O +
networks O -
. O +

Their O +
discovery O +
has O +
evoked O +
great O +
excitement O +
in O +
biomedical O +
research O +
for O +
their O +
promise O +
as O +
potential O +
disease O +
biomarkers O +
and O +
therapeutic O +
targets O -
. O +

MicroRNAs O +
are O +
one O +
of O +
the O +
major O +
noncoding O +
RNAs O +
that O +
function O +
as O +
negative O +
regulators O +
to O +
silence O +
or O +
suppress O +
gene O +
expression O +
via O +
translational O +
inhibition O +
or O +
message O +
degradation O -
. O +

Unlike O +
the O +
familial O +
forms O +
of O +
AD O -
, O +
the O +
genetic O +
and O +
environmental O +
risks O +
factors O +
identified O +
for O +
sporadic O +
AD O +
are O +
extensive O -
. O +

Understanding O +
complex O +
diseases O +
such O +
as O +
sporadic O +
Alzheimer O +
disease O +
( O -
AD O -
) O +
has O +
been O +
a O +
major O +
challenge O -
. O +

MicroRNA O -
: O +
Implications O +
for O +
Alzheimer O +
Disease O +
and O +
other O +
Human B-Species +
CNS O +
Disorders O -
. O +

Here O -
, O +
the O +
current O +
understanding O +
of O +
the O +
role O +
of O +
miRNAs O +
in O +
the O +
central O +
nervous O +
system O +
is O +
reviewed O +
with O +
emphasis O +
on O +
their O +
impact O +
on O +
the O +
etiopathogenesis O +
of O +
sporadic O +
AD O -
. O +

Dysfunctional O +
microRNA O -
- O -
mediated O +
regulation O +
has O +
been O +
implicated O +
in O +
the O +
pathogenesis O +
of O +
many O +
disease O +
states O -
. O +

We O +
explored O +
the O +
role O +
of O +
microRNAs O +
( O -
miRNAs O -
) O +
in O +
glioma O +
progression O +
by O +
investigating O +
the O +
expression O +
profiles O +
of O +
157 O +
miRNAs O +
in O +
four O +
patients B-Species +
with O +
primary O +
WHO O +
grade O +
II O +
gliomas O +
that O +
spontaneously O +
progressed O +
to O +
WHO O +
grade O +
IV O +
secondary O +
glioblastomas O -
. O +

Thereby O -
, O +
we O +
identified O +
12 O +
miRNAs O +
( O -
miR-9 O -
, O +
miR-15a O -
, O +
miR-16 O -
, O +
miR-17 O -
, O +
miR-19a O -
, O +
miR-20a O -
, O +
miR-21 O -
, O +
miR-25 O -
, O +
miR-28 O -
, O +
miR-130b O -
, O +
miR-140 O +
and O +
miR-210 O -
) O +
showing O +
increased O +
expression O -
, O +
and O +
two O +
miRNAs O +
( O -
miR-184 O +
and O +
miR-328 O -
) O +
showing O +
reduced O +
expression O +
upon O +
progression O -
. O +

Identification O +
and O +
functional O +
characterization O +
of O +
microRNAs O +
involved O +
in O +
the O +
malignant O +
progression O +
of O +
gliomas O -
. O +

Diffuse O +
astrocytoma O +
of O +
World O +
Health O +
Organization O +
( O -
WHO O -
) O +
grade O +
II O +
has O +
an O +
inherent O +
tendency O +
to O +
spontaneously O +
progress O +
to O +
anaplastic O +
astrocytoma O +
WHO O +
grade O +
III O +
or O +
secondary O +
glioblastoma O +
WHO O +
grade O +
IV O -
. O +

Taken O +
together O -
, O +
our O +
results O +
support O +
an O +
important O +
role O +
of O +
altered O +
miRNA O +
expression O +
in O +
gliomas O -
, O +
and O +
suggest O +
miR-17 O +
and O +
miR-184 O +
as O +
interesting O +
candidates O +
contributing O +
to O +
glioma O +
progression O -
. O +

Using O +
mRNA O +
and O +
protein O +
expression O +
profiling O -
, O +
we O +
identified O +
distinct O +
sets O +
of O +
transcripts O +
and O +
proteins O +
that O +
were O +
differentially O +
expressed O +
after O +
inhibition O +
of O +
miR-17 O +
or O +
overexpression O +
of O +
miR-184 O +
in O +
glioma O +
cells O -
. O +

These O +
studies O +
revealed O +
miRNA O -
- O -
specific O +
influences O +
on O +
the O +
viability O -
, O +
proliferation O -
, O +
apoptosis O +
and O +
invasive O +
growth O +
properties O +
of O +
A172 O +
and O +
T98 O -
G O +
glioma O +
cells O +
in O +
vitro O -
. O +

Validation O +
experiments O +
on O +
independent O +
series O +
of O +
primary O +
low O -
- O -
grade O +
and O +
secondary O +
high O -
- O -
grade O +
astrocytomas O +
confirmed O +
miR-17 O +
and O +
miR-184 O +
as O +
promising O +
candidates O -
, O +
which O +
were O +
selected O +
for O +
functional O +
analyses O -
. O +

MicroRNAs O +
( O -
miRNAs O -
) O +
in O +
neurodegenerative O +
diseases O -
. O +

Prior O +
studies O +
have O +
shown O +
that O +
RNAs O +
are O +
pathologically O +
altered O +
during O +
the O +
inexorable O +
course O +
of O +
some O +
NDs O -
. O +

Aging O -
- O -
related O +
neurodegenerative O +
diseases O +
( O -
NDs O -
) O +
are O +
the O +
culmination O +
of O +
many O +
different O +
genetic O +
and O +
environmental O +
influences O -
. O +

miRNAs O +
are O +
brain O -
- O -
enriched O -
, O +
small O +
( O +
approximately O +
22 O +
nucleotides O -
) O +
non O -
- O -
coding O +
RNAs O +
that O +
participate O +
in O +
mRNA O +
translational O +
regulation O -
. O +

Recent O +
evidence O +
suggests O +
that O +
microRNAs O +
( O -
miRNAs O -
) O +
may O +
be O +
a O +
contributing O +
factor O +
in O +
neurodegeneration O -
. O +

Research O +
about O +
miRNAs O +
in O +
the O +
context O +
of O +
neurodegeneration O +
is O +
accumulating O +
rapidly O -
, O +
and O +
the O +
goal O +
of O +
this O +
review O +
is O +
to O +
provide O +
perspective O +
for O +
these O +
new O +
data O +
that O +
may O +
be O +
helpful O +
to O +
specialists O +
in O +
either O +
field O -
. O +

Although O +
discovered O +
in O +
the O +
framework O +
of O +
worm O +
development O -
, O +
miRNAs O +
are O +
now O +
appreciated O +
to O +
play O +
a O +
dynamic O +
role O +
in O +
many O +
mammalian O +
brain O -
- O -
related O +
biochemical O +
pathways O -
, O +
including O +
neuroplasticity O +
and O +
stress O +
responses O -
. O +

Recently O +
published O +
studies O +
pertaining O +
to O +
the O +
roles O +
of O +
miRNAs O +
in O +
NDs O -
-- O -
including O +
Alzheimer O -
's O +
disease O -
, O +
Parkinson O -
's O +
disease O +
and O +
triplet O +
repeat O +
disorders O -
- O -
are O +
described O -
. O +

An O +
overview O +
is O +
provided O +
about O +
the O +
normal O +
functions O +
for O +
miRNAs O -
, O +
including O +
some O +
of O +
the O +
newer O +
concepts O +
related O +
to O +
the O +
human B-Species +
brain O -
. O +

Finally O -
, O +
a O +
discussion O +
is O +
included O +
with O +
theoretical O +
syntheses O +
and O +
possible O +
future O +
directions O +
in O +
exploring O +
the O +
nexus O +
between O +
miRNA O +
and O +
ND O +
research O -
. O +

MicroRNA-328 O +
( O -
miR-328 O -
) O +
is O +
underexpressed O +
in O +
many O +
cancers O +
including O +
glioblastoma O +
multiforme O +
and O +
contributes O +
to O +
tumor O +
resistance O +
to O +
chemotherapy O -
. O +

MicroRNAs O +
control O +
a O +
wide O +
array O +
of O +
biological O +
processes O +
( O -
e.g. O -
, O +
cell O +
differentiation O -
, O +
proliferation O +
and O +
apoptosis O -
) O +
whose O +
dysregulation O +
is O +
a O +
hallmark O +
of O +
cancer O -
. O +

ABCG2 O -
, O +
which O +
encodes O +
an O +
ATP O -
- O -
binding O +
cassette O +
transporter O +
protein O -
, O +
is O +
associated O +
with O +
the O +
phenotype O +
of O +
cancer O +
stem O +
cells O +
and O +
is O +
used O +
to O +
define O +
the O +
pluripotential O +
side O +
population O +
cells O +
by O +
flow O +
cytometry O +
and O +
slide O -
- O -
cytometry O -
. O +

Downregulation O +
of O +
ABCG2 O +
expression O +
in O +
glioblastoma O +
cancer O +
stem O +
cells O +
with O +
miRNA-328 O +
may O +
decrease O +
their O +
chemoresistance O -
. O +

Thus O -
, O +
we O +
hypothesize O +
that O +
modulating O +
ABCG2 O +
expression O +
by O +
targeting O +
miRNA-328 O +
in O +
glioblastoma O +
cancer O +
stem O +
cells O +
could O +
represent O +
a O +
promising O +
strategy O +
for O +
therapeutic O +
manipulation O +
to O +
increase O +
the O +
efficacy O +
of O +
chemotherapeutic O +
agents O +
for O +
glioblastoma O -
, O +
a O +
highly O +
lethal O +
type O +
of O +
cancer O -
. O +

ABCG2 O +
is O +
associated O +
with O +
multi O -
- O -
drug O +
resistance O +
and O +
is O +
also O +
highly O +
expressed O +
in O +
glioblastoma O -
. O +

Some O +
preliminary O +
studies O +
have O +
shown O +
that O +
ABCG2 O +
is O +
the O +
target O +
gene O +
for O +
miRNA-328 O -
. O +

Traumatic O +
brain O +
injury O +
( O -
TBI O -
) O +
initiates O +
many O +
different O +
signaling O +
cascades O +
throughout O +
the O +
brain O +
that O +
impact O +
both O +
pathophysiological O +
and O +
neuroprotective O +
processes O -
. O +

Altered O +
expression O +
of O +
miRNA-21 O +
and O +
its O +
targets O +
in O +
the O +
hippocampus O +
after O +
traumatic O +
brain O +
injury O -
. O +

In O +
situ O +
localization O +
of O +
miR-21 O +
transcripts O +
indicates O +
widespread O +
expression O +
in O +
normal O +
brain O -
, O +
with O +
a O +
pronounced O +
increase O +
in O +
expression O +
after O +
TBI O +
evident O +
throughout O +
the O +
cortex O +
and O +
hippocampus O -
, O +
including O +
the O +
dentate O +
gyrus O +
and O +
CA3 O +
cell O +
layer O -
. O +

We O +
report O +
that O +
miR-21 O +
expression O +
is O +
significantly O +
up O -
- O -
regulated O +
in O +
the O +
hippocampus O +
after O +
rodent O +
TBI O -
, O +
with O +
expression O +
levels O +
peaking O +
by O +
3 O +
days O +
postinjury O +
and O +
returning O +
to O +
near O +
sham O +
levels O +
by O +
15 O +
days O +
postinjury O -
. O +

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
an O +
important O +
class O +
of O +
noncoding O +
regulatory O +
RNAs O +
providing O +
an O +
epigenetic O +
mechanism O +
for O +
the O +
regulation O +
of O +
protein O +
expression O +
levels O +
of O +
target O +
genes O -
. O +

Cellular O +
mechanisms O +
that O +
can O +
modulate O +
these O +
processes O +
may O +
play O +
an O +
important O +
role O +
in O +
determining O +
the O +
nature O +
and O +
extent O +
of O +
the O +
damage O +
suffered O +
after O +
TBI O +
and O +
therefore O +
influence O +
overall O +
outcome O +
after O +
injury O -
. O +

These O +
results O +
suggest O +
that O +
increased O +
miR-21 O +
expression O +
in O +
the O +
hippocampus O +
may O +
influence O +
multiple O +
components O +
of O +
TBI O +
pathophysiology O -
. O +

Analysis O +
of O +
these O +
genes O -
' O +
annotated O +
Gene O +
Ontology O +
molecular O +
function O +
and O +
biological O +
process O +
terms O +
revealed O +
an O +
overrepresentation O +
of O +
genes O +
involved O +
in O +
enzyme O -
- O -
linked O +
receptor O +
signaling O -
, O +
transcriptional O +
regulation O -
, O +
and O +
developmental O +
processes O -
. O +

We O +
used O +
a O +
combination O +
of O +
the O +
miRanda O -
, O +
TargetScan O -
, O +
and O +
PicTar O +
prediction O +
algorithms O +
to O +
identify O +
99 O +
potential O +
target O +
genes O +
that O +
possess O +
miR-21 O +
binding O +
sites O +
within O +
their O +
3 O -
' O +
untranslated O +
regions O -
. O +

This O +
is O +
the O +
first O +
study O +
suggesting O +
that O +
plasma O +
miRs O +
might O +
be O +
used O +
as O +
biomarkers O +
for O +
HD O -
. O +

Huntington O -
's O +
disease O +
( O -
HD O -
) O +
is O +
a O +
devastating O -
, O +
neurodegenerative O +
condition O -
, O +
which O +
lacks O +
effective O +
treatment O -
. O +

Hsa O -
- O -
miR-34b O +
is O +
a O +
plasma O -
- O -
stable O +
microRNA O +
that O +
is O +
elevated O +
in O +
pre O -
- O -
manifest O +
Huntington O -
's O +
disease O -
. O +

Importantly O -
, O +
miRs O +
are O +
present O +
in O +
a O +
bio O -
- O -
stable O +
form O +
in O +
human B-Species +
peripheral O +
blood O +
plasma O +
and O +
have O +
recently O +
been O +
shown O +
to O +
be O +
useful O +
biomarkers O +
in O +
other O +
diseases O -
. O +

Normal O +
Huntingtin O +
( O -
HTT O -
) O +
and O +
mutant O +
Huntingtin O +
( O -
mHTT O -
) O +
are O +
expressed O +
in O +
multiple O +
tissues O +
and O +
can O +
alter O +
transcription O +
of O +
microRNAs O +
( O -
miRs O -
) O -
. O +

In O +
a O +
cell O +
line O +
over O -
- O -
expressing O +
mHTT O -
- O -
Exon-1 O -
, O +
miR O +
microarray O +
analysis O +
was O +
used O +
to O +
identify O +
candidate O +
miRs O -
. O +

We O +
therefore O +
sought O +
to O +
identify O +
potential O +
miR O +
biomarkers O +
of O +
HD O +
that O +
are O +
present O +
in O -
, O +
and O +
have O +
functional O +
consequences O +
for O -
, O +
neuronal O +
and O +
non O -
- O -
neuronal O +
tissues O -
. O +

We O +
found O +
that O +
miR-34b O +
is O +
significantly O +
elevated O +
in O +
response O +
to O +
mHTT O -
- O -
Exon-1 O -
, O +
and O +
its O +
blockade O +
alters O +
the O +
toxicity O +
of O +
mHTT O -
- O -
Exon-1 O +
in O +
vitro O -
. O +

We O +
then O +
examined O +
their O +
presence O +
and O +
bio O -
- O -
stability O +
in O +
control O +
and O +
HD O +
plasma O -
. O +

We O +
also O +
show O +
that O +
miR-34b O +
is O +
detectable O +
in O +
plasma O +
from O +
small O +
input O +
volumes O +
and O +
is O +
insensitive O +
to O +
freeze O -
- O -
thaw O -
- O -
induced O +
RNA O +
degradation O -
. O +

Interestingly O -
, O +
miR-34b O +
is O +
significantly O +
elevated O +
in O +
plasma O +
from O +
HD O +
gene O +
carriers O +
prior O +
to O +
symptom O +
onset O -
. O +

MiRNA O +
expression O +
profiling O +
of O +
human B-Species +
tumors O +
has O +
led O +
to O +
the O +
identification O +
of O +
signatures O +
correlated O +
with O +
the O +
tumor O +
diagnosis O -
, O +
staging O -
, O +
progression O -
, O +
prognosis O +
and O +
response O +
to O +
treatment O -
. O +

MiRNA O +
fingerprinting O +
can O +
therefore O +
be O +
added O +
to O +
the O +
diagnostic O +
and O +
prognostic O +
tools O +
used O +
by O +
medical O +
oncologists O -
. O +

Furthermore O -
, O +
new O +
therapeutic O +
strategies O +
involving O +
miRNA O +
silencing O +
or O +
miRNA O +
mimics O +
could O +
be O +
proposed O +
based O +
on O +
the O +
roles O +
of O +
these O +
small O +
non O -
- O -
coding O +
RNAs O +
as O +
oncogenes O +
and O +
tumor O +
suppressors O +
in O +
brain O +
tumors O -
. O +

MicroRNA O +
involvement O +
in O +
brain O +
tumors O -
: O +
from O +
bench O +
to O +
bedside O -
. O +

MicroRNAs O +
( O -
miRNAs O -
) O -
, O +
a O +
novel O +
class O +
of O +
small O +
non O -
- O -
coding O +
RNAs O -
, O +
are O +
effective O +
post O -
- O -
transcriptional O +
regulators O +
of O +
gene O +
expression O -
, O +
exhibiting O -
, O +
when O +
altered O +
in O +
human B-Species +
tumors O -
, O +
both O +
oncogenic O +
and O +
tumor O +
suppressive O +
potential O -
. O +

Recently O -
, O +
miRNA O +
involvement O +
in O +
the O +
pathophysiology O +
of O +
brain O +
cancer O +
has O +
been O +
assessed O -
. O +

Aberrant O +
gene O +
expression O +
is O +
the O +
main O +
mechanism O +
of O +
miRNAs O +
dysfunction O +
in O +
cancer O -
, O +
with O +
abnormal O +
expression O +
levels O +
of O +
mature O +
and/or O +
precursor O +
miRNA O +
expression O +
in O +
tumor O +
samples O +
versus O +
normal O -
. O +

MiRNA O +
germline O +
and O +
somatic O +
mutations O +
or O +
polymorphisms O +
in O +
the O +
protein O +
coding O +
messenger O +
RNA O +
targeted O +
by O +
miRNAs O +
may O +
also O +
occur O -
, O +
contributing O +
to O +
cancer O +
predisposition O -
, O +
initiation O +
and/or O +
progression O -
. O +

If O +
present O +
in O +
somatic O +
cells O -
, O +
miRNA O +
alterations O +
may O +
play O +
a O +
role O +
in O +
tumor O +
initiation O -
, O +
while O +
if O +
present O +
in O +
germ O +
line O +
cells O +
they O +
could O +
constitute O +
a O +
cancer O +
predisposing O +
event O -
. O +

Additionally O -
, O +
gene O +
ontology O +
analyses O +
of O +
the O +
target O +
genes O +
suggested O +
a O +
distinct O +
role O +
for O +
each O +
miRNA O -
. O +

Our O +
results O +
show O +
that O +
NPC O +
fibroblasts O +
have O +
an O +
altered O +
miRNA O +
expression O +
profile O +
and O +
certain O +
miRNAs O +
have O +
importance O +
in O +
disease O +
pathogenesis O +
as O +
well O +
as O +
the O +
therapeutic O +
capacity O +
to O +
correct O +
lipid O +
related O +
pathophysiologies O +
in O +
the O +
NPC O +
cells O -
. O +

Expression O +
differences O +
between O +
the O +
healthy O +
and O +
NPC O +
cells O +
were O +
detected O +
according O +
to O +
the O +
relative O +
quantification O +
values O -
. O +

Target O +
genes O +
were O +
predicted O +
by O +
using O +
three O +
different O +
algorithms O +
and O +
classified O +
regarding O +
NPC O +
related O +
biological O +
processes O +
and O +
cellular O +
components O -
. O +

We O +
found O +
that O +
three O +
miRNAs O -
, O +
miR-196a O -
, O +
miR-196b O +
and O +
miR-296 O +
were O +
up O -
- O -
regulated O +
( O -
> O -
3.5-fold O +
increase O -
, O +
p<0.05 O -
) O +
whereas O +
38 O +
miRNAs O +
were O +
significantly O +
down O -
- O -
regulated O +
in O +
NPC O +
cells O +
( O -
> O -
3.5-fold O +
decrease O -
, O +
p<0.05 O -
) O -
. O +

Among O +
these O +
non O -
- O -
coding O +
RNAs O -
, O +
miR-98 O +
was O +
the O +
most O +
down O -
- O -
regulated O +
( O -
-33.3-fold O -
) O +
miRNA O +
and O +
miR-143 O -
, O +
the O +
lipid O +
biosynthesis O +
associated O +
miRNA O -
, O +
had O +
a O +
20-fold O +
decreased O +
expression O +
in O +
the O +
NPC O +
cells O -
. O +

Dysregulation O +
of O +
miRNA O +
expression O +
may O +
lead O +
to O +
severe O +
pathophysiologies O +
in O +
human B-Species +
cells O -
. O +

Niemann O -
- O -
Pick O +
type O +
C O +
( O -
NPC O -
) O +
disease O +
is O +
a O +
complex O +
lipid O +
storage O +
disease O +
characterized O +
by O +
late O +
endosomal O -
- O -
lysosomal O +
accumulation O +
of O +
multiple O +
lipid O +
molecules O -
. O +

Our O +
aim O +
was O +
to O +
characterize O +
the O +
miRNA O +
profile O +
in O +
NPC O +
fibroblasts O +
as O +
they O +
may O +
play O +
an O +
active O +
role O +
in O +
the O +
NPC O +
disease O +
associated O +
changes O +
in O +
the O +
cellular O +
physiology O -
. O +

To O +
investigate O +
the O +
miRNA O +
expression O -
, O +
total O +
RNAs O +
were O +
isolated O +
from O +
cultured O +
human B-Species +
NPC O +
fibroblasts O +
and O +
healthy O +
fibroblasts O +
and O +
then O -
, O +
TaqMan O +
Low O -
- O -
Density O +
Array O +
system O +
containing O +
365 O +
mature O +
human B-Species +
miRNAs O +
was O +
used O -
. O +

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
non O -
- O -
coding O +
RNAs O +
that O +
regulate O +
gene O +
expression O +
at O +
post O -
- O -
transcriptional O +
level O -
. O +

Niemann O -
- O -
Pick O +
type O +
C O +
fibroblasts O +
have O +
a O +
distinct O +
microRNA O +
profile O +
related O +
to O +
lipid O +
metabolism O +
and O +
certain O +
cellular O +
components O -
. O +

RESULTS O -
: O +
We O +
detected O +
a O +
total O +
of O +
360 O +
miRNAs O -
. O +

Selective O +
miRNAs O +
then O +
were O +
synthesized O +
and O +
transfected O +
into O +
Neuro-2a O +
cells O +
before O +
oxygen O -
- O -
glucose O +
deprivation O -
. O +

Transfections O +
of O +
some O +
of O +
these O +
were O +
neuroprotective O +
in O +
in O +
vitro O +
ischemia O -
. O +

Two O +
miRNA O +
families O -
, O +
miR-200 O +
and O +
miR-182 O -
, O +
were O +
selectively O +
upregulated O +
at O +
3 O +
hours O +
after O +
ischemic O +
preconditioning O -
. O +

Although O +
miRNAs O +
control O +
a O +
number O +
of O +
conditions O +
and O +
diseases O -
, O +
few O +
neuroprotective O +
miRNAs O +
have O +
been O +
described O -
. O +

In O +
this O +
study O -
, O +
we O +
investigated O +
neuroprotective O +
miRNAs O +
induced O +
early O +
in O +
ischemic O +
preconditioning O -
. O +

METHODS O -
: O +
Ischemic O +
preconditioning O +
or O +
focal O +
cerebral O +
ischemia O +
was O +
induced O +
in O +
mice B-Species +
by O +
transient O +
occlusion O +
of O +
the O +
middle O +
cerebral O +
artery O +
for O +
15 O +
or O +
120 O +
minutes O -
. O +

We O +
prepared O +
RNA O +
samples O +
from O +
the O +
ischemic O +
cortex O +
at O +
3 O +
or O +
24 O +
hours O +
after O +
the O +
onset O +
of O +
ischemia O -
. O +

MicroRNAs O +
induced O +
during O +
ischemic O +
preconditioning O -
. O +

BACKGROUND O +
AND O +
PURPOSE O -
: O +
MicroRNAs O +
( O -
miRNA O -
) O +
are O +
single O -
- O -
stranded O +
short O +
RNA O +
molecules O +
that O +
regulate O +
gene O +
expression O +
by O +
either O +
degradation O +
or O +
translational O +
repression O +
of O +
mRNA O -
. O +

Among O +
them O -
, O +
miR-200b O -
, O +
miR-200c O -
, O +
and O +
miR-429 O +
targeted O +
prolyl O +
hydroxylase O +
2 O +
and O +
had O +
the O +
best O +
neuroprotective O +
effect O -
. O +

CONCLUSIONS O -
: O +
Two O +
miRNA O +
families O -
, O +
miR-200 O +
and O +
miR-182 O -
, O +
were O +
upregulated O +
early O +
after O +
ischemic O +
preconditioning O +
and O +
the O +
miR-200 O +
family O +
was O +
neuroprotective O +
mainly O +
by O +
downregulating O +
prolyl O +
hydroxylase O +
2 O +
levels O -
. O +

These O +
miRNAs O +
may O +
be O +
useful O +
in O +
future O +
research O +
and O +
therapeutic O +
applications O -
. O +

Frequent O +
amplification O +
of O +
a O +
chr19q13.41 O +
microRNA O +
polycistron O +
in O +
aggressive O +
primitive O +
neuroectodermal O +
brain O +
tumors O -
. O +

microRNA O +
( O -
miRNA O -
) O +
cluster O +
( O -
C19MC O -
) O +
in O +
11 O -
/ O -
45 O +
( O +
approximately O +
25 O -
% O -
) O +
primary O +
CNS O -
- O -
PNET O -
, O +
which O +
results O +
in O +
striking O +
overexpression O +
of O +
miR-517c O +
and O +
520 O -
g O -
. O +

We O +
discovered O +
a O +
high O -
- O -
level O +
amplicon O +
involving O +
the O +
chr19q13.41 O +

Remarkably O -
, O +
the O +
C19MC O +
amplicon O -
, O +
which O +
is O +
very O +
rare O +
in O +
other O +
brain O +
tumors O +
( O -
1 O -
/ O -
263 O -
) O -
, O +
identifies O +
an O +
aggressive O +
subgroup O +
of O +
CNS O -
- O -
PNET O +
with O +
distinct O +
gene O -
- O -
expression O +
profiles O -
, O +
characteristic O +
histology O -
, O +
and O +
dismal O +
survival O -
. O +

Constitutive O +
expression O +
of O +
miR-517c O +
or O +
520 O -
g O +
promotes O +
in O +
vitro O +
and O +
in O +
vivo O +
oncogenicity O -
, O +
modulates O +
cell O +
survival O -
, O +
and O +
robustly O +
enhances O +
growth O +
of O +
untransformed O +
human B-Species +
neural O +
stem O +
cells O +
( O -
hNSCs O -
) O +
in O +
part O +
by O +
upregulating O +
WNT O +
pathway O +
signaling O +
and O +
restricting O +
differentiation O +
of O +
hNSCs O -
. O +

Our O +
data O +
implicate O +
miR-517c O +
and O +
520 O -
g O +
as O +
oncogenes O +
and O +
promising O +
biological O +
markers O +
for O +
CNS O -
- O -
PNET O +
and O +
provide O +
important O +
insights O +
into O +
oncogenic O +
properties O +
of O +
the O +
C19MC O +
locus O -
. O +

A O +
significant O +
association O +
with O +
death O +
was O +
found O +
for O +
major O +
adverse O +
events O -
, O +
medical O +
adverse O +
events O -
, O +
and O +
nosocomial O +
infections O -
, O +
with O +
adjusted O +
odds O +
ratio O +
estimates O +
of O +
3.74 O +
[ O -
95 O -
% O +
confidence O +
interval O +
( O -
CI O -
) O +
1.64 O -
- O -
8.54 O -
] O -
, O +
3.71 O +
( O -
95 O -
% O +
CI O +
1.61 O -
- O -
8.53 O -
) O -
, O +
and O +
3.22 O +
( O -
95 O -
% O +
CI O +
1.21 O -
- O -
8.59 O -
) O -
, O +
respectively O -
. O +

CONCLUSION O -
: O +
Adverse O +
events O -
, O +
mostly O +
severe O -
, O +
predominated O +
among O +
deceased O +
patients B-Species -
, O +
resulting O +
mainly O +
from O +
diagnostic O +
or O +
therapeutic O +
procedures O +
and O +
nursing O +
activities O -
. O +

In O +
spite O +
of O +
limitations O +
concerning O +
the O +
observational O +
retrospective O +
nature O +
of O +
this O +
study O -
, O +
we O +
found O +
that O +
severe O +
adverse O +
events O -
, O +
medical O +
adverse O +
events O -
, O +
and O +
nosocomial O +
infections O +
were O +
significantly O +
associated O +
with O +
death O +
in O +
stroke O +
patients B-Species -
. O +

OBJECTIVES O -
: O +
To O +
identify O +
the O +
occurrence O +
of O +
adverse O +
events O +
in O +
stroke O +
patients B-Species +
presenting O +
to O +
the O +
emergency O +
department O +
of O +
a O +
tertiary O +
university O +
facility O -
, O +
and O +
to O +
disclose O +
the O +
categories O +
of O +
adverse O +
events O +
associated O +
with O +
death O -
. O +

Adverse O +
events O +
and O +
death O +
in O +
stroke O +
patients B-Species +
admitted O +
to O +
the O +
emergency O +
department O +
of O +
a O +
tertiary O +
university O +
hospital O -
. O +

Major O +
adverse O +
events O +
equaled O +
54.1 O -
% O +
of O +
all O +
events O +
( O -
659 O +
episodes O -
) O -
: O +
538 O +
events O +
in O +
143 O +
cases O +
and O +
121 O +
in O +
65 O +
controls O -
. O +

RESULTS O -
: O +
Adverse O +
events O +
totaled O +
1218 O +
and O +
occurred O +
in O +
295 O +
patients B-Species -
: O +
932 O +
events O +
( O -
76.5 O -
% O -
) O +
in O +
170 O +
cases O +
and O +
286 O +
( O -
23.5 O -
% O -
) O +
in O +
125 O +
controls O -
. O +

Nursing O +
( O -
38.4 O -
% O -
) O +
and O +
medical O +
( O -
31 O -
% O -
) O +
adverse O +
events O +
represented O +
the O +
most O +
common O +
related O +
professional O +
categories O -
. O +

Diagnostic O +
or O +
therapeutic O +
procedures O +
and O +
nursing O +
activities O +
accounted O +
for O +
55.2 O -
% O +
of O +
events O -
. O +

The O +
cases O +
comprised O +
234 O +
consecutive O +
deaths O +
and O +
the O +
controls O +
234 O +
discharged O +
patients B-Species -
, O +
matched O +
for O +
primary O +
diagnosis O +
and O +
admission O +
period O -
. O +

METHODS O -
: O +
This O +
matched O +
case O -
- O -
control O +
study O +
enrolled O +
468 O +
patients B-Species +
admitted O +
with O +
stroke O +
to O +
the O +
emergency O +
department O +
from O +
March O +
1996 O +
to O +
September O +
1999 O -
. O +

The O +
association O +
with O +
death O +
was O +
analysed O +
by O +
conditional O +
logistic O +
regression O -
. O +

Adverse O +
events O -
, O +
detected O +
by O +
chart O +
review O -
, O +
were O +
classified O +
according O +
to O +
the O +
degree O +
of O +
severity O -
, O +
immediate O +
causes O -
, O +
and O +
professional O +
category O -
. O +

Our O +
findings O +
suggest O +
that O +
microRNAs O +
are O +
important O +
determinants O +
of O +
glioblastoma O +
subclasses O +
through O +
their O +
ability O +
to O +
regulate O +
developmental O +
growth O +
and O +
differentiation O +
programs O +
in O +
several O +
transformed O +
neural O +
precursor O +
cell O +
types O -
. O +

Foremost O +
among O +
these O +
is O +
miR-9 O -
, O +
which O +
suppresses O +
mesenchymal O +
differentiation O +
in O +
glioblastoma O +
by O +
downregulating O +
expression O +
of O +
JAK O +
kinases O +
and O +
inhibiting O +
activation O +
of O +
STAT3 O -
. O +

Taken O +
together O -
, O +
our O +
results O +
define O +
developmental O +
microRNA O +
expression O +
signatures O +
that O +
both O +
characterize O +
and O +
contribute O +
to O +
the O +
phenotypic O +
diversity O +
of O +
glioblastoma O +
subclasses O -
, O +
thereby O +
providing O +
an O +
expanded O +
framework O +
for O +
understanding O +
the O +
pathogenesis O +
of O +
glioblastoma O +
in O +
a O +
human O +
neurodevelopmental O +
context O -
. O +

These O +
microRNA O -
- O -
based O +
glioblastoma O +
subclasses O +
displayed O +
microRNA O +
and O +
mRNA O +
expression O +
signatures O +
resembling O +
those O +
of O +
radial O +
glia O -
, O +
oligoneuronal O +
precursors O -
, O +
neuronal O +
precursors O -
, O +
neuroepithelial O -
/ O -
neural O +
crest O +
precursors O -
, O +
or O +
astrocyte O +
precursors O -
. O +

In O +
this O +
study O -
, O +
we O +
analyzed O +
261 O +
microRNA O +
expression O +
profiles O +
from O +
The O +
Cancer O +
Genome O +
Atlas O +
( O -
TCGA O -
) O -
, O +
identifying O +
five O +
clinically O +
and O +
genetically O +
distinct O +
subclasses O +
of O +
glioblastoma O +
that O +
each O +
related O +
to O +
a O +
different O +
neural O +
precursor O +
cell O +
type O -
. O +

We O +
also O +
identified O +
several O +
microRNAs O +
as O +
potent O +
regulators O +
of O +
subclass O -
- O -
specific O +
gene O +
expression O +
networks O +
in O +
glioblastoma O -
. O +

Each O +
subclass O +
was O +
determined O +
to O +
be O +
genetically O +
distinct O -
, O +
based O +
on O +
the O +
significant O +
differences O +
they O +
displayed O +
in O +
terms O +
of O +
patient B-Species +
race O -
, O +
age O -
, O +
treatment O +
response O -
, O +
and O +
survival O -
. O +

mRNA O +
expression O +
profiling O +
has O +
suggested O +
the O +
existence O +
of O +
multiple O +
glioblastoma O +
subclasses O -
, O +
but O +
their O +
number O +
and O +
characteristics O +
vary O +
among O +
studies O +
and O +
the O +
etiology O +
underlying O +
their O +
development O +
is O +
unclear O -
. O +

A O +
developmental O +
taxonomy O +
of O +
glioblastoma O +
defined O +
and O +
maintained O +
by O +
MicroRNAs O -
. O +

These O +
findings O +
reveal O +
a O +
novel O +
mechanism O +
of O +
targeted O +
intercellular O +
protein O +
regulation O +
between O +
brain O +
tumor O +
cells O -
. O +

Here O -
, O +
we O +
transformed O +
rat B-Species +
9L O +
gliosarcoma O +
cells O +
to O +
express O +
cel O -
- O -
miR-67 O -
, O +
a O +
miRNA O +
that O +
lacks O +
homology O +
in O +
rat B-Species -
. O +

Coculture O +
of O +
these O +
cells O +
with O +
cells O +
that O +
expressed O +
a O +
luciferase O +
reporter O +
that O +
contained O +
a O +
complementary O +
sequence O +
to O +
cel O -
- O -
miR-67 O +
resulted O +
in O +
significant O +
suppression O +
of O +
luciferase O +
expression O -
. O +

Functional O +
microRNA O +
is O +
transferred O +
between O +
glioma O +
cells O -
. O +

MicroRNAs O +
( O -
miRNA O -
) O +
are O +
single O -
- O -
stranded O +
17- O +
to O +
27-nucleotide O +
RNA O +
molecules O +
that O +
regulate O +
gene O +
expression O +
by O +
posttranscriptional O +
silencing O +
of O +
target O +
mRNAs O -
. O +

Finally O -
, O +
in O +
situ O +
hybridization O +
revealed O +
the O +
presence O +
of O +
cel O -
- O -
miR-67 O +
in O +
cel O -
- O -
miR-67-null O +
9L O +
cells O +
after O +
coculture O +
with O +
cel O -
- O -
miR-67-expressing O +
cells O -
. O +

Our O +
data O +
show O +
that O +
miRNA O +
transcribed O +
in O +
glioma O +
cells O +
can O +
be O +
transferred O +
to O +
adjacent O +
cells O +
and O +
induces O +
targeted O +
inhibition O +
of O +
protein O +
expression O +
in O +
the O +
acceptor O +
cells O -
. O +

This O +
effect O +
was O +
also O +
observed O +
in O +
the O +
U87-MG O +
human B-Species +
glioma O +
cell O +
line O -
. O +

Moreover O -
, O +
luciferase O +
suppression O +
was O +
inhibited O +
by O +
the O +
addition O +
of O +
carbenoxolone O +
to O +
cocultures O -
, O +
suggesting O +
that O +
gap O +
junction O +
communication O +
regulates O +
intercellular O +
transfer O +
of O +
miRNA O -
. O +

miRNAs O +
are O +
small O -
, O +
endogenously O +
expressed O +
noncoding O +
RNAs O +
that O +
regulate O +
gene O +
expression O -
, O +
mainly O +
at O +
the O +
post O -
- O -
transcriptional O +
level O -
, O +
via O +
degradation O +
or O +
translational O +
inhibition O +
of O +
their O +
target O +
mRNAs O -
. O +

Functionally O -
, O +
an O +
individual O +
miRNA O +
can O +
regulate O +
the O +
expression O +
of O +
multiple O +
target O +
genes O -
. O +

miRNAs O -
: O +
roles O +
and O +
clinical O +
applications O +
in O +
vascular O +
disease O -
. O +

The O +
study O +
of O +
miRNAs O +
is O +
rapidly O +
growing O +
and O +
recent O +
studies O +
have O +
revealed O +
a O +
significant O +
role O +
of O +
miRNAs O +
in O +
vascular O +
biology O +
and O +
disease O -
. O +

Many O +
miRNAs O +
are O +
highly O +
expressed O +
in O +
the O +
vasculature O -
, O +
and O +
their O +
expression O +
is O +
dysregulated O +
in O +
diseased O +
vessels O -
. O +

Several O +
miRNAs O +
have O +
been O +
found O +
to O +
be O +
critical O +
modulators O +
of O +
vascular O +
pathologies O -
, O +
such O +
as O +
atherosclerosis O -
, O +
lipoprotein O +
metabolism O -
, O +
inflammation O -
, O +
arterial O +
remodeling O -
, O +
angiogenesis O -
, O +
smooth O +
muscle O +
cell O +
regeneration O -
, O +
hypertension O -
, O +
apoptosis O -
, O +
neointimal O +
hyperplasia O +
and O +
signal O +
transduction O +
pathways O -
. O +

Thus O -
, O +
miRNAs O +
may O +
serve O +
as O +
novel O +
biomarkers O +
and/or O +
therapeutic O +
targets O +
for O +
vascular O +
disease O -
. O +

This O +
article O +
summarizes O +
the O +
current O +
studies O +
related O +
to O +
the O +
disease O +
correlations O +
and O +
functional O +
roles O +
of O +
miRNAs O +
in O +
the O +
vascular O +
system O +
and O +
discusses O +
the O +
potential O +
applications O +
of O +
miRNAs O +
in O +
vascular O +
disease O -
. O +

Moreover O -
, O +
bioinformatics O +
analyses O +
revealed O +
a O +
theoretical O +
basis O +
for O +
many O +
other O +
potential O +
interactions O +
between O +
natural O +
antisense O +
transcripts O +
and O +
miRNAs O +
at O +
the O +
binding O +
sites O +
of O +
the O +
latter O -
. O +

In O +
addition O -
, O +
mammalian O +
genomes O +
contain O +
numerous O +
natural O +
antisense O +
transcripts O -
, O +
most O +
of O +
which O +
appear O +
to O +
be O +
non O -
- O -
protein O -
- O -
coding O +
RNAs O +
( O -
ncRNAs O -
) O -
. O +

BACKGROUND O -
: O +
MicroRNAs O +
( O -
miRNAs O -
) O +
have O +
the O +
potential O +
to O +
regulate O +
diverse O +
sets O +
of O +
mRNA O +
targets O -
. O +

Evidence O +
for O +
natural O +
antisense O +
transcript O -
- O -
mediated O +
inhibition O +
of O +
microRNA O +
function O -
. O +

Indeed O -
, O +
miR-485 O -
- O -
5p O +
and O +
BACE1-antisense O +
compete O +
for O +
binding O +
within O +
the O +
same O +
region O +
in O +
the O +
open O +
reading O +
frame O +
of O +
the O +
BACE1 O +
mRNA O -
. O +

RESULTS O -
: O +
We O +
report O +
here O +
that O +
BACE1-antisense O +
prevents O +
miRNA O -
- O -
induced O +
repression O +
of O +
BACE1 O +
mRNA O +
by O +
masking O +
the O +
binding O +
site O +
for O +
miR-485 O -
- O -
5p O -
. O +

The O +
BACE1-antisense O +
transcript O +
is O +
markedly O +
up O -
- O -
regulated O +
in O +
brain O +
samples O +
from O +
Alzheimer O -
's O +
disease O +
patients B-Species +
and O +
promotes O +
the O +
stability O +
of O +
the O +
( O -
sense O -
) O +
BACE1 O +
transcript O -
. O +

We O +
have O +
recently O +
identified O +
and O +
characterized O +
a O +
highly O +
conserved O +
non O -
- O -
coding O +
antisense O +
transcript O +
for O +
beta O -
- O -
secretase-1 O +
( O -
BACE1 O -
) O -
, O +
a O +
critical O +
enzyme O +
in O +
Alzheimer O -
's O +
disease O +
pathophysiology O -
. O +

We O +
observed O +
opposing O +
effects O +
of O +
BACE1-antisense O +
and O +
miR-485 O -
- O -
5p O +
on O +
BACE1 O +
protein O +
in O +
vitro O +
and O +
showed O +
that O +
Locked O +
Nucleic O +
Acid O -
- O -
antimiR O +
mediated O +
knockdown O +
of O +
miR-485 O -
- O -
5p O +
as O +
well O +
as O +
BACE1-antisense O +
over O -
- O -
expression O +
can O +
prevent O +
the O +
miRNA O -
- O -
induced O +
BACE1 O +
suppression O -
. O +

We O +
found O +
that O +
the O +
expression O +
of O +
BACE1-antisense O +
as O +
well O +
as O +
miR-485 O -
- O -
5p O +
are O +
dysregulated O +
in O +
RNA O +
samples O +
from O +
Alzheimer O -
's O +
disease O +
subjects O +
compared O +
to O +
control O +
individuals O -
. O +

CONCLUSIONS O -
: O +
Our O +
data O +
demonstrate O +
an O +
interface O +
between O +
two O +
distinct O +
groups O +
of O +
regulatory O +
RNAs O +
in O +
the O +
computation O +
of O +
BACE1 O +
gene O +
expression O -
. O +

Mice B-Species +
deficient O +
in O +
cystathionine O +
beta O +
synthase O +
display O +
altered O +
homocysteine O +
remethylation O +
pathway O -
. O +

In O +
order O +
to O +
show O +
the O +
effects O +
of O +
CBS O +
deficiency O +
onto O +
the O +
activity O +
of O +
the O +
enzymes O +
involved O +
in O +
the O +
remethylation O +
pathway O -
, O +
we O +
used O +
the O +
well O +
characterized O +
genetic O +
model O +
of O +
severe O +
hyperhomocysteinemia O +
in O +
mice B-Species -
. O +

Cystathionine O +
beta O +
synthase O +
( O -
CBS O -
) O +
deficiency O +
is O +
a O +
metabolic O +
disorder O +
that O +
is O +
biochemically O +
characterized O +
by O +
severe O +
hyperhomocysteinemia O -
. O +

We O +
showed O +
that O +
CBS O +
deficiency O +
in O +
mice B-Species +
reduced O +
hepatic O +
methionine O +
synthase O +
and O +
betaine O -
- O -
homocysteine O +
methyltransferase O +
activities O -
, O +
whereas O +
5,10-methylene O +
tetrahydrofolate O +
reductase O +
activity O +
was O +
increased O -
. O +

Western O +
blot O +
analysis O +
of O +
human B-Species +
glioblastoma O +
specimens O +
showed O +
high O +
levels O +
of O +
PKM2 O +
protein O -
, O +
but O +
none O +
was O +
observed O +
in O +
normal O +
brain O +
samples O -
. O +

Our O +
data O +
suggest O +
PKM2 O +
inhibition O +
as O +
a O +
therapy O +
for O +
glioblastoma O -
, O +
with O +
the O +
potential O +
for O +
minimal O +
toxicity O +
to O +
the O +
brain O -
. O +

Strikingly O -
, O +
cells O +
with O +
high O +
levels O +
of O +
PKM2 O +
expressed O +
lower O +
levels O +
of O +
miR-326 O -
, O +
suggestive O +
of O +
endogenous O +
regulation O +
of O +
PKM2 O +
by O +
miR-326 O -
. O +

Emerging O +
studies O +
have O +
identified O +
microRNAs O +
( O -
miRNAs O -
) O +
as O +
possible O +
therapeutic O +
tools O +
for O +
the O +
treatment O +
of O +
glioma O -
, O +
the O +
most O +
aggressive O +
brain O +
tumor O -
. O +

Pyruvate O +
kinase O +
M2 O +
is O +
a O +
target O +
of O +
the O +
tumor O -
- O -
suppressive O +
microRNA-326 O +
and O +
regulates O +
the O +
survival O +
of O +
glioma O +
cells O -
. O +

Their O +
important O +
targets O +
in O +
this O +
tumor O +
are O +
not O +
well O +
understood O -
. O +

We O +
recently O +
found O +
that O +
the O +
Notch O +
pathway O +
is O +
a O +
target O +
of O +
miRNA-326 O -
. O +

Ectopic O +
expression O +
of O +
miRNA-326 O +
in O +
glioma O +
and O +
glioma O +
stem O +
cells O +
induced O +
their O +
apoptosis O +
and O +
reduced O +
their O +
metabolic O +
activity O -
. O +

Computational O +
target O +
gene O +
prediction O +
revealed O +
pyruvate O +
kinase O +
type O +
M2 O +
( O -
PKM2 O -
) O +
as O +
another O +
target O +
of O +
miRNA-326 O -
. O +

PKM2 O +
has O +
recently O +
been O +
shown O +
to O +
play O +
a O +
key O +
role O +
in O +
cancer O +
cell O +
metabolism O -
. O +

To O +
investigate O +
whether O +
it O +
might O +
be O +
a O +
functionally O +
important O +
target O +
of O +
miR-326 O -
, O +
we O +
used O +
RNA O +
interference O +
to O +
knockdown O +
PKM2 O +
expression O +
in O +
glioma O +
cells O -
. O +

Transfection O +
of O +
the O +
established O +
glioma O +
and O +
glioma O +
stem O +
cells O +
with O +
PKM2 O +
siRNA O +
reduced O +
their O +
growth O -
, O +
cellular O +
invasion O -
, O +
metabolic O +
activity O -
, O +
ATP O +
and O +
glutathione O +
levels O -
, O +
and O +
activated O +
AMP O -
- O -
activated O +
protein O +
kinase O -
. O +

The O +
cytotoxic O +
effects O +
exhibited O +
by O +
PKM2 O +
knockdown O +
in O +
glioma O +
and O +
glioma O +
stem O +
cells O +
were O +
not O +
observed O +
in O +
transformed O +
human B-Species +
astrocytes O -
. O +

Interestingly O -
, O +
the O +
above O +
data O +
suggested O +
that O +
in O +
both O +
the O +
PTEN O +
mutant O +
and O +
the O +
wild O -
- O -
type O +
GBM O +
cells O -
, O +
miR-21 O +
blockage O +
increased O +
the O +
chemosensitivity O +
to O +
taxol O -
. O +

It O +
is O +
worth O +
noting O +
that O +
the O +
miR-21 O +
inhibitor O +
additively O +
interacted O +
with O +
taxol O +
on O +
U251cells O +
and O +
synergistically O +
on O +
LN229 O +
cells O -
. O +

Furthermore O -
, O +
the O +
miR-21 O +
inhibitor O +
significantly O +
enhanced O +
apoptosis O +
in O +
both O +
U251 O +
cells O +
and O +
LN229 O +
cells O -
, O +
and O +
cell O +
invasiveness O +
was O +
obviously O +
weakened O -
. O +

The O +
data O +
strongly O +
suggested O +
that O +
a O +
regulatory O +
loop O +
between O +
miR-21 O +
and O +
STAT3 O +
might O +
provide O +
an O +
insight O +
into O +
the O +
mechanism O +
of O +
modulating O +
EGFR O -
/ O -
STAT3 O +
signaling O -
. O +

CONCLUSIONS O -
: O +
Taken O +
together O -
, O +
the O +
miR-21 O +
inhibitor O +
could O +
enhance O +
the O +
chemo O -
- O -
sensitivity O +
of O +
human B-Species +
glioblastoma O +
cells O +
to O +
taxol O -
. O +

Thus O -
, O +
the O +
miR-21 O +
inhibitor O +
might O +
interrupt O +
the O +
activity O +
of O +
EGFR O +
pathways O -
, O +
independently O +
of O +
PTEN O +
status O -
. O +

Meanwhile O -
, O +
the O +
expression O +
of O +
STAT3 O +
and O +
p O -
- O -
STAT3 O +
decreased O +
to O +
relatively O +
low O +
levels O +
after O +
miR-21 O +
inhibitor O +
and O +
taxol O +
treatment O -
. O +

A O +
combination O +
of O +
miR-21 O +
inhibitor O +
and O +
taxol O +
could O +
be O +
an O +
effective O +
therapeutic O +
strategy O +
for O +
controlling O +
the O +
growth O +
of O +
GBM O +
by O +
inhibiting O +
STAT3 O +
expression O +
and O +
phosphorylation O -
. O +

Expression O +
of O +
miR-21 O +
was O +
investigated O +
by O +
RT O -
- O -
PCR O -
, O +
and O +
western O +
blotting O +
was O +
performed O +
to O +
evaluate O +
malignancy O +
related O +
protein O +
alteration O -
. O +

RESULTS O -
: O +
IC O -
( O -
50 O -
) O +
values O +
were O +
dramatically O +
decreased O +
in O +
cells O +
treated O +
with O +
miR-21 O +
inhibitor O +
combine O +
with O +
taxol O -
, O +
to O +
a O +
greater O +
extent O +
than O +
those O +
treated O +
with O +
taxol O +
alone O -
. O +

The O +
mechanism O +
between O +
the O +
miR-21 O +
inhibitor O +
and O +
the O +
anticancer O +
drug O +
taxol O +
was O +
analyzed O +
using O +
the O +
Zheng O -
- O -
Jun O +
Jin O +
method O -
. O +

Annexin O +
V O -
/ O -
PI O +
staining O +
was O +
performed O -
, O +
and O +
apoptosis O +
and O +
the O +
cell O +
cycle O +
were O +
evaluated O +
by O +
flow O +
cytometry O +
analysis O -
. O +

BACKGROUND O -
: O +
Substantial O +
data O +
indicate O +
that O +
the O +
oncogene O +
microRNA O +
21 O +
( O -
miR-21 O -
) O +
is O +
significantly O +
elevated O +
in O +
glioblastoma O +
multiforme O +
( O -
GBM O -
) O +
and O +
regulates O +
multiple O +
genes O +
associated O +
with O +
cancer O +
cell O +
proliferation O -
, O +
apoptosis O -
, O +
and O +
invasiveness O -
. O +

MicroRNA-21 O +
inhibitor O +
sensitizes O +
human B-Species +
glioblastoma O +
cells O +
U251 O +
( O -
PTEN O -
- O -
mutant O -
) O +
and O +
LN229 O +
( O -
PTEN O -
- O -
wild O +
type O -
) O +
to O +
taxol O -
. O +

The O +
50 O -
% O +
inhibitory O +
concentration O +
and O +
cell O +
viability O +
were O +
determined O +
by O +
the O +
MTT O +
assay O -
. O +

METHODS O -
: O +
Human B-Species +
glioblastoma O +
U251 O +
( O -
PTEN O -
- O -
mutant O -
) O +
and O +
LN229 O +
( O -
PTEN O +
wild O -
- O -
type O -
) O +
cells O +
were O +
treated O +
with O +
taxol O +
and O +
the O +
miR-21 O +
inhibitor O +
( O -
in O +
a O +
poly O +
( O -
amidoamine O -
) O +
( O -
PAMAM O -
) O +
dendrimer O -
) O -
, O +
alone O +
or O +
in O +
combination O -
. O +

So O +
far O -
, O +
the O +
effect O +
of O +
downregulating O +
miR-21 O +
to O +
enhance O +
the O +
chemotherapeutic O +
effect O +
to O +
taxol O +
has O +
not O +
been O +
studied O +
in O +
human B-Species +
GBM O -
. O +

Thus O -
, O +
miR-21 O +
can O +
theoretically O +
become O +
a O +
target O +
to O +
enhance O +
the O +
chemotherapeutic O +
effect O +
in O +
cancer O +
therapy O -
. O +

MiR-107 O +
is O +
reduced O +
in O +
Alzheimer O -
's O +
disease O +
brain O +
neocortex O -
: O +
validation O +
study O -
. O +

MiR-107 O +
is O +
a O +
microRNA O +
( O -
miRNA O -
) O +
that O +
we O +
reported O +
previously O +
to O +
have O +
decreased O +
expression O +
in O +
the O +
temporal O +
cortical O +
gray O +
matter O +
early O +
in O +
the O +
progression O +
of O +
Alzheimer O -
's O +
disease O +
( O -
AD O -
) O -
. O +

Correlation O +
was O +
observed O +
between O +
decreased O +
miR-107 O +
expression O +
and O +
increased O +
neuritic O +
plaque O +
counts O +
( O -
P O -
< O +
0.05 O -
) O +
and O +
neurofibrillary O +
tangle O +
counts O +
( O -
P O -
< O +
0.02 O -
) O +
in O +
adjacent O +
brain O +
tissue O -
. O +

Adjusted O +
miR-107 O +
and O +
BACE1 O +
mRNA O +
levels O +
tended O +
to O +
correlate O +
negatively O +
( O -
trend O +
with O +
regression O +
P O -
< O +
0.07 O -
) O -
. O +

Here O +
we O +
study O +
a O +
new O +
group O +
of O +
well O -
- O -
characterized O +
human B-Species +
temporal O +
cortex O +
samples O +
( O -
N=19 O -
) O -
. O +

MiR-107 O +
expression O +
was O +
assessed O -
, O +
normalized O +
to O +
miR-124 O +
and O +
let-7a O -
. O +

In O +
sum O -
, O +
miR-107 O +
expression O +
tends O +
to O +
be O +
lower O +
relative O +
to O +
other O +
miRNAs O +
as O +
AD O +
progresses O -
. O +

MicroRNAs O -
: O +
biology O +
and O +
roles O +
in O +
neurodegeneration O +
and O +
brain O +
tumours O -
. O +

Introduction O +
and O +
historical O +
background O -
. O +

Small O +
RNAs O +
are O +
short O +
( O -
approximately O +
18 O +
to O +
30 O +
nucleotides O -
) O -
, O +
non O -
- O -
coding O +
RNA O +
molecules O +
that O +
can O +
regulate O +
gene O +
expression O +
in O +
both O +
the O +
cytoplasm O +
and O +
the O +
nucleus O +
via O +
post O -
- O -
transcriptional O +
gene O +
silencing O +
( O -
PTGS O -
) O -
, O +
chromatin O -
- O -
dependent O +
gene O +
silencing O +
( O -
CDGS O -
) O +
or O +
RNA O +
activation O +
( O -
RNAa O -
) O -
. O +

Novel O +
functions O +
for O +
small O +
RNA O +
molecules O -
. O +

Research O +
has O +
indicated O +
that O +
small O +
RNAs O +
play O +
important O +
roles O +
in O +
cellular O +
processes O +
such O +
as O +
cell O +
differentiation O -
, O +
growth O -
/ O -
proliferation O -
, O +
migration O -
, O +
apoptosis O -
/ O -
death O -
, O +
metabolism O +
and O +
defense O -
. O +

Three O +
classes O +
of O +
small O +
RNAs O +
have O +
been O +
defined O -
: O +
microRNAs O +
( O -
miRNAs O -
) O -
, O +
siRNAs O +
and O +
Piwi O -
- O -
interacting O +
RNAs O +
( O -
piRNAs O -
) O -
. O +

More O +
interestingly O -
, O +
increasing O +
evidence O +
indicates O +
that O +
small O +
RNAs O +
are O +
involved O +
in O +
the O +
pathogenesis O +
of O +
diverse O +
diseases O +
including O +
cancer O -
, O +
cardiovascular O +
disease O -
, O +
stroke O -
, O +
neurodegenerative O +
disease O -
, O +
diabetes O -
, O +
liver O +
disease O -
, O +
kidney O +
disease O +
and O +
infectious O +
disease O -
. O +

Accordingly O -
, O +
small O +
RNAs O +
are O +
critical O +
regulators O +
of O +
normal O +
development O +
and O +
physiology O -
. O +

Additionally O -
, O +
small O +
RNAs O +
may O +
serve O +
as O +
novel O +
biomarkers O +
and O +
therapeutic O +
targets O +
for O +
the O +
majority O +
of O +
diseases O -
. O +

More O +
than O +
20 O +
clinical O +
trials O +
are O +
ongoing O +
to O +
evaluate O +
therapies O +
based O +
on O +
small O +
RNA O -
. O +

These O +
novel O +
findings O +
suggest O +
that O +
miR-21 O +
may O +
be O +
an O +
attractive O +
therapeutic O +
molecule O +
for O +
treatment O +
of O +
stroke O -
. O +

MicroRNAs O +
are O +
small O +
RNAs O +
that O +
attenuate O +
protein O +
expression O +
by O +
complementary O +
binding O +
to O +
the O +
3'-UTR O +
of O +
a O +
target O +
mRNA O -
. O +

MicroRNA-21 O +
protects O +
neurons O +
from O +
ischemic O +
death O -
. O +

In O +
particular O -
, O +
microRNA-21 O +
( O -
miR-21 O -
) O +
is O +
a O +
strong O +
antiapoptotic O +
factor O +
in O +
some O +
biological O +
systems O -
. O +

Currently O -
, O +
very O +
little O +
is O +
known O +
about O +
microRNAs O +
after O +
cerebral O +
ischemia O -
. O +

We O +
employed O +
in O +
situ O +
hybridization O +
and O +
laser O +
capture O +
microdissection O +
in O +
combination O +
with O +
real O -
- O -
time O +
RT O -
- O -
PCR O +
to O +
investigate O +
the O +
expression O +
of O +
miR-21 O +
after O +
stroke O -
. O +

We O +
investigated O +
the O +
role O +
of O +
miR-21 O +
after O +
stroke O +
in O +
the O +
rat B-Species -
. O +

In O +
vitro O -
, O +
overexpression O +
of O +
miR-21 O +
in O +
cultured O +
cortical O +
neurons O +
substantially O +
suppressed O +
oxygen O +
and O +
glucose O +
deprivation O -
- O -
induced O +
apoptotic O +
cell O +
death O -
, O +
whereas O +
attenuation O +
of O +
endogenous O +
miR-21 O +
by O +
antisense O +
inhibition O +
exacerbated O +
cell O +
death O +
after O +
oxygen O +
and O +
glucose O +
deprivation O -
. O +

In O +
situ O +
hybridization O +
revealed O +
that O +
miR-21 O +
expression O +
was O +
upregulated O +
in O +
neurons O +
of O +
the O +
ischemic O +
boundary O +
zone O -
, O +
and O +
quantitative O +
real O -
- O -
time O +
RT O -
- O -
PCR O +
analysis O +
revealed O +
that O +
stroke O +
increased O +
mature O +
miR-21 O +
levels O +
by O +
approximately O +
threefold O +
in O +
neurons O +
isolated O +
from O +
the O +
ischemic O +
boundary O +
zone O +
by O +
laser O +
capture O +
microdissection O +
as O +
compared O +
with O +
homologous O +
contralateral O +
neurons O +
2 O +
days O +
( O -
n O +
= O +
4 O -
; O +
P O +
< O +
0.05 O -
) O +
and O +
7 O +
days O +
( O -
n O +
= O +
3 O -
; O +
P O +
< O +
0.05 O -
) O +
after O +
stroke O -
. O +

Our O +
data O +
indicate O +
that O +
overexpression O +
of O +
miR-21 O +
protects O +
against O +
ischemic O +
neuronal O +
death O -
, O +
and O +
that O +
downregulation O +
of O +
FASLG O -
, O +
a O +
tumor O +
necrosis O +
factor O -
- O -
α O +
family O +
member O +
and O +
an O +
important O +
cell O +
death O -
- O -
inducing O +
ligand O +
whose O +
gene O +
is O +
targeted O +
by O +
miR-21 O -
, O +
probably O +
mediates O +
the O +
neuroprotective O +
effect O -
. O +

Moreover O -
, O +
overexpression O +
of O +
miR-21 O +
in O +
neurons O +
significantly O +
reduced O +
FASLG O +
levels O -
, O +
and O +
introduction O +
of O +
an O +
miR-21 O +
mimic O +
into O +
293-HEK O +
cells O +
substantially O +
reduced O +
luciferase O +
activity O +
in O +
a O +
reporter O +
system O +
containing O +
the O +
3'-UTR O +
of O +
Faslg O -
. O +

We O +
also O +
discuss O +
the O +
implications O +
of O +
these O +
findings O +
with O +
respect O +
to O +
the O +
involvement O +
of O +
miRNAs O +
in O +
the O +
etiopathology O +
of O +
brain O +
disorders O +
and O +
pinpoint O +
the O +
emerging O +
therapeutic O +
potential O +
of O +
miRNAs O +
for O +
the O +
treatment O +
of O +
human B-Species +
diseases O -
. O +

They O +
are O +
now O +
thought O +
to O +
be O +
involved O +
in O +
the O +
control O +
of O +
about O +
one O +
third O +
of O +
all O +
protein O -
- O -
coding O +
genes O +
and O +
play O +
a O +
role O +
in O +
the O +
majority O +
of O +
cellular O +
processes O +
that O +
have O +
been O +
studied O -
. O +

We O +
focus O +
on O +
the O +
role O +
of O +
the O +
miRNA O +
pathway O +
in O +
brain O +
development O -
, O +
function O -
, O +
and O +
disease O +
by O +
highlighting O +
recent O +
observations O +
with O +
respect O +
to O +
miRNA O -
- O -
mediated O +
gene O +
regulation O +
in O +
neuronal O +
differentiation O -
, O +
synaptic O +
plasticity O -
, O +
and O +
the O +
circadian O +
clock O -
. O +

MicroRNAs O +
in O +
brain O +
function O +
and O +
disease O -
. O +

MicroRNAs O +
( O -
miRNAs O -
) O -
, O +
a O +
class O +
of O +
small O -
, O +
non O -
- O -
protein O -
- O -
coding O +
transcripts O +
about O +
21 O +
nucleotides O +
long O -
, O +
have O +
recently O +
entered O +
center O +
stage O +
in O +
the O +
study O +
of O +
posttranscriptional O +
gene O +
regulation O -
. O +

This O +
mechanism O +
may O +
have O +
broad O +
implications O +
for O +
microRNA O -
- O -
regulated O +
macrophage O +
activation O +
in O +
inflammatory O +
diseases O -
. O +

Our O +
findings O +
suggest O +
that O +
microRNA O +
dysregulated O +
in O +
multiple O +
sclerosis O +
lesions O +
reduce O +
CD47 O +
in O +
brain O +
resident O +
cells O -
, O +
releasing O +
macrophages O +
from O +
inhibitory O +
control O -
, O +
thereby O +
promoting O +
phagocytosis O +
of O +
myelin O -
. O +

Three O +
microRNA O +
upregulated O +
in O +
active O +
multiple O +
sclerosis O +
lesions O +
( O -
microRNA-34a O -
, O +
microRNA-155 O +
and O +
microRNA-326 O -
) O +
targeted O +
the O +
3'-untranslated O +
region O +
of O +
CD47 O +
in O +
reporter O +
assays O -
, O +
with O +
microRNA-155 O +
even O +
at O +
two O +
distinct O +
sites O -
. O +

This O +
converged O +
on O +
CD47 O -
, O +
which O +
functions O +
as O +
a O +
' O -
do O -
n't O +
eat O +
me O -
' O +
signal O +
inhibiting O +
macrophage O +
activity O -
. O +

We O +
established O +
microRNA O +
profiles O +
from O +
active O +
and O +
inactive O +
multiple O +
sclerosis O +
lesions O -
. O +

Using O +
laser O +
capture O +
microdissection O +
from O +
multiple O +
sclerosis O +
lesions O +
to O +
pool O +
single O +
cells O +
and O +
in O +
vitro O +
cultures O -
, O +
we O +
assigned O +
differentially O +
expressed O +
microRNA O +
to O +
specific O +
cell O +
types O -
. O +

MicroRNA O +
profiling O +
of O +
multiple O +
sclerosis O +
lesions O +
identifies O +
modulators O +
of O +
the O +
regulatory O +
protein O +
CD47 O -
. O +

This O +
was O +
confirmed O +
with O +
astrocyte O +
cultures O +
from O +
microRNA-155-|-lacZ O +
mice B-Species -
. O +

We O +
matched O +
microRNA O +
upregulated O +
in O +
phagocytically O +
active O +
multiple O +
sclerosis O +
lesions O +
with O +
downregulated O +
protein O +
coding O +
transcripts O -
. O +

Astrocytes O +
contained O +
all O +
10 O +
microRNA O +
that O +
were O +
most O +
strongly O +
upregulated O +
in O +
active O +
multiple O +
sclerosis O +
lesions O -
, O +
including O +
microRNA-155 O -
, O +
which O +
is O +
known O +
to O +
modulate O +
immune O +
responses O +
in O +
different O +
ways O +
but O +
so O +
far O +
had O +
not O +
been O +
assigned O +
to O +
central O +
nervous O +
system O +
resident O +
cells O -
. O +

MicroRNA-155 O +
was O +
expressed O +
in O +
human B-Species +
astrocytes O +
in O +
situ O -
, O +
and O +
further O +
induced O +
with O +
cytokines O +
in O +
human B-Species +
astrocytes O +
in O +
vitro O -
. O +

This O +
approach O +
protected O +
HSCs O +
from O +
GALC O +
toxicity O +
and O +
allowed O +
successful O +
treatment O +
of O +
a O +
mouse B-Species +
GLD O +
model O -
, O +
providing O +
a O +
rationale O +
to O +
explore O +
HSC O -
- O -
based O +
gene O +
therapy O +
for O +
GLD O -
. O +

Globoid O +
cell O +
leukodystrophy O +
( O -
GLD O -
; O +
also O +
known O +
as O +
Krabbe O +
disease O -
) O +
is O +
an O +
invariably O +
fatal O +
lysosomal O +
storage O +
disorder O +
caused O +
by O +
mutations O +
in O +
the O +
galactocerebrosidase O +
( O -
GALC O -
) O +
gene O -
. O +

Hematopoietic O +
stem O +
cell O +
( O -
HSC O -
) O -
-based O +
gene O +
therapy O +
is O +
being O +
explored O +
for O +
GLD O -
; O +
however O -
, O +
we O +
found O +
that O +
forced O +
GALC O +
expression O +
was O +
toxic O +
to O +
HSCs O +
and O +
early O +
progenitors O -
, O +
highlighting O +
the O +
need O +
for O +
improved O +
regulation O +
of O +
vector O +
expression O -
. O +

Identification O +
of O +
hematopoietic O +
stem O +
cell O -
- O -
specific O +
miRNAs O +
enables O +
gene O +
therapy O +
of O +
globoid O +
cell O +
leukodystrophy O -
. O +

Moreover O -
, O +
repopulating O +
HSCs O +
could O +
be O +
purified O +
solely O +
on O +
the O +
basis O +
of O +
miRNA O +
expression O -
, O +
providing O +
a O +
new O +
method O +
relevant O +
for O +
human B-Species +
HSC O +
isolation O -
. O +

By O +
incorporating O +
miR-126 O +
target O +
sequences O +
into O +
a O +
GALC O -
- O -
expressing O +
vector O -
, O +
we O +
suppressed O +
GALC O +
expression O +
in O +
HSCs O +
while O +
maintaining O +
robust O +
expression O +
in O +
mature O +
hematopoietic O +
cells O -
. O +

We O +
used O +
a O +
genetic O +
reporter O +
strategy O +
based O +
on O +
lentiviral O +
vectors O +
to O +
detect O +
microRNA O +
activity O +
in O +
hematopoietic O +
cells O +
at O +
single O -
- O -
cell O +
resolution O -
. O +

We O +
report O +
that O +
miR-126 O +
and O +
miR-130a O +
were O +
expressed O +
in O +
HSCs O +
and O +
early O +
progenitors O +
from O +
both O +
mice B-Species +
and O +
humans B-Species -
, O +
but O +
not O +
in O +
differentiated O +
progeny O -
. O +

MicroRNAs O +
( O -
miRNAs O -
) O +
predominantly O +
induce O +
translational O +
repression O +
and O +
are O +
emerging O +
as O +
a O +
major O +
regulators O +
of O +
mRNA O +
and O +
subsequent O +
protein O +
expression O +
after O +
ischemia O -
. O +

The O +
miRNA O +
miR-23a O +
was O +
predicted O +
to O +
bind O +
XIAP O +
mRNA O -
. O +

miR-23a O +
directly O +
bound O +
the O +
3 O -
' O +
UTR O +
of O +
XIAP O -
, O +
and O +
miR-23a O +
inhibition O +
led O +
to O +
an O +
increase O +
in O +
XIAP O +
mRNA O +
in O +
vitro O -
, O +
demonstrating O +
that O +
XIAP O +
is O +
a O +
previously O +
uncharacterized O +
target O +
for O +
miR-23a O -
. O +

Embelin O +
treatment O +
significantly O +
exacerbated O +
stroke O -
- O -
induced O +
injury O +
in O +
females O +
but O +
had O +
no O +
effect O +
in O +
males O -
, O +
demonstrating O +
that O +
XIAP O +
is O +
an O +
important O +
mediator O +
of O +
sex O -
- O -
specific O +
responses O +
after O +
stroke O -
. O +

miR-23a O +
levels O +
differed O +
in O +
male O +
and O +
female O +
ischemic O +
brains O -
, O +
providing O +
evidence O +
for O +
sex O -
- O -
specific O +
miRNA O +
expression O +
in O +
stroke O -
. O +

Embelin O -
, O +
a O +
small O -
- O -
molecule O +
inhibitor O +
of O +
XIAP O -
, O +
decreased O +
the O +
interaction O +
between O +
XIAP O +
and O +
caspase-3 O +
and O +
led O +
to O +
enhanced O +
caspase O +
activity O -
. O +

It O +
is O +
increasingly O +
recognized O +
that O +
the O +
mechanisms O +
underlying O +
ischemic O +
cell O +
death O +
are O +
sexually O +
dimorphic O -
. O +

miR-23a O +
regulation O +
of O +
X O -
- O -
linked O +
inhibitor O +
of O +
apoptosis O +
( O -
XIAP O -
) O +
contributes O +
to O +
sex O +
differences O +
in O +
the O +
response O +
to O +
cerebral O +
ischemia O -
. O +

In O +
contrast O -
, O +
ischemic O +
cell O +
death O +
in O +
females O +
is O +
primarily O +
triggered O +
by O +
mitochondrial O +
cytochrome O +
c O +
release O +
with O +
subsequent O +
caspase O +
activation O -
. O +

Stroke O -
- O -
induced O +
cell O +
death O +
in O +
males O +
is O +
initiated O +
by O +
the O +
mitochondrial O +
release O +
of O +
apoptosis O -
- O -
inducing O +
factor O -
, O +
resulting O +
in O +
caspase O -
- O -
independent O +
cell O +
death O -
. O +

XIAP O +
mRNA O +
levels O +
were O +
higher O +
in O +
females O +
at O +
baseline O -
. O +

Because O +
X O -
- O -
linked O +
inhibitor O +
of O +
apoptosis O +
( O -
XIAP O -
) O +
is O +
the O +
primary O +
endogenous O +
inhibitor O +
of O +
caspases O -
, O +
its O +
regulation O +
may O +
play O +
a O +
unique O +
role O +
in O +
the O +
response O +
to O +
injury O +
in O +
females O -
. O +

However O -
, O +
XIAP O +
protein O +
levels O +
were O +
decreased O +
in O +
both O +
sexes O +
after O +
stroke O -
. O +

Stroke O +
induced O +
a O +
significant O +
decrease O +
in O +
XIAP O +
mRNA O +
in O +
females O -
, O +
whereas O +
no O +
changes O +
were O +
seen O +
in O +
the O +
male O +
brain O -
. O +

The O +
genomic O +
sequences O +
predict O +
that O +
miRNAs O +
are O +
likely O +
to O +
be O +
derived O +
from O +
larger O +
precursors O +
that O +
have O +
the O +
capacity O +
to O +
form O +
stem O -
- O -
loop O +
structures O -
. O +

Here O +
we O +
report O +
that O +
Gemin3 O +
and O +
Gemin4 O +
are O +
also O +
in O +
a O +
separate O +
complex O +
that O +
contains O +
eIF2C2 O -
, O +
a O +
member O +
of O +
the O +
Argonaute O +
protein O +
family O -
. O +

The O +
SMN O +
complex O +
has O +
critical O +
functions O +
in O +
the O +
assembly O -
/ O -
restructuring O +
of O +
diverse O +
ribonucleoprotein O +
( O -
RNP O -
) O +
complexes O -
. O +

We O +
describe O +
40 O +
miRNAs O -
, O +
a O +
few O +
of O +
which O +
are O +
identical O +
to O +
recently O +
described O +
human B-Species +
miRNAs O -
, O +
a O +
class O +
of O +
small O +
endogenous O +
RNAs O -
. O +

This O +
novel O +
complex O +
is O +
a O +
large O +
approximately O +
15S O +
RNP O +
that O +
contains O +
numerous O +
microRNAs O +
( O -
miRNAs O -
) O -
. O +

miRNPs O -
: O +
a O +
novel O +
class O +
of O +
ribonucleoproteins O +
containing O +
numerous O +
microRNAs O -
. O +

Reduction O +
in O +
SMN O +
protein O +
results O +
in O +
Spinal O +
muscular O +
atrophy O +
( O -
SMA O -
) O -
, O +
a O +
common O +
neurodegenerative O +
disease O -
. O +

Gemin3 O +
is O +
a O +
DEAD O -
- O -
box O +
RNA O +
helicase O +
that O +
binds O +
to O +
the O +
Survival O +
of O +
Motor O +
Neurons O +
( O -
SMN O -
) O +
protein O +
and O +
is O +
a O +
component O +
of O +
the O +
SMN O +
complex O -
, O +
which O +
also O +
comprises O +
SMN O -
, O +
Gemin2 O -
, O +
Gemin4 O -
, O +
Gemin5 O -
, O +
and O +
Gemin6 O -
. O +

We O +
also O +
demonstrate O +
that O +
the O +
single O -
- O -
nucleotide O +
polymorphism O +
( O -
SNP O -
) O +
that O +
is O +
located O +
immediately O +
adjacent O +
( O -
3 O -
' O -
) O +
to O +
the O +
repeats O +
of O +
the O +
SCA3 O +
transcript O +
modulates O +
the O +
structures O +
formed O +
by O +
these O +
sequences O -
, O +
and O +
may O +
have O +
functional O +
significance O -
, O +
as O +
only O +
one O +
of O +
its O +
variants O +
is O +
selected O +
in O +
human B-Species +
evolution O -
. O +

We O +
provide O +
evidence O +
that O +
the O +
hairpin O +
structure O +
formed O +
by O +
CAG O +
repeats O +
in O +
mRNA O +
fragments O +
is O +
preserved O +
in O +
full O -
- O -
length O +
mRNA O -
. O +

Here O -
, O +
we O +
show O +
that O +
the O +
structures O +
formed O +
by O +
the O +
repeats O +
and O +
their O +
natural O +
flanking O +
sequences O +
in O +
the O +
spinocerebellar O +
ataxia O +
( O -
SCA O -
) O +
type O +
3 O +
and O +
type O +
6 O -
, O +
and O +
dentatorubral O -
- O -
palidoluysian O +
atrophy O +
( O -
DRPLA O -
) O +
transcripts O +
have O +
different O +
molecular O +
architectures O +
which O +
may O +
have O +
functional O +
meaning O -
. O +

The O +
expanded O +
CAG O +
repeats O +
are O +
present O +
in O +
transcripts O +
from O +
several O +
mutant O +
genes O +
associated O +
with O +
hereditary O +
neurodegenerative O +
diseases O +
but O +
their O +
contribution O +
to O +
pathogenesis O +
has O +
not O +
been O +
documented O +
convincingly O -
. O +

CAG O +
repeats O +
are O +
present O +
in O +
numerous O +
human B-Species +
transcripts O +
but O +
neither O +
their O +
structures O +
nor O +
physiological O +
functions O +
have O +
been O +
satisfactorily O +
recognized O -
. O +

Molecular O +
architecture O +
of O +
CAG O +
repeats O +
in O +
human B-Species +
disease O +
related O +
transcripts O -
. O +

Defective O +
RNA O +
metabolism O +
is O +
an O +
emerging O +
mechanism O +
involved O +
in O +
ALS O +
pathogenesis O +
and O +
possibly O +
in O +
other O +
neurodegenerative O +
disorders O -
. O +

miRNA O +
malfunction O +
causes O +
spinal O +
motor O +
neuron O +
disease O -
. O +

Thus O -
, O +
mice B-Species +
that O +
do O +
not O +
process O +
miRNA O +
in O +
SMNs O +
exhibit O +
hallmarks O +
of O +
spinal O +
muscular O +
atrophy O +
( O -
SMA O -
) O -
, O +
including O +
sclerosis O +
of O +
the O +
spinal O +
cord O +
ventral O +
horns O -
, O +
aberrant O +
end O +
plate O +
architecture O -
, O +
and O +
myofiber O +
atrophy O +
with O +
signs O +
of O +
denervation O -
. O +

Here O -
, O +
we O +
show O +
that O +
microRNA O +
( O -
miRNA O -
) O +
activity O +
is O +
essential O +
for O +
long O -
- O -
term O +
survival O +
of O +
postmitotic O +
spinal O +
motor O +
neurons O +
( O -
SMNs O -
) O +
in O +
vivo O -
. O +

We O +
demonstrate O +
that O +
the O +
heavy O +
neurofilament O +
subunit O +
is O +
a O +
target O +
of O +
miR-9 O -
, O +
a O +
miRNA O +
that O +
is O +
specifically O +
down O -
- O -
regulated O +
in O +
a O +
genetic O +
model O +
of O +
SMA O -
. O +

Furthermore O -
, O +
a O +
neurofilament O +
heavy O +
subunit O +
previously O +
implicated O +
in O +
motor O +
neuron O +
degeneration O +
is O +
specifically O +
up O -
- O -
regulated O +
in O +
miRNA O -
- O -
deficient O +
SMNs O -
. O +

These O +
data O +
provide O +
evidence O +
for O +
miRNA O +
function O +
in O +
SMN O +
diseases O +
and O +
emphasize O +
the O +
potential O +
role O +
of O +
miR-9-based O +
regulatory O +
mechanisms O +
in O +
adult O +
neurons O +
and O +
neurodegenerative O +
states O -
. O +

Proteasomal O +
degradation O +
of O +
myocardin O +
is O +
required O +
for O +
its O +
transcriptional O +
activity O +
in O +
vascular O +
smooth O +
muscle O +
cells O -
. O +

Myocardin O +
is O +
a O +
transcriptional O +
co O -
- O -
activator O +
of O +
serum O +
response O +
factor O +
( O -
SRF O -
) O +
and O +
can O +
be O +
degraded O +
through O +
ubiquitin O -
- O -
proteasome O +
system O -
. O +

Our O +
preliminary O +
studies O +
unexpectedly O +
revealed O +
that O +
accumulation O +
of O +
myocardin O +
in O +
response O +
to O +
proteasome O +
inhibition O +
by O +
MG132 O +
or O +
lactacystin O +
resulted O +
in O +
decrease O +
of O +
transcriptional O +
activity O +
of O +
myocardin O +
as O +
indicated O +
by O +
reduced O +
expression O +
of O +
SMC O +
contractile O +
marker O +
genes O +
( O -
SM O +
α O -
- O -
actin O -
, O +
SM22 O -
, O +
and O +
calponin O -
) O +
and O +
muscle O -
- O -
enriched O +
microRNAs O +
( O -
miR-143 O -
/ O -
145 O +
and O +
miR-1 O -
/ O -
133a O -
) O -
, O +
and O +
reduced O +
contractility O +
of O +
human B-Species +
vascular O +
smooth O +
muscle O +
cells O +
( O -
SMCs O -
) O +
embedded O +
in O +
collagen O +
gel O +
lattices O -
, O +
suggesting O +
that O +
myocardin O +
degradation O +
is O +
required O +
for O +
its O +
transcriptional O +
activity O -
. O +

Further O +
studies O +
using O +
chromatin O +
immunoprecipitation O +
assay O +
revealed O +
that O +
proteasome O +
inhibition O -
, O +
although O +
increased O +
the O +
occupancy O +
of O +
myocardin O +
and O +
SRF O +
on O +
the O +
promoter O +
of O +
SM O +
α O -
- O -
actin O +
gene O -
, O +
abolished O +
myocardin O -
- O -
dependent O +
recruitment O +
of O +
RNA O +
polymerase O +
II O -
. O +

We O +
further O +
examined O +
the O +
degradation O +
of O +
myocardin O +
in O +
epithelioid O +
and O +
spindle O -
- O -
shaped O +
SMCs O +
and O +
revealed O +
that O +
myocardin O +
in O +
more O +
differentiated O +
spindle O -
- O -
shaped O +
SMCs O +
was O +
more O +
quickly O +
degraded O +
and O +
had O +
shorter O +
half O -
- O -
life O +
than O +
in O +
epithelioid O +
SMCs O -
. O +

In O +
neointimal O +
lesions O -
, O +
we O +
found O +
that O +
stabilization O +
of O +
myocardin O +
protein O +
was O +
companied O +
by O +
downregulation O +
of O +
transcripts O +
of O +
ubiquitin O +
and O +
proteasome O +
subunits O -
, O +
further O +
illustrating O +
the O +
mechanism O +
underlying O +
reduction O +
of O +
myocardin O +
transcriptional O +
activity O -
. O +

In O +
summary O -
, O +
our O +
results O +
have O +
suggested O +
that O +
proteasomal O +
degradation O +
of O +
myocardin O +
is O +
required O +
for O +
its O +
transcriptional O +
activity O -
. O +

However O -
, O +
prior O +
to O +
expression O -
, O +
it O +
is O +
necessary O +
to O +
convert O +
the O +
single O -
- O -
stranded O +
DNA O +
genome O +
into O +
double O -
- O -
stranded O +
DNA O -
, O +
which O +
hinders O +
the O +
efficiency O +
of O +
these O +
vectors O -
. O +

Numerous O +
studies O +
and O +
clinical O +
trials O +
have O +
demonstrated O +
the O +
efficacy O +
of O +
recombinant O +
adeno O -
- O -
associated O +
virus O +
gene O +
delivery O +
vectors O -
. O +

[ O -
Trends O +
in O +
development O +
of O +
self O -
- O -
complementary O +
adeno O -
- O -
associated O +
virus O +
vector O -
] O -
. O +

We O +
can O +
entirely O +
circumvent O +
this O +
step O +
through O +
the O +
use O +
of O +
self O -
- O -
complementary O +
recombinant O +
adeno O -
- O -
associated O +
virus O +
vector O +
( O -
scrAAV O -
) O -
. O +

ScrAAV O +
packages O +
an O +
inverted O +
repeat O +
genome O +
that O +
can O +
fold O +
into O +
double O -
- O -
stranded O +
DNA O +
without O +
the O +
requirement O +
for O +
DNA O +
synthesis O +
or O +
base O -
- O -
pairing O +
between O +
multiple O +
vector O +
genomes O -
. O +

By O +
using O +
scrAAV O -
, O +
we O +
could O +
increase O +
expression O +
efficiency O +
and O +
reduce O +
immune O +
response O +
caused O +
by O +
vectors O +
themselves O -
. O +

Therefore O -
, O +
it O +
is O +
a O +
promising O +
vector O +
for O +
gene O +
therapy O -
. O +

So O +
far O -
, O +
it O +
has O +
been O +
used O +
in O +
the O +
treatment O +
of O +
hepatic O +
diseases O -
, O +
central O +
nervous O +
system O +
diseases O -
, O +
and O +
eye O +
diseases O -
. O +

It O +
has O +
also O +
been O +
used O +
in O +
the O +
modifications O +
of O +
stem O +
cells O +
and O +
as O +
vectors O +
for O +
siRNA O -
/ O -
miRNA O +
and O +
ribozymes O -
. O +

In O +
this O +
review O -
, O +
we O +
focused O +
on O +
the O +
preparation O -
, O +
expression O +
and O +
location O +
of O +
scrAAV O +
both O +
in O +
vitro O +
and O +
in O +
vivo O -
. O +

We O +
mainly O +
introduced O +
the O +
recent O +
progress O +
of O +
scrAAV O +
based O +
therapy O +
of O +
Hemophilia O +
B O -
, O +
in O +
order O +
to O +
elucidate O +
the O +
potential O +
and O +
prospects O +
of O +
scrAAV O +
in O +
gene O +
therapy O -
. O +

Since O +
neuron O -
- O -
specific O +
microRNA-7 O +
is O +
downregulated O +
in O +
gliomas O +
but O +
highly O +
expressed O +
in O +
normal O +
brain O +
tissue O -
, O +
we O +
engineered O +
a O +
microRNA O -
- O -
sensitive O +
virus O +
containing O +
target O +
sites O +
for O +
microRNA-7 O +
in O +
the O +
3'-untranslated O +
region O +
of O +
the O +
viral O +
fusion O +
gene O -
. O +

Recent O +
preclinical O +
studies O +
have O +
shown O +
that O +
the O +
cellular O +
tropism O +
of O +
several O +
viruses O +
can O +
be O +
controlled O +
by O +
inserting O +
microRNA O -
- O -
target O +
sequences O +
into O +
their O +
genomes O -
, O +
thereby O +
inhibiting O +
spread O +
in O +
tissues O +
expressing O +
cognate O +
microRNAs O -
. O +

Oncolytic O +
measles O +
viruses O +
( O -
MV O -
) O +
derived O +
from O +
the O +
live O +
attenuated O +
vaccine O +
strain O +
have O +
been O +
engineered O +
for O +
increased O +
tumor O -
- O -
cell O +
specificity O -
, O +
and O +
are O +
currently O +
under O +
investigation O +
in O +
clinical O +
trials O +
including O +
a O +
phase O +
I O +
study O +
for O +
glioblastoma O +
multiforme O +
( O -
GBM O -
) O -
. O +

MicroRNA O -
- O -
sensitive O +
oncolytic O +
measles O +
viruses O +
for O +
cancer O -
- O -
specific O +
vector O +
tropism O -
. O +

This O +
is O +
proof O -
- O -
of O -
- O -
concept O +
that O +
tropism O +
restriction O +
by O +
tissue O -
- O -
specific O +
microRNAs O +
can O +
be O +
adapted O +
to O +
oncolytic O +
MV O +
to O +
regulate O +
viral O +
replication O +
and O +
gene O +
expression O +
to O +
maximize O +
tumor O +
specificity O +
without O +
compromising O +
oncolytic O +
efficacy O -
. O +

Furthermore O -
, O +
microRNA O -
- O -
mediated O +
inhibition O +
protected O +
genetically O +
modified O +
mice B-Species +
susceptible O +
to O +
MV O +
infection O +
from O +
a O +
potentially O +
lethal O +
intracerebral O +
challenge O -
. O +

Importantly O -
, O +
endogenous O +
microRNA-7 O +
expression O +
in O +
primary O +
human B-Species +
brain O +
resections O +
tightly O +
restricted O +
replication O +
and O +
spread O +
of O +
microRNA O -
- O -
sensitive O +
virus O -
. O +

In O +
presence O +
of O +
microRNA-7 O +
this O +
modification O +
inhibits O +
translation O +
of O +
envelope O +
proteins O -
, O +
restricts O +
viral O +
spread O -
, O +
and O +
progeny O +
production O -
. O +

Even O +
though O +
highly O +
attenuated O +
in O +
presence O +
of O +
microRNA-7 O -
, O +
this O +
virus O +
retained O +
full O +
efficacy O +
against O +
glioblastoma O +
xenografts O -
. O +

Expression O +
profile O +
of O +
MicroRNAs O +
in O +
young O +
stroke O +
patients B-Species -
. O +

BACKGROUND O -
: O +
The O +
methods O +
currently O +
available O +
for O +
diagnosis O +
and O +
prognosis O +
of O +
cerebral O +
ischaemia O +
still O +
require O +
further O +
improvements O -
. O +

Blood O +
samples O +
from O +
normal O +
( O -
n=5 O -
) O +
individuals O +
were O +
used O +
as O +
controls O -
. O +

Total O +
RNA O +
extracted O +
from O +
whole O +
blood O +
was O +
subjected O +
to O +
miroRNA O +
profiling O +
and O +
real O -
- O -
time O +
PCR O +
analysis O -
. O +

miRNAs O +
that O +
are O +
implicated O +
in O +
the O +
endothelial O -
/ O -
vascular O +
function O -
, O +
erythropoiesis O -
, O +
angiogenesis O +
and O +
neural O +
function O +
showed O +
differential O +
expression O +
profile O +
as O +
compared O +
to O +
the O +
normal O +
control O -
. O +

Interestingly O -
, O +
miRNAs O +
that O +
are O +
involved O +
in O +
hypoxic O +
conditions O +
have O +
also O +
been O +
found O +
in O +
our O +
miRNA O +
profiles O -
. O +

Micro O -
- O -
RNAs O +
( O -
small O +
non O -
- O -
coding O +
RNAs O -
) O +
have O +
been O +
recently O +
reported O +
as O +
useful O +
biomarkers O +
in O +
diseases O +
such O +
as O +
cancer O +
and O +
diabetes O -
. O +

We O +
therefore O +
carried O +
out O +
microRNA O +
( O -
miRNA O -
) O +
profiling O +
from O +
peripheral O +
blood O +
to O +
detect O +
and O +
identify O +
characteristic O +
patterns O +
in O +
ischaemic O +
stroke O -
. O +

METHODS O -
/ O -
PRINCIPAL O +
FINDINGS O -
: O +
The O +
ischaemic O +
stroke O +
patients B-Species +
aged O +
between O +
18 O -
- O -
49 O +
years O -
, O +
characterized O +
based O +
on O +
World O +
Health O +
Organization O +
clinical O +
criteria O +
were O +
further O +
classified O +
according O +
to O +
TOAST O +
classification O -
, O +
a O -
) O +
Large O -
- O -
vessel O +
atherosclerosis O +
[ O -
n=8 O -
] O +
b O -
) O +
Small O -
- O -
vessel O +
disease O +
[ O -
n=3 O -
] O +
c O -
) O +
Cardioembolism O +
[ O -
n=5 O -
] O +
d O -
) O +
Undetermined O +
cause O +
[ O -
n=3 O -
] O -
. O +

The O +
patients B-Species -
' O +
functional O +
status O +
at O +
the O +
time O +
of O +
blood O +
sampling O +
( O -
at O +
the O +
outpatient O +
clinics O -
) O +
was O +
evaluated O +
with O +
the O +
modified O +
Rankin O +
Scale O +
( O -
mRS O -
) O -
. O +

CONCLUSION O -
: O +
We O +
demonstrate O +
that O +
the O +
peripheral O +
blood O +
miRNAs O +
and O +
their O +
profiles O +
can O +
be O +
developed O +
as O +
biomarkers O +
in O +
diagnosis O +
and O +
prognosis O +
of O +
cerebral O +
ischaemic O +
stroke O -
. O +

The O +
dysregulated O +
miRNAs O +
have O +
been O +
detectable O +
even O +
after O +
several O +
months O +
from O +
the O +
onset O +
of O +
stroke O +
in O +
what O +
is O +
usually O +
regarded O +
as O +
neurologically O +
stable O +
patients B-Species -
. O +

Finally O -
, O +
the O +
association O +
of O +
the O +
variant O +
with O +
stroke O +
was O +
tested O +
in O +
438 O +
stroke O +
patients B-Species +
and O +
890 O +
controls O -
, O +
and O +
replicated O +
in O +
an O +
independent O +
population O +
of O +
1791 O +
stroke O +
patients B-Species +
and O +
1843 O +
controls O -
. O +

The O +
TT O +
genotype O +
resulted O +
in O +
a O +
significant O +
reduction O +
in O +
overall O +
stroke O +
risk O +
{ O -
OR O -
, O +
0.51 O +
[ O -
95 O -
% O +
confidence O +
interval O +
( O -
CI O -
) O -
, O +
0.36 O -
- O -
0.74 O -
] O -
, O +
P O +
= O +
0.0003 O -
} O -
, O +
ischemic O +
stroke O +
[ O -
OR O -
, O +
0.56 O +
( O -
95 O -
% O +
CI O -
, O +
0.36 O -
- O -
0.85 O -
) O -
, O +
P O +
= O +
0.007 O -
] O +
and O +
hemorrhagic O +
stroke O +
[ O -
OR O -
, O +
0.46 O +
( O -
95 O -
% O +
CI O -
, O +
0.26 O -
- O -
0.80 O -
) O -
, O +
P O +
= O +
0.007 O -
] O -
. O +

We O +
found O +
that O +
the O +
A O +
allele O +
of O +
rs2507800 O +
suppressed O +
angiopoietin-1 O +
translation O +
by O +
facilitating O +
miR-211 O +
binding O -
, O +
but O +
not O +
the O +
T O +
allele O -
. O +

Subjects O +
carrying O +
the O +
TT O +
genotype O +
had O +
higher O +
plasma O +
angiopoietin-1 O +
levels O +
than O +
those O +
with O +
the O +
A O +
allele O -
. O +

To O +
test O +
our O +
hypothesis O -
, O +
a O +
predicted O +
microRNA O -
- O -
binding O +
site O +
was O +
found O +
in O +
the O +
3'-UTR O +
of O +
angiopoietin-1 O +
using O +
bioinformatics O -
; O +
variant O +
rs2507800 O +
was O +
identified O +
to O +
be O +
located O +
in O +
the O +
miR-211-binding O +
site O +
of O +
angiopoietin-1 O -
. O +

Secondly O -
, O +
the O +
effects O +
of O +
the O +
identified O +
variant O +
on O +
angiopoietin-1 O +
translation O +
were O +
assessed O +
using O +
a O +
luciferase O +
reporter O +
assay O +
and O +
ELISA O -
. O +

Angiopoietin-1 O +
is O +
a O +
vascular O +
strengthening O +
factor O +
during O +
vascular O +
development O +
and O +
a O +
protective O +
factor O +
for O +
pathological O +
vascular O +
inflammation O +
and O +
leakage O -
. O +

Brain O +
vascular O +
leaking O +
and O +
inflammation O +
are O +
two O +
important O +
pathological O +
processes O +
of O +
stroke O -
; O +
therefore O -
, O +
we O +
hypothesized O +
that O +
variants O +
of O +
the O +
microRNA O -
- O -
binding O +
site O +
in O +
angiopoietin-1 O +
would O +
affect O +
its O +
expression O +
and O +
confer O +
a O +
risk O +
of O +
stroke O -
. O +

A O +
functional O +
variant O +
in O +
the O +
3'-UTR O +
of O +
angiopoietin-1 O +
might O +
reduce O +
stroke O +
risk O +
by O +
interfering O +
with O +
the O +
binding O +
efficiency O +
of O +
microRNA O +
211 O -
. O +

Our O +
results O +
provide O +
evidence O +
that O +
the O +
TT O +
genotype O +
( O -
rs2507800 O -
) O +
in O +
the O +
3'-UTR O +
of O +
angiopoietin-1 O +
might O +
reduce O +
the O +
risk O +
of O +
stroke O +
by O +
interfering O +
with O +
miR-211 O +
binding O -
. O +

These O +
results O +
were O +
confirmed O +
in O +
an O +
independent O +
study O -
. O +

We O +
also O +
indentified O +
97 O +
differentially O +
expressed O +
microRNAs O +
among O +
240 O +
tumor O +
and O +
10 O +
normal O +
samples O -
. O +

22 O +
of O +
which O +
have O +
been O +
reported O +
to O +
affect O +
glioblastoma O +
and O +
50 O +
of O +
which O +
were O +
implicated O +
in O +
other O +
cancers O +
and O +
brain O +
diseases O -
. O +

Though O +
a O +
lot O +
of O +
research O +
has O +
been O +
focused O +
on O +
this O +
disease O -
, O +
the O +
causes O +
and O +
pathogenesis O +
of O +
glioblastoma O +
have O +
not O +
been O +
indentified O +
clearly O -
. O +

RESULTS O -
: O +
We O +
indentified O +
1,236 O +
significantly O +
differentially O +
expressed O +
genes O -
, O +
and O +
30 O +
pathways O +
enriched O +
in O +
the O +
set O +
of O +
differentially O +
expressed O +
genes O +
among O +
243 O +
tumor O +
and O +
11 O +
normal O +
samples O -
. O +

Investigation O +
gene O +
and O +
microRNA O +
expression O +
in O +
glioblastoma O -
. O +

BACKGROUND O -
: O +
Glioblastoma O +
is O +
the O +
most O +
common O +
primary O +
brain O +
tumor O +
in O +
adults O -
. O +

CONCLUSION O -
: O +
We O +
investigated O +
gene O +
and O +
microRNA O +
Expression O +
in O +
Glioblastoma O +
and O +
gave O +
a O +
comprehensive O +
function O +
study O +
of O +
differential O +
expressed O +
gene O +
and O +
microRNA O +
in O +
glioblastoma O +
patients B-Species -
. O +

Further O +
function O +
analysis O +
of O +
target O +
genes O +
suggested O +
that O +
microRNAs O +
most O +
frequently O +
targeted O +
genes O +
associated O +
with O +
Cell O +
Signalling O +
and O +
Nervous O +
System O -
. O +

We O +
found O +
two O +
experimentally O +
validated O +
microRNA O +
targets O +
and O +
1,094 O +
miRNA O -
- O -
target O +
gene O +
pairs O +
in O +
our O +
datasets O +
which O +
were O +
predicted O +
by O +
miRanda O +
algorithm O -
, O +
8 O +
of O +
the O +
target O +
genes O +
were O +
tumor O +
suppressor O +
genes O +
and O +
3 O +
were O +
oncogenes O -
. O +

We O +
regressed O +
gene O +
expression O +
on O +
microRNA O +
expression O +
in O +
237 O +
tumor O +
tissues O +
and O +
10 O +
normal O +
tissues O +
comprehensively O -
. O +

These O +
findings O +
gave O +
important O +
clues O +
to O +
study O +
of O +
the O +
carcinogenic O +
process O +
in O +
glioblastomas O -
. O +

Does O +
the O +
effect O +
of O +
microRNAs O +
in O +
vascular O +
neointimal O +
formation O +
depend O +
on O +
cell O +
cycle O +
phase O -
? O +

CONCLUSION O -
: O +
Our O +
results O +
indicate O +
a O +
time O -
- O -
dependent O +
expression O +
pattern O +
of O +
miR-223 O +
and O +
miR-124a O +
in O +
a O +
mouse B-Species +
model O +
of O +
SCI O -
. O +

In O +
this O +
study O -
, O +
the O +
time O +
course O +
of O +
miRNA-223 O +
expression O +
may O +
be O +
related O +
to O +
inflammatory O +
responses O +
after O +
SCI O -
, O +
and O +
the O +
time O +
course O +
of O +
decreased O +
miR-124a O +
expression O +
may O +
reflect O +
cell O +
death O -
. O +

However O -
, O +
miR-124a O -
, O +
which O +
was O +
present O +
in O +
the O +
normal O +
spinal O +
cord O -
, O +
was O +
not O +
observed O +
at O +
the O +
injured O +
site O -
. O +

RESULTS O -
: O +
Quantitative O +
PCR O +
revealed O +
two O +
peaks O +
of O +
miR-223 O +
expression O +
at O +
6 O +
and O +
12 O +
h O +
and O +
3 O +
days O +
after O +
SCI O -
. O +
MiR-124a O +
expression O +
decreased O +
significantly O +
from O +
1 O +
day O +
to O +
7 O +
days O +
after O +
SCI O -
. O +

In O +
situ O +
hybridization O +
demonstrated O +
the O +
presence O +
of O +
miR-223 O +
around O +
the O +
injured O +
site O -
. O +

METHODS O -
: O +
We O +
examined O +
the O +
expression O +
of O +
miRNA O +
( O -
miR O -
) O -
-223 O +
and O +
miR-124a O +
in O +
a O +
mouse B-Species +
model O +
at O +
6 O +
h O -
, O +
12 O +
h O -
, O +
1 O +
day O -
, O +
3 O +
days O +
and O +
7 O +
days O +
after O +
SCI O +
using O +
quantitative O +
PCR O -
. O +

The O +
miRNA O +
expression O +
was O +
confirmed O +
by O +
in O +
situ O +
hybridization O -
. O +

MiRNAs O +
are O +
short O +
noncoding O +
RNAs O +
that O +
suppress O +
the O +
translation O +
of O +
target O +
genes O +
by O +
binding O +
to O +
their O +
mRNAs O -
, O +
and O +
play O +
a O +
central O +
role O +
in O +
gene O +
regulation O +
in O +
health O +
and O +
disease O -
. O +

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
examine O +
miRNA O +
expression O +
after O +
SCI O -
. O +
SETTING O -
: O +
Department O +
of O +
Orthopaedic O +
Surgery O -
, O +
Graduate O +
School O +
of O +
Biomedical O +
Sciences O -
, O +
Hiroshima O +
University O -
. O +

STUDY O +
DESIGN O -
: O +
We O +
investigated O +
microRNA O +
( O -
miRNA O -
) O +
expression O +
after O +
spinal O +
cord O +
injury O +
( O -
SCI O -
) O +
in O +
mice B-Species -
. O +

OBJECTIVES O -
: O +
The O +
recent O +
discovery O +
of O +
miRNAs O +
suggests O +
a O +
novel O +
regulatory O +
control O +
over O +
gene O +
expression O +
during O +
plant O +
and O +
animal O +
development O -
. O +

Responses O +
of O +
microRNAs O +
124a O +
and O +
223 O +
following O +
spinal O +
cord O +
injury O +
in O +
mice B-Species -
. O +

The O +
characteristics O +
of O +
tumors O +
induced O +
in O +
NG2-KO O +
were O +
compared O +
to O +
those O +
of O +
tumors O +
induced O +
in O +
wild O +
type O +
mice B-Species +
by O +
immunostaining O +
for O +
different O +
cell O +
lineage O +
markers O +
and O +
by O +
transplantation O +
assays O +
in O +
adult O +
mice B-Species -
. O +

METHODS O -
: O +
The O +
survival O +
curves O +
of O +
NG2-KO O +
mice B-Species +
overexpressing O +
PDGF O -
- O -
B O +
were O +
compared O +
to O +
controls O +
by O +
using O +
a O +
Log O -
- O -
rank O +
test O -
. O +

We O +
have O +
recently O +
generated O +
a O +
glioma O +
model O +
based O +
on O +
the O +
overexpression O +
of O +
PDGF O -
- O -
B O +
in O +
neural O +
progenitors O +
and O +
here O +
we O +
investigated O +
the O +
possible O +
relevance O +
of O +
NG2 O +
during O +
PDGF O -
- O -
driven O +
gliomagenesis O -
. O +

NG2 O +
has O +
been O +
shown O +
to O +
function O +
as O +
a O +
co O -
- O -
receptor O +
for O +
PDGF O +
ligands O +
whose O +
aberrant O +
expression O +
is O +
common O +
in O +
gliomas O -
. O +

BACKGROUND O -
: O +
In O +
the O +
last O +
years O -
, O +
the O +
transmembrane O +
proteoglycan O +
NG2 O +
has O +
gained O +
interest O +
as O +
a O +
therapeutic O +
target O +
for O +
the O +
treatment O +
of O +
diverse O +
tumor O +
types O -
, O +
including O +
gliomas O -
, O +
because O +
increases O +
of O +
its O +
expression O +
correlate O +
with O +
dismal O +
prognosis O -
. O +

PDGF O -
- O -
B O -
- O -
driven O +
gliomagenesis O +
can O +
occur O +
in O +
the O +
absence O +
of O +
the O +
proteoglycan O +
NG2 O -
. O +

On O +
the O +
basis O +
of O +
the O +
data O +
obtained O -
, O +
we O +
therefore O +
suggest O +
that O +
the O +
role O +
of O +
NG2 O +
as O +
a O +
target O +
molecule O +
for O +
glioma O +
treatment O +
should O +
be O +
carefully O +
reconsidered O -
. O +

CONCLUSIONS O -
: O +
Our O +
analysis O -
, O +
using O +
both O +
NG2-KO O +
mice B-Species +
and O +
a O +
miRNA O +
based O +
silencing O +
approach O -
, O +
clearly O +
demonstrates O +
that O +
NG2 O +
is O +
not O +
required O +
for O +
PDGF O -
- O -
B O +
to O +
efficiently O +
induce O +
and O +
maintain O +
gliomas O +
from O +
neural O +
progenitors O -
. O +

RESULTS O -
: O +
We O +
showed O +
that O +
the O +
lack O +
of O +
NG2 O +
does O +
not O +
appreciably O +
affect O +
any O +
of O +
the O +
characterized O +
steps O +
of O +
PDGF O -
- O -
driven O +
brain O +
tumorigenesis O -
, O +
such O +
as O +
oligodendrocyte O +
progenitor O +
cells O +
( O -
OPC O -
) O +
induction O -
, O +
the O +
recruitment O +
of O +
bystander O +
OPCs O +
and O +
the O +
progression O +
to O +
full O +
malignancy O -
, O +
which O +
take O +
place O +
as O +
in O +
wild O +
type O +
animals O -
. O +

Aberrant O +
microRNA O +
expression O +
in O +
the O +
brains O +
of O +
neurodegenerative O +
diseases O -
: O +
miR-29a O +
decreased O +
in O +
Alzheimer O +
disease O +
brains O +
targets O +
neurone O +
navigator O +
3 O -
. O +
AIMS O -
: O +
MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
small O +
non O -
- O -
coding O +
RNAs O +
that O +
regulate O +
translational O +
repression O +
of O +
target O +
mRNAs O -
. O +

MiR-29a O -
- O -
mediated O +
down O -
- O -
regulation O +
of O +
NAV3 O +
was O +
verified O +
by O +
the O +
luciferase O +
reporter O +
assay O -
. O +

However O -
, O +
we O +
found O +
significant O +
down O -
- O -
regulation O +
of O +
miR-29a O +
in O +
Alzheimer O +
disease O +
( O -
AD O -
) O +
brains O -
. O +

The O +
database O +
search O +
on O +
TargetScan O -
, O +
PicTar O +
and O +
miRBase O +
Target O +
identified O +
neurone O +
navigator O +
3 O +
( O -
NAV3 O -
) O -
, O +
a O +
regulator O +
of O +
axon O +
guidance O -
, O +
as O +
a O +
principal O +
target O +
of O +
miR-29a O -
, O +
and O +
actually O +
NAV3 O +
mRNA O +
levels O +
were O +
elevated O +
in O +
AD O +
brains O -
. O +

This O +
was O +
followed O +
by O +
enlargement O +
of O +
study O +
population O +
with O +
quantitative O +
RT O -
- O -
PCR O +
analysis O +
( O -
n O +
= O +
21 O -
) O -
. O +

RESULTS O -
: O +
By O +
microarray O +
analysis O -
, O +
we O +
identified O +
up O -
- O -
regulation O +
of O +
miR-29a O -
, O +
miR-29b O +
and O +
miR-338 O -
- O -
3p O +
in O +
amyotrophic O +
lateral O +
sclerosis O +
brains O -
, O +
but O +
due O +
to O +
a O +
great O +
interindividual O +
variation O -
, O +
we O +
could O +
not O +
validate O +
these O +
results O +
by O +
quantitative O +
RT O -
- O -
PCR O -
. O +

To O +
identify O +
miRNAs O +
closely O +
associated O +
with O +
neurodegeneration O -
, O +
we O +
performed O +
miRNA O +
expression O +
profiling O +
of O +
brain O +
tissues O +
of O +
various O +
neurodegenerative O +
diseases O -
. O +

METHODS O -
: O +
We O +
initially O +
studied O +
the O +
frontal O +
cortex O +
derived O +
from O +
three O +
amyotrophic O +
lateral O +
sclerosis O +
patients B-Species +
by O +
using O +
a O +
microarray O +
of O +
723 O +
human B-Species +
miRNAs O -
. O +

Accumulating O +
evidence O +
indicates O +
that O +
various O +
miRNAs O -
, O +
expressed O +
in O +
a O +
spatially O +
and O +
temporally O +
controlled O +
that O +
manner O +
in O +
the O +
brain O +
plays O +
a O +
key O +
role O +
in O +
neuronal O +
development O -
. O +

However O -
, O +
at O +
present O -
, O +
the O +
pathological O +
implication O +
of O +
aberrant O +
miRNA O +
expression O +
in O +
neurodegenerative O +
events O +
remains O +
largely O +
unknown O -
. O +

By O +
immunohistochemistry O -
, O +
NAV3 O +
expression O +
was O +
most O +
evidently O +
enhanced O +
in O +
degenerating O +
pyramidal O +
neurones O +
in O +
the O +
cerebral O +
cortex O +
of O +
AD O -
. O +
CONCLUSIONS O -
: O +
These O +
observations O +
suggest O +
the O +
hypothesis O +
that O +
underexpression O +
of O +
miR-29a O +
affects O +
neurodegenerative O +
processes O +
by O +
enhancing O +
neuronal O +
NAV3 O +
expression O +
in O +
AD O +
brains O -
. O +

The O +
emerging O +
therapeutic O +
role O +
of O +
RNA O +
interference O +
in O +
disorders O +
of O +
the O +
central O +
nervous O +
system O -
. O +

Knockdown O +
of O +
GAD67 O +
protein O +
levels O +
normalizes O +
neuronal O +
activity O +
in O +
a O +
rat B-Species +
model O +
of O +
Parkinson O -
's O +
disease O -
. O +

METHODS O -
: O +
To O +
normalize O +
the O +
GAD67 O +
expression O +
in O +
the O +
striatum O +
after O +
dopamine O +
depletion O -
, O +
we O +
developed O +
several O +
lentiviral O +
vectors O +
that O +
express O +
RNA O +
interference O +
( O -
RNAi O -
) O +
directed O +
against O +
GAD67 O +
mitochondrial O +
RNA O -
. O +

The O +
vectors O +
were O +
injected O +
into O +
the O +
striatum O +
of O +
hemiparkinsonian O +
rats B-Species +
and O +
the O +
level O +
of O +
GAD67 O +
protein O +
as O +
well O +
as O +
a O +
marker O +
of O +
neuronal O +
activity O -
, O +
mtCO1 O -
, O +
was O +
analyzed O +
using O +
western O +
blots O -
. O +

BACKGROUND O -
: O +
Dopamine O +
depletion O +
of O +
the O +
striatum O +
is O +
one O +
of O +
the O +
hallmarks O +
of O +
Parkinson O -
's O +
disease O -
. O +

The O +
loss O +
of O +
dopamine O +
upregulates O +
GAD67 O +
expression O +
in O +
the O +
striatal O +
projection O +
neurons O +
and O +
causes O +
other O +
changes O +
in O +
the O +
activity O +
of O +
the O +
basal O +
ganglia O +
circuit O -
. O +

Using O +
a O +
lentiviral O +
vectors O +
with O +
a O +
synthetic O +
miRNA O +
scaffold O +
to O +
deliver O +
RNAi O -
, O +
we O +
were O +
able O +
to O +
normalize O +
the O +
GAD67 O +
protein O +
levels O +
in O +
the O +
parkinsonian O +
rat B-Species +
striatum O -
. O +

In O +
addition O -
, O +
we O +
were O +
able O +
to O +
normalize O +
the O +
increased O +
neural O +
activity O -
, O +
which O +
resulted O +
from O +
the O +
loss O +
of O +
dopamine O +
as O +
measured O +
by O +
the O +
marker O +
mtCO1 O -
. O +

RESULTS O -
: O +
Unilateral O +
lesions O +
of O +
the O +
dopamine O +
neurons O +
in O +
substantia O +
nigra O +
resulted O +
in O +
an O +
increased O +
level O +
of O +
GAD67 O +
protein O +
in O +
the O +
ipsilateral O +
striatum O -
. O +

Furthermore O -
, O +
we O +
detected O +
significantly O +
higher O +
levels O +
of O +
mtCO1 O -
, O +
after O +
dopamine O +
depletion O +
in O +
the O +
striatum O -
. O +

CONCLUSIONS O -
: O +
We O +
conclude O +
that O +
RNAi O +
directed O +
against O +
GAD67 O +
may O +
be O +
a O +
valid O +
approach O +
to O +
correct O +
the O +
dysregulation O +
of O +
the O +
basal O +
ganglia O +
circuit O +
in O +
a O +
rat B-Species +
model O +
of O +
Parkinson O -
's O +
disease O -
. O +

The O +
possibility O +
to O +
correct O +
for O +
a O +
loss O +
of O +
dopamine O +
using O +
nondopamimetic O +
tools O +
is O +
interesting O +
because O +
it O +
may O +
be O +
more O +
directed O +
towards O +
the O +
casual O +
mechanisms O +
of O +
the O +
motor O +
symptoms O -
. O +

Copyright O +
© O +
2011 O +
John O +
Wiley O +
& O +
Sons O -
, O +
Ltd. O +

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
small O +
noncoding O +
RNA O +
molecules O +
that O +
regulate O +
protein O +
expression O +
by O +
cleaving O +
or O +
repressing O +
the O +
translation O +
of O +
target O +
mRNAs O -
. O +

MiR-21 O +
protected O +
human B-Species +
glioblastoma O +
U87MG O +
cells O +
from O +
chemotherapeutic O +
drug O +
temozolomide O +
induced O +
apoptosis O +
by O +
decreasing O +
Bax O -
/ O -
Bcl-2 O +
ratio O +
and O +
caspase-3 O +
activity O -
. O +

Several O +
miRNAs O +
have O +
been O +
recently O +
reported O +
to O +
be O +
involved O +
in O +
modulation O +
of O +
glioma O +
development O -
, O +
especially O +
some O +
up O -
- O -
regulated O +
miRNAs O -
, O +
such O +
as O +
microRNA-21 O +
( O -
miR-21 O -
) O -
, O +
which O +
has O +
been O +
found O +
to O +
function O +
as O +
an O +
oncogene O +
in O +
cultured O +
glioblastoma O +
multiforme O +
cells O -
. O +

In O +
mammal O +
animals O -
, O +
their O +
function O +
mainly O +
represses O +
the O +
target O +
mRNAs O +
transcripts O +
via O +
imperfectly O +
complementary O +
to O +
the O +
3'UTR O +
of O +
target O +
mRNAs O -
. O +

However O -
, O +
resistance O +
develops O +
quickly O +
and O +
with O +
high O +
frequency O -
. O +

Temozolomide O +
( O -
TMZ O -
) O -
, O +
an O +
alkylating O +
agent O -
, O +
is O +
a O +
promising O +
chemotherapeutic O +
agent O +
for O +
treating O +
glioblastoma O -
. O +

Our O +
studies O +
showed O +
that O +
TMZ O +
markedly O +
enhanced O +
apoptosis O +
in O +
U87MG O +
cells O +
compared O +
with O +
untreated O +
cells O +
( O -
P<0.05 O -
) O -
. O +

To O +
explore O +
the O +
mechanism O +
of O +
resistance O -
, O +
we O +
found O +
that O +
miR-21 O +
could O +
protect O +
human B-Species +
glioblastoma O +
U87MG O +
cells O +
from O +
TMZ O +
induced O +
apoptosis O -
. O +

However O -
, O +
over O -
- O -
express O +
miR-21 O +
in O +
U87MG O +
cells O +
could O +
significantly O +
reduce O +
TMZ O -
- O -
induced O +
apoptosis O +
( O -
P<0.05 O -
) O -
. O +

Pro O -
- O -
apoptotic O +
Bax O +
and O +
anti O -
- O -
apoptotic O +
Bcl-2 O +
proteins O +
are O +
known O +
to O +
regulate O +
the O +
apoptosis O +
of O +
glioma O +
cells O -
. O +

Further O +
research O +
demonstrated O +
that O +
the O +
mechanism O +
was O +
associated O +
with O +
a O +
shift O +
in O +
Bax O -
/ O -
Bcl-2 O +
ratio O +
and O +
change O +
in O +
caspase-3 O +
activity O -
. O +

Bax O +
is O +
shown O +
to O +
correlate O +
with O +
an O +
increased O +
survival O +
of O +
glioblastoma O +
multiforme O +
patients B-Species -
. O +

However O -
, O +
such O +
effect O +
was O +
partly O +
prevented O +
by O +
treatment O +
of O +
cells O +
with O +
miR-21 O +
overexpression O +
before O -
, O +
which O +
appeared O +
to O +
downregulate O +
the O +
Bax O +
expression O -
, O +
upregulate O +
the O +
Bcl-2 O +
expression O +
and O +
decrease O +
caspase-3 O +
activity O -
. O +

Compared O +
to O +
control O +
cells O -
, O +
cells O +
treated O +
with O +
TMZ O +
showed O +
a O +
significant O +
increase O +
in O +
the O +
Bax O -
/ O -
Bcl-2 O +
ratio O +
and O +
caspase-3 O +
activity O +
( O -
P<0.01 O -
) O -
. O +

Taken O +
together O -
, O +
these O +
results O +
suggested O +
that O +
over O -
- O -
express O +
miR-21 O +
could O +
inhibit O +
TMZ O -
- O -
induced O +
apoptosis O +
in O +
U87MG O +
cells O -
, O +
at O +
least O +
in O +
part O -
, O +
by O +
decreasing O +
Bax O -
/ O -
Bcl-2 O +
ratio O +
and O +
caspase-3 O +
activity O -
, O +
which O +
highlighted O +
the O +
possibility O +
of O +
miR-21 O +
overexpression O +
in O +
the O +
clinical O +
resistance O +
to O +
chemotherapeutic O +
therapy O +
of O +
TMZ O -
. O +

Bcl-2 O -
, O +
resistance O +
to O +
induction O +
of O +
apoptosis O -
, O +
constitutes O +
one O +
major O +
obstacle O +
to O +
chemotherapy O +
in O +
many O +
cancer O +
cells O -
. O +

CONCLUSIONS O -
: O +
Our O +
results O +
indicate O +
that O +
altered O +
miRNAs O +
expression O +
is O +
involved O +
in O +
GH O -
- O -
secreting O +
pituitary O +
adenomas O +
transformation O -
, O +
which O +
will O +
shed O +
light O +
on O +
the O +
mechanisms O +
for O +
the O +
treatment O +
of O +
acromegaly O +
by O +
SSA O -
. O +

Identification O +
and O +
characterization O +
of O +
the O +
targets O +
of O +
altered O +
miRNAs O +
genes O +
may O +
elucidate O +
molecular O +
mechanisms O +
involved O +
in O +
the O +
pathogenesis O +
of O +
pituitary O +
adenoma O -
. O +

Several O +
identified O +
miRNAs O +
may O +
be O +
involved O +
in O +
cell O +
proliferation O -
, O +
apoptosis O -
, O +
cancer O +
development O +
and O +
progression O -
. O +

Seven O +
miRNAs O +
were O +
differentially O +
expressed O +
between O +
SSA O +
responders O +
or O +
GH O +
nonresponders O -
. O +

RESULTS O -
: O +
Fifty O -
- O -
two O +
miRNAs O +
were O +
differentially O +
expressed O +
between O +
GH O -
- O -
secreting O +
pituitary O +
adenomas O +
and O +
normal O +
pituitaries O -
. O +

We O +
analyzed O +
the O +
miRNAs O +
in O +
21 O +
GH O -
- O -
secreting O +
pituitary O +
adenomas O +
and O +
6 O +
normal O +
pituitaries O +
by O +
miRCURY O -
™ O +
LNA O +
array O +
and O +
some O +
differentially O +
expressed O +
miRNAs O +
were O +
validated O +
by O +
quantitative O +
real O -
- O -
time O +
PCR O -
. O +

Thirteen O +
miRNAs O +
were O +
differentially O +
expressed O +
between O +
tumor O +
samples O +
from O +
lanreotide O -
- O -
treated O +
patients B-Species +
and O +
those O +
from O +
lanreotide O -
- O -
untreated O +
patients B-Species -
. O +

Differential O +
expression O +
of O +
9 O +
miRNAs O +
was O +
observed O +
between O +
micro- O +
and O +
macro O -
- O -
adenomas O -
. O +

Differential O +
expression O +
of O +
microRNAs O +
in O +
GH O -
- O -
secreting O +
pituitary O +
adenomas O -
. O +

BACKGROUND O -
: O +
The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
( O -
1 O -
) O +
identify O +
specific O +
miRNAs O +
in O +
growth O +
hormones O +
( O -
GH O -
) O -
-secreting O +
pituitary O +
adenomas O -
; O +
( O -
2 O -
) O +
determine O +
the O +
relationship O +
between O +
the O +
expression O +
of O +
these O +
miRNAs O +
and O +
tumor O +
size O -
, O +
somatostatin O +
analogs O +
treatment O -
, O +
and O +
responsiveness O +
to O +
somatostatin O +
analogs O +
( O -
SSA O -
) O -
. O +

METHODS O -
: O +
Fifteen O +
GH O -
- O -
secreting O +
adenomas O +
patients B-Species +
were O +
treated O +
with O +
lanreotide O +
for O +
4 O +
months O +
before O +
surgery O -
. O +

Patients B-Species +
with O +
50 O -
% O +
reduction O +
of O +
GH O +
secretion O +
by O +
lanreotide O +
were O +
considered O +
as O +
SSA O +
responders O -
, O +
while O +
patients B-Species +
with O +
less O +
than O +
50 O -
% O +
of O +
GH O +
reduction O +
were O +
considered O +
as O +
SSA O +
nonresponders O -
. O +

Hypoxia O +
induces O +
microRNA O +
miR-210 O +
in O +
vitro O +
and O +
in O +
vivo O +
ephrin O -
- O -
A3 O +
and O +
neuronal O +
pentraxin O +
1 O +
are O +
potentially O +
regulated O +
by O +
miR-210 O -
. O +

Shortage O +
of O +
oxygen O +
is O +
one O +
of O +
the O +
prime O +
stress O +
conditions O +
in O +
tissues O -
. O +

In O +
this O +
study O -
, O +
we O +
looked O +
for O +
microRNAs O +
expressed O +
during O +
hypoxia O +
and O +
showed O +
that O +
miR-210 O +
expression O +
was O +
upregulated O +
in O +
response O +
to O +
hypoxia O +
in O +
vitro O +
and O +
in O +
vivo O -
. O +

An O +
active O +
form O +
of O +
the O +
HIF-1alpha O +
induced O +
the O +
expression O +
of O +
miR-210 O -
, O +
showing O +
the O +
involvement O +
of O +
the O +
HIF-1 O +
signaling O +
pathway O +
in O +
miR-210 O +
gene O +
transcription O -
. O +

Furthermore O -
, O +
miR-210 O +
was O +
shown O +
to O +
bind O +
to O +
the O +
predicted O +
target O +
sites O +
of O +
ephrin O -
- O -
A3 O +
or O +
neuronal O +
pentraxin O +
1 O -
, O +
causing O +
repression O +
in O +
luciferase O +
reporter O +
activity O -
. O +

Thus O -
, O +
the O +
regulatory O +
effects O +
of O +
miR-210 O +
on O +
its O +
targets O +
in O +
vivo O +
need O +
to O +
be O +
further O +
characterized O -
. O +

Contrary O +
to O +
the O +
microRNA O -
- O -
mediated O +
repression O +
hypothesis O -
, O +
ephrin O -
- O -
A3 O +
was O +
expressed O +
at O +
very O +
high O +
levels O +
in O +
post O -
- O -
ischemic O +
mouse B-Species +
hippocampus O +
in O +
vivo O -
. O +

We O +
recently O +
showed O +
in O +
HeLa O +
cells O +
that O +
two O +
components O +
of O +
the O +
SMN O +
complex O -
, O +
Gemin3 O +
and O +
Gemin4 O -
, O +
together O +
with O +
the O +
argonaute O +
protein O +
eIF2C2 O -
, O +
also O +
associate O +
with O +
microRNAs O +
( O -
miRNAs O -
) O +
as O +
part O +
of O +
a O +
novel O +
class O +
of O +
RNPs O +
termed O +
miRNPs O -
. O +

SMN O +
is O +
part O +
of O +
a O +
large O +
complex O +
that O +
functions O +
in O +
the O +
assembly O -
/ O -
restructuring O +
of O +
ribonucleoprotein O +
( O -
RNP O -
) O +
complexes O -
. O +

Spinal O +
muscular O +
atrophy O +
( O -
SMA O -
) O +
is O +
a O +
common O +
neurodegenerative O +
disease O +
that O +
is O +
caused O +
by O +
deletions O +
or O +
loss O -
- O -
of O -
- O -
function O +
mutations O +
in O +
the O +
Survival O +
of O +
Motor O +
Neuron O +
( O -
SMN O -
) O +
protein O -
. O +

Numerous O +
microRNPs O +
in O +
neuronal O +
cells O +
containing O +
novel O +
microRNAs O -
. O +

The O +
chromosomal O +
locations O +
of O +
most O +
of O +
the O +
novel O +
miRNAs O +
were O +
identified O +
and O +
indicate O +
some O +
phylogenetic O +
conservation O +
of O +
the O +
likely O +
precursor O +
structures O -
. O +

Interestingly O +
the O +
gene O +
locus O +
of O +
one O +
miRNA O -
, O +
miR-175 O -
, O +
is O +
a O +
candidate O +
region O +
for O +
two O +
neurologic O +
diseases O -
: O +
early O -
- O -
onset O +
parkinsonism O +
( O -
Waisman O +
syndrome O -
) O +
and O +
X O -
- O -
linked O +
mental O +
retardation O +
( O -
MRX3 O -
) O -
. O +

Here O +
we O +
report O +
on O +
miRNPs O +
isolated O +
from O +
neuronal O +
cell O +
lines O +
of O +
mouse B-Species +
and O +
human B-Species -
, O +
and O +
describe O +
53 O +
novel O +
miRNAs O -
. O +

Several O +
of O +
these O +
miRNAs O +
are O +
conserved O +
in O +
divergent O +
organisms O -
, O +
including O +
rat B-Species -
, O +
zebrafish B-Species -
, O +
pufferfish O -
, O +
and O +
the O +
nematode B-Species +
Caenorhabditis B-Species +
elegans I-Species -
. O +

Also O -
, O +
several O +
miRNAs O +
identified O +
as O +
part O +
of O +
miRNPs O +
in O +
these O +
cells O +
appear O +
to O +
constitute O +
two O +
distinct O +
subfamilies O -
. O +

These O +
subfamilies O +
comprise O +
multiple O +
copies O +
of O +
miRNAs O +
on O +
different O +
chromosomes O -
, O +
suggesting O +
an O +
important O +
function O +
in O +
the O +
regulation O +
of O +
gene O +
expression O -
. O +

Cells O +
stably O +
transfected O +
with O +
LAT O +
or O +
trigeminal O +
ganglionic O +
neurons O +
of O +
mice O +
infected O +
with O +
a O +
LAT O +
expressing O +
virus O +
appeared O +
to O +
express O +
the O +
L2 O +
or O +
L8 O +
ORF O -
. O +

Peptide O -
- O -
specific O +
immunoglobulin O +
G O +
( O -
IgG O -
) O +
was O +
generated O +
against O +
open O +
reading O +
frames O +
( O -
ORFs O -
) O +
that O +
are O +
located O +
within O +
the O +
first O +
1.5 O +
kb O +
of O +
LAT O +
coding O +
sequences O -
. O +

Only O +
L2 O +
ORF O +
expression O +
was O +
readily O +
detected O +
in O +
trigeminal O +
ganglionic O +
neurons O +
of O +
latently O +
infected O +
mice B-Species -
. O +

Expression O +
of O +
the O +
first O +
1.5 O +
kb O +
of O +
the O +
latency O -
- O -
associated O +
transcript O +
( O -
LAT O -
) O +
that O +
is O +
encoded O +
by O +
herpes O +
simplex O +
virus O +
type O +
1 O +
( O -
HSV-1 O -
) O +
is O +
sufficient O +
for O +
wild O -
- O -
type O +
( O -
wt O -
) O +
levels O +
of O +
reactivation O +
from O +
latency O +
in O +
small O +
animal O +
models O -
. O +

Identification O +
of O +
herpes O +
simplex O +
virus O +
type O +
1 O +
proteins O +
encoded O +
within O +
the O +
first O +
1.5 O +
kb O +
of O +
the O +
latency O -
- O -
associated O +
transcript O -
. O +

Here O +
we O +
show O +
that O +
human B-Species +
platelets O +
harbor O +
an O +
abundant O +
and O +
diverse O +
array O +
of O +
microRNAs O +
( O -
miRNAs O -
) O -
, O +
which O +
are O +
known O +
as O +
key O +
regulators O +
of O +
mRNA O +
translation O +
in O +
other O +
cell O +
types O -
. O +

Further O +
analyses O +
revealed O +
that O +
platelets O +
contain O +
the O +
Dicer O +
and O +
Argonaute O +
2 O +
( O -
Ago2 O -
) O +
complexes O -
, O +
which O +
function O +
in O +
the O +
processing O +
of O +
exogenous O +
miRNA O +
precursors O +
and O +
the O +
control O +
of O +
specific O +
reporter O +
transcripts O -
, O +
respectively O -
. O +

Detection O +
of O +
the O +
receptor O +
P2Y O -
( O -
12 O -
) O +
mRNA O +
in O +
Ago2 O +
immunoprecipitates O +
suggests O +
that O +
P2Y O -
( O -
12 O -
) O +
expression O +
may O +
be O +
subjected O +
to O +
miRNA O +
control O +
in O +
human B-Species +
platelets O -
. O +

Our O +
study O +
lends O +
an O +
additional O +
level O +
of O +
complexity O +
to O +
the O +
control O +
of O +
gene O +
expression O +
in O +
these O +
anucleate O +
elements O +
of O +
the O +
cardiovascular O +
system O -
. O +

Existence O +
of O +
a O +
microRNA O +
pathway O +
in O +
anucleate O +
platelets O -
. O +

Platelets O +
have O +
a O +
crucial O +
role O +
in O +
the O +
maintenance O +
of O +
hemostasis O +
as O +
well O +
as O +
in O +
thrombosis O +
and O +
vessel O +
occlusion O -
, O +
which O +
underlie O +
stroke O +
and O +
acute O +
coronary O +
syndromes O -
. O +

Anucleate O +
platelets O +
contain O +
mRNAs O +
and O +
are O +
capable O +
of O +
protein O +
synthesis O -
, O +
raising O +
the O +
issue O +
of O +
how O +
these O +
mRNAs O +
are O +
regulated O -
. O +

Mutations O +
in O +
the O +
Drosophila O +
gene O +
lethal O +
( O -
3 O -
) O +
malignant O +
brain O +
tumor O +
cause O +
malignant O +
growth O +
in O +
the O +
larval O +
brain O -
. O +

Here O +
we O +
show O +
that O +
l O -
( O -
3 O -
) O -
mbt O +
tumors O +
exhibited O +
a O +
soma O -
- O -
to O -
- O -
germline O +
transformation O +
through O +
the O +
ectopic O +
expression O +
of O +
genes O +
normally O +
required O +
for O +
germline O +
stemness O -
, O +
fitness O -
, O +
or O +
longevity O -
. O +

Orthologs O +
of O +
some O +
of O +
these O +
genes O +
were O +
also O +
expressed O +
in O +
human B-Species +
somatic O +
tumors O -
. O +

In O +
addition O -
, O +
inactivation O +
of O +
any O +
of O +
the O +
germline O +
genes O +
nanos O -
, O +
vasa O -
, O +
piwi O -
, O +
or O +
aubergine O +
suppressed O +
l O -
( O -
3 O -
) O -
mbt O +
malignant O +
growth O -
. O +

Ectopic O +
expression O +
of O +
germline O +
genes O +
drives O +
malignant O +
brain O +
tumor O +
growth O +
in O +
Drosophila O -
. O +

Model O +
organisms O +
such O +
as O +
the O +
fruit O +
fly O +
Drosophila B-Species +
melanogaster I-Species +
can O +
help O +
to O +
elucidate O +
the O +
molecular O +
basis O +
of O +
complex O +
diseases O +
such O +
as O +
cancer O -
. O +

Our O +
results O +
demonstrate O +
that O +
germline O +
traits O +
are O +
necessary O +
for O +
tumor O +
growth O +
in O +
this O +
Drosophila B-Species +
model O +
and O +
suggest O +
that O +
inactivation O +
of O +
germline O +
genes O +
might O +
have O +
tumor O -
- O -
suppressing O +
effects O +
in O +
other O +
species O -
. O +

TAKE O +
HOME O +
MESSAGE O -
: O +
Based O +
on O +
current O +
data O -
, O +
although O +
limited O -
, O +
the O +
mesenchymal O -
- O -
epithelial O +
transition O +
is O +
proposed O +
to O +
be O +
one O +
of O +
the O +
important O +
ways O +
for O +
MSCs O +
to O +
participate O +
tissue O +
repair O -
. O +

AREAS O +
COVERED O +
IN O +
THIS O +
REVIEW O -
: O +
This O +
review O +
focuses O +
on O +
recent O +
understanding O +
on O +
MSC O -
's O +
basic O +
biological O +
characteristics O +
and O +
the O +
mechanisms O +
underlying O +
the O +
therapeutic O +
effects O +
of O +
MSCs O +
in O +
vivo O -
. O +

IMPORTANCE O +
OF O +
THE O +
FIELD O -
: O +
The O +
pan O -
- O -
tissue O +
existence O +
and O +
multipotency O +
of O +
differentiation O +
make O +
mesenchymal O +
stem O +
cells O +
( O -
MSCs O -
) O +
an O +
attractive O +
source O +
of O +
cells O +
as O +
tissue O +
repair O +
cells O -
, O +
seeds O +
of O +
engineered O +
tissue O -
, O +
vehicles O +
for O +
gene O +
therapy O +
or O +
in O +
combination O +
to O +
promote O +
tissue O +
regeneration O +
in O +
wound O +
healing O +
and O +
disease O +
recovery O -
. O +

More O +
insight O +
into O +
mesenchymal O +
stem O +
cells O +
and O +
their O +
effects O +
inside O +
the O +
body O -
. O +

As O +
examples O -
, O +
a O +
detailed O +
description O +
is O +
given O +
on O +
the O +
regeneration O +
of O +
functional O +
sweat O +
glands O +
on O +
burned O +
skin O +
as O +
well O +
as O +
neural O +
cells O +
in O +
middle O +
cerebral O +
artery O +
occlusion O +
( O -
MCAO O -
) O +
animals O +
upon O +
MSC O +
transplantation O -
. O +

The O +
mechanisms O +
of O +
therapeutic O +
effects O +
of O +
MSCs O +
are O +
attributed O +
to O +
their O +
ability O +
to O +
migrate O +
along O +
chemokine O +
gradients O -
, O +
differentiate O +
into O +
tissue O -
- O -
specific O +
cells O -
, O +
enhance O +
angiogenesis O +
of O +
wound O +
tissue O +
and O +
regulate O +
immune O +
response O -
. O +

Special O +
attention O +
is O +
given O +
to O +
miRNA O +
expression O +
and O +
its O +
relationship O +
with O +
the O +
characteristics O +
of O +
MSCs O -
. O +

WHAT O +
THE O +
READER O +
WILL O +
GAIN O -
: O +
The O +
gene O +
expression O +
profiles O +
for O +
mRNA O -
, O +
protein O -
, O +
microRNA O +
and O +
cell O +
surface O +
marker O +
of O +
MSCs O +
are O +
summarized O -
. O +

We O +
also O +
identified O +
a O +
potential O +
feedback O +
loop O +
between O +
LKB1 O +
and O +
miR-451 O -
, O +
which O +
allows O +
a O +
sustained O +
and O +
robust O +
response O +
to O +
glucose O +
deprivation O -
. O +

We O +
then O +
found O +
that O +
by O +
targeting O +
the O +
LKB1 O +
kinase O +
complex O +
miR-451 O +
suppresses O +
the O +
activity O +
of O +
downstream O +
protein O +
kinases O +
including O +
the O +
major O +
energy O +
biosensor O +
AMPK O -
. O +

We O +
initially O +
identified O +
miR-451 O +
due O +
to O +
its O +
downregulation O +
in O +
a O +
glioma O +
cell O +
migration O +
assay O -
. O +

Under O +
conditions O +
of O +
glucose O +
withdrawal O -
, O +
miR-451 O +
downregulation O +
is O +
necessary O +
for O +
AMPK O +
pathway O +
activation O -
, O +
leading O +
to O +
suppressed O +
proliferation O +
rates O -
, O +
increased O +
cell O +
survival O +
and O +
migration O -
. O +

MiR-451 O +
levels O +
are O +
regulated O +
by O +
glucose O -
; O +
under O +
conditions O +
of O +
abundant O +
energy O +
miR-451 O +
expression O +
is O +
high O -
, O +
and O +
the O +
suppression O +
of O +
AMPK O +
signaling O +
allows O +
cells O +
to O +
maintain O +
elevated O +
proliferation O +
rates O +
via O +
unrestrained O +
mTOR O +
activation O -
. O +

Incomplete O +
knowledge O +
of O +
the O +
molecular O +
biology O -
, O +
genetics O -
, O +
causes O +
and O +
cellular O +
origin O +
of O +
these O +
tumors O +
may O +
limit O +
the O +
development O +
of O +
improved O +
therapeutics O -
. O +

Glioblastoma O -
, O +
the O +
most O +
common O +
and O +
aggressive O +
primary O +
brain O +
tumor O -
, O +
is O +
rapidly O +
growing O +
and O +
highly O +
infiltrative O -
. O +

Here O +
we O +
will O +
discuss O +
further O +
our O +
recently O +
published O +
data O +
on O +
the O +
role O +
of O +
miR-451 O +
in O +
the O +
biology O +
of O +
glioblastoma O -
. O +

A O +
major O +
and O +
fundamental O +
advance O +
in O +
recent O +
years O +
has O +
been O +
the O +
identification O +
of O +
microRNAs O +
as O +
highly O +
conserved O +
regulators O +
of O +
gene O +
expression O -
. O +

microRNA-451 O -
: O +
A O +
conditional O +
switch O +
controlling O +
glioma O +
cell O +
proliferation O +
and O +
migration O -
. O +

This O +
data O +
will O +
be O +
discussed O +
in O +
the O +
context O +
of O +
potential O +
biological O +
significance O +
and O +
therapeutic O +
implications O -
. O +

MicroRNA O +
expression O +
in O +
the O +
blood O +
and O +
brain O +
of O +
rats B-Species +
subjected O +
to O +
transient O +
focal O +
ischemia O +
by O +
middle O +
cerebral O +
artery O +
occlusion O -
. O +

BACKGROUND O +
AND O +
PURPOSE O -
: O +
Several O +
hundred O +
small O +
RNAs O +
called O +
microRNAs O +
( O -
miRNAs O -
) O +
have O +
been O +
identified O +
and O +
characterized O +
from O +
various O +
organisms O -
, O +
including O +
humans B-Species -
. O +

In O +
humans B-Species -
, O +
some O +
of O +
these O +
miRNAs O +
have O +
been O +
found O +
to O +
regulate O +
( O -
patho O -
) O -
physiologic O +
conditions O +
such O +
as O +
tumor O +
progression O -
/ O -
regression O -
, O +
cholesterol O +
and O +
glucose O +
homeostasis O -
, O +
etc O -
. O +

In O +
this O +
report O -
, O +
we O +
present O +
data O +
on O +
the O +
miRNAs O +
expressed O +
under O +
ischemic O +
conditions O +
in O +
both O +
the O +
brain O +
and O +
blood O +
of O +
rats B-Species +
subjected O +
to O +
middle O +
cerebral O +
artery O +
occlusion O +
( O -
MCAo O -
) O -
. O +

METHODS O -
: O +
Sprague O -
- O -
Dawley O +
rats B-Species +
subjected O +
to O +
MCAo O +
were O +
reperfused O +
for O +
either O +
24 O +
or O +
48 O +
hours O -
, O +
and O +
both O +
blood O +
and O +
brain O +
samples O +
were O +
harvested O -
. O +

miRNA O +
expression O +
profiling O +
and O +
oligonucleotide O +
microarray O +
were O +
carried O +
out O -
, O +
and O +
the O +
data O +
were O +
validated O +
by O +
quantitative O +
real O -
- O -
time O +
polymerase O +
chain O +
reaction O +
and O +
correlated O +
with O +
published O +
data O +
on O +
protein O +
and O +
gene O +
expression O +
in O +
MCAo O +
rats B-Species -
. O +

RESULTS O -
: O +
We O +
report O +
here O +
for O +
the O +
first O +
time O +
the O +
involvement O +
of O +
miRNA O +
regulation O +
in O +
brain O +
pathogenesis O +
associated O +
with O +
MCAo O -
. O +

Comparison O +
with O +
the O +
corresponding O +
DNA O +
microarray O +
data O +
revealed O +
that O +
the O +
target O +
mRNA O +
expression O +
is O +
correlated O +
with O +
the O +
regulation O +
of O +
miRNA O -
. O +

We O +
have O +
also O +
provided O +
evidence O +
that O +
some O +
of O +
the O +
miRNAs O +
that O +
are O +
highly O +
expressed O +
in O +
the O +
ischemic O +
brain O +
can O +
be O +
detected O +
in O +
blood O +
samples O -
. O +

CONCLUSIONS O -
: O +
Further O +
studies O +
are O +
needed O +
to O +
evaluate O +
the O +
possible O +
use O +
of O +
miRNAs O +
as O +
biomarkers O +
in O +
stroke O +
and O +
related O +
pathologies O -
. O +

An O +
association O +
study O +
of O +
rs9897526 O +
and O +
rs5848 O +
was O +
carried O +
out O +
in O +
an O +
Italian O +
population O +
and O +
in O +
a O +
replication O +
population O +
of O +
European O +
American O +
patients B-Species +
and O +
controls O -
. O +

The O +
influence O +
of O +
GRN O +
genetic O +
variability O +
on O +
susceptibility O +
to O +
AD O +
and O +
on O +
expression O +
levels O +
in O +
a O +
series O +
of O +
neuropathologically O -
- O -
confirmed O +
AD O +
patients B-Species +
as O +
well O +
as O +
in O +
peripheral O +
mononuclear O +
cells O +
( O -
PBMC O -
) O +
and O +
in O +
cells O +
isolated O +
from O +
cerebrospinal O +
fluid O +
( O -
CSF O -
) O +
was O +
investigated O -
. O +

Mutations O +
in O +
the O +
progranulin O +
gene O +
( O -
GRN O -
) O -
, O +
causative O +
for O +
Frontotemporal O +
Lobar O +
Degeneration O +
with O +
ubiquitin O -
- O -
immunoreactive O +
neuronal O +
inclusions O +
( O -
FTLD O -
- O -
U O -
) O -
, O +
could O +
also O +
be O +
associated O +
with O +
Alzheimer O -
's O +
disease O +
( O -
AD O -
) O -
. O +

Rs5848 O +
variant O +
influences O +
GRN O +
mRNA O +
levels O +
in O +
brain O +
and O +
peripheral O +
mononuclear O +
cells O +
in O +
patients B-Species +
with O +
Alzheimer O -
's O +
disease O -
. O +

Despite O +
no O +
significant O +
differences O +
were O +
found O +
in O +
the O +
relative O +
PBMC O +
and O +
CSF O +
GRN O +
expression O +
in O +
patients B-Species +
compared O +
to O +
controls O -
, O +
stratifying O +
patients B-Species +
according O +
to O +
the O +
presence O +
of O +
rs5848 O +
T O +
allele O -
, O +
a O +
0.57-fold O +
decrease O +
in O +
GRN O +
mRNA O +
levels O +
over O +
C O +
carriers O +
was O +
found O +
in O +
PBMC O +
( O -
1.22 O +
+ O -
/- O +
0.23 O +
versus O +
0.70 O +
+ O -
/- O +
0.12 O -
, O +
P O +
= O +
0.04 O -
) O -
. O +

Patients B-Species +
carrying O +
the O +
rs5848 O +
TT O +
genotype O +
had O +
the O +
lowest O +
GRN O +
expression O +
levels O +
( O -
0.96 O +
+ O -
/- O +
0.12 O -
, O +
P O +
= O +
0.014 O -
) O -
. O +

GRN O +
expression O +
in O +
the O +
parietal O +
lobe O +
of O +
AD O +
cases O +
showed O +
a O +
0.76-fold O +
decrease O +
compared O +
with O +
controls O +
( O -
1.31 O +
+ O -
/- O +
0.07 O +
versus O +
1.73 O +
+ O -
/- O +
0.12 O -
, O +
P O +
= O +
0.0025 O -
) O -
. O +

None O +
of O +
the O +
variants O +
tested O +
act O +
as O +
unequivocal O +
susceptibility O +
factor O +
in O +
both O +
populations O +
although O +
rs9897526 O +
anticipated O +
the O +
onset O +
of O +
the O +
disease O +
in O +
the O +
Italian O +
population O -
. O +

Similarly O +
to O +
data O +
obtained O +
in O +
brain O +
samples O -
, O +
patients O +
carrying O +
the O +
TT O +
genotype O +
showed O +
the O +
lowest O +
GRN O +
mRNA O +
levels O +
( O -
TT O +
= O +
0.46 O +
+ O -
/- O +
0.14 O -
, O +
CC O +
= O +
1.22 O +
+ O -
/- O +
0.23 O -
; O +
P O +
= O +
0.013 O -
) O -
. O +

These O +
data O +
argue O +
against O +
a O +
direct O +
role O +
of O +
GRN O +
as O +
a O +
susceptibility O +
factor O +
for O +
sporadic O +
AD O +
but O +
support O +
a O +
role O +
of O +
GRN O +
as O +
a O +
disease O -
- O -
modifying O +
gene O -
, O +
possibly O +
contributing O +
to O +
the O +
failure O +
of O +
neuronal O +
survival O -
. O +

Yet O -
, O +
genetic O +
testing O +
for O +
CADASIL O +
is O +
associated O +
with O +
a O +
nameable O +
proportion O +
of O +
false O -
- O -
negative O +
results O -
. O +

Thus O -
, O +
genetic O +
testing O +
should O +
initially O +
be O +
focused O +
on O +
these O +
exons O -
, O +
with O +
some O +
variation O +
depending O +
on O +
the O +
population O +
in O +
whom O +
it O +
is O +
being O +
performed O -
. O +

CONCLUSIONS O -
: O +
Almost O +
90 O -
% O +
of O +
mutations O +
could O +
be O +
detected O +
within O +
a O +
few O +
exons O +
( O -
exons O +
2 O -
- O -
6 O -
) O -
. O +

Cases O +
with O +
a O +
high O +
index O +
of O +
clinical O +
suspicion O +
should O +
be O +
investigated O +
by O +
skin O +
biopsy O +
if O +
genetic O +
testing O +
is O +
negative O -
. O +

Of O +
the O +
mutations O -
, O +
58.3 O -
% O +
were O +
located O +
in O +
exon O +
4 O +
and O +
85.8 O -
% O +
in O +
exons O +
2 O +
through O +
6 O -
. O +

In O +
5 O +
patients B-Species +
( O -
4.0 O -
% O -
) O -
, O +
no O +
mutation O +
was O +
identified O -
. O +

Results O +
were O +
compared O +
with O +
those O +
of O +
previously O +
published O +
studies O -
. O +

RESULTS O -
: O +
We O +
detected O +
54 O +
distinct O +
mutations O +
( O -
117 O +
missense O +
mutations O +
and O +
3 O +
in O -
- O -
frame O +
deletions O -
) O +
in O +
120 O +
( O -
96.0 O -
% O -
) O +
of O +
the O +
125 O +
patients B-Species -
. O +

BACKGROUND O -
: O +
Mutations O +
in O +
the O +
NOTCH3 O +
gene O +
are O +
the O +
cause O +
of O +
cerebral O +
autosomal O +
dominant O +
arteriopathy O +
with O +
subcortical O +
infarcts O +
and O +
leukoencephalopathy O +
( O -
CADASIL O -
) O -
, O +
which O +
is O +
an O +
important O +
cause O +
of O +
stroke O +
in O +
young O +
adults O -
. O +

Spectrum O +
of O +
mutations O +
in O +
biopsy O -
- O -
proven O +
CADASIL O -
: O +
implications O +
for O +
diagnostic O +
strategies O -
. O +

DESIGN O -
: O +
Screening O +
for O +
NOTCH3 O +
mutations O +
was O +
performed O +
in O +
125 O +
unrelated O +
German O +
CADASIL O +
patients B-Species +
with O +
biopsy O -
- O -
proven O +
disease O +
by O +
direct O +
sequencing O +
of O +
exons O +
coding O +
for O +
epidermal O +
growth O +
factor O -
- O -
like O +
repeats O -
. O +

OBJECTIVES O -
: O +
To O +
identify O +
the O +
spectrum O +
of O +
NOTCH3 O +
mutations O +
in O +
CADASIL O +
and O +
to O +
discuss O +
the O +
implications O +
for O +
diagnostic O +
strategies O -
. O +

Identification O +
of O +
the O +
mutation O +
is O +
critical O +
for O +
genetic O +
counseling O +
and O +
testing O +
of O +
relatives O +
at O +
risk O -
. O +

Mutations O +
are O +
typically O +
located O +
within O +
epidermal O +
growth O +
factor O -
- O -
like O +
repeat O +
domains O +
in O +
the O +
extracellular O +
part O +
of O +
the O +
Notch3 O +
receptor O -
. O +

Molecular O +
biology O -
. O +

miRNAs O +
in O +
neurodegeneration O -
. O +

HIV-1-infected B-Species +
opiate O +
abusers O +
often O +
exhibit O +
an O +
accelerated O +
form O +
of O +
HIV-1-associated B-Species +
dementia O +
and O +
enhanced O +
neurological O +
dysfunction O -
. O +

Morphine O +
treatment O +
of O +
human B-Species +
monocyte O -
- O -
derived O +
macrophages O +
induces O +
differential O +
miRNA O +
and O +
protein O +
expression O -
: O +
impact O +
on O +
inflammation O +
and O +
oxidative O +
stress O +
in O +
the O +
central O +
nervous O +
system O -
. O +

In O +
order O +
to O +
understand O +
the O +
role O +
of O +
morphine O +
in O +
this O +
process O -
, O +
we O +
performed O +
a O +
genome O -
- O -
wide O +
association O +
study O +
at O +
the O +
micro O +
RNA O +
( O -
miRNA O -
) O +
and O +
protein O +
levels O +
in O +
human B-Species +
monocyte O -
- O -
derived O +
macrophages O +
( O -
h O -
- O -
mdms O -
) O -
. O +

Productive O +
HIV-1 B-Species +
infection O +
of O +
microglia O +
and O +
perivascular O +
macrophages O +
and O +
the O +
resultant O +
secretion O +
of O +
neurotoxic O +
molecules O +
by O +
these O +
cells O +
contribute O +
to O +
this O +
phenomenon O -
. O +

Computational O +
analysis O +
predicted O +
fibroblast O +
growth O +
factor-2 O +
( O -
FGF-2 O -
) O +
as O +
the O +
strongest O +
target O +
gene O +
for O +
hsa O -
- O -
miR15b O -
. O +

A O +
total O +
of O +
26 O +
differentially O +
expressed O +
miRNA O +
were O +
identified O +
( O -
P O +
< O +
0.01 O -
) O -
, O +
of O +
which O +
hsa O -
- O -
miR-15b O +
and O +
hsa O -
- O -
miR-181b O +
had O +
the O +
greatest O +
increase O +
and O +
decrease O +
in O +
expression O +
levels O -
, O +
respectively O -
. O +

Both O +
hsa O -
- O -
miR-15b O +
and O +
hsa O -
- O -
miR-181b O +
have O +
several O +
predicted O +
gene O +
targets O +
involved O +
in O +
inflammation O +
and O +
T O -
- O -
cell O +
activation O +
pathways O -
. O +

Of O +
note O -
, O +
we O +
observed O +
a O +
decrease O +
in O +
FGF-2 O +
protein O +
expression O +
in O +
response O +
to O +
morphine O -
. O +

Moreover O -
, O +
proteomic O +
analysis O +
revealed O +
the O +
induction O +
of O +
mitochondrial O +
superoxide O +
dismutase O +
in O +
response O +
to O +
morphine O +
treatment O -
. O +

In O +
this O +
context O -
, O +
we O +
observed O +
induction O +
of O +
MCP-2 O +
and O +
IL-6 O +
by O +
morphine O -
. O +

Of O +
note O -
, O +
differentially O +
expressed O +
miRNAs O +
( O -
hsa O -
- O -
miR-15b O +
and O +
181-b O -
) O +
may O +
have O +
a O +
potential O +
role O +
in O +
regulating O +
these O +
processes O -
. O +

Collectively O -
, O +
these O +
observations O +
demonstrate O +
that O +
morphine O +
induces O +
inflammation O +
and O +
oxidative O +
stress O +
in O +
h O -
- O -
mdms O +
thereby O +
contributing O +
to O +
expansion O +
of O +
HIV-1 B-Species +
CNS O +
reservoir O +
expansion O +
and O +
disease O +
progression O -
. O +

HIV-1 B-Species +
infection O +
did O +
not O +
induce O +
mitochondrial O +
superoxide O +
dismutase O -
. O +

The O +
advent O +
of O +
next O -
- O -
generation O +
sequencing O +
technologies O +
promises O +
to O +
greatly O +
transform O +
our O +
understanding O +
of O +
medulloblastoma O +
pathogenesis O +
in O +
the O +
next O +
few O +
years O -
, O +
permitting O +
comprehensive O +
analyses O +
of O +
all O +
aspects O +
of O +
the O +
genome O +
and O +
increasing O +
the O +
likelihood O +
that O +
genomic O +
medicine O +
will O +
become O +
part O +
of O +
the O +
routine O +
diagnosis O +
and O +
treatment O +
of O +
medulloblastoma O -
. O +

The O +
application O +
of O +
high O -
- O -
resolution O +
microarray O +
platforms O +
to O +
the O +
study O +
of O +
medulloblastoma O +
has O +
revealed O +
new O +
oncogenes O +
and O +
tumor O +
suppressors O +
and O +
has O +
implicated O +
changes O +
in O +
DNA O +
copy O +
number O -
, O +
gene O +
expression O -
, O +
and O +
methylation O +
state O +
in O +
its O +
etiology O -
. O +

Additionally O -
, O +
the O +
integration O +
of O +
medulloblastoma O +
genomics O +
with O +
patient O +
clinical O +
data O +
has O +
confirmed O +
molecular O +
markers O +
of O +
prognostic O +
significance O +
and O +
highlighted O +
the O +
potential O +
utility O +
of O +
molecular O +
disease O +
stratification O -
. O +

Genomics O +
of O +
medulloblastoma O -
: O +
from O +
Giemsa O -
- O -
banding O +
to O +
next O -
- O -
generation O +
sequencing O +
in O +
20 O +
years O -
. O +

Advances O +
in O +
the O +
field O +
of O +
genomics O +
have O +
recently O +
enabled O +
the O +
unprecedented O +
characterization O +
of O +
the O +
cancer O +
genome O -
, O +
providing O +
novel O +
insight O +
into O +
the O +
molecular O +
mechanisms O +
underlying O +
malignancies O +
in O +
humans B-Species -
. O +

RESULTS O -
: O +
We O +
hypothesized O +
that O +
schizophrenia O +
might O +
be O +
associated O +
with O +
altered O +
miRNA O +
profiles O -
. O +

To O +
investigate O +
this O +
possibility O +
we O +
compared O +
the O +
expression O +
of O +
264 O +
human B-Species +
miRNAs O +
from O +
postmortem O +
prefrontal O +
cortex O +
tissue O +
of O +
individuals O +
with O +
schizophrenia O +
( O -
n O +
= O +
13 O -
) O +
or O +
schizoaffective O +
disorder O +
( O -
n O +
= O +
2 O -
) O +
to O +
tissue O +
of O +
21 O +
psychiatrically O +
unaffected O +
individuals O +
using O +
a O +
custom O +
miRNA O +
microarray O -
. O +

Allowing O +
a O +
5 O -
% O +
false O +
discovery O +
rate O -
, O +
we O +
found O +
that O +
16 O +
miRNAs O +
were O +
differentially O +
expressed O +
in O +
prefrontal O +
cortex O +
of O +
patient B-Species +
subjects O -
, O +
with O +
15 O +
expressed O +
at O +
lower O +
levels O +
( O -
fold O +
change O +
0.63 O +
to O +
0.89 O -
) O +
and O +
1 O +
at O +
a O +
higher O +
level O +
( O -
fold O +
change O +
1.77 O -
) O +
than O +
in O +
the O +
psychiatrically O +
unaffected O +
comparison O +
subjects O -
. O +

The O +
expression O +
levels O +
of O +
12 O +
selected O +
miRNAs O +
were O +
also O +
determined O +
by O +
quantitative O +
RT O -
- O -
PCR O +
in O +
our O +
lab O -
. O +

For O +
the O +
eight O +
miRNAs O +
distinguished O +
by O +
being O +
expressed O +
at O +
lower O +
microarray O +
levels O +
in O +
schizophrenia O +
samples O +
versus O +
comparison O +
samples O -
, O +
seven O +
were O +
also O +
expressed O +
at O +
lower O +
levels O +
with O +
quantitative O +
RT O -
- O -
PCR O -
. O +

CONCLUSION O -
: O +
This O +
study O +
is O +
the O +
first O +
to O +
find O +
altered O +
miRNA O +
profiles O +
in O +
postmortem O +
prefrontal O +
cortex O +
from O +
schizophrenia O +
patients B-Species -
. O +

microRNA O +
expression O +
in O +
the O +
prefrontal O +
cortex O +
of O +
individuals O +
with O +
schizophrenia O +
and O +
schizoaffective O +
disorder O -
. O +

BACKGROUND O -
: O +
microRNAs O +
( O -
miRNAs O -
) O +
are O +
small O -
, O +
noncoding O +
RNA O +
molecules O +
that O +
are O +
now O +
thought O +
to O +
regulate O +
the O +
expression O +
of O +
many O +
mRNAs O -
. O +

They O +
have O +
been O +
implicated O +
in O +
the O +
etiology O +
of O +
a O +
variety O +
of O +
complex O +
diseases O -
, O +
including O +
Tourette O -
's O +
syndrome O -
, O +
Fragile O +
x O +
syndrome O -
, O +
and O +
several O +
types O +
of O +
cancer O -
. O +

Here O -
, O +
we O +
report O +
an O +
elegant O +
mechanism O +
of O +
Tau O +
degradation O +
involving O +
the O +
cochaperone O +
BAG2 O -
. O +

The O +
BAG2 O -
/ O -
Hsp70 O +
complex O +
is O +
tethered O +
to O +
the O +
microtubule O +
and O +
this O +
complex O +
can O +
capture O +
and O +
deliver O +
Tau O +
to O +
the O +
proteasome O +
for O +
ubiquitin O -
- O -
independent O +
degradation O -
. O +

The O +
components O +
of O +
a O +
Tau O +
protein O +
triage O +
system O +
consisting O +
of O +
CHIP O -
/ O -
Hsp70 O +
and O +
other O +
chaperones O +
have O +
begun O +
to O +
emerge O -
. O +

However O -
, O +
the O +
site O +
of O +
triage O +
and O +
the O +
master O +
regulatory O +
elements O +
are O +
unknown O -
. O +

Tau O +
inclusions O +
are O +
a O +
prominent O +
feature O +
of O +
many O +
neurodegenerative O +
diseases O +
including O +
Alzheimer O -
's O +
disease O -
. O +

Their O +
accumulation O +
in O +
neurons O +
as O +
ubiquitinated O +
filaments O +
suggests O +
a O +
failure O +
in O +
the O +
degradation O +
limb O +
of O +
the O +
Tau O +
pathway O -
. O +

The O +
cochaperone O +
BAG2 O +
sweeps O +
paired O +
helical O +
filament- O +
insoluble O +
tau O +
from O +
the O +
microtubule O -
. O +

Thus O -
, O +
we O +
propose O +
that O +
ubiquitinated O +
Tau O +
inclusions O +
arise O +
due O +
to O +
shunting O +
of O +
Tau O +
degradation O +
toward O +
a O +
less O +
efficient O +
ubiquitin O -
- O -
dependent O +
pathway O -
. O +

This O +
complex O +
preferentially O +
degrades O +
Sarkosyl O +
insoluble O +
Tau O +
and O +
phosphorylated O +
Tau O -
. O +

BAG2 O +
levels O +
in O +
cells O +
are O +
under O +
the O +
physiological O +
control O +
of O +
the O +
microRNA O +
miR-128a O -
, O +
which O +
can O +
tune O +
paired O +
helical O +
filament O +
Tau O +
levels O +
in O +
neurons O -
. O +

We O +
explored O +
to O +
what O +
extent O +
abnormalities O +
of O +
echogenicity O +
of O +
the O +
periventricular O +
crossroads O +
correlate O +
with O +
changes O +
in O +
size O +
of O +
the O +
corpus O +
callosum O -
. O +

These O +
lesions O +
damage O +
the O +
periventricular O +
crossroads O +
of O +
commissural O -
, O +
projection O +
and O +
associative O +
pathways O -
, O +
which O +
are O +
in O +
a O +
close O +
topographical O +
relationship O +
with O +
the O +
lateral O +
ventricles O -
. O +

Periventricular O +
areas O -
, O +
which O +
topographically O +
correspond O +
to O +
the O +
frontal O -
, O +
main O +
and O +
occipital O +
crossroad O -
, O +
were O +
readily O +
visualized O +
by O +
cranial O +
ultrasound O +
scans O -
, O +
performed O +
during O +
the O +
first O +
two O +
weeks O +
after O +
birth O -
. O +

Our O +
study O +
included O +
nine O +
infants O +
( O -
gestation O +
from O +
26 O -
- O -
41 O +
weeks O -
; O +
birth O +
weight O +
between O +
938 O -
- O -
4450 O +
grams O -
) O +
with O +
perinatal O +
brain O +
injury O -
. O +

We O +
found O +
a O +
statistically O +
significant O +
correlation O +
between O +
the O +
increased O +
echogenicity O +
in O +
the O +
crossroad O +
areas O +
and O +
the O +
decrease O +
of O +
the O +
corpus O +
callosum O +
midsagittal O +
area O +
( O -
p O +
< O +
0.05 O -
) O -
. O +

Corpus O +
callosum O +
mediosagittal O +
area O +
measurements O +
were O +
performed O +
using O +
magnetic O +
resonance O +
images O -
, O +
acquired O +
between O +
the O +
first O +
and O +
sixth O +
postnatal O +
month O +
( O -
postmenstrual O +
age O +
40 O -
- O -
49 O +
weeks O -
) O -
. O +

This O +
supports O +
the O +
hypothesis O +
that O +
callosal O +
fibers O +
can O +
be O +
damaged O -
, O +
during O +
growth O +
through O +
the O +
periventricular O +
crossroads O +
of O +
pathways O -
. O +

Changes O +
of O +
the O +
corpus O +
callosum O +
in O +
children B-Species +
who O +
suffered O +
perinatal O +
injury O +
of O +
the O +
periventricular O +
crossroads O +
of O +
pathways O -
. O +

There O +
is O +
a O +
high O +
incidence O +
of O +
periventricular O +
leukomalacia O -
, O +
caused O +
by O +
hypoxia O -
- O -
ischemia O -
, O +
in O +
preterm O +
infants O -
. O +

miR-15a O +
and O +
miR-16 O -
- O -
1 O +
down O -
- O -
regulation O +
in O +
pituitary O +
adenomas O -
. O +

We O +
found O +
that O +
miR-15a O +
and O +
miR-16 O -
- O -
1 O +
are O +
expressed O +
at O +
lower O +
levels O +
in O +
pituitary O +
adenomas O +
as O +
compared O +
to O +
normal O +
pituitary O +
tissue O -
. O +

We O +
explored O +
miR-15a O +
and O +
miR-16 O -
- O -
1 O +
expression O +
in O +
10 O +
GH O -
- O -
secreting O +
and O +
in O +
10 O +
PRL O -
- O -
secreting O +
pituitary O +
macroadenomas O +
by O +
Northern O +
blot O -
, O +
and O +
investigated O +
the O +
possible O +
correlation O +
with O +
in O +
vivo O +
and O +
in O +
vitro O +
characteristics O -
. O +

Therefore O -
, O +
miR15 O +
and O +
miR16 O +
down O -
- O -
regulation O +
in O +
pituitary O +
adenomas O +
correlates O +
with O +
a O +
greater O +
tumor O +
diameter O +
and O +
a O +
lower O +
p43 O +
secretion O -
, O +
suggesting O +
that O +
these O +
genes O +
may O -
, O +
at O +
least O +
in O +
part O -
, O +
influence O +
tumor O +
growth O -
. O +

Moreover O -
, O +
their O +
expression O +
inversely O +
correlates O +
with O +
tumor O +
diameter O +
and O +
with O +
RARS O +
expression O +
( O -
P O +
< O +
0.05 O -
) O -
, O +
but O +
directly O +
correlates O +
with O +
p43 O +
secretion O +
( O -
P O +
< O +
0.02 O -
) O -
. O +

miR-15a O +
and O +
miR-16 O -
- O -
1 O +
genes O +
are O +
located O +
at O +
chromosome O +
13q14 O -
, O +
a O +
region O +
which O +
is O +
frequently O +
deleted O +
in O +
pituitary O +
tumors O -
. O +

Micro O +
RNAs O +
( O -
miRs O -
) O +
are O +
small O +
noncoding O +
RNAs O -
, O +
functioning O +
as O +
antisense O +
regulators O +
of O +
other O +
RNAs O -
. O +

When O +
secreted O -
, O +
p43 O +
regulates O +
local O +
inflammatory O +
response O +
and O +
macrophage O +
chemotaxis O -
, O +
and O +
seems O +
to O +
have O +
anti O -
- O -
neoplastic O +
properties O +
in O +
mice B-Species -
. O +

An O +
inverse O +
correlation O +
has O +
been O +
shown O +
in O +
B O +
cell O +
chronic O +
lymphocytic O +
leukemia O +
( O -
B O -
- O -
CLL O -
) O +
between O +
miR-15a O +
and O +
miR-16 O -
- O -
1 O +
expression O +
and O +
the O +
expression O +
levels O +
of O +
arginyl O -
- O -
tRNA O +
synthetase O +
( O -
RARS O -
) O -
, O +
an O +
enzyme O +
which O +
associates O +
with O +
the O +
cofactor O +
p43 O +
in O +
the O +
aminoacyl O -
- O -
tRNA O +
synthetase O +
complex O -
. O +

These O +
results O +
confirm O +
those O +
of O +
other O +
studies O +
with O +
animals O +
and O +
humans B-Species +
using O +
novel O +
imaging O +
techniques O -
, O +
suggesting O +
that O +
the O +
motor O +
homunculus O +
may O +
not O +
always O +
be O +
considered O +
a O +
definite O +
and O +
absolute O +
representation O +
of O +
M1 O -
. O +

The O +
results O +
of O +
this O +
study O +
challenge O +
the O +
notion O +
of O +
orderly O +
topographic O +
relationships O +
between O +
the O +
human B-Species +
sensorimotor O +
functions O +
and O +
their O +
representation O +
in O +
the O +
primary O +
motor O +
cortex O -
. O +

Electrode O +
position O +
was O +
represented O +
graphically O +
whenever O +
a O +
stimulus O +
was O +
delivered O -
. O +

A O +
total O +
of O +
43 O +
maps O +
from O +
36 O +
patients B-Species +
were O +
analyzed O -
. O +

The O +
authors O +
found O +
variations O +
in O +
the O +
organization O +
of O +
M1 O +
( O -
primary O +
motor O +
cortex O -
) O +
in O +
seven O +
patients B-Species +
( O -
19.4 O -
% O -
) O -
. O +

Four O +
patients B-Species +
( O -
11.1 O -
% O -
) O +
presented O +
mosaicism O +
( O -
overlapping O +
of O +
functional O +
areas O -
) O -
, O +
two O +
( O -
5.6 O -
% O -
) O +
presented O +
variability O +
( O -
inverted O +
disposition O +
of O +
M1 O +
functional O +
areas O -
) O -
, O +
and O +
one O +
( O -
2.8 O -
% O -
) O +
had O +
both O -
. O +

Functional O +
variability O +
of O +
the O +
human B-Species +
cortical O +
motor O +
map O -
: O +
electrical O +
stimulation O +
findings O +
in O +
perirolandic O +
epilepsy O +
surgery O -
. O +

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
assess O +
the O +
cortical O +
representation O +
of O +
sensorimotor O +
functions O +
in O +
patients B-Species +
undergoing O +
perirolandic O +
epilepsy O +
surgery O -
, O +
focusing O +
on O +
somatotopy O -
, O +
mosaicism O -
, O +
and O +
variability O +
of O +
function O +
in O +
relation O +
to O +
the O +
classic O +
motor O +
homunculus O -
. O +

The O +
authors O +
studied O +
36 O +
patients B-Species +
in O +
whom O +
intraoperative O +
or O +
extraoperative O +
electrical O +
cortical O +
stimulation O +
to O +
map O +
motor O +
functions O +
was O +
performed O -
. O +

A O +
computer O +
program O +
was O +
devised O +
to O +
register O +
electrode O +
number O -
, O +
stimulation O +
parameters O -
, O +
and O +
response O +
to O +
each O +
stimulus O -
. O +

Finally O -
, O +
we O +
will O +
discuss O +
fundamental O +
issues O +
to O +
be O +
considered O +
in O +
study O +
design O +
when O +
targeting O +
the O +
epigenome O -
. O +

Pharmacology O +
of O +
epigenetics O +
in O +
brain O +
disorders O -
. O +

Epigenetics O +
is O +
a O +
rapidly O +
growing O +
field O +
and O +
holds O +
great O +
promise O +
for O +
a O +
range O +
of O +
human B-Species +
diseases O -
, O +
including O +
brain O +
disorders O +
such O +
as O +
Rett O +
syndrome O -
, O +
anxiety O +
and O +
depressive O +
disorders O -
, O +
schizophrenia O -
, O +
Alzheimer O +
disease O +
and O +
Huntington O +
disease O -
. O +

This O +
review O +
is O +
concerned O +
with O +
the O +
pharmacology O +
of O +
epigenetics O +
to O +
treat O +
disorders O +
of O +
the O +
epigenome O +
whether O +
induced O +
developmentally O +
or O +
manifested O -
/ O -
acquired O +
later O +
in O +
life O -
. O +

In O +
particular O -
, O +
we O +
will O +
focus O +
on O +
brain O +
disorders O +
and O +
their O +
treatment O +
by O +
drugs O +
that O +
modify O +
the O +
epigenome O -
. O +

While O +
the O +
use O +
of O +
DNA O +
methyl O +
transferase O +
inhibitors O +
and O +
histone O +
deacetylase O +
inhibitors O +
in O +
in O +
vitro O +
and O +
in O +
vivo O +
models O +
have O +
demonstrated O +
improvements O +
in O +
disease O -
- O -
related O +
deficits O -
, O +
clinical O +
trials O +
in O +
humans B-Species +
have O +
been O +
less O +
promising O -
. O +

We O +
will O +
address O +
recent O +
advances O +
in O +
our O +
understanding O +
of O +
the O +
complexity O +
of O +
the O +
epigenome O +
with O +
its O +
many O +
molecular O +
players O -
, O +
and O +
discuss O +
evidence O +
for O +
a O +
compromised O +
epigenome O +
in O +
the O +
context O +
of O +
an O +
ageing O +
or O +
diseased O +
brain O -
. O +

We O +
will O +
also O +
draw O +
on O +
examples O +
of O +
species O +
differences O +
that O +
may O +
exist O +
between O +
humans B-Species +
and O +
model O +
systems O -
, O +
emphasizing O +
the O +
need O +
for O +
more O +
robust O +
pre O -
- O -
clinical O +
testing O -
. O +

The O +
authors O +
review O +
the O +
literature O +
on O +
the O +
role O +
of O +
miRNAs O +
in O +
the O +
formation O +
and O +
propagation O +
of O +
gliomas O +
and O +
medulloblastomas O -
, O +
highlighting O +
the O +
potential O +
of O +
these O +
molecules O +
and O +
their O +
inhibitors O +
as O +
therapeutics O -
. O +

In O +
addition O +
to O +
the O +
established O +
role O +
of O +
miRNAs O +
as O +
developmental O +
regulators O +
of O +
normal O +
cellular O +
function O -
, O +
they O +
have O +
recently O +
been O +
shown O +
to O +
be O +
important O +
players O +
in O +
pathological O +
states O +
such O +
as O +
cancer O -
. O +

The O +
many O +
roles O +
of O +
microRNAs O +
in O +
brain O +
tumor O +
biology O -
. O +

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
now O +
recognized O +
as O +
the O +
primary O +
RNAs O +
involved O +
in O +
the O +
purposeful O +
silencing O +
of O +
the O +
cell O -
's O +
own O +
message O -
. O +

This O +
review O +
discusses O +
potential O +
RNAi O -
- O -
based O +
targets O +
that O +
are O +
of O +
interest O +
for O +
epilepsy O +
therapy O -
, O +
including O +
adenosine O +
kinase O +
( O -
ADK O -
) O -
, O +
the O +
key O +
negative O +
regulator O +
of O +
the O +
brain O -
's O +
endogenous O +
anticonvulsant O +
adenosine O -
. O +

Therapeutic O +
RNAi O +
has O +
been O +
widely O +
explored O +
for O +
dominant O +
targets O +
involved O +
in O +
neurodegenerative O +
diseases O -
; O +
however O -
, O +
their O +
use O +
for O +
epilepsy O +
therapy O +
has O +
received O +
less O +
attention O -
. O +

Therefore O -
, O +
RNAi O -
- O -
strategies O +
aimed O +
at O +
reducing O +
ADK O +
( O -
and O +
increasing O +
adenosine O -
) O +
are O +
based O +
on O +
a O +
direct O +
neurochemical O +
rationale O +
that O +
has O +
recently O +
been O +
explored O +
experimentally O +
using O +
ex O +
vivo O +
and O +
in O +
vivo O +
gene O +
therapy O +
approaches O -
. O +

Overexpression O +
of O +
ADK O -
, O +
and O +
the O +
resulting O +
adenosine O +
deficiency O -
, O +
are O +
pathologic O +
hallmarks O +
of O +
the O +
sclerotic O +
epileptic O +
brain O -
, O +
and O +
have O +
been O +
implicated O +
in O +
seizure O +
generation O -
. O +

Inhibitory O +
RNA O +
in O +
epilepsy O -
: O +
research O +
tools O +
and O +
therapeutic O +
perspectives O -
. O +

In O +
contrast O +
to O +
conventional O +
antiepileptic O +
drugs O +
( O -
AEDs O -
) O +
that O +
target O +
specific O +
proteins O +
such O +
as O +
ion O +
channels O +
or O +
receptors O -
, O +
RNAi O -
- O -
based O +
therapeutics O +
exploit O +
an O +
endogenous O +
regulatory O +
mechanism O +
of O +
gene O +
expression O +
and O +
thereby O +
are O +
poised O +
to O +
prevent O +
or O +
reverse O +
pathogenetic O +
mechanisms O +
involved O +
in O +
seizure O +
development O -
. O +

Since O +
its O +
discovery O +
a O +
decade O +
ago O -
, O +
RNA O +
interference O +
( O -
RNAi O -
) O +
has O +
been O +
developed O +
not O +
only O +
into O +
powerful O +
experimental O +
tools O +
but O +
also O +
into O +
promising O +
novel O +
therapeutics O -
. O +

Technical O +
issues O +
and O +
challenges O +
remain O +
before O +
those O +
promising O +
tools O +
can O +
be O +
developed O +
into O +
future O +
therapeutics O +
for O +
epilepsy O -
. O +

Micro O +
RNAs O +
( O -
miRNAs O -
) O +
are O +
post O -
- O -
transcriptional O +
modulators O +
of O +
gene O +
expression O +
that O +
regulate O +
the O +
stability O +
and O +
translation O +
of O +
their O +
target O +
messenger O +
RNAs O +
( O -
mRNAs O -
) O -
. O +

Micro O +
RNA-125b O +
( O -
miRNA-125b O -
) O +
function O +
in O +
astrogliosis O +
and O +
glial O +
cell O +
proliferation O -
. O +

In O +
vitro O -
, O +
anti O -
- O -
miRNA-125b O +
added O +
exogenously O +
to O +
IL-6-stressed O +
NHA O +
cultures O +
attenuated O +
both O +
glial O +
cell O +
proliferation O +
and O +
increased O +
the O +
expression O +
of O +
the O +
cyclin O -
- O -
dependent O +
kinase O +
inhibitor O +
2A O +
( O -
CDKN2A O -
) O -
, O +
a O +
miRNA-125b O +
target O +
and O +
negative O +
regulator O +
of O +
cell O +
growth O -
. O +

Here O +
we O +
report O +
that O +
the O +
levels O +
of O +
a O +
human B-Species +
brain O -
- O -
enriched O +
miRNA-125b O +
are O +
up O -
- O -
regulated O +
in O +
interleukin-6 O +
( O -
IL-6 O -
) O -
-stressed O +
normal O +
human B-Species +
astrocytes O +
( O -
NHA O -
) O -
, O +
a O +
treatment O +
known O +
to O +
induce O +
astrogliosis O -
. O +

The O +
results O +
suggest O +
that O +
miRNA-125b O +
up O -
- O -
regulation O +
contributes O +
to O +
astrogliosis O +
and O +
to O +
defects O +
in O +
the O +
cell O +
cycle O +
that O +
are O +
characteristic O +
of O +
degenerating O +
brain O +
tissues O -
. O +

A O +
strong O +
positive O +
correlation O +
between O +
miRNA-125b O +
abundance O +
and O +
the O +
glial O +
cell O +
markers O +
glial O +
fibrillary O +
acidic O +
protein O +
( O -
GFAP O -
) O +
and O +
vimentin O -
, O +
and O +
CDKN2A O +
down O -
- O -
regulation O +
was O +
noted O +
in O +
advanced O +
Alzheimer O -
's O +
disease O +
( O -
AD O -
) O +
and O +
in O +
Down O -
's O +
syndrome O +
( O -
DS O -
) O +
brain O -
, O +
chronic O +
neurological O +
disorders O +
associated O +
with O +
astrogliosis O -
. O +

Recently O -
, O +
it O +
was O +
demonstrated O +
that O +
podoplanin O +
membrane O +
sialo O -
- O -
glycoprotein O +
encoded O +
by O +
PDPN O +
gene O +
is O +
over O -
- O -
expressed O +
and O +
related O +
to O +
cellular O +
invasion O +
in O +
astrocytic O +
tumors O -
; O +
however O +
the O +
mechanisms O +
of O +
regulation O +
are O +
still O +
unknown O -
. O +

Glioblastoma O +
is O +
the O +
most O +
frequent O +
and O +
malignant O +
brain O +
tumor O -
, O +
characterized O +
by O +
an O +
elevated O +
capacity O +
for O +
cellular O +
proliferation O +
and O +
invasion O -
. O +

miR-29b O +
and O +
miR-125a O +
regulate O +
podoplanin O +
and O +
suppress O +
invasion O +
in O +
glioblastoma O -
. O +

Taken O +
together O -
, O +
these O +
results O +
suggest O +
that O +
miR-29b O +
and O +
miR-125a O +
represent O +
potential O +
therapeutic O +
targets O +
in O +
glioblastoma O -
. O +

In O +
this O +
study O -
, O +
we O +
focused O +
on O +
miR-29b O +
and O +
miR-125a O -
, O +
which O +
were O +
predicted O +
to O +
regulate O +
PDPN O -
, O +
and O +
demonstrated O +
that O +
these O +
microRNAs O +
directly O +
target O +
the O +
3 O -
' O +
untranslated O +
region O +
of O +
PDPN O +
and O +
inhibit O +
invasion O -
, O +
apoptosis O -
, O +
and O +
proliferation O +
of O +
glioblastomas O -
. O +

Furthermore O -
, O +
we O +
report O +
that O +
miR-29b O +
and O +
miR-125a O +
are O +
downregulated O +
in O +
glioblastomas O +
and O +
also O +
in O +
CD133-positive O +
cells O -
. O +

MicroRNAs O +
are O +
noncoding O +
RNAs O +
that O +
regulate O +
gene O +
expression O +
and O +
several O +
biological O +
processes O +
and O +
diseases O -
, O +
including O +
cancer O -
. O +

Nevertheless O -
, O +
their O +
roles O +
in O +
invasion O -
, O +
proliferation O -
, O +
and O +
apoptosis O +
of O +
glioblastoma O +
are O +
not O +
completely O +
understood O -
. O +

MicroRNAs O +
and O +
apoptosis O -
: O +
implications O +
in O +
the O +
molecular O +
therapy O +
of O +
human B-Species +
disease O -
. O +

1 O -
. O +
MicroRNAs O +
( O -
miRNAs O -
) O -
, O +
the O +
small O +
non O -
- O -
coding O +
RNAs O +
of O +
approximately O +
22 O +
nucleotides O -
, O +
are O +
now O +
recognized O +
as O +
a O +
very O +
large O +
family O +
present O +
throughout O +
the O +
genomes O +
of O +
plants O +
and O +
metazoans O -
. O +

These O +
small O +
transcripts O +
modulate O +
protein O +
expression O +
by O +
binding O +
to O +
complementary O +
or O +
partially O +
complementary O +
target O +
protein O -
- O -
coding O +
mRNAs O +
and O +
targeting O +
them O +
for O +
degradation O +
or O +
translational O +
inhibition O -
. O +

2 O -
. O +
The O +
discovery O +
of O +
miRNAs O +
has O +
revolutionized O +
our O +
understanding O +
of O +
the O +
mechanisms O +
that O +
regulate O +
gene O +
expression O -
, O +
with O +
the O +
addition O +
of O +
an O +
entirely O +
novel O +
level O +
of O +
regulatory O +
control O -
. O +

3 O -
. O +
One O +
of O +
the O +
most O +
active O +
fields O +
of O +
miRNA O +
research O +
is O +
miRNA O +
regulation O +
of O +
apoptosis O -
, O +
a O +
programmed O +
cell O +
death O +
implicated O +
in O +
many O +
human B-Species +
diseases O -
, O +
such O +
as O +
cancer O -
, O +
Alzheimer O -
's O +
disease O -
, O +
hypertrophy O +
and O +
heart O +
failure O -
. O +

Indeed O -
, O +
aberrant O +
miRNA O +
expression O +
has O +
been O +
documented O +
in O +
human B-Species +
disease O +
as O +
well O +
as O +
in O +
animal O +
models O -
, O +
with O +
evidence O +
for O +
a O +
causative O +
role O +
in O +
tumourigenesis O -
. O +

We O +
now O +
know O +
that O +
miRNAs O +
play O +
pivotal O +
roles O +
in O +
diverse O +
processes O -
, O +
such O +
as O +
development O +
and O +
differentiation O -
, O +
control O +
of O +
cell O +
proliferation O +
and O +
death O -
, O +
stress O +
response O +
and O +
metabolism O -
. O +

Considerable O +
information O +
on O +
miRNAs O +
has O +
been O +
accumulated O +
in O +
this O +
rapidly O +
evolving O +
research O +
field O -
. O +

4 O -
. O +
The O +
present O +
review O +
provides O +
a O +
comprehensive O +
summary O +
and O +
analysis O +
of O +
the O +
currently O +
available O +
data O -
, O +
focusing O +
on O +
the O +
transcriptional O +
controls O -
, O +
target O +
genes O +
and O +
signalling O +
pathways O +
linking O +
the O +
apoptosis O -
- O -
regulating O +
miRNAs O +
and O +
apoptotic O +
cell O +
death O -
. O +

Thus O +
far O -
, O +
nearly O +
30 O +
of O +
500 O +
human B-Species +
miRNAs O +
have O +
been O +
validated O +
experimentally O +
to O +
regulate O +
apoptosis O -
; O +
this O +
number O +
is O +
likely O +
to O +
increase O +
with O +
future O +
studies O -
. O +

We O +
also O +
found O +
that O +
miR-326 O +
promoted O +
T O -
( O -
H O -
) O -
-17 O +
differentiation O +
by O +
targeting O +
Ets-1 O -
, O +
a O +
negative O +
regulator O +
of O +
T O -
( O -
H O -
) O -
-17 O +
differentiation O -
. O +

Our O +
data O +
show O +
a O +
critical O +
role O +
for O +
microRNA O +
in O +
T O -
( O -
H O -
) O -
-17 O +
differentiation O +
and O +
the O +
pathogenesis O +
of O +
multiple O +
sclerosis O -
. O +

Interleukin O +
17 O +
( O -
IL-17 O -
) O -
-producing O +
T O +
helper O +
cells O +
( O -
T O -
( O -
H O -
) O -
-17 O +
cells O -
) O +
are O +
increasingly O +
recognized O +
as O +
key O +
participants O +
in O +
various O +
autoimmune O +
diseases O -
, O +
including O +
multiple O +
sclerosis O -
. O +

Although O +
sets O +
of O +
transcription O +
factors O +
and O +
cytokines O +
are O +
known O +
to O +
regulate O +
T O -
( O -
H O -
) O -
-17 O +
differentiation O -
, O +
the O +
role O +
of O +
noncoding O +
RNA O +
is O +
poorly O +
understood O -
. O +

Here O +
we O +
identify O +
a O +
T O -
( O -
H O -
) O -
-17 O +
cell O -
- O -
associated O +
microRNA O -
, O +
miR-326 O -
, O +
whose O +
expression O +
was O +
highly O +
correlated O +
with O +
disease O +
severity O +
in O +
patients B-Species +
with O +
multiple O +
sclerosis O +
and O +
mice B-Species +
with O +
experimental O +
autoimmune O +
encephalomyelitis O +
( O -
EAE O -
) O -
. O +

In O +
vivo O +
silencing O +
of O +
miR-326 O +
resulted O +
in O +
fewer O +
T O -
( O -
H O -
) O -
-17 O +
cells O +
and O +
mild O +
EAE O -
, O +
and O +
its O +
overexpression O +
led O +
to O +
more O +
T O -
( O -
H O -
) O -
-17 O +
cells O +
and O +
severe O +
EAE O -
. O +

MicroRNA O +
miR-326 O +
regulates O +
TH-17 O +
differentiation O +
and O +
is O +
associated O +
with O +
the O +
pathogenesis O +
of O +
multiple O +
sclerosis O -
. O +

Additionally O -
, O +
several O +
research O +
groups O +
have O +
established O +
that O +
inserting O +
microRNA O +
( O -
miRNA O -
) O -
-targeted O +
sequences O +
into O +
the O +
adenoviral O +
genome O +
can O +
modulate O +
adenoviral O +
protein O +
expression O +
to O +
confer O +
tissue O +
and O +
tumor O +
selectivity O -
. O +

It O +
has O +
been O +
suggested O +
that O +
the O +
use O +
of O +
autophagy O +
inducers O -
, O +
such O +
as O +
rapamycin O -
, O +
can O +
enhance O +
the O +
oncolytic O +
potency O +
of O +
recombinant O +
adenoviruses O -
. O +

This O +
review O +
discusses O +
three O +
aspects O +
of O +
the O +
use O +
of O +
oncolytic O +
adenoviruses O +
to O +
treat O +
cancer O -
: O +
( O -
i O -
) O +
the O +
induction O +
of O +
autophagy O +
and O +
autophagic O +
cell O +
death O +
during O +
adenoviral O +
replication O -
; O +
( O -
ii O -
) O +
the O +
opportunities O +
and O +
strategies O +
involved O +
in O +
the O +
exploitation O +
of O +
miRNA O +
specificity O +
to O +
generate O +
tissue- O +
and O +
tumor O -
- O -
selective O +
oncolytic O +
viruses O -
; O +
and O +
( O -
iii O -
) O +
the O +
rationale O +
for O +
combining O +
oncolytic O +
adenoviruses O +
with O +
chemotherapeutic O +
agents O -
. O +

Furthermore O -
, O +
the O +
capability O +
of O +
adenoviruses O +
to O +
inhibit O +
the O +
expression O +
of O +
the O +
DNA O +
repair O +
enzyme O +
MGMT O +
and O +
to O +
chemosensitize O +
glioma O +
cells O +
to O +
temozolomide O +
has O +
been O +
demonstrated O -
. O +

In O +
recent O +
years O -
, O +
oncolytic O +
viruses O +
have O +
been O +
genetically O +
engineered O +
to O +
target O +
cancer O +
cells O +
selectively O -
. O +

Oncolytic O +
adenoviruses O +
for O +
the O +
treatment O +
of O +
brain O +
tumors O -
. O +

The O +
observation O +
that O +
cells O +
infected O +
with O +
replication O -
- O -
competent O +
adenoviruses O +
undergo O +
autophagy O +
has O +
provided O +
new O +
options O +
for O +
investigating O +
the O +
mechanism O +
of O +
adenovirus O -
- O -
induced O +
cell O +
death O -
. O +

Adenovirus O +
is O +
one O +
such O +
oncolytic O +
virus O +
that O +
is O +
being O +
tested O +
in O +
clinical O +
trials O +
for O +
the O +
treatment O +
of O +
cancer O -
. O +

Parkinson O +
disease O +
( O -
PD O -
) O +
is O +
a O +
common O +
neurodegenerative O +
disorder O +
caused O +
by O +
environmental O +
and O +
genetic O +
factors O -
. O +

Variation O +
in O +
the O +
miRNA-433 O +
binding O +
site O +
of O +
FGF20 O +
confers O +
risk O +
for O +
Parkinson O +
disease O +
by O +
overexpression O +
of O +
alpha O -
- O -
synuclein O -
. O +

Subsequently O -
, O +
fibroblast O +
growth O +
factor O +
20 O +
( O -
FGF20 O -
) O +
at O +
8p21.3 O -
- O -
22 O +
was O +
identified O +
as O +
a O +
risk O +
factor O +
in O +
several O +
association O +
studies O -
. O +

We O +
have O +
previously O +
shown O +
linkage O +
of O +
PD O +
to O +
chromosome O +
8p O -
. O +

In O +
a O +
sample O +
of O +
729 O +
nuclear O +
families O +
with O +
1089 O +
affected O +
and O +
1165 O +
unaffected O +
individuals O -
, O +
the O +
strongest O +
evidence O +
of O +
association O +
came O +
from O +
rs12720208 O +
in O +
the O +
3 O -
' O +
untranslated O +
region O +
of O +
FGF20 O -
. O +

To O +
identify O +
the O +
risk O -
- O -
conferring O +
polymorphism O +
in O +
FGF20 O -
, O +
we O +
performed O +
genetic O +
and O +
functional O +
analysis O +
of O +
single O -
- O -
nucleotide O +
polymorphisms O +
within O +
the O +
gene O -
. O +

In O +
a O +
cell O -
- O -
based O +
system O +
and O +
in O +
PD O +
brains O -
, O +
this O +
increase O +
in O +
translation O +
of O +
FGF20 O +
is O +
correlated O +
with O +
increased O +
alpha O -
- O -
synuclein O +
expression O -
, O +
which O +
has O +
previously O +
been O +
shown O +
to O +
cause O +
PD O +
through O +
both O +
overexpression O +
and O +
point O +
mutations O -
. O +

We O +
show O +
in O +
several O +
functional O +
assays O +
that O +
the O +
risk O +
allele O +
for O +
rs12720208 O +
disrupts O +
a O +
binding O +
site O +
for O +
microRNA-433 O -
, O +
increasing O +
translation O +
of O +
FGF20 O +
in O +
vitro O +
and O +
in O +
vivo O -
. O +

We O +
propose O +
this O +
is O +
likely O +
to O +
be O +
a O +
common O +
mechanism O +
of O +
genetic O +
modulation O +
of O +
individual O +
susceptibility O +
to O +
complex O +
disease O -
. O +

We O +
suggest O +
a O +
novel O +
mechanism O +
of O +
action O +
for O +
PD O +
risk O +
in O +
which O +
the O +
modulation O +
of O +
the O +
susceptibility O +
gene O -
's O +
translation O +
by O +
common O +
variations O +
interfere O +
with O +
the O +
regulation O +
mechanisms O +
of O +
microRNA O -
. O +

BACE1 O +
mRNA O +
levels O +
tended O +
to O +
increase O +
as O +
miR-107 O +
levels O +
decreased O +
in O +
the O +
progression O +
of O +
AD O -
. O +
Cell O +
culture O +
reporter O +
assays O +
performed O +
with O +
a O +
subset O +
of O +
the O +
predicted O +
miR-107 O +
binding O +
sites O +
indicate O +
the O +
presence O +
of O +
at O +
least O +
one O +
physiological O +
miR-107 O +
miRNA O +
recognition O +
sequence O +
in O +
the O +
3'-UTR O +
of O +
BACE1 O +
mRNA O -
. O +

Computational O +
analysis O +
predicted O +
that O +
the O +
3'-untranslated O +
region O +
( O -
UTR O -
) O +
of O +
beta O -
- O -
site O +
amyloid O +
precursor O +
protein O -
- O -
cleaving O +
enzyme O +
1 O +
( O -
BACE1 O -
) O +
mRNA O +
is O +
targeted O +
multiply O +
by O +
miR-107 O -
. O +

From O +
the O +
same O +
RNA O +
material O +
analyzed O +
on O +
miRNA O +
microarrays O -
, O +
mRNA O +
expression O +
profiling O +
was O +
performed O +
using O +
Affymetrix O +
Exon O +
Array O +
microarrays O +
on O +
nondemented O -
, O +
MCI O -
, O +
and O +
AD O +
patients B-Species -
. O +

Among O +
the O +
AD O -
- O -
related O +
miRNA O +
expression O +
changes O -
, O +
miR-107 O +
was O +
exceptional O +
because O +
miR-107 O +
levels O +
decreased O +
significantly O +
even O +
in O +
patients B-Species +
with O +
the O +
earliest O +
stages O +
of O +
pathology O -
. O +

In O +
situ O +
hybridization O +
with O +
cross O -
- O -
comparison O +
to O +
neuropathology O +
demonstrated O +
that O +
particular O +
cerebral O +
cortical O +
laminas O +
involved O +
by O +
AD O +
pathology O +
exhibit O +
diminished O +
neuronal O +
miR-107 O +
expression O -
. O +

We O +
used O +
miRNA O +
expression O +
microarrays O +
on O +
RNA O +
extracted O +
from O +
human B-Species +
brain O +
tissue O +
from O +
the O +
University O +
of O +
Kentucky O +
Alzheimer O -
's O +
Disease O +
Center O +
Brain O +
Bank O +
with O +
near O -
- O -
optimal O +
clinicopathological O +
correlation O -
. O +

Cases O +
were O +
separated O +
into O +
four O +
groups O -
: O +
elderly O +
nondemented O +
with O +
negligible O +
AD O -
- O -
type O +
pathology O -
, O +
nondemented O +
with O +
incipient O +
AD O +
pathology O -
, O +
mild O +
cognitive O +
impairment O +
( O -
MCI O -
) O +
with O +
moderate O +
AD O +
pathology O -
, O +
and O +
AD O -
. O +

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
small O +
regulatory O +
RNAs O +
that O +
participate O +
in O +
posttranscriptional O +
gene O +
regulation O +
in O +
a O +
sequence O -
- O -
specific O +
manner O -
. O +

However O -
, O +
little O +
is O +
understood O +
about O +
the O +
role O -
( O -
s O -
) O +
of O +
miRNAs O +
in O +
Alzheimer O -
's O +
disease O +
( O -
AD O -
) O -
. O +

Together O -
, O +
the O +
coordinated O +
application O +
of O +
miRNA O +
profiling O -
, O +
Affymetrix O +
microarrays O -
, O +
new O +
bioinformatics O +
predictions O -
, O +
in O +
situ O +
hybridization O -
, O +
and O +
biochemical O +
validation O +
indicate O +
that O +
miR-107 O +
may O +
be O +
involved O +
in O +
accelerated O +
disease O +
progression O +
through O +
regulation O +
of O +
BACE1 O -
. O +

The O +
expression O +
of O +
microRNA O +
miR-107 O +
decreases O +
early O +
in O +
Alzheimer O -
's O +
disease O +
and O +
may O +
accelerate O +
disease O +
progression O +
through O +
regulation O +
of O +
beta O -
- O -
site O +
amyloid O +
precursor O +
protein O -
- O -
cleaving O +
enzyme O +
1 O -
. O +

